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 iii. Summary 
Clathrin-mediated endocytosis (CME) plays a central role in fundamental 
processes such as synaptic vesicle recycling, receptor recycling, signaling 
and development. CME begins with clathrin assembly on the plasma 
membrane, facilitated by adaptor proteins. This process forms an endocytic 
vesicle that allows transport of cargo into the cell, and is followed by clathrin 
disassembly through the action of different adaptor/accessory proteins. A 
large number of different adaptor and accessory proteins are recruited during 
CME, in a spatially and temporally ordered manner. Although our 
understanding is growing as to the roles of individual adaptor proteins, we 
still do not understand the way in which some adaptors interact with clathrin 
or the molecular details of their interactions with one another in the presence 
of clathrin. Clathrin adaptor proteins contain short, linear clathrin-binding 
motifs, which form the basis of their interaction with the four distinct sites on 
the clathrin N-terminal domain (TD). An adaptor protein with tighter binding 
or more numerous clathrin binding sequences could displace one with 
weaker or fewer binding elements. This raises the question of whether 
adaptor proteins compete for binding to clathrin or whether they can bind 
simultaneously.  
 
Using certain biochemical and biophysical techniques in vitro and purified 
WT and mutant adaptor proteins, I have shown the complex ‘multiple TD 
linking effect’ of epsin 1 via the cooperative action of its two clathrin box 
motifs and unstructured region. Using the newly developed SPR/IAC (2-
injection) method, I explored competition between five purified structurally 
and functionally diverse adaptor proteins when simultaneously binding to 
clathrin TD. I have shown how the complex structure of epsin 1 causes 
competition with β-arrestin 1 for clathrin TD binding. Such competition is 
observed between espin 1 and auxilin 1 as well, which reveals information 
about the mechanism of disassembly. However, β2-adaptin and auxilin 1 
demonstrate no such competition. 
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Chapter 1: Introduction 
1.0.0 Overview  
In this chapter I introduce the topic of my PhD project, emphasizing the 
structures and functions of a variety of different proteins that are involved in 
the clathrin mediated endocytosis (CME) process, with a focus on the 
proteins used in this thesis. The aims and objectives of this thesis are stated 
in section 1.11.0. 
 
1.1.0 Endocytosis  
Endocytosis is a fundamental process involved in engulfing and selective 
packing of cell-surface proteins in cytoplasmic vesicles in order to be 
internalized into the cell to be targeted to the appropriate organelle. Any 
alterations into this fundamental process could lead to serious implications to 
variety of disease states such as for cancer cell development (Mellman and 
Yosef, 2013).  
 
Endocytosis can be categorised into three major types: phagocytosis (cell 
cargo eating); pinocytosis (cell drinking of small fluids) and ‘receptor 
mediated endocytosis’ (Doherty and Mcmahon, 2009). Mechanisms of 
endocytosis have been classified into (I) caveolae-dependent (II) clathrin-
independent and (III) clathrin-dependent (Doherty and Mcmahon, 2009; 
McMahon and Boucrot, 2011; Mayor et al., 2014). The caveolae-dependent 
mechanism utilises caveolae, which are ∼ 60 nm lipid and protein rafts that 
are released into the cell response to stimuli (Parton and Del Pozo, 2013; 
Kovtun et al., 2015). Clathrin independent endocytosis (CIE) is involved in 
internalization of specific cargo without the use of clathrin. An example of this 
is the Arf6-associated pathway where histocompatibility complex class I 
proteins (MHCI), β-integrin, and the GPI-anchored protein CD59 are 
internalized (Karnik et al., 2013; Mayor et al., 2014). Clathrin-mediated 
endocytosis (CME) is one of the earliest endocytic pathways to be 
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discovered for receptor-mediated endocytosis with the aid of clathrin. It is the 
best studied and characterised up till now and is the main pathway focused 
in this thesis.  
 
1.2.0 Clathrin mediated endocytosis 
The assembly and disassembly of clathrin structure in vitro provides a model 
system in order to further understand how proteins can contribute 
mechanically in concert to perform CME. Brown and Goldstein were the first 
to demonstrate the uptate of the low-density lipoproteins (LDL) via CME, 
which was not observed in patients with Familiar Hypercholesterolemia (FH) 
(Goldstein et al., 1985). Through the years, CME has shown to underpin 
important processes, such as nutrient uptake, synaptic vesicle recycling, viral 
and bacteria entry, signaling mechanisms and determination of cell polarity 
(Goldstein et al., 1985; Pizarro-Cerda et al., 2010; Young et al., 2013). 
 
The stages of CME begin with clathrin forming interactions with different 
adaptor/accessory proteins during its assembly for the construction of a coat 
around the newly developing endocytic vesicle. This coat engages with cargo 
on the cell surface and facilitates the inclusion of the cargo into the vesicle. 
Once the vesicle has budded from the plasma membrane, the clathrin coat 
disassembles using different adaptor/accessory proteins e.g. Hsc70/auxilin, 
allowing the endocytic machinery to be recycled, and the vesicle goes on to 
deliver cargo in the cell (McMahon & Boucrot, 2011; Young et al., 2013) 
(Figure 1.2.0 (A)).  
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1.3.0 The stages of clathrin mediated endocytosis 
1.3.1 Assembly: adaptor protein recruitment  
 A number of studies have monitored the activity and recruitment of adaptor 
proteins at the plasma membrane to promote coordinated clathrin assembly 
(Mettlen et al., 2009; Saffarian et al., 2009; Mettheyses et al., 2011; Taylor et 
al., 2011; Avinoam et al., 2015). At least 25 adaptor proteins are recruited at 
specific times to the plasma membrane according to their role in clathrin 
assembly and nucleation process (Traub, 2011; Taylor et al., 2011). 
 
 
Figure 1.2.0: The general steps of clathrin mediated endocytosis (CME) with 
the addition of key adaptor and accessory proteins involved. The endocytic 
cargo is detected by adaptor proteins such as AP2 or β-arrestin at the plasma 
membrane and recruitment of other adaptor proteins, e.g. epsin, causes curvature 
of plasma membrane. Further recruitment of other adaptor proteins along with 
cytoskeletal components e.g. actin, results in membrane invagination and the 
formation of a clathrin coated pit (CCP) after the clathrin assembly completition. The 
maturation of the CCP continues until scission begins with the activation of the 
GTPase dynamin causing the CCP to “pinch off” forming a clathrin coated vesicle 
(CCV). The clathrin coat is disassembled by the coordinated function of ATP 
hydrolysis by Hsc70 mediated by GAK (cyclin-G associated kinase)/auxilin. Once 
clathrin disassembly is complete, the vesicle is able to fuse with its target 
compartment in the cell. The endocytic components are then recycled ready for the 
next round of endocytosis. 
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In certain situations, during low membrane curvature and depending on the 
cell type and cargo, FCHo proteins, which are BAR domains (Bin–
Amphiphysin–Rvs) are initially recruited at the surface causing activation of 
the adaptor protein, AP2, which is the primary adaptor protein for clathrin 
assembly (Godlee and Kaksonen, 2013; Liu et al., 2015; Hollopeter et al., 
2014). The AP2 complex interacts with the plasma membrane, clathrin, 
cargo and other adaptors to promote the initiation of the clathrin coat 
assembly. This is carried out with AP2 binding to cytoplasmic motifs on cargo 
(e.g. receptors bound to ligands- such as transferrin receptors) (Traub, 
2009), enabling clathrin to assemble around the vesicle. This process 
progresses with the aid of multiple endocytic proteins, which have been 
previously identified to be recruited at the surface. Additionally, β-arrestins 
are used for receptor internalization and detect changes in cargo such as G-
protein coupled receptors (GPCR) serine/threonine phosphorylated tail 
(Lefkowitz et al., 2006). These classes of adaptor proteins will bind to clathrin 
and AP2 and recruit them to the surface for progression of the internalisation 
of the GPCR via CME (Laporte et al., 2000; Burtey et al., 2007). Overall, a 
variety of different adaptor proteins are recruited at the surface during the 
initiation of the clathrin assembly around the outer layer of the newly forming 
coated vesicle (Ungewickell and Hinrichsen, 2007; Traub, 2009) enabling the 
formation of the characteristic, continuously remodeling clathrin lattice 
(Ungewickell and Hinrichsen, 2007; Avinoam et al., 2015). 
 
1.3.2 Clathrin coat vesicle (CCV) maturation  
In the lattice, clathrin is essential for driving coated pit invagination, where 
the coated surface remains constant and the engagement of clathrin with 
multiple binding partners at the surface promotes its maturation and 
increases the clathrin coat curvature. Each adaptor protein performs their 
targeted role and change conformation to induce the clathrin coated pits 
(CCPs) formation (Hinrichsen et al., 2006). Bending of the dynamic clathrin 
lattice coat is involved in the budding of the CCV (Avinoam et al., 
2015). Hence, following the clathrin assembly initiation process, clathrin a 
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flat-to-curved lattice transition takes place to form the clathrin-coated pits 
(CCPs) (Ungewickell and Hinrichsen, 2007; Burtey et al., 2007). This 
transition initiates with the clathrin assembly growing as a flat structure, 
which then begins to bend when clathrin has reached 70% final content, a 
change in clathrin/adaptor (AP2) ratio occurs prior to the completion of coat 
assembly (Bucher et al., 2017). The bending process is carried out with the 
help of specific adaptor proteins, which maintain a constant surface area 
(Traub, 2009; Bucher et al., 2017). Such adaptor proteins are epsin and 
eps15 (Cocucci et al, 2012; Hollopeter et al., 2014; Ma et al., 2016) which 
bind to ubiquitinated proteins via its ubiquitin interacting motifs (UIM) (Traub, 
2005). AP180/CALM and epsin 1 use their ANTH/ENTH domains to bind to 
phosphatidyl-inositol 4,5 bis-phosphate (PI(4,5)P2) (Ford et al., 2001; Ford et 
al., 2002). The ENTH domain of epsin changes the membrane fluidity 
promoting bending for invagination (Hom et al., 2007; Lai et al., 2012; Busch 
et al., 2015), and the unstructured C-terminal domains of both AP180 and 
epsin are hypothesized to control the clathrin coated vesicle (CCV) size to a 
uniform size distribution (Kalthoff et al., 2002; Jakobsso et al., 2008; Holkar 
et al., 2015). 
 
1.3.3 Elongation and Scission of CCPs 
Once the CCP has been fully formed, amphiphysin and endophilin, which are 
BAR domain containing proteins, recruit the GTPase dynamin, which wraps 
around the narrow neck of the CCP (Verstreken et al., 2003; Loerke et al., 
2009; Mettlen et al., 2010; Neumann and Schmid, 2013). These ring-like 
dynamin layers contract in a GTP-hydrolysis dependent manner, causing 
stretching of the neck until the CCP is pinched off (scission) (Loerke et al., 
2009). In certain cases, the elongation and scission process is actin-
dependent, depending on specific cargo and membrane tension, especially 
in yeast (Saffarian et al., 2009; Mishra et al., 2014). Actin assembles at the 
neck of the CCP by the help of cortactin (Le Clainche et al., 2007), however 
the plasma membrane remains flat (Picco et al., 2017). Epsin and 
Hip1/Hip1R act cooperatively to couple actin and the plasma membrane and 
 6 
drive membrane bending and the subsequent growth of the plasma 
membrane, invagination and the elongation of the CCP neck (Fujimoto et al., 
2000; Wilbur et al., 2008; Picco et al., 2017). Thus, the changes to the 
plasma membrane are physically linked to the actin network, which has been 
identified to have a  ‘two phase’ mechanism to drive the membrane 
reshaping process (Picco et al., 2017). Once scission of the CCP is 
completed, myosin II and myosin IV have been suggested to facilitate the 
closure of the neck before the CCP enters into the cell (Buss et al., 2001; 
Chandrasekar et al., 2014). 
 1.3.4 Un-coating of the CCVs 
Once the CCV enters the cell the clathrin coat disassembly process initiates, 
where the clathrin cage will dismantle, allowing the vesicle to fuse with the 
target organelle and recycling of the adaptor proteins and clathrin to prepare 
for further endocytic events (Xing et al., 2010; Sousa et al., 2016). It has 
been suggested that clathrin disassembly onset could be based on 
competition of auxilin with AP2 for clathrin binding, due to similarities in 
clathrin binding motifs (Scheele et al., 2003; Smith et al., 2004), as well as 
the recruitment of the phosphatase synaptojanin prior the completion of 
scission (Taylor et al., 2011) via interactions with the BAR domain of 
endophilin (Milosevic et al., 2011). PI(4,5)P2 is dephosphorylated to PI(4)P 
by phosphatases such as synaptojanin, releasing many adaptors from the 
membrane due to reducing their affinity (Stefan et al., 2002; Verstreken et al., 
2003; Stefan et al., 2005). This disassembly mechanism of clathrin is 
mediated by the interactions of different adaptors proteins/chaperones such 
as Hsc70, which interact with the J- domain of auxilin/GAK in an ATP-
dependent manner (Greener et al., 2000; Umeda et al., 2000; Kirchhausen et 
al., 2014; Xing et al., 2010; Sousa et al., 2016). This occurs when the auxilin 
binds to the clathrin cage which recruits the Hsc70 to bind under the vertex 
of the clathrin triskelia trimerisation domain where it binds to a QLMLT motif 
on the clathrin C-terminus, (Rappoport et al., 2006; Xing et al., 2010; Sousa 
et al., 2016). The final process involves the vesicle being targeted to the 
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appropriate organelle via the interaction CALM and EpsinR (Miller et al., 
2011; Hirst et al., 2004). 
1.4.0 Clathrin structure and function  
1.4.1 Overview of clathrin  
In 1975, Barbara Pearse first purified clathrin from clathrin-coated vesicles. 
The name clathrin arose from its ability to form lattice structures, enclosing a 
protein-lipid cargo in a cage (Pearse, 1975). Clathrin has a distinct three-
legged structure, called triskelion, which was confirmed as the basic building 
block for clathrin assembly to form a cage structure (Ungewickell and 
Branton, 1981). Each triskelion trimer is composed of three ~190 kDa long 
and thin heavy chain (CHC) subunits which connect at the trimerisation hub, 
each of which associates with three ~25 kDa light chain (CLC) subunit 
(Figure 1.4.1 (A) and (B)), forming heterogeneous (according to its 
transporting cargo) cage sizes (Fotin et al., 2004)."
 
 
  
 
 
Figure 1.4.1: The structural features of a clathrin triskelion extracted from the 
alpha carbon model. (A) The alpha carbon model used was from Fotin et al., 2004. 
View from above with domains labelled as follows. Terminal domain (orange); distal 
domain (pink); proximal domain (red); trimerisation domain (green) and light chain 
(cyan). (B) Side view of a clathrin triskelion. The images is constructed using 
3iyv.pdb in UCSF Chimera (Pettersen et al. 2004) and adapted from (Halebian et al., 
2017) 
‘Redac
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1.4.1.1 The role of clathrin in disease 
Defects in clathrin assembly or disassembly are associated with 
neurodegenerative disease e.g. Alzheimer’s disease (Wu and Yao, 2009), as 
clathrin has a major role in synaptic vesicle recycling. Additionally, CME is a 
major means of viral entry into the cell, for example in recent studies by 
Huang et al., 2017; where the main nervous necrosis virus (betanodavirus) 
enters the cell via CME pathway (Huang et al., 2017). Therefore, 
understanding the mechanism by which clathrin functions in CME are 
extremely important for therapeutical use. 
 
1.4.2 Clathrin Structure 
1.4.3 Clathrin heavy chain (CHC)  
The proximal leg consists of CHC repeats (CHCRs) comprising 10 helices of 
10–12 residues each connected by loops, creating two helical and two loop 
faces to the triskelion leg (Ybe et al., 1999). The CHC is divided up into 8 
distinct regions (CHCR0-CHCR7), which begin from the trimerisation domain 
until the N-terminal domain at the end of the clathrin leg (Ybe et al., 1999; 
Fotin et al., 2004). Clathrin triskelion can self-assemble into a polyhedral 
lattice facilitated by a pH change (~ pH 6.4) in vitro (Ybe et al., 1998; Chen 
and Brodsky, 2005). This is due to interactions between the proximal and 
distal regions of the CHC, which facilitate interactions between triskelia, by 
salt bridges of histidines with glutamates in neighboring triskelia legs (Ybe et 
al., 1998; Bocking et al., 2014). There are two isoforms of CHC in humans; 
the CHC17 and CHC22 from the two genes located on chromosome 17 and 
22. The CHC17 is the most abundant isoform, whereas the major role of the 
CHC22 is trafficking of the insulin-responsive glucose transporter (GLUT4) in 
skeletal muscle (Vassilopoulos et al., 2009). However, the biochemical 
properties of CHC22 have yet to be elucidated (Brodsky, 2012). Thus, in this 
thesis the CHC17 isoform has been used. 
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1.4.3.1 Clathrin N-terminal Domain (TD) 
An essential component of clathrin heavy chain (CHC), the N- terminal 
domain (TD) (residues 1-330) consists of a β-propeller structure formed by 
seven ‘‘WD40 repeats’’, with tryptophans and aspartic acids at the canonical 
positions in most of its seven blades (ter Haar et al., 2000), (Lemmon and 
Traub, 2012; Willox and Royle, 2012). The TD is the major binding site for 
most endocytic adaptor proteins, which is considered an ideal position, as it 
is the positioned closest to the membrane surface in the clathrin lattice 
(Willox and Royle, 2012). In 1998, ter Harr et al., showed the 2.6 Å crystal 
structure of the 55 kDa N-terminal domain suggesting that this region in the 
CHC could bind to multiple adaptor proteins in its packing of the β-sheets (ter 
Haar et al., 1998). Acidic and bulky hydrophobic residues, L(L, I)(D, E, N)(L, 
F)(D, E) (Dell'Angelica et al., 1998); Drake and Traub, 2000), termed  the 
‘clathrin box’ motif (ter Haar et al., 2000), which are highly-conserved in 
many proteins for example epsin’s two clathrin binding motifs (LMDLADV 
and LVDLD) (Darke et al., 2000; Drake and Traub, 2001), which could 
occupy the same TD sites and aid in the membrane bending (Hom et al., 
2007; Lai et al., 2012; Busch et al., 2015).  
 
Despite its relatively small size, the TD has four distinct binding sites for 
adaptor proteins, as seen in Figure 1.4.3.1. Certain adaptor proteins are 
hypothesized to interact with multiple of these TD sites, which are essential 
for assembly and disassembly of clathrin function in vivo (Zhuo et al., 2015; 
Muezner et al., 2017). These four sites/motifs are: CBox (LΦXΦ[DE]), the ‘W-
box’ motifs (PWXXW), ‘Arrestin box’ (LI][LI]GXL) and the Royle box, as 
shown in Figure 1.4.3.1 (ter Harr et al., 2000; Lemmon and Traub, 2012; 
Willox and Royle, 2012; Zhuo et al., 2015; Muenzner et al., 2017). The major 
site for the adaptor-TD interaction is via the conserved ‘CBox (LΦXΦ[DE])’ 
TD site located in the blades 1 and 2 in the TD structure (Drake et al., 2000; 
Lemmon and Traub 2012; Willox and Royle 2012; Zhuo et al., 2015; 
Muezner et al., 2017). A 2.3 Å crystal structure of amphiphysin 1 peptide 
bound to clathrin TD reveled the site 2 on TD, the ‘W-box’ with a sequence of 
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PWXXW which is located in the middle of the TD structure (Miele et al., 
2004). The TD site 3, ‘ArrestinBox’ was shown by Kang et al., 2009 where β-
arrestin 1L (longer isoform) bound to blades 4 and 5 on the TD, via the 
extended 8-amino acid loop on the N-terminal domain (Kang et al., 2009). 
The newly discovered site 4 named “Royle box” was initially described by 
Willox and Royle, 2012, where they showed how clathrin/AP2 mediated 
endocytosis in HEK293 cells was successful even when mutating three TD 
sites (CBM, W-box, ArrestinBox). The location of the “RoyleBox” was 
revealed to be between blades 6 and 7 of the TD, but a consensus sequence 
has not yet been discovered (Muenzner et al., 2017). 
 
 
 
 
 
 
 
 
Figure 1.4.3.1: The location of the N-terminal domain and illustrating the four 
adaptor binding sites on the TD. (A) Clathrin cages are formed by triskelia 
monomers, formed of trimer of CHC (orange) and their equivalent CLC (pink). The 
TD (cyan) is the primary binding location for adaptor proteins and is located at the 
inner layer of the cage closest to the plasma membrane. (B) The TD consists of 
four sites, which interact though binding motifs on adaptor proteins. Site 1 is 
situated in blades 1 and 2 and it is the conserved clathrin box site (LFXF[DE]) 
(turquoise). Site 2 situated in the center of the  propeller, the W-box (PWXXW) 
(blue). Site 3 is the Arrestin-box ([LI][LI]GXL)  (Pink) which is situated in blades 4 
and 5; and Site 4 is the Royle Box (purple), which located at blades 6 and 7 with no 
interaction sequence yet. Image adapted from (Smith et al., 2017) (in press). The 
structures  adapted from PDB code: 3IYV (A) (Fotin et al., 2004), 5M5R (B) 
(Muenzner  et al., 2017). 
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1.4.4 Clathrin light chain (CLC) 
CLC are tightly associated at 1:1 ratio with CHC, which require strong 
denaturants, such as sodium isothiocyanate, to achieve dissociation (Winkler 
and Stanley, 1983; Girard et al., 2005). The biological role of the light chains 
has not yet been fully established (Brodsky, 2012). The light chains are  
categorized into light chain types α and b, and neuronal splice variants have 
been identified for each type (Brodsky, 2012). The consensus region shared 
by both light chains has been shown to bind to the Hip1 protein family, which 
interact with actin and actin-associated proteins (Chen and Brodsky, 2005), 
however light chains which interact with the Hip1/R family reduce their affinity 
to interact with actin  (Wilbu et al., 2008; Wilbur et al., 2010). Both types of 
CLC but more specifically type b have been shown to be necessary for the 
endocytosis of some G-protein coupled receptors (Ferreira et al., 2012). Both 
light chains are able to negatively regulate clathrin assembly in vitro and play 
a significant role in stabilizing the trimerisation domain (Ybe et al., 2007; 
Chen et al., 2002). They may also regulate the degree of bending that the 
triskelion legs adopt (Wilbur et al., 2010). Interestingly, CLC have been 
shown to influence the ‘stiffness’ of clathrin lattices (Dannhauser  et al., 
2015). The difference between light chain α and b is that CLCa contains 
Hsc70 site but not CLCb (De Luca-Flaherty et al., 1990). In addition, there is 
a negative regulator assembly effect through interactions with calcium and 
magnesium on CLCb as well as a phosphorylation site (Brodsky et al., 1991; 
Liu et al., 1995). 
 
1.4.5 Clathrin cage structures 
Clathrin-coated vesicles in cells can vary in size within a range of 50 to 80 
nm depending on the cargo they internalize, however in vitro clathrin triskelia 
assemble (pH sensitive) to form heterogeneous cage structures (Fotin et al., 
2004). Some of these have symmetry, e.g. D6 hexagonal barrel (Fotin et al., 
2004). To obtain clathrin cage structures, X-ray crystallography has been 
unfeasible for entire cages due to the large cage size, but vital information 
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has been gained through crystallographic analysis of fragments of CHC. 
Therefore, single particle cryogenic electron microscopy (cryo-EM) was used 
to investigate the large heterogeneous sized clathrin cages. Using a 
combination of the information derived from X-ray crystallography of CHC 
regions and cryo-EM data has given us our current picture and knowledge of 
the structure of the clathrin cage.  
 
In 1986, the first cryoEM map of a clathrin cage was published by Vigers, 
Crowther and Pearse indicating how clathrin forms an outer layer around the 
vesicle with adaptor proteins located inside the cage between clathrin and 
the membrane (Vigers et al., 1986). Most interestingly, the next clathrin cage 
structure was obtained from Smith et al., a 21 Å clathrin hexagonal barrel 
confirming the arrangement and interaction of triskelions in the cage and the 
location of AP2 in the center of the clathrin cage structure (Smith et al., 
1998). The most current cryoEM map of 7.9 Å from Fotin et al., revealed 
detail of the trimerisation domain secondary structure (ankle and terminal 
domain), showing key points of interaction between the legs supporting the 
cage structure, and the location of the clathrin light chain (CLCs) (Fotin et al., 
2004). The highest resolution structures revealed have been obtained bound 
to regulatory adaptors Hsc70 and auxilin, revealing how Hsc70 and the 
auxilin J-domain bound beneath the clathrin vertex where they disrupt 
multiple leg contacts (Young et al., 2013; Xing et al., 2010). Identifying 
location of adaptor proteins in the clathrin cage has proved informative but 
the mode of interaction of the clathrin cage with its other adaptor proteins still 
remains unclear. 
 
1.5.0 Structure, function and role of adaptor proteins 
In CME, a large number of different proteins, are required to recruit, 
assemble and disassemble clathrin at the plasma membrane. Therefore, 
CME is considered a tremendously complex mechanism with a combination 
of at least 25 different adaptor proteins recruited to the plasma membrane 
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during CME in an ordered sequence and with different roles (Figure 1.5.0) 
(Merrifield and Kaksonen, 2014; Traub, 2011; Taylor et al., 2011). The 
pivotal study of Taylor et al., 2011 enabled these proteins according to their 
proposed functions and time of recruitment to the surface at different stages 
(assembly, maturation, disassembly). There are still unanswered questions 
as to the precise organisation of these proteins together during CME stages 
to facilitate efficient endocytosis. It is of great interest to understand how 
adaptor proteins co-exist and whether they function cooperatively or 
competitively for clathrin binding, promoting successful assembly and 
disassembly. In this section, I introduce the structure, function and role of 
certain adaptor proteins, from different stages of endocytosis, which are 
further used in this thesis. These adaptor proteins are AP2, epsin 1, β-
arrestin 1L, auxilin 1 and Hip1/Hip1R.  
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Figure 1.5.0: The huge complex of adaptor protein network involved in 
different stages of CME. A large number of proteins involved in CME grouped 
according to their proposed functionality and recruitment timings during 
endocytosis, separated in hubs in the spider diagram. Hubs with dark circles 
indicate proteins that bind to phospholipids. Image adapted from (Traub, 2011).  
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1.5.1 Assembly adaptor proteins 
1.5.2 Structure of Adaptor Protein 2 (AP2)  
The primary adaptor proteins are AP1, AP2, AP3 and AP4, from which AP1, 
AP2 and AP3 are involved in the CME by interacting with clathrin, and AP4 
doesn’t bind to clathrin at all (Collins et al., 2002; Edeling et al., 2006a). The 
main AP used in this thesis is the AP2 complex, which is found at the plasma 
membrane instead of localized in the endosomes like AP1, AP3, AP4 
(Edeling et al., 2006a). The heterotrimeric adaptor protein, AP2, has two 
large subunits corresponding to the 100–110kD, called adaptins (β2-adaptin 
and γ2- or α-adaptin), together with a medium-sized (μ2) subunit of ∼50 kD 
and a small (σ2) subunit of ∼20 kD (Collins et al., 2002; Edeling et al., 2006a; 
Jackson et al., 2010, Paczkowski et al., 2015) (Figure 1.5.2). AP2 interacts 
with two canonical internalization motifs found in the cytoplasmic domains of 
endocytic cargo proteins; YXX Ø (X-amino acids, Ø-bulky hydrophobic amino 
acid), which binds to the μ2 subunit; and the [DE]XXXL[LI} motif in the 
cytoplasmic domain of the receptors (Owen and Evans, 1998; Kelly et al., 
2008; Jackson et al., 2010; Traub and Bonifacino, 2013). The AP2 complex 
also interacts with phosphatidylinositol 4,5-bisphosphate (PIP2), clathrin, 
several endocytic accessory and adaptor proteins (Traub, 2009; Jackson et 
al., 2010). 
 
 
 
Figure 1.5.2: The heterotrimeric AP2 
complex. The complex is made up of two 
large subunits corresponding to the 100–
110kD, called adaptins (β2-adaptin in 
green and γ2- or α-adaptin in blue), A 
medium-sized (μ2) subunit in purple of ∼50 
kD and a small (σ2) subunit of ∼20 kD in 
cyan. A clathrin box is situated at the long 
flexible linker region of the large β2- 
adaptin subunit. This diagram illustrates 
the open conformation of AP2 with the 
‘clathrin box’ accessible. Image adapted 
from Paczkowski et al. 2015.  
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1.5.3 AP2 structure conformational changes  
In the cytoplasm, AP2 ‘clathrin binding box’ (LLNLD) is located on the long 
flexible unstructured linker of the large β2 subunit, which is hidden in the core 
of the AP2 structure when in its locked/closed conformation (Shih et al., 
1995; Owen et al., 2000; Collins et al., 2002; Paczkowski et al., 2015). The 
cargo binding sites on the AP2 complex are obscured when free in the 
cytosol (Figure 1.5.3 (A)), but when AP2 is recruited onto the appropriate 
membrane surface, phosphorylation of Thr156 by AAK1 (Olusanya et al., 
2001; Ricotta et al., 2002) or even GAK (Umeda et al., 2000) triggers the 
release of μ2 subunit of the AP2 complex and other sites for its interaction 
with PIP2 (Owen et al., 2000; Kelly et al., 2014; Paczkowski et al., 2015). 
This releases the long flexible loop, which in turn exposes the clathrin 
binding box motifs. This conformational change of the AP2 complex allows 
its interaction with clathrin, cargo proteins and other adaptor proteins (Figure 
1.5.3 (B)) (Paczkowski et al., 2015).  
 
AP2 and FCHo are both essential CCV initiators, at the early stages of 
endocytosis (Henne et al., 2010; Godlee and Kaksonen, 2013). However, 
AP2 is not essential for the initiation of endocytosis in yeast (Owen and 
Evans, 1998; Collins et al. 2002). Interestingly, the closed- AP2 conformation 
could still bind weakly to clathrin via its α-ear domain, which is always 
exposed, however there are no know motifs for this interaction yet (Smith et 
al., 1998; Fotin et al., 2004; Boecking et al., 2011; Kelly et al., 2014). 
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1.5.4 AP2/clathrin and other adaptor proteins 
The ear domains (also referred to as the appendage domains) and the hinge 
regions of α and β2-adaptin (residues 619−944) are important for the 
interaction of AP2 with other adaptors (Paczkowski et al., 2015). There are 
two modes of binding between AP2 and clathrin: (i) The β2-ear of AP2 binds 
to the clathrin heavy chain ankle, (ii) the β2 hinge which contains a clathrin 
box motif (LLNLD) in its unstructured region interacts with the clathrin N-
terminal domain (TD) (Shih et al., 1995; Clairmont et al., 1997; Owen et al., 
2000) with a stoichiometry of 3:1 (Zhuo et al., 2015). The ‘clathrin box motif’ 
peptides of AP180, another assembly adaptor protein, and AP2 peptides 
interaction with clathrin TD could simultaneously bind not only to TD site 1 
Figure 1.5.3: Conformational change of the AP2 complex by its interaction 
with cargo, adaptors and plasma membrane, and its interaction with clathrin.  
(A) In the closed conformation of AP2, the clathrin box in the flexible linker region 
but once the μ subunit (purple) of the AP2 complex interacts with PIP2 and cargo 
(navy red), the flexible linker region causes the release forming an open 
conformation of the AP2 complex (B), which can now interact with clathrin (red star) 
via the clathrin box (LLNLD) (orange box) (C). Image adapted from Paczkowski et 
al. 2015.  
‘Redac
ted du
e to co
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ski et a
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)’ 
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(CBM) sites 2 (the “W-box”) and site 3 (Arrestin box) on a single TD with low 
affinity of 800-900 μM KD (Zhuo et al., 2015), which are common TD sites 
with variety clathrin adaptor proteins. 
 
The multiple interactions of AP2 with clathrin suggests a cooperative action, 
which stabilises cage polymerization (Knuehl et al., 2006). More interestingly, 
a change in the clathrin:AP2 ratio takes place when changing from flat-to-
curved transition of the clathrin lattice in vivo. This transition occurs when the 
content of clathrin is around 70% indicating the completion of the coat 
assembly (Bucher  et al., 2017). This flat-to-curved transition is hypothesised 
to be controlled by biophysical properties of the plasma membrane (e.g. 
tension) (Bucher   et al., 2017). It has been suggested that there is a 
cooperative interaction between certain endocytic adaptors proteins with AP2 
for clathrin recruitment and assembly around the budding vesicle. This is due 
to the fact that, AP2 may be preferentially present at different stages during 
endocytosis, and the α and β2 appendages are a common location for 
interaction with a variety of adaptor proteins (Traub, 2011; Praefcke et al., 
2004).  
1.6.0 Epsin 
Epsin is a key CLASP (Cytoplasmic Linker Associated Protein) protein, 
discovered in 1998 by Chen et al., (Chen et al., 1998) highly expressed in 
the brain (Rosenthal et al., 1999). Epsin is an important clathrin assembly 
adaptor protein at the early stages of CME, but it is also important in the later 
stages of CME, as loss of epsin interferes with the recruitment of HipR 
(Brady et al., 2010) and results in a reduction in the maturation of CCPs 
(Mettlen et al., 2009). Epsin reduces its affinity for AP2 when 
phosphorylated, which allows it to fulfill separate roles in mitosis (Kariya et 
al., 2000). 
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 1.6.1 The structure of epsin  
Epsin 1 is a membrane binding protein that binds to the clathrin coat 
components, clathrin, Eps15 and the AP2 complex to promote clathrin 
assembly (Drake et al., 2000). Epsin has an ENTH domain (N-terminal 
homology domain) that binds to PI(4,5)P2 and contains an amphipathic helix 
which modifies the membrane curvature (Ford et al. 2002; Hawryluk et al., 
2006; Hom et al., 2007; Busch et al., 2015; Skruzny et al., 2015) by the 
insertion of this helix into the membrane and increasing its fluidity (Lai et al., 
2012; Holkar et al. 2015). This domain also facilitates interactions with other 
adaptors such as Hip1R for its recruitment to the plasma membrane during 
CME (Brady et al., 2010; Lai et al., 2012; Messa et al., 2014; Holkar et al. 
2015). Following the ENTH domain, epsin has 3 ubiquitin-interacting motifs 
(UIM) (Hawryluk et al., 2006) used for internalisation of ubiquitinated 
receptors such as VEGFR2 (Dong et al., 2015) and EGFR (Fortian et al., 
2015).  
 
The middle region of the epsin structure contains two clathrin box motifs 
(LMDLA (starting residue 257) and LVDLD (starting residue 480)) at the C-
terminal end, which have been shown to bind to clathrin heavy chain (CHC) 
and more specifically to the clathrin N-terminal domain (TD) (Drake et al., 
2000). The unstructured central region in between these two boxes contains 
tripeptide motif aspartic acid-proline-tryptophan (DPW) motifs, which have 
also been hypothesized to bind to clathrin independently (Drake et al. 2000; 
Brett et al., 2002; Kalthoff et al., 2002) (Figure 1.6.1). Additionally, the central 
region of epsin with the eight DPW motif structure bind to the a-ear of the 
AP2 and at the β2 –ear with a lower affinity (Drake et al. 2002; Brett et al. 
2002; Dafforn and Smith, 2004; Edeling et al., 2006a). 
 
These two chemically distinct motifs are hypothesized to bind to different 
sites on the clathrin N-terminal domain (Drake et al., 2000). The 
hypothesized sites are: 1(CBM), 2 (W box) and 3 (Arrestin box) and 
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additional binding is likely provided by the multiple DPW motifs (Drake et al., 
2000; Drake and Traub, 2001; Kalthoff et al., 2002; (Collette et al., 2009). 
Therefore, considering the location of the two clathrin binding boxes and the 
unstructured flexible large region in between; it has been hypothesized that 
epsin 1 could be interacting with multiple clathrin triskelia to facilitate efficient 
clathrin assembly (Kalthoff et al., 2002; Dannhauser and Ungewickell, 2012; 
Holkar et al. 2015), which has yet to be confirmed. Following the clathrin box 
motif in the epsin structure, three NPF repeats exist, which are known to 
interact with Eps15 homology domains (Chen et al., 1998; Rosenthal et al., 
1999). 
 
 
 
1.6.2 The role of epsin in CME 
Epsin has been shown to have a fundamental role in endocytosis, as well as 
influencing the size of clathrin-coated vesicles, promoting small cage 
structures in vitro (Kalthoff et al., 2002). This property of epsin has been 
attributed to the location of the two clathrin binding boxes on epsin in 
combination with the flexible unstructured region in between, which could 
stretch and allow binding to different multiple triskelia (Drake et al., 2000; 
Drake and Traub, 2001; Miele et al., 2004). This hypothesis was supported 
Figure 1.6.5: Linear representation of the structure of epsin. At the N-terminal 
there is the ENTH domain (green/white) which interacts with PI(4,5)P2 to promote 
membrane binding and promote membrane curvature and recruits Hip1R; following 
with three ubiquitin-interacting motifs (UIM) (dark green). There are two clathrin 
box motifs at starting residue 257 and 480 (two yellow boxes), which are separated 
by a long and unstructured region, which contains eight DPW motifs (red). At the 
C-terminal there are three NPF motifs (blue), which interact with Eps15 homology 
domains.  
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when one of the two clathrin box motifs were mutated and clathrin was 
unable to assemble on liposomes (Holkar et al., 2015). This led to the 
suggestion that clathrin assembly was successful with the action of both 
epsin clathrin box motifs, but also via this unstructured region between the 
two clathrin binding boxes which facilitates membrane curvature especially 
(Busch et al., 2015). 
 
At the later stages of CME, epsin accumulates at the neck of the CCP 
(Saffarian et al., 2009) and any loss of epsin function, potentially at the 
ENTH domain, results in defects in actin recruitment and Hip1R recruitment 
(Brady et al., 2010), and thus reduction in the maturation of CCPs (Mettlen et 
al. 2009), (Messa et al., 2014). Epsin has also an important role in mitosis, 
where knocking down three epsins in mice resulted in severe division defects 
leading to death of the mice after 4 weeks (Smith and Chircop, 2012; Messa 
et al., 2014). This resulted in accumulation of early U-shaped pits (Messa et 
al., 2014). Epsin is also involved in the synaptic development and plasticity 
(Vanlandingham et al., 2013).  
 
However, the precise location or fate of epsin after completing its role in 
endocytosis and during cage disassembly is still unknown and debatable 
(Chen et al., 1998; Edeling et al., 2006a; Hawryluk et al., 2006; Saffarian et 
al. 2009). It has been suggested that during CCP maturation, epsin would 
migrate to the neck of the CCP as it’s involved with Hip1R functionality to 
elongate the CCP neck (Jakobsson et al., 2008; Mettlen et al., 2009). 
Although, it has been also suggested that epsin could localize at the edges 
and be excluded from the budded clathrin coated vesicle/pit (Drake et al., 
2000; Praefcke et al., 2004; Saffarian et al., 2009), based on observations of 
competition between AP2/clathrin complex and epsin (Edeling et al., 2006a; 
Schmid et al., 2006).  
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1.7.0 Huntingtin-interacting protein 1 (Hip1/Hip1R) 
1.7.1 Structure of Hip1/Hip1R 
Another class of endocytic adaptor homodimer proteins Huntingtin-
interacting protein 1 (HIP1 and HIP1R), yeast homolog of Slap2 which 
contribute to the budding of clathrin-coated vesicles (CCVs), at the later 
stages of CME (Engqvist-Goldstein et al., 2001; Legendre-Guillemin et al., 
2004; Brett et al., 2006; Le Clainche et al., 2007; Wilbur et al., 2008; 
Gottfried et al., 2010). They are associated with other cellular processes 
such as tumorigenesis (e.g. prostate cancer) with the associating of Hip1 
with EGF receptor, transcription regulation and cell death (Hyun et al., 2004; 
Niu and Ybe, 2008; Gottfried et al., 2010; Boettner et al., 2011). 
 
The structures of Hip1 and Hip1R are very similar, with an ANTH domain, a 
coil-coil domain and a talin-like domain. The membrane ANTH binding 
domain at the N terminus binds phospholipids e.g. PI(3,4)P2 (Legendre-
Guillemin et al., 2004; Gottfried et al., 2010). A 2.8 Å structure of the helical 
central domain of the Hip1/Hip1R structure the coiled-coil (CC) domain has 
been shown to promote dimerization of the protein and it has been identified 
to interact with clathrin light chain (CLC), which promotes the formation of the 
clathrin cages in vitro (Ybe et al., 2007; Niu and Ybe, 2008; Ybe et al., 2009). 
This allows the recruitment of Hip1 to the membrane (Hyun et al. 2004; Ybe 
et al., 2009; Gottfried et al., 2010). On the N-terminal domain of Hip1/R, talin-
like domain (THATCH) binds to the F-actin, however this interaction is 
blocked and regulated by the C-terminus of upstream helix (USH) when the 
Hip1/R CC interacts with the CLC (Brett et al., 2006). This caused the 
regions to fold back forming ‘dumbbell’ (Engqvist-Goldstein et al., 2001; 
Brodsky, 2012). 
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1.7.2 Major differences between Hip1 and Hip1R 
Hip1 has a clathrin box motif (LMDMD), which binds to clathrin N-terminal 
domain, and FXDXF and DPF motifs (X denotes any amino acid) bind to the 
AP2 complex (α-adaptin) (Mishra et al., 2001; Legendre-Guillemin et al., 
2002; Chen and Brodsky, 2005; Hyun et al., 2004; Ybe et al., 2009). More 
interestingly, Hip1 CC was demonstrated to interact with CHC via a proposed 
motif of VDLE, which was suggested by Waelter et al., 2001 (Waelter et al., 
2001). Whereas Hip1R has been shown to bind weakly to clathrin N-terminal 
domain compared to Hip1 (Legendre- Guillemin et al., 2002; Hyun et al., 
2004). The role of Hip1R is the control of actin polymerization and 
organization as it interacts with cortactin via a C-terminal proline rich domain 
(PRD) in the talin-like domain (Le Clainche et al., 2007).  
 
1.8.0 β -arrestin 
There are four small gene families in vertebrates, which have multifunctional 
roles. These are visual arrestins (arrestin 1 and 4) expressed in rods and 
cones, non-visual arrestins (β-arrestin 1/arrestin 2 and β-arrestin 2/arrestin 
3) which are ubiquitously expressed in mammalian cells, cone arrestins (X-
arrestins), α-arrestins (Gurevich, 2014). However, for the purpose of this 
project, I focused on the β-arrestin 1 (non-visual). 
 
1.8.1 Structure of β-arrestin 1 
A 1.9 Å resolution crystal structure of inactive β-arrestin 1 by Han et al., 2001 
and Milano et al., 2002 revealed that the unbound/inactive β-arrestin 1 has a 
ribbon–like elongated structure divided into two domains; the C-terminus and 
the N-terminus composed entirely of anti-parallel β-sheets connected by a 
12-residue linker (hinge) region (Han et al., 2001; Milano et al., 2002) These 
two domains are separated by a polar core (hydrogen bonded network of 
charged residues) at its’ centre and has one short α-helix at the back of the 
N-terminal domain. β-arrestin 1 has two concave pocket sites for receptor 
interaction at a cationic amphipathic helix and allows high-affinity binding (N-
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terminus site) with the ligand activated- GPCR. Phosphatidylinositol 4,5-
bisphosphate (PIP2) also play an important role in delivering the receptor–
arrestin complex to CCPs (Figure 1.8.1) (Han et al., 2001; Milano et al., 
2002) The high-affinity phosphoinositide-binding site is located in the C-
terminal domain (Gurevich, 2014). 
 
The convex sides allow docking of other proteins such as clathrin and β2-
adaptin required for endocytic receptor internalization. Both β-arrestin 1S 
(shorter isoform) and β-arrestin 1L (longer isoform) bind to the to clathrin 
terminal domain (TD) β-propeller blades 1 and 2 by hydrophobic interactions 
via a LIELD (LØXØ[DE]) single letter amino acid code where Ø represents a 
hydrophobic residue) clathrin-box motif (residues 357-383) with a KD of 10-
60 nM (Goodman et al., 1997; Kang et al., 2009). The β-arrestin 1L LIELD 
clathrin box motif deleted still binds to clathrin TD (N-terminal domain, 
residues 1-363) regions upon agonist treatment (Lefkowitz et al. 2006; Kang 
et al., 2009; Lemmon and Traub, 2012; Kang et al., 2015; Gurevich, 2014). 
The eight-amino acid β-arrestin 1L splice loop has also been proposed to 
bind to a shallow hydrophobic groove in blades 4 and 5 of clathrin TD at a 
different clathrin box motif ([LI][LI]GXL) (Kang et al., 2009). Kang et al., 2009 
proposed that β-arrestin 1L effectively localizes to CCPs even in the absence 
of the conserved clathrin box motif, thus demonstrating that the eight- amino 
acid splice loop can mediate arrestin redistribution to CCPs (Kang et al., 
2009). Each clathrin box motif is independent and that is functionally relevant 
in CCPs, but the second clathrin box motif having a low affinity for clathrin 
(Kang et al., 2009). A 2:1 β-arrestin 1L to clathrin stoichiometry was 
observed in the crystal structure but this was hypothesized to be different in 
cells as a number of loops on opposing β-arrestin 1L domains are disordered 
and were not clearly defined (Kang et al., 2009).  
 
It has also been shown that β2-adaptin, a subunit of AP2 complex, also 
binds to β-arrestins (Ferguson, 2001; (Keyel et al., 2008). In 2000, Laporte et 
al., proved the binding of specific arginine residues (Arg 394 and Arg 396) in 
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the C-terminus of β-arrestin 1L in vitro to AP2 was independent of clathrin 
binding (Laporte et al., 2000), and residues Glu 849 and Glu 902 in β2-
adaptin (AP2) interact with β-arrestin (Laporte et al., 2002). More specifically, 
the isoleucine-valine-phenylalanine (IVF) motif of the C-terminal tail of β-
arrestin has been confirmed to be the key motif for its interaction with AP2 
(Burtey et al., 2007). The F residue of the IVF motif is stated to be 
responsible for the AP2 binding, with the I and V residues, enhancing the 
affinity for AP2 (Edeling et al., 2006; Burtey et al., 2007). 
 
 
 
 
 
 
 
 
 
Figure 1.8.1: Structure of inactive β-arrestin 1L. The structure illustrates the N- 
and C- domains, the polar core, the two GPCR receptor binding sites (concave 
sites) with high affinity binding at the C-terminal end, phosphoinositol (PIP2, PIP3, 
IP6) binding site, two clathrin binding sites which are exposed for binding when the 
ribbon-like shape of inactive β-arrestin 1 becomes active clamp-shell structure (not 
shown here) and β2- adaptin binding site on the N-domain. Protein structure was 
produced using the PDB 1G4M (Han et al., 2001) and displayed using UCSF 
Chimera (Chimera (Pettersen et al., 2004). 
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1.8.2 Function of β -arrestin 1 in endocytosis 
β-arrestin 1 is a multifunctional protein involved in the “turning-off” 
(desensitization) and uncoupling of GPCRs from G-proteins causing loss of 
responsiveness of the receptor to ongoing stimulus (Lefkowitz et al., 2006; 
(Kang et al., 2009; Lemmon and Traub, 2012; Kang et al., 2015; Gurevich, 
2014). The desensitized receptor is then recycled through the process of 
receptor internalization. β-arrestin 1 internalization involves the interaction 
with both cargo and clathrin. Initially, β-arrestin 1 binds to the phosphorylated 
GPCR (Kang et al., 2009; Lemmon & Traub, 2012; Shukla et al., 2013; 
Shukla et al., 2014). This interaction allows the β-arrestin 1 conformational to 
change to an “open” conformation exposing clathrin binding sites, which are 
hidden in a “closed” β-arrestin 1 conformation. This internalization occurs via 
clathrin coated pit (CCP) machinery (Figure 1.8.2). Its main role in CME is to 
recruit clathrin and other vital adaptors, such as β2-adaptin (AP2), to the 
plasma membrane to facilitate receptor internalization (Kang et al., 2009; 
Gurevich, 2014; Goodman et al., 1997). However, AP2 and clathrin are not 
sufficient individually for CCP targeting and thus both need to be present and 
cooperate for this function (Burtey et al., 2007). Lastly, it acts as scaffold 
protein (signaling intermediates) to initiate a signaling cascade by the 
mitogen-activated signaling pathways (MAPK 1/3, ERK 1/2, Src etc) for 
downstream signaling and generation of endocytic vesicles (“signalosomes”), 
which result in ERK1/2 activation via the β-arrestin 1 scaffolding action 
(Lefkowitz et al., 2006; Shenoy and Lefkowitz, 2011; Smith and Rajagopal, 
2016; Kumari et al., 2016). 
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1.8.3 Transition: “inactive” to “active” β-arrestin 1 state 
β-arrestin 1 adopts an inactive (ribbon shape) ‘closed’ cytoplasmic form in 
the cytoplasm with its polar core stabilized by an extended C-terminal tail. 
This tail locks β-arrestin 1 into an inactive state (Laporte et al., 2000). Upon 
agonist-GPCR interaction, G-protein association with the receptor triggers 
GRKinase recruitment to the plasma membrane for phosphorylation of the 
receptor C-tail. This recruits β-arrestin 1 to the surface allowing it to bind in a 
biphasic manner, at the tail and the core of the GPCR (class A and B 
GPCRs) (Shukla et al., 2014). After β-arrestin 1 binds to these sites it 
Figure 1.8.2: Diagram representing GPCR internalization via CME with the aid 
of β-arrestin. Ligand binds to the GPCR causing G-protein binding to the receptor 
resulting to Gα and Gβγ dissociation. The receptor activation promotes GRKinases 
(GRK) binding to mediate phosphorylation within the third intracellular loop domain 
or the C-terminal tail of the GPCR. The β-arrestin 1L will then localize near the 
plasma surface and associate with the ‘receptor tail and core’ causing its 
conformational change into active/open conformation, exposing/unmasking its 
LIELD clathrin binding site (loop) and β2-adaptin site in the N-terminal end for 
binding, which would allow recruitment of clathrin at the plasma surface and 
assembly to clathrin cages (action of β2-adaptin and other accessory proteins) to 
form GPCR-β-arrestin 1L complex and promote receptor internalization. 
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changes its conformation (polar region rotation, residues Arg169 and 
Asp290) to an active ‘open’ state (clam-shell shape) upon binding to those 
phosphate group regions, with a ~ 20 o inter-domain rotation between the 
amino and carboxyl domains (Yang et al., 2015; Kang et al., 2015) and the 
breakage of the polar core (Scheerer and Sommer, 2017). The β-arrestin 1 
remains active and at the cell surface performing other independent cell 
signaling/trafficking roles after dissociation from the receptor (Nuber et al., 
2016).  
1.8.4 GPCR "
GPCRs are composed of seven-transmembrane helices in the plasma 
membrane and represent by far the largest, most versatile family of plasma 
membrane due to their importance in drug development (~ 60% of prescribed 
drugs targeted to these receptors) (Ladds et al., 2005).  
 
 1.8.5 Vasopressin type 2 GPCR 
The structural organisation of type 2 Vasopressin GPCR is currently 
undetermined and has been of great interest in the GPCR community due to 
its role in renal kidney homeostasis and diabetes insipidus (Birnbaumer, 
2000). There are over 150 mutations of the V2R, which have been identified 
resulting in congenital nephrogenic diabetes insipidus (cNDI) (Birnbaumer, 
2000). This condition causes improper water reabsorption by kidneys, as the 
mutated V2R does not respond to vasopressin appropriately because the 
miss-folded receptor limits its expression on the cell membrane. This 
disorder has extensive complications such as dehydration, and the drugs 
available are considered toxic (Gastrointestinal NSAID toxicity) causing 
gastric bleeding (Birnbaumer, 2000). Class B GPCRs, such as V2R, form a 
complex with β- arrestin and remain tightly bound to β- arrestin upon 
internalisation with a slower recycling rate (60 minutes) compared to other 
GPCRs (Terrillon et al., 2004; Lefkowitz et al., 2006; Thomsen et al., 2016; 
Suleymanova et al., 2017). Additionally, GRK- mediated phosphorylation of 
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V2R and consequent β–arrestin recruitment are due to GRK 2 and GRK 3 
(Ren et al., 2005; Yang et al., 2015).  
 
Shukla et al., 2013 obtained a 2.6 Å crystal structure of activated β-arrestin 
1-human V2Rpp (29-amino acid C-terminal peptide)-Fab30 (antigen binding 
fragments) complex, which provides novel insight into the mechanism of the 
receptor-mediated β-arrestin 1 activation (Shukla et al., 2013). The following 
year, Shukla et al., 2014 visualized β-arrestin recruitment by β2-adrenergic 
receptor with its C terminus replaced with that of arginine vasopressin 2 
receptor (AVV2) using the single particle negative stain EM imaging 
technique. They published a 29 Å model of β2V2R –β-arrestin 1-Fab30 
complex, from 3D negative stain computational reconstruction (Shukla et al. 
2014). According to Shukla et al., 2014, this model confirms that β2V2R can 
activate β-arrestin 1 entirely (confirmation with clathrin pull-down assays) 
and suggested the biophasic mechanism of β- arrestin to engage with the 
receptor (Shukla et al., 2014). The biphasic interaction of β-arrestin 1 with 
the ‘receptor tail and core’ causes the formation of two GPCR/ β-arrestin 1 
conformations, which have been shown to perform distinct functionality 
(Shukla et al., 2014), (Ranjan et al., 2017). The biphasic mechanism is 
divided into two steps, the ‘low-affinity pre-complex’ formation between the β-
arrestin 1 and the receptor C-tail, and then a high affinity complex if formed 
once the β-arrestin 1 binds to the receptor core (Shukla et al., 2014; Ranjan 
et al., 2017; Scheerer and Sommer, 2017). The complex with ‘receptor tail’ 
formed can internalize the GPCR but does not ‘turn off’ the G-protein 
signaling pathway (Thomsen et al., 2016; Cahill et al., 2017).  
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1.9.0 Clathrin disassembly adaptor proteins 
Separation of the clathrin-adaptor coat is important in order to allow the 
clathrin and adaptors to be recycled and be used for the next endocytosis 
process. The vesicle can then be targeted to the appropriate organelle.  This 
process in CME is mediated by the interactions of different adaptor 
proteins/chaperones such as Hsc70 chaperone, which interacts with its co-
chaperone auxilin or GAK (auxilin2) (Greener et al., 2000; Umeda et al. 
2000; Zhang et al., 2005). Auxilin/GAK bind to clathrin and recruits the Hsc70 
under the clathrin hub domain where it binds to a QLMLT motif on the 
clathrin C-terminus (Ahle and Ungewickell, 1990; Ungewickell et al., 1995; 
Rapoport et al., 2008; Xing et al. 2010). ATP hydrolysis to ADP in Hsc70 
stimulated by the J-domain of auxilin/GAK induces tight binding to clathrin, 
which destabilises triskelia interactions through a collision-induced 
mechanism (Sousa et al., 2016) (Figure 1.9.0). 
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Figure 1.9.0: Diagram illustrating the steps of clathrin cage disassembly by 
the action of auxilin and Hsc70 recruited to the clathrin trimerisation domain. 
Auxilin (red) is recruited through the terminal domain-leg interactions (blue) under 
the hub, which contains the unstructured C-terminal tails containing the Hsc70 
binding motif (orange), which allows the recruitment of Hsc70 (green). Hsc70 is 
tightly bound to the clathrin due to the ATP hydrolysis carried out by the J-domain. 
This causes the disassembly of the clathrin to be recycled, and once the ATP 
regenerated ADP+Pi, auxilin is removed from clathrin and recycled as well. Image 
adapted from (Xing et al., 2010). 
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1.9.1 Structure and function of auxilin 1 
The auxilin 1 adaptor protein has a unique structure of 100 kDa that allows 
the interaction of chaperones, assembled clathrin and lipids, and is involved 
in the clathrin disassembly process along with Hsc70 chaperone (Fotin et al. 
2004; Young et al., 2013; Xing et al., 2010).  The J-domain allows auxilin 1 to 
interact with Hsc70 and recruit it to clathrin. The N-terminal domain of auxilin 
1 has a phosphopeptide phosphatase homology domain (PTEN) that binds 
to lipids (e.g. PIP2) (Massol et al., 2006). Importantly, auxilin 1 interacts with 
AP1 and AP2 complex (μ2 subunit), dynamin and clathrin (Umeda et al., 
2000). Auxilin has several binding sites for clathrin via a range of motifs 
including DLL and DPF (Scheele et al., 2001; Scheele et al., 2003). More 
specifically, the DPF motifs bind to both the CHC and the ear domain of α-
adaptin in AP2 and DLL motifs bind to clathrin (Scheele et al., 2001). 
In addition, auxilin contains a clathrin binding box ‘LLGLE’ motif (residues 
495-500), which allows the interaction with the clathrin N-terminal domain 
and the clathrin ‘leg’ (Smith et al., 2004). One auxilin molecule per triskelion 
is optimal for Hsc70 ATP hydrolysis and for the maximal rate of cage 
disassembly (Holstein et al., 1996) Clathrin/auxilin binding causes the N- 
terminal domains on clathrin to twist outwards, thus causing change in the 
position of the ‘ankle’ (Fotin et al., 2004). This causes an increase in the 
diameter of the entire lattice leading to a global distortion of the clathrin coat 
(Popova and Petrenko, 2013). But, assembled clathrin can be disassembled 
even when auxilin does not bind to the clathrin N-terminal domain directly 
(Ungewickell et al., 1995), as auxilin binds to multiple sites on the clathrin leg 
(Edeling et al., 2006b; Young et al., 2013)  (Figure 1.9.1).  However, auxilin 
alone is not sufficient to initiate clathrin coat disassembly, it needs the aid of 
Hsc70 ATP hydrolysis, as auxilin alone can in fact promote clathrin assembly 
in vitro (Holstein et al., 1996; Scheele et al., 2003). On the other hand, the 
role of auxilin as a disassembly adaptor protein has an additional important 
aspect, which involves the ability of auxilin to discriminate between free and 
polymerized clathrin triskelia via its multiple low affinity interactions with the 
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clathrin TD and α-appendage domain of AP2 complex, which are 
hypothesized to have competition for auxilin 1 binding (Scheele et al., 2001).  
Whilst CHC are very important in the disassembly process, CLC have been 
stated to be important for the dissociation and recycling of auxilin after the 
completion of the disassembly process, as removal of CLCs has been shown 
to affect the catalytic mechanism (Young et al., 2013). In yeast, the CCVs 
accumulate more when in an auxilin depleted environment in vivo (Pichvaee 
et al., 2000). Therefore, the onset of uncoating is based on the timing of 
auxilin burst, but Hannan et al., 1998 stated that the uncoating process 
(clathrin, auxilin/GAK and Hsc70) does not remove adaptor proteins, AP2 
from coated vesicles in vitro (Hannan et al., 1998).  Interestingly, auxilin is 
recruited transiently in small amounts during the endocytosis process with 
the larger burst occurring after the peak of dynamin signal in vesicle budding, 
where the PTEN domain interacts with PIP(4) recruiting auxilin to the coat to 
begin uncoating (Massol et al., 2006; Taylor et al., 2011). 
 
Figure 1.9.1: Representing auxilin: 
CHC domain interaction locations. 
An α-carbon map of a single CHC leg 
with the colours representing each 
segment individually in the box below 
the figure. A linear representation of 
auxilin structure, demonstrating the 
auxilin clathrin box motif (LLGLE) at a 
starting residue 495. The clathrin 
binging domain (CBD) of auxilin binds 
at the distal region, with other clathrin 
binding domains (e.g. DLL motifs). The 
PTEN domain binds to the membrane 
and the J-domain interacts with the 
Hsc70 chaperone (linear representation 
in green). The Hsc70 substrate binding 
domain motif on clathrin (QLMLT)  
found under the trimerisation domain at 
clathrin C-terminus. Abbreviations: 
nucleotide-binding domain (NBD), 
substrate-binding domain (SBD) and C-
terminal domain (CTD). Image adapted 
from (Edeling et al., 2006b). 
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1.11.0 Overall aim and objectives of this investigation 
Despite the large amount of research dedicated to understand the roles that 
some adaptor proteins play at different stages of endocytosis, we still do not 
understand the manner in which some adaptors interact with clathrin or the 
molecular details of their interactions with one another. Therefore, using 
purified adaptor proteins, clathrin cages/clathrin TD, I tried to address the 
above questions using variety of biophysical and structural techniques, in 
vitro: 
 
1. To carry out optimization to obtain optimal buffer/pH conditions for the 
binding interaction between whole clathrin cages and clathrin TD with 
active β-arrestin 1L in vitro. Furthermore, explore the buffer/pH 
conditions for clathrin cages assembled with epsin 1 and β-arrestin 1L 
individually and in combination with SDS-PAGE binding assays and 
negative stain electron microscopy (EM). 
 
2. β-arrestin 1L mutagenesis studies, SDS-PAGE binding assays and 
surface plasmon resonance (SPR) were used to investigate: 
 
I. Whether the two clathrin box motifs on β-arrestin 1L act 
synergistically or antagonistically. This will enhance our 
knowledge from the work of Kang et al., 2009 (Kang et al., 
2009). 
II. To confirm the functionality of the optimized SPR/IAC system 
relative to aim number 3. 
III. How the second clathrin box of β-arrestin 1L and the 
hypothesised linking effect of multiple TDs that active β-arrestin 
1L could promote, could interfere with the interaction of other 
adaptor proteins for clathrin TD binding. 
 
3. Despite the large amount of research dedicated to understand the 
CME, we are still unclear how clathrin assembly and disassembly 
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adaptor protein sequence takes place and how the adaptors co-exist. 
Therefore, I aimed to further understand how the unique structure of 
epsin 1, one of the main assembly proteins, binds to clathrin forming 
uniform clathrin cages (Kalthoff et al., 2002). In order to address this 
aim I used mutagenesis studies of the whole protein epsin 1 (clathrin 
box motifs and unstructured/DPW region). To explore the binding 
events between clathrin TD and epsin 1 mutants, I used the SPR/IAC 
method, which I optimized for epsin 1 whole proteins in this thesis. 
 
4. As there are numerous potential clathrin-adaptor protein interactions 
during the different stages of the endocytosis, this raises the question 
of whether some adaptor proteins compete for binding to clathrin or 
whether some adaptor proteins can bind to clathrin simultaneously.  I 
aimed to address these questions using ultracentrifugation/GST-
pulldown binding assays and a newly developed SPR/IAC (2-injection) 
method. Intially, well-characterised adaptor proteins known to play a 
significant role in clathrin-mediated endocytosis would be investgated. 
These are β2-adaptin, epsin 1, auxilin 1 and β-arrestin 1L, 
Hip1CC/Hip1RCC. It was hypothesised that these adaptor proteins 
bind to multiple sites on the clathrin TD, as they have one or more 
similar clathrin box motifs. Different adaptor protein peptide ligands 
have been shown to bind to one or more of these sites simultaneously 
(Muenzner et al., 2017). Alternatively, the affinity and number of 
clathrin binding sites could allow one adaptor protein to displace 
another from the clathrin TD, influencing the progress of clathrin CCV 
(Zhuo et al., 2015). Therefore, our hypothesis was that both 
competition and simultaneous binding play a role in the engagement 
of different adaptor protein combinations to clathrin TD. This 
hypothesis was investigated using the SPR/IAC (2-injection) system.  
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Chapter 2:  
Materials and Methods 
 
2.0.0 Overview   
This is an overview chapter including the methods and materials used in 
each experiment carried out in my project. Any changes to protocols, that are 
specific to a particular chapter will be documented in the relevant chapters. 
 
2.1.0 Materials and Reagents  
All the companies that supplied the chemicals, reagents and materials are 
listed below: 
Abcam (UK): Prism Ultra Protein Ladder (10-245 kDa) 
Affymetrix (USA): 2-(N-morpholino)ethanesulfonic acid monohydrate (MES)  
Agar Scientific (UK): Formvar/Carbon 300 mesh copper grids   
AGTC Alfa Aesar (USA): Manganese chloride  
AMRESCO (USA): Hepes free acid  
Applichem Lifesciences (USA): Dithiothreitol (DTT), sodium dodecyl sulphate 
(SDS)  
Biological Industries (USA): EZ-ECL Chemiluminescence Detection Kit for 
HRP 
Biacore (Slovakia): Surface Plasmon Resonance 2000 instrument 
Bioproducts Ltd. (UK): Agarose  
Bio-Rad (USA): Hydroxyapatite Bio-Gel HG Ge 
Cell Signaling (USA): His-Tag (27E8) Mouse mAb, GST (26H1) Mouse 
mAb,Anti-mouse IgG HRP-linked Antibody. 
Expedeon (UK): Instant Blue  
First Link Ltd. (UK): Porcine brain  
Fisher Scientific (UK): Ammonium sulphate, glycerol, magnesium acetate 
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tetrahydrate, nitric acid, potassium acetate, potassium chloride, potassium 
phosphate dihydrate, potassium phosphate monohydrate, sodium chloride, 
sodium hydroxide 
GE Healthcare (USA): ECL Western Blotting Detection Reagents, Ficoll
™  
PM70, Glutathione sepharose 4B, GSTrap™FF column, HiLoad 26/600 
Superdex 200 pg column, HiPrep 26/60 Sephacryl S-500 HR, HWM-SDS 
Marker Kit, Hybond TM-P PVDF membrane, L WM-SDS Marker Kit, 
PreScission Protease, XK 16/100 Superdex 75 column, Sensor Chip CM5, 
Rubber Caps and Plastic Vials, o.d. 7 mm, amine coupling kit. 
Life Technologies (USA): NuPAGE Transfer Buffer (x20) 
Melford Laboratories Ltd. (UK): Isopropyl β-D-1-thiogalactopyranoside 
(IPTG)  
Medicell Membranes Ltd. (UK): visking dialysis tubing 19 mm 12-14 kDa cut-
off  
National Diagnostics (USA): 30% w/v Accugel acrylamide (acrylamide 29:1 
bis- acrylamide)  
New England Bioscience (USA): 10x NEB buffer, Gel loading dye (6x)  
PanReac AppliChem (USA): 4-(2-Aminoethyl) benzenesulfonyl fluoride 
hydrochloride (AEBSF), Color Protein Standard Broad Range (P77125) 
Parr Instrument Company (USA): Nitrogen Cavitation Vessel 
Premier International Foods (UK): Marvel Milk Powder  
Qiagen (Germany): QIAprep Spin Miniprep Kit  
Roche Diagnostics Ltd. (Switzerland): c0mplete HisTrap, c0mplete Protease 
Inhibitor Tablets  
Sartorius Stedim (Germany): Vivaspin 20 centrifugal concentrators  
Sigma-Aldrich (UK): Ammonium per sulphate (APS), ampicilin, β2-
mercaptoethanol (βME), bovine serum albumin (BSA), chloramphenicol, 
dimethyl sulphoxide (DMSO), ethylene-diamine-tetraacetic acid (EDTA), 
ethylene-glycol-bis(β aminoethyl ether)-tetraacetic acid (EGTA), glutathione 
(GSH), glycine, hydrochloric acid, imidazole, kanamycin, magnesium chloride 
hexahydrate, rubidium chloride, sucrose, triethylamine (TEA), tetra-methyl-
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ethylene-diamine (TEMED), thrombin, Tris-HCl, Monoclonal Anti-Glutathione-
S-Transferase (GST) antibody produced in mouse (G1160), Tris(2-
carboxyethyl) phosphine hydrochloride (TCEP) 
SPI-Supplies (USA): Uranyl acetate  
Thermo Scientific (USA): Pierce BCA Protein Assay Reagents, Slide-A-Lyzer 
MINI Dialysis Units 7000 MWCO  
VWR Chemicals (UK): bromophenol blue, ethanol, methanol  
Whatmann (UK): 3 mm filter paper 0.2 ìm, blotting paper  
 
2.2.0 Buffers and gel compositions 
Buffer Name Ingredients pH 
β-arrestin 1L WT and mutants purification and GST-TD 
CB1 10mM Tris-HCL, 150 mM NaCl, 1 mM EDTA, 
2mM DTT 
8.0 
GSH elution buffer 
CB1 
20 mM Tsi-HCL, 150 mM NaCl, 1mM EDTA, 
2mM DTT, 10 mM GSH 
7.2 
Analytical experiments 
HKM 
 
25 mM Hepes, 125 mM Potassium acetate, 5 
mM Magnesium acetate 
6.4 7.0 
7.2 
 
Surface plasmon resonance experiments 
Antibody 
immobilization buffer 
10mM Sodium Acetate 5.5 
SPR Buffer 1 10mM HEPES, 150mM NaCl, 1mM TCEP, 3 mM 
EDTA, 0.05% Tween 20 
7.4 
 39 
SPR Buffer 2 10mM HEPES, 500mM NaCl, 1mM TCEP, 3 mM 
EDTA, 0.05% Tween 20 
7.4 
 
For GST- auxilin401-910  and GST-β2 adaptin695-983 purification 
Buffer A 
 
20 mM Hepes, 200 mM NaCl 7.2 
GSH elution buffer A 
 
20 mM Hepes, 200 mM NaCl, 10 mM GSH 7.0 
His6 -epsin1 WT/mutants and Hip1/R purification 
Buffer B 50 mM Tris, 500 mM NaCl 7.9 
Imidazole washing 
buffer 
50 mM Tris, 500 mM NaCl, 20 mM imidazole 7.9 
Imidazole elution 
buffer 
50 mM Tris, 500 mM NaCl, 200 mM imidazole 
 
7.9 
SDS PAGE gel 
4% SDS PAGE 
stacking mix 
 
150 mM Tris, 4% acrylamide - 29% acylamide, 
1%bis-acrylamide, 0.12% SDS 
6.8 
12% SDS PAGE 
resolving mix 
 
250 mM Tris HCl, 12% acylamide - 29% 
acylamide, 1%bis-acrylamide, 0.12% SDS 
8.8 
Loading dye 
 
250 mM Tris-HCl, 5 % w/v SDS, 25 % w/v 
glycerol, 50 mM DTT, 4 % w/v β-
6.8 
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mercaptoethanol, 0.05 % w/v Bromophenol blue 
 
clathrin purification 
Depolymerisation 
buffer (DEPOL) 
 
20 mM TEA, 1 mM EDTA, 1 mM DTT  
 
8.0 
Saturated 
Ammonium Sulphate 
770g ammonium sulphate, 10mM Tris, 0.1 mM 
EDTA 
7.1 
2 x 1M Tris 0.1 M Tris base, 1.9M Tris-HCL, 2mM EDTA, 
2mM DTT 
7.1 
6.25% Ficoll/6.25% 
sucrose 
 
0.0625 g/ml Ficoll PM70, 0.0625 g/ml sucrose, 
25 mM Hepes, 125 mM Potassium acetate, 5 
mM Magnesium acetate 
 
Polymerisation 
buffer (POL) 
100 mM MES, 1.5 mM MgCl2 , 200 mM EGTA 6.4 
 
competent cells 
TFB1 
 
30 mM potassium acetate, 10 mM calcium 
chloride, 50 mM manganese chloride, 100 mM 
rubidium chloride, 15 % w/v glycerol 
5.8 
TFB2 
 
10 mM MOPS, 75 mM calcium chloride, 10 mM 
rubidium chloride, 15 % w/v glycerol 
5.8 
Western Blot 
Transfer Buffer  25 mM Tris 190 mM glycine and 20% methanol  - 
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TBS-Tween 20 mM Tris and 150 mM NaCl and 0.1% Tween 
20  
- 
5% milk 5g Milk powder in 100ml of TBS-Tween - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.0.0: Buffer components and gel mixture components used in this thesis 
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2.3.0 Expression DNA constructs  
The Table 1.1.0 below documents all the DNA constructs used in this thesis 
for expression of recombinant proteins in E.coli or insect cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.0 Generation of β-arrestin 1L and epsin 1 mutants  
The mutagenesis described in this section was conducted by GenScript (NJ, 
USA) who provide a commercial cloning and mutagenisis service. 
 
 
 
 
 
Construct Description Source Reference 
    
pGEX4T2-  β2 
adaptinHA 
pGEX4T2 + GST- 
β2695-983   
David Owen 
(Bristol) 
Owen et al., 
2000 
pGEX6P3-β-
arrestin 1L 
pGEX6P3 + GST- β 
-arrestin 1L1-418 
- Keyel et al., 
2008 
pGEX4T2- TD pGEX4T2 + GST-
TD1-363 
Owen (MRC) Smith et al., 
2004 
pGEX4T2-β2HA pGEX4T2 + GST- 
β2 adaptin616-951  
Owen et al. 2000  
 
David Owen 
(CIMR)  
 
ET32c-epsin 1 ET32c +
thioredoxi -His6 - 
epsin11-575  
Ernst Ungewickell 
(Hannover Medical 
School)  
K lthoff et al.,
2002  
pGEX4T2- auxilin 
 
pGEX4T2   
GST- auxilin401-910 
Helen Kent (MRC 
LMB) 
Smith et al. 2004 
pETDuet-1- 
mHip1RCC 
 
pETDuet-1 + His6- 
mHip1RCC346-655 
Frances Brodsky 
(UCL) 
Wilbur et al., 
2008 
pETDuet-1- Hip1cc  pETDuet-1 + His6- 
Hip1346-637 
Frances Brodsky 
(UCL) 
Wilbur et al., 
2008 
GST tag pGEX6P3 - - 
Table 1.1.0 Details of DNA constructs for expression of recombinant 
proteins in E.coli. 
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2.4.1 β-arrestin 1L 
Design of the mutations to β-arrestin 1L clathrin-binding motifs was 
conducted with reference to Keyel et al., 2008. The following mutants were 
designed using a pGEX6P3 plasmid with numbers indicating the first residue 
of each motif:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name Original motif -> mutated motif and/or deletions 
Active (IVF) 386IVF->AAF 
IVF-ΔCB 386IVF -> AAF + 376clathrin box deleted 
WT-ΔCB WT + 376clathrin box deleted 
IVF-AAEA 386IVF + 
376
clathrin box (LIEL->AAEA)   
WT-AAEA WT + 376clathrin box (LIEL ->AAEA)   
Table 1.2.0: Description of all the GST-β-arrestin 1L mutants. 
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2.4.2 Epsin 1 
Generation of epsin 1 clathrin box motif mutants (257, 480 and DKO) were 
conducted in line with reference to Drake et al., 2000. The ½ DPW, ¼ DPW 
and ΔDPW mutants were generated by the Smith’s Group. The following 
mutants were generated from the base pET32c-epsin 1 construct with 
numbers indicating the first residue of each motif in epsin 1.  
 
 
1) Alaline substitution of the clathrin box motifs in epsin 1 
Name Original motif-> mutated to 
257 LMDLA -> AAAAA 
480 LVDLD -> AAAAA 
DKO LMDLA -> AAAAA and LVDLD -> AAAAA 
2) Shortening/Deletion of unstructured region (containing DPW 
motifs) of epsin 1 
Name Residue deletions 
½ DPW At 123rd residue we cut out 93 AAs – approx. half of 
the DPW unstructured region 
1/4th DPW At 63rd residue – cut out 60 AAs- approximately 1/4th of 
the DPW unstructured region 
ΔDPW deletion of the whole unstructured region keeping 7 
AAs between the two clathrin box motifs 
Table 1.3.0: Description of all His6-epsin 1 mutants. These mutations are 
carried out in reference from Drake et al., 2000 and the mutagenisis was 
conducted from GenScript (NJ, USA). 
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2.5.0 Cell lines  
2.5.1 E.coli cell lines for protein expression 
 2.5.2 Generation of chemically competent E.coli cells  
The chemically competent BL21 (DE3) cells were transformed on LB-agar 
plate and a single colony was inoculate 5 ml of LB (10 g/l NaCl, 10 g/L 
bactotryptone and 5 g/l yeast extract) which was in turn grown overnight at 
37°C. The 5 ml culture was then used to inoculate 250 ml of LB 
supplemented with 20 mM MgSO4 and grown whilst shaking at 180 rpm at 
37°C until OD600 reached 0.4-0.6. Cells were harvested at 4500 x g for 5 
minutes at 4°C. 100 ml of TFB1 buffer was then used to re-suspend the cell 
pellet chilled on ice, with a further incubation of the cell suspension on ice for 
5 minutes. The cells were then pelleted again as described previously. 10 ml 
of TFB2 was used to re-suspend the final cell pellet on ice and incubated for 
1 hour. Finally, the cells were aliquoted into 50-100 μl aliquots and snap 
frozen in dry ice/ liquid nitrogen. Aliquots were stored at -80°C.  
Strain Genomic information 
BL21 (DE3)  
 
huA2 [lon], ompT gal, (λ DE3) [dcm], ∆hsdS λ DE3 = 
λ sBamHIo, ∆EcoRI-B int::(lacI::PlacUV5::T7 
gene1), i21 ∆nin5  
MAX Efficiency® 
DH10BacTM   
 
F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80dlacZ∆M15 
lacX74 recA1 endA1 araD139 ∆(ara- leu)7697 galU 
galK rpsL nupG λ- tonA (confers resistance to phage 
T1)  
Table 1.4.0: The E.coli strains and their genetic propertied which have been 
used in this thesis 
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2.5.3 Purification of plasmid DNA from E.coli  
Purification of plasmid DNA from E.coli was conducted from 5 mL of 
overnight culture using the QIAprep Spin Miniprep Kit (Qiagen) following 
manufacturers instructions.  
2.6.0 Protein expression and purification  
2.6.1 Transformation of plasmid DNA 
An aliquot of 50 μl of competent E.coli cells were defrosted on ice before the 
addition of 100 ng of plasmid DNA of each protein and incubation on ice for 
20 minutes. The reaction was stopped when the cells were heat shock in a 
42°C water bath for 30 seconds and incubated on ice for a further 5 minutes. 
450 μl of SOC media was added to the competent cells and incubated at 
37°C for 30 minutes at a 250 rpm speed. The cell suspensions were 
streaked onto LB-agar plates inoculated with an antibiotic appropriate to the 
strain and plasmid (e.g. ampicillin 100 μg/ml) at 20 μl and 100 μl dilution. 
Plates were incubated overnight at 37oC to allow colonies to grow.  
2.6.2 Clathrin purification  
Clathrin purification protocol was adapted from Rothnie et al. 2011 (Rothnie 
et al. 2011). Clathrin triskelia were purified from clathrin-coated vesicles 
extracted from eight frozen (liquid N2) pig brains (approximately 600g) by 
differential centrifugation and gel filtration. The first step involves 
homogenizing the brains in a blender with HKM buffer with a protease 
inhibitor tablet. Following a low-speed spin at 12 000 × g for 30 min at 4°C, 
the supernatant of this is then ultracentrifuged at 140 000 × g, 45 min, 4 °C, 
to pellet lipid membrane components. This step was repeated to form 
‘double’ pellet depending on the volume of supernatant in each prep. 
The ‘double’ pellets were re-suspended in approximately 50 ml of buffer 1 
and homogenized (>20 strokes). In order to isolate CCV need to remain in 
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the supernatant, hence the homogenate was then mixed with 6.25% 
Ficoll/6.25% sucrose buffer and spun at 44 000 × g for 20 min at 4 °C, 
leaving in the supernatant. A further ultracentrifugation step at 140 000 × g 
for 1 hour at 4 °C pelleted the CCV and allowed removal of the 
Ficoll/sucrose. The clathrin-coated vesicles were re-suspended in a small 
volume of HKM buffer and homogenized and spun in a microfuge to remove 
small cytoskeletal contaminants. The protein coats were stripped off of the 
lipids by mixing the sample with an equal volume of 2× 1M Tris buffer (1 M 
Tris, 1 mM EDTA, 2mM DTT, 0.02% sodium azide) and incubating for 1 hour 
at 4 °C, followed by centrifugation to remove most of the lipids at 135 000 × g 
for 20 min at 4 °C.  
Clathrin was then purified by loading the supernatant after the last spin on a 
Sephacryl 500 HR column (GE) attached to an ÄKTA FPLC system (GE 
Healthcare). This column allows the separation of clathrin from remaining 
lipids in the sample and the various adaptor proteins present in coated 
vesicles. The fractions were analysed by SDS PAGE gel electrophoresis and 
the fractions containing the purest clathrin were pooled together and 
concentrated by adding an equal volume of saturated ammonium sulphate, 
which precipitated the protein and helped to remove contaminants before 
overnight storage in 4oC.  
The precipitated protein was isolated by centrifugation at 48,000 x g and re- 
suspended in a low volume of 1 M Tris buffer before dialysis into 
depolymerisation buffer for a minimum of 2 hours. Clathrin that failed to 
depolymerise was removed by centrifugation at 130,000 x g. The 
supernatant was the loaded onto a Superdex 200 HR column to clean it up 
and elute pure clathrin. The fractions containing pure clathrin were pooled 
and again precipitated with ammonium sulphate before overnight storage. 
Precipitated protein was then re- suspended as previously and dialysed into 
depolymerisation buffer for a minimum of 2 hours. The dialysis buffer was 
then switched to polymerisation buffer (pH 6.4) and left to dialyse over night 
with at least one buffer change. Polymerised clathrin was isolated after 
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centrifugation at 135,000 x g and re-suspension in polymerisation buffer. 
2.6.3 SDS poly acrylamide gel electrophoresis  
Gels were cast using a 12 % resolving gel and a 4 % stacking gel for use in a 
Mini-PROTEAN® system (Bio-Rad). Samples were diluted 1:1 with gel 
loading dye (x2) and incubated at 37oC for 10 minutes before loading onto 
the gel. Gels were run at 160 V (~50 mA) for 1 hour or until the dye front 
reached the bottom of the gel. Gels were stained using Instant Blue Quant 
LAS 4000 from GE. Protein purity was analysed by running SDS PAGE after 
purification and for V2R expression. SDS PAGE was used to analyse all the 
ultracentrifugation/GST pull-down experiments. 
2.6.4 Western blot analysis 
Appropriate samples were sonicated to lyse the cells in the pellet and break 
down genomic DNA. After resolving by SDS-PAGE as described protein was 
transferred to a methanol activated PVDF membrane using a Mini Trans-
Blot® system (Bio-Rad) or a semi-dry system (Sigma, UK). Transfer was 
conducted in NuPAGE buffer for a period of 90 minutes at 160 mA or 2 hours 
for 200 mA for semi-dry transfer. After transfer the membrane was blocked 
using a 5 % w/v milk powder TBS-tween solution overnight at 4°C. The 
membrane was washed thoroughly with TBS-Tween before 1 hour incubation 
with anti-His antibody (Cell Signaling) in 5% w/v milk (1:1000 dilution). The 
membrane was then rinsed with 3 successive 15 minute PBS-tween washes 
before incubation with secondary IgG mouse antibody (Cell Signalling) in 5 % 
w/v milk powder PBS-tween (dilution of 1:2000) for 1 hour. The membrane 
was then rinsed with 3 successive 15 minute PBS-tween washes before 
imaging. Finally, the membrane was washed with ECL reagents as per 
manufacturers instructions. Image Quant LAS 4000 (GE) was used to image 
the membrane. 
 
 49 
2.6.5 GST-fused protein expression and purification  
2.6.6 GST β-Arrestin 1L1-418 WT and Mutants 
Expression: Single colonies from overnight LB/AMP plates were picked to 
produce 10ml overnight cultures (6x) with 100 μg/ml of ampicillin of the GST 
β-arrestin 1L WT or mutants. Those overnight cultures were then used to 
infect 6 x 400ml LB media (total of 2.4 liters). The cultures were incubated at 
37oC, 240 rpm and 1mM IPTG was added to each culture after the OD600 
had reached 0.7-0.9. Post-induction, the cultures were incubated at 160 rpm 
at 16oC, overnight. The cells were harvested at 4,000 x g for 10 min before 
re-suspending the cell pellets with PBS and storage at -80oC. 
Purification: Glutathione (GSH) affinity chromatography and Superdex 75 
size exclusion chromatography column were used to purify the protein, using 
an ÄKTA FPLC system. The purification protocol was adapted and changed 
from (Nobles et al., 2007). The plasmid constructs were transformed as 
described in section 2.6.1. The 5 ml expressed pellet was then re-suspended 
in CB1 buffer, pH 8.0 with protease inhibitor tables and lysed by sonication 5 
x 15 sec. Cell debris was removed by centrifugation at 44,000 x g for 20 
minutes and the supernatant loaded onto a GSTrap FF column. The GST β-
arrestin 1L was eluted after running the 10mM GSH elution buffer, pH 7.2. 
Excess GSH was removed by dialysis against CB1 buffer and addition of 
Prescission Cleaving Enzyme (Sigma) (2 Unit/100 μg protein) for cleavage of 
the GST tag for all the β- arrestin 1L mutants, where necessary. The sample 
was dialysed at 4oC overnight. After cleaving, the sample was loaded on the 
GSTrap FF column (GE) again to separate the cleaved protein from the un-
cleaved. The same procedure was carried out as above with he GST elution 
buffer. The fractions containing the cleaved protein were concentrated to 
approximately 1-2 ml and loaded on a Superdex 75 size exclusion column 
(GE) for further purification. The eluted fractions were concentrated by 
centrifugation to 1ml. The sample was snap-frozen and stored at -80oC. The 
protein was quantified as per section 2.8.0. 
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2.6.7 GST- auxilin401-910 WT 
Transfection of GST- auxilin401-910 was carried out as in section 2.6.1. The 
expression was carried out as per GST- β-arrestin 1L1-418 with the exception 
of 25oC overnight incubation of the induced cultures. The GST tag of the 
GST- auxilin401-910 was removed using digestion with thrombin (Sigma) for 3 
hours at a ratio of 1 unit/10 μg protein. The cleaved auxilin and GST tag were 
separated by GST affinity chromatography in Buffer A, where the GST tag 
was eluted in GSH elution Buffer A. The cleaved auxilin was concentrated by 
centrifugation, snap-frozen and stored at -80oC. The protein was quantified 
as described in section 2.8.0. 
2.6.8 GST- β2HA695-983 WT 
GST-β2 adaptin695-983 was transformed and expressed as per the GST- β-
arrestin 1L1-418 above with the exception of 25oC overnight incubation of the 
induced cultures. PreScission Cleaving Buffer enzyme was used to cleave 
the GST tag. The purification was only by GST affinity chromatography as 
per the GST- auxilin401-910. The protein was quantified as per section 2.8.0 
2.6.9 GST- N-terminal domain (TD)1-363 WT  
The clathrin TD1-363 WT were transformed as described in section 2.6.1. A 
total of 800ml LB media, 10ml overnight cultures, 100 μg/ml of ampicillin was 
used to grown up to an OD600 of 0.7-0.8 while incubating at 37oC, 240rpm. 
The cultures were induced with 0.1 mM IPTG and grew overnight at 25°C, 
160rpm. The 5ml expressed pellet was then re-suspended in CB1 buffer, pH 
8.0 with protease inhibitor table and lysed by sonication 5 x 15 sec. Cell 
debris was removed by centrifugation at 44,000 x g for 20 minutes and the 
supernatant loaded onto a GSTrap FF column. After loading on the column, 
the GST-TD1-363 was purified as per the GST- auxilin401-910 with the addition 
of 10 mM GSH. The GST tag was retained for use in pull downs via the 
affinity tag.  
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2.6.10 GST-tag purification 
A pGEX6P3 (containing GST-tag) was expressed as per GST- beta arrestin 
1L and purified using a GST affinity chromatography. The pure GST tag was 
eluted after the addition of the 10mM GSH Buffer CB1. This GST-tag was 
used as a control in binding assays and SPR experiments in the next 
chapters. 
2.7.0 His6 -fused protein expression and purification 
2.7.1 His6 –epsin11-575 
The His6 –epsin11-575 WT and mutants were transformed as described in 
section 2.6.1. The epsin1 was expressed in 2 x YT media of 2 liters in total at 
37oC for 4 hours with 1mM IPTG induction. The harvested cell pellets were 
re-suspended in buffer B with a protease inhibitor tablet spun at 50,000 x g 
for 30 minutes to remove lipid contaminants. The supernatant was loaded on 
a c0mplete His-trap column (Roche) and allowed binding to the column. A 
washing step was carried out before elution in 20 mM imidazole washing 
buffer and the His-tagged protein was eluted using 200 mM imidazole elution 
buffer. The fractions that contain the epsin 1 were dialysed overnight against 
base buffer to remove the imidazole and then concentrated and loaded on a 
superdex 200 size exclusion column. The fractions eluted from the Superdex 
200 column, pure protein were pooled and concentrated by (centrifugation), 
snap-frozen and stored at -80°C. The protein was quantified as per section 
2.8.0.  
2.7.2 His6 -Hip1RCC346-655 
The His6 -Hip1RCC346-655 was transformed as described in 2.7.1 and plated 
on Kanamycin and Ampicilin LB plates. The Hip1CC expression was carried 
out in LB media of 2.4 litres in total with 1 mM IPTG induction for 4 hours at 
22oC. Cell pellets (5ml) were re-suspended in buffer B with a protease 
inhibitor tablet spun at 50,000 x g to remove lipid contaminants. The 
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supernatant was loaded on a c0mplete His-trap column (Roche) and allowed 
binding to the column. A washing step was carried out before elution in 20 
mM imidazole washing buffer and the His-tagged protein was eluted using 
200 mM imidazole elution buffer. Those fractions containing the His-
Hip1RCC were run on SDS-PAGE gel to confirm the purity of the protein 
before dialyzing overnight in base buffer (to remove 200mM imidazole) and 
concentrate to be stored for later use.  
2.8.0 Protein quantification  
The extinction coefficient of each protein (obtained from ProtParam 
(ExPaSy)) calculated from their amino acid sequence, was used along with 
the A280 readings from the NanoDrop ND-1000 Spectrophotometer (DE 
USA), to quantify GST and His – tagged proteins. Clathrin concentration was 
assayed by titration in 1M Tris-HCl buffer to disassemble cages into triskelia 
before assaying absorbance at 280 nm using a Cary 100 UV-Vis 
Spectrophotometer.  
2.9.0 Analytical Techniques   
2.9.1 Clathrin cage assembled with His6-epsin1 WT  
Clatrhin cages were disassembled at concentrations of 12 μM though dilution 
in 1 M Tris buffer and dialysis into DEPOL buffer pH 8.0 for a minimum of 4 
hours with a buffer change (dialysis buffer volume ratio of 1:200). 
Disassembled triskelia were then assembled against POL buffer pH 6.4 with 
the addition of epsin 1 WT at a 30 μM concentration at a final volume of 100 
μL, incubated at 4oC overnight. Active β-arrestin 1L (30 μM) was then added 
to the clathrin cage:epsin complex to then visualize the complex in negative 
stain electron microscopy. 
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2.9.2 GST-pulldown binding assays 
Glutathione Sepharose 4B beads (Sigma) (50 μl) were added to mini bio-
spin® chromatography columns (Biorad) along with the different 
concentration of the GST- fused protein, for example GST- clathrin N-
terminal domain at a constant concentration (e.g. 3 μM) and incubate for 10 
minutes at 4oC. This allows the immobilizion of the GST-fused protein on the 
GSH beads. The samples were then incubated at 4oC for 1 hour after adding 
the appropriate HKM buffer pH 7.2 volumes and the non-GST tagged protein 
at appropriate concentration (different ratios), to allow binding of the 2 
proteins before elution. The spin columns were washed 3 x with a buffer 
containing 1x Triton100% and centrifuged in a microfuge at 4oC at 13,000 
rpm for 30 seconds. The flow-through after the first wash was saved 
(supernatant) and subsequently discarded after each wash. This step was 
repeated 1 x more but this time using the normal HKM buffer pH 7.2 without 
Triton100%. The protein complex is eluted by the addition of 50 μl of 1x SDS 
loading dye and allowing the samples to denature before spinning to collect 
the proteins. The supernatant (unbound) and pellet (bound) samples (1 μg of 
protein) were analysed by SDS- PAGE in order to visualize the binding or 
lack of binding of the two-protein complex.  
2.9.3 Ultracentrifugation binding assays  
The purified 3-2 μM clathrin cages were either dialyzed overnight (where 
appropriate) in a suitable buffer with the adaptor (β-arrestin 1L) or just added 
to the β-arrestin 1L directly with incubation for 1 hour only. In the case of no 
dialysis, the sample containing 2 μM clathrin and increasing concentrations 
of β-arrestin 1L were incubated for 1 hour at 4oC. The samples were spun 
using an Beckman benchtop ultracentrifuge (rotor TLA 120.0) for 30 minutes 
at 55,000 rpm. The supernatant (unbound) was then collected and the pellets 
(bound) were re-suspended with SDS loading buffer in a volume that will give 
a 5 folds more concentrated sample. SDS-PAGE gel electrophoresis was 
used to visualize the samples. 
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2.9.4 Surface Plasmon Resonance  
Quantitative binding studies were carried out using the antibody indirect 
capturing method (IAC) on a BIAcore 2000 SPR instrument. In general, 
monoclonal anti-GST antibody (Sigma-Aldrich, USA) pH scouting was carried 
out using 3.0-5.5 pH range of 10mM sodium acetate to identify the ideal pH 
for capturing on the chip surface. The anti- GST mAb was then immobilized 
on a CM5 chip using an amine coupling procedure at 5 μl/min for 12 
injections in 10 mM sodium acetate at pH 5.5 (about 16,000-18,000 
response units (RU) for the 2 injection experiments and <400 RU for kinetic 
models) using a programmed procedure on BIAcore 2000 instrument (GE 
Healthcare, USA).  
 
The anti-GST immobilized chips were then coupled with ~ 800-1000 RUs 
(with a 1:10 dilution of the anti-GST antibody) of purified pGEX4T2 clathrin-
TD WT in buffer (10mM HEPES, 150 mM NaCl, 1mM TCEP, 0.05% Tween 
20 pH 7.4) for competition experiments and ~ 20-50 RU for kinetic assays. 
Initially, binding experiments were performed using the indirect antibody 
capturing method to investigate the interactions the GST-clathrin TD WT with 
purified adaptor proteins (WT and mutant forms).  
 
The GST- clathrin TD (ligand) were bound on already coupled (with anti-GST 
antibody) chips at 20 μl/min flow rate and 40 μl/min for kinetic runs with ~ 
200 seconds on injection time, following an equilibration time of 1000 
seconds. The adaptor protein (analyte) was then injected for ~ 200 seconds 
(3 minutes) following an ~ 500 seconds (8 minutes) of dissociation time, at 
room temperature (20-25 oC). The chip was regenerated (double injection) 
with 10 mM glycine HCl pH 3.0-2.0, with a flow rate 30 μl/min, for 30 sec. 
Where possible, each binding experiment was carried out with a series of 
three repeat trials on different flow cells, in a random order, with 
approximately the same anti- GST antibody immobilization (response units). 
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The SPR technique was further used as 2 – injection experiments, where 
different adaptors were injected one after the other to determine any 
competition or cooperate binding. After binding the anti-GST antibody on the 
chip as above and the GST- clathrin TD binding on the antibody with ~ 800-
1000 RU, the first adaptor was passed over in the first injection ~ 200 
seconds (3 minutes). A small equilibration time was followed with buffer, and 
the second injection followed with a different adaptor protein for ~ 200 
seconds (3 minutes). Finally, the chip was regenerated as above. The order 
of the experiments was varied because we observed deterioration in the 
binding capacity for the GST-fused protein by the anti-GST on the chip in 
each run, even after successful regeneration. Chapter 5 contains more 
details on how SPR works and the optimization stages. 
 
2.10.0 General analysis and plotting software  
ÄKTA purifier FPLC system (GE healthcare) was operated by the 
UNICORN® 7.0 software. All graphs were generated using Microsoft Excel 
(2011) and GraphPad Prism 6.0. Manipulation of protein structural data and 
images was conducted using USCF Chimera (version 1.11). The 
visualization of negative stain micrograph was conducted using Image J 
(Fiji). SPR data analysis of kinetic models was carried out using 
BIAevaluation software version 4.1 of BIACORE. Word processing was 
conducted using Microsoft Word (2011). Figures were prepared using 
Microsoft PowerPoint (2011).  
2.11.0 Negative stain Electron microscopy  
Copper Formvar/carbon grids (300 mesh) glow-discharged (EMtech K100x 
unit) at 10mA for 30 seconds before the 5 μL of sample of clathrin only or 
clathrin with epsin and/or active beta-arrestin 1L was added at 0.5-1 μM 
concentration. The sample was incubated on the grid for 1 minute and the 
remaining sample was blotted from the grids using filter paper. The grids 
were then negatively-stained with the addition of 5 μl of uranium acetate 
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(2%) and air-dried for 30 seconds and excess uranium acetate was blotted 
away, prior to imaging. The JEOL 2011 with Gatan Ultrascan 4000 CCD 
were used to image and collect the data. Images of cages were taken at a 
range of x 20,000-30,000 magnification unless otherwise stated. 
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Chapter 3:  
Protein Expression and 
Purification 
3.0.0 Introduction  
This chapter includes the results from purification methods of clathrin and 
adaptor proteins by column chromatography and the purity for the proteins 
were analysed by SDS-PAGE. Adaptor proteins were expressed in E.coli and 
purified via affinity tags while clathrin was purified from porcine brains. These 
purified proteins were used in binding assays, SPR and microscopy 
experiments detailed in the future chapters. 
3.1.0 Clathrin purification 
  3.1.1 Formation of clathrin coated vesicles (CCVs)  
The clathrin purification procedure was adapted from Rothnie et al., 2011 
(Rothnie et al., 2011). Clathrin triskelia were purified from clathrin-coated 
vesicles extracted from eight frozen (liquid N2) pig brains by differential 
centrifugation and gel filtration. The first step involves homogenizing the 
600g of pig brains in a blender with HKM buffer (25 mM Hepes pH 7.0, 125 
mM pottasium acetate, 5 mM magnesium acetate, 0.02% sodium azide and 
a protease inhibitor tablet). Following a low-speed spin (12 000 × g, 30 min, 
4 °C) to further purify and collect the supernatant of this is ultracentrifuged at 
140 000 × g, 45 min, 4 °C, to pellet lipid membrane components. This step 
was repeated to form a ‘double’ pellet if necessary. 
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The pellets were re-suspended in approximately 50 ml of HKM buffer and 
homogenized (>20 strokes). The clathrin coated vesicles need to remain in 
the supernatant, hence the homogenate was then mixed with buffer 
containing 6.25% Ficoll/6.25% sucrose and spun at 44 000 × g, 20 min, 4 °C. 
The Ficoll/sucrose is then removed by ultracentrifugation at 140 000 × g for 1 
hour at 4 °C. The clathrin-coated vesicles were re-suspended in a small 
volume of HKM buffer and homogenized and spun in a microfuge to remove 
small cytoskeletal contaminants. The protein coats were stripped off of the 
lipids by mixing the sample with an equal volume of 2× 1M Tris buffer and 
incubating for 1 h at 4 °C, followed by centrifugation at 135 000 × g for 20 
min at 4 °C to remove most of the lipids.  
3.1.2 Size exclusion chromatography and dialysis 
Following the centrifugation steps, size exclusion chromatography was used 
to separate clathrin from the remaining adaptor proteins. The supernatant 
after the previous spin was loaded on a Sephacryl S500 column equilibrated 
in 1 x 1M Tris buffer. This column allows the separation of clathrin from 
remaining lipids in the sample and the various adaptor proteins present in 
coated vesicles. The lipids were eluted at ~ 140 to 225 ml and clathrin was 
eluted at ~ 230 to 320 ml peak, following a ‘adaptor tail’ around 320 ml. 
Clathrin was concentrated by ammonium sulphate precipitation, which also 
helped to remove contaminants and preserve the protein overnight.  
The pure clathrin was dialyzed overnight at 4oC into depolymerization 
(DEPOL) buffer  (20 mM triethanolamine pH 8.0, 1 mM EDTA, 1mM DTT, 
0.02% sodium azide), which prevent large cage formation as it disrupts 
triskelia-triskelia formation before concentrated by ammonium sulphate 
precipitation. A superdex 200 size exclusion column was used to clean it up 
and elute the pure clathrin. This step removes low molecular weight 
contaminants with clathrin eluting as a single broad peak between 90-120 
mL (Figure 3.1.2). Cages were formed in vitro by dialyzing overnight at 4oC 
into polymerization (POL) buffer (100 mM MES pH 6.4, 15 mM MgCl2, 0.2 
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mM EGTA, 0.02% sodium azide). The pure clathrin was harvested by 
centrifugation at 135 000 × g for 20 min at 4 °C to concentrate it and increase 
its stabilityas clathrin cages have formed and re-suspended in approximately 
100-200 μl of POL and stored at 4 °C for long-term storage up to one month. 
 
 
 
 
Figure 3.1.2: Clathrin purification by size exclusion chromatography monitored 
by the A280 absorbance (A, C) and SDS-PAGE gel analysis to confirm the 
presence and purify of the clathrin at each stage (B, D). (A) A sephacryl 500 
column was used to separate the lipids and the clathrin and adaptors. The lipids 
eluted between 140-225ml and clathrin elutes at 230-320ml with adaptors eluting 
320-400ml. The fractions containing the clathrin (*) are run on SDS-PAGE gel (B) to 
confirm the presence of clathrin. Clathrin light chains (CLC) are also visible in these 
fractions. Those fractions were kept in ammonium sulphate overnight before they are 
loaded on the Superdex 200 column. Fractions also contain contaminants from 
adaptor proteins (***) (C) The clathrin heavy chain (CHC) elutes at 90-120ml as a 
broad peak (*). (D) These fractions were run on SDS-PAGE gel (**), before kept in 
ammonium sulphate overnight before the final purification stages of dialysing. Clathrin 
light chains (CLC) are also visible in these fractions. 
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3.1.3 Purified clathrin quantification and concentration  
To obtain an accurate absorbance measurement (280 nm) the pure clathrin 
in POL buffer is diluted in 1 M Tris buffer, pH 8.0 in a concentration titration 
curve manner, which will allow the fast disassembly of the clathrin cages to 
triskelia, which are easier to measure, reducing interference from light 
scattering caused by clathrin cage structures. The Beer’s Lambert Law was 
used to determine protein concentration. Both light chains (CLCa and CLCb) 
were seen by SDS- PAGE analysis, however it is not clear what the relative 
abundance of each light chain (α and b) are in each clathrin prep. Mass 
spectrometry analysis could be an option to determine the exact amount 
ratios of CHC:CLCa:CLCb, even with the evidence that almost all CHCs are 
saturated with CLC (Girard et al., 2005). However this is considered costly, 
therefore a 1:1 molar ratio of CHC to CLCb was used. Figure 3.1.3 illustrates 
an example of such clathrin quantification method using a Cary 100 UV-Vis 
Spectrophotometer with a yield of 84.4 μM, which is considered an optimal 
yield. 
 
 
Figure 3.1.3 Quantification of clathrin via titration and absorbance at 280 
nm. (A) Increasing volumes of stock purified clathrin were diluted in 1 M Tris 
buffer measured at absorbance spectrum of 250 to 350 nm using a Cary 100 UV-
Vis spectrophotometer from 2 to 8 μl). (B) The peak absorbance at 280 nm was 
plotted against the dilution factor to generate a standard curve. Beer’s Law using 
the extinction coefficient= 222780 M-1 cm-1 to measure the pure clathrin 
concentration for CHC:CLCb, e.g. 84.4 μM in this example. 
 
(A) (B) 
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3.2.0 Purification of GST-tagged proteins  
Some of the adaptor proteins are GST-tagged. These include, GST- β-
arrestin 1L1-418, GST-auxilin401-910 and GST β2-adaptin616-937(β2-HA), GST-
clathrin TD1-363, in pGEX4T-2 or pGEX6P-3 plasmids expressed and purified 
in E. coli cells. All of these proteins were initially purified using GSTrap FF 
affinity column with subsequent cleavage of the GST-tag using thrombin or 
Precission Protease Cleaving Enzyme. Size exclusion chromatography was 
only used for GST- β -Arrestin 1L. 
3.2.1 Purification of GST-β-Arrestin 1L1-418 WT and 
mutants 
BL21 (DE3) competent E. coli cells were transformed with the GST-β-
Arrestin 1L1-418 WT or Mutants plasmids and the protein was expressed as 
described in Chapter 2. Following pelleting of the cells and lysis the cell 
debris by 4,000 x g for 10 min before re-suspending the cell pellets with PBS 
and storage at -80oC, purification of GST-β-Arrestin 1L1-418 was carried out 
following the method of Nobles et al., 2007. However, the protocol was 
modified by eliminating the use of a Hi-Trap ion exchange column and all 
data here is from protein purified without a Hi-Trap column. The reason for 
this change in protocol was that no significant increase in purity of the protein 
was observed after His trap purification and the added step also resulted in 
loss of protein.  
The GST-β-Arrestin 1L1-418 constructs of WT and mutants in pGEX-6P3 
plasmid were transformed and expressed as per section 2.3.2. The 5ml 
expressed pellet was then re-suspended in CB1 buffer, pH 8.0 with protease 
inhibitor tables and lysed by sonication 5 x 15 sec. Cell debris was removed 
by centrifugation at 44,000 x g for 20 minutes and the supernatant loaded 
onto a GSTrap FF column. The GST-β-Arrestin 1L1-418 was eluted after 
running the 10mM GSH elution buffer, pH 7.2 (Figure 3.2.1). Excess GSH 
was removed by dialysis against CB1 buffer and addition of Prescission 
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Cleaving Enzyme (Sigma) (2 Unit/100 μg protein) for cleavage of the GST 
tag for all the β-arrestin 1L mutants. The sample was dialysed at 4oC 
overnight. After cleaving, the sample was loaded on the GSTrap FF column 
(GE) again to separate the cleaved protein from the un-cleaved. The same 
procedure was carried out as above with the GST elution buffer (Figure 
3.2.1). The fractions containing the cleaved protein were concentrated to 
approximately 1-2ml and loaded on a Superdex 75 size exclusion column 
(GE) for further purification. The eluted fractions containing GST- β-arrestin 
1L eluted at ~ 35-45 ml were concentrated by centrifugation to 1ml and 
quantified (Figure 3.2.1). The sample was snap-frozen and stored at -80oC.  
 
 
 
 
Figure 3.2.1 GST- β—arrestin 1L was purified  by affinity and size exclusion 
chromatography (GST Trap FF and Superdex 75) as monitored by A280 
absorbance (A,B,C) and by SDS-PAGE (D). (A) The supernatant from lysed E. 
coli cells expressing the protein was loaded onto a GSTrap FF affinity column. The 
GST- β-arrestin 1L was eluted with GSH buffer (10 mM GSH). Those fractions were 
dialysed overnight against CB1 buffer with the addition of PreScission Protease 
Cleaving Enzyme to cleave the GST-tag. (B) The fractions containing cleaved beta-
arrestin 1L were pooled together and concentrated before loading on Superdex 75 
size exclusion column for further purification. (C) The cleaved beta-arrestin 1L was 
eluted at approximately 35ml. These fractions were pooled and concentrated for 
storage. (D) SDS-PAGE confirmed the purified β–arrestin 1L. 
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3.2.2 Purification of GST- auxilin401-910 WT 
The GST- auxilin401-910 was transformed and expressed as described in 
Chapter 2 section (2.7.1 and 2.7.6). The GST tag of the GST- auxilin401-910 
was removed using digestion with thrombin (Sigma) for 3 hours at 10units 
per 1 mg of protein per 1 mL, at 4oC dialyzing against buffer A. The cleaved 
auxilin and GST tag were separated by GST affinity chromatography in 
Buffer A. The GST tag was eluted after the addition of 10 mM GSH elution 
buffer A, as shown in Figure 3.2.2. The cleaved auxilin was concentrated by 
centrifugation, snap-frozen and stored at -80oC. The protein was quantified 
as described in section 2.9.0. 
  
 
 
 
 
 
 
 
Figure 3.2.2 GST-auxilin by affinity chromatography as monitored by A280 
absorbance and the protein purity was determined by SDS-PAGE analysis. (A) 
Lysed pellets containing GST-auxilin were loaded on a GSTrap FF affinity column. 
GST-auxilin was eluted through the addition of 10mM GSH onto the column (B) 
Thrombin is added to those fractions containing GST-Auxilin to cleave the GST- 
tag, and fractions were dialysed for 3 hours against buffer A (remove GSH). This 
sample was loaded back onto a GST Trap FF affinity column and the cleaved 
auxilin was eluted in the flow through, was collected, concentrated and stored. The 
left over GST –tag was eluted by 10 mM GSH buffer A. (C) SDS-PAGE gel shows 
the cleaved auxilin after concentrated (*). 
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3.2.3 Purification of GST β2-adaptin616-951  
GST-β2 adaptin695-983 was transformed and expressed in the same manner 
as GST-β-arrestin 1L1- 418 above with the use of the PreScission Cleaving 
Buffer enzyme to cleave the GST tag. The purification was carried out by 
GST affinity chromatography as per the GST- auxilin401-910. Figure 3.2.3 show 
the purification traces and the SDS-PAGE gels confirming the protein purity. 
The concentrated protein was quantified as per section 2.9.0. 
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Figure 3.2.3 GST β2-adaptin by affinity chromatography as monitored by A280 
absorbance, and SDS-PAGE analysis. The GST-tag was cleaved from the β2-
adaptin and determined the protein purity by SDS-PAGE analysis. (A) GST β2-
adaptin collected after a GST-Trap FF affinity column, and pooled together to be 
concentrated and stored. (B) SDS-PAGE determine the presence of the GST β2-
adaptin in those fractions. (C) GST β2-adaptin sample was dialysed overnight against 
buffer A to remove GSH and cleave the GST-tag using Precision Cleaving Buffer. 
This sample was loaded onto a GST Trap FF affinity column and the cleaved β2-
adaptin was eluted, concentrated and stored. GSH buffer eluted the left over GST–
tag. (D) SDS-PAGE determines the cleaved β2-adaptin, which was pooled and 
concentrated.  
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3.2.4 Expression and purification of GST-TD1-363 WT  
The clathrin TD1-363 WT were transformed as described in Chapter 2. The cell 
debris was removed by centrifugation at 44,000 x g for 20 minutes and the 
supernatant loaded onto a GSTrap FF column. After loading on the column, 
the GST-TD1-363 was purified as per the GST- auxilin401-910 with the addition 
of 10 mM GSH (Figure 3.2.4). The GST tag was retained for use in pull 
downs and SPR via the affinity tag. 
(A)                                                          (B)                       
 
 
 
 
 
 
Flow-Through 
Flow-Through * 
Figure 3.2.4 GST-TD was purified using affinity chromatography as per the 
absorbance of the A280, and the purity protein was determined by SDS-PAGE gel 
analysis. (A) The supernatant of E.coli lysed cells from pellet expressing GST-TD was 
loaded on the GST Trap FF column. The flow-through was mainly non-binding proteins 
and the GST-TD was eluted after the addition of the GSH buffer. Those fractions (*) 
were pooled together, concentrated and stored appropriately. (B) SDS-PAGE gel 
confirming the presence and purify of those eluted fraction containing the GST-TD 
protein. 
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3.2.5 Purification of GST-tag 
A GST-tag (pGEX6P3 construct) was expressed as per GST- beta arrestin 
1L and purified using a GST affinity chromatography. The pure GST tag was 
eluted after the addition of the 10mM GSH Buffer CB1 as shown in Figure 
3.2.5. This GST-tag was used as a control in GST- pulldowns and SPR 
experiments in the next chapters. 
 
 
 
 
 
 
 
 
 
Elution* 
  
Flow-Through 
GST-tag 
  
Figure 3.2.5: GST-tag was purified using affinity chromatography as per the 
absorbance of the A280 and SDS-PAGE gel determined the presence of the GST-
tag. The supernatant of E.coli lysed cells from pellet expressing GST-tag was loaded 
on the GST Trap FF column. The flow-through was mainly non-binding proteins and the 
GST-tag was eluted after the addition of the GSH buffer (data not shown). Those 
fractions (Elution*) were pooled together, concentrated and stored appropriately. The 
SDS-PAGE gel confirms the presence and purify of those eluted fraction containing the 
GST-tag. 
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3.3.0 Purification of His6 -tagged proteins  
Three different proteins: His6 epsin1-575 (epsin 1) WT and six mutants, His6 
Hip1RCC346-655 and Hip1C361-637, were expressed in E. coli cells. A His-Trap 
affinity column was used for all the purifications initially. A size exclusion step 
using superdex 200 was followed to purify degradation products for epsin 1. 
3.3.1 His6 epsin 11-575 WT and mutants 
The His6 –epsin11-575 WT and mutants (257, 480, DKO, ½ DPW, ¼ DPW, 
ΔDPW) proteins were transformed and expressed as described in section 
2.7.5 in Chapter 2. Cell pellets (5ml) were re-suspended in buffer B with a 
protease inhibitor tablet spun at 50,000 x g to remove lipid contaminants. 
The supernatant was loaded on a c0mplete His-trap column (Roche) and 
allowed binding to the column. A washing step was carried out before elution 
in 20 mM imidazole washing buffer and the His-tagged protein was eluted 
using 250 mM imidazole elution buffer. The fractions that contain the epsin 1 
were dialysed overnight against base buffer to remove the imidazole. Those 
fractions were then concentrated and loaded on a superdex 200 Size 
exclusion column. The fractions eluted (Figure 3.3.1) from the superdex 200 
column, pure protein were pooled and concentrated by (centrifugation), snap-
frozen and stored at -80°C. The protein was quantified as per Section 2.8.0. 
The expression and purification of epsin 1 257,480 and DKO mutants were 
conducted in the help of Dr. Michael Baker and Dr. Sarah Smith (WT), in 
some cases. Figure 3.3.1 is the elution profile and the SDS-PAGE gels of the 
WT epsin, which are representative of the 257, 480, DKO, ½ DPW, ¼ DPW, 
ΔDPW epsin mutants. 
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3.3.2 His6 -Hip1RCC346-655  and His6 –Hip1CC361-637 
The His6 -Hip1RCC346-655 and His6 -Hip1CC361-637 expressions were carried 
out as described in Chapter 2. The purification was carried out from E.coli 
lysed cell supernatant that was loaded onto the c0mplete His trap column. 
The proteins were eluted through the addition of 200 mM imidazole (Figure 
(B) 
(C) 
(A) 
(D) 
 
 
 
 
* 
 
His6-epsin 1 
His6-epsin 1 
Figure 3.3.1: His6 epsin 1 WT and mutants were purified by affinity and size 
exclusion chromatography (c0mplete His-Trap column and Superdex 75) as 
monitored by A280 absorbance (A,C) and by SDS-PAGE (B,D). (A) The supernatant 
from E. coli lysed cells expressing the protein was loaded onto a c0mplete His-Trap 
affinity column. The flow-through was all the non-binding proteins mostly E.coli 
proteins. The His-epsin 1 was eluted with 200-250mM imidazole in base buffer. Those 
fractions of 10 ml each were dialysed overnight against base buffer to remove the 
imidazole. (B) The dialysed fractions presented on this SDS PAGE gel were 
concentrated before loading on Superdex 200 size exclusion column for further 
purification. (C) The His- epsin 1 protein was eluted at approximately 100-180ml. These 
fractions were pooled and concentrated for storage. (D) SDS-PAGE confirmed the 
presence of purified His-epsin 1 in those eluted fractions (*) of 10 ml each. These 
fractions were concentrated down to ~1ml before stored in -80°C. 
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3.3.2 (A) and (B)). Those fractions containing the protein were run on SDS-
PAGE gel before dialyzing overnight in base buffer (to remove 200mM 
imidazole) and concentrate to be stored for later use. Figure 3.3.2 shows the 
purification trace and the SDS-PAGE gel for the His6 -Hip1RCC346-655, which 
representative to the His6 -Hip1CC361-637 purification as well, which was 
conducted by Dr. Michael Baker. 
 
 
 
 
 
 
3.4.0 Protein quantification  
The online tool, ProtParam (http://web.expasy.org/protparam/) was used to 
analyse the protein sequence of each adaptor protein. The extinction co-
efficient listed in the Table 1.6.0 below were then used from there to derive 
the final concentration of the proteins using the Beer’s Lambert Law. All 
purified adaptor proteins, except clathrin, were conducted using A280 
absorbance determined using of a Nanodrop ND-1000 spectrophotometer. 
(A) (B) 
Figure 3.3.2 His6- Hip1CC was purified by affinity chromatography (c0mplete 
His-Trap column) as monitored by A280 absorbance (A) and by SDS-PAGE 
(B). (A) The supernatant from E. coli lysed cells expressing the protein was 
loaded onto a c0mplete His-Trap affinity column. The flow-through was all the 
non-binding proteins mostly E.coli proteins. The His- Hip1CC was eluted with 200-
250mM imidazole in base buffer. The eluted protein fractions were pooled and 
concentrated for storage. (B) SDS-PAGE confirmed the presence of purified His-
Hip1RCC in those eluted fractions (*). 
   
* 
Flow-Through 
* 
Hip1RCC 
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Purified proteins 
 
Extinction co-efficient (M-1 cm-1) 
 
Clathrin (CHC:CLCb) 222780 
GST- β-arrestin  1L WT or Mutants 
62230 
 
Beta-Arrestin 1L WT or Mutants 
19370 
 
Auxilin 1 
58440 
 
 
His6 -epsin 1 
 
97650 
GST-clathrin TD 
 
39420 
 
His6 -Hip1 (Hip1CC) 10095 
His6 -Hip1R (Hip1RCC) 2980 
β2 adaptin (β2HA) 
30035 
 
Table 1.5.0: The extinction co-efficient used to calculate the purified 
proteins stated this chapter. Extinction co-efficient were calculated from the 
protein sequence using the ProtParam online tool  
(http://web.expasy.org/protparam/).  
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3.5.0 Conclusion 
In this chapter I have documented each adaptor and clathrin successful 
protein expression and purification. The Table 1.7.0 lists the approximate 
purified concentrations (mg/ml) of these purified proteins (WT and mutants), 
used for all the experimental work in the future chapters of my thesis. 
 
 
Proteins Concentration (mg/ml) Variants and Mutants 
Clathrin (CHC:CLCb) 18 (40-80 uM) WT 
β-arrestin 1L 21.4 WT 
β-arrestin 1L 40.7 Active 
β-arrestin 1L 11.1 IVF-AAEA 
β-arrestin 1L 25.1 WT-AAEA 
β-arrestin 1L 4.6 IVF-ΔCB 
β-arrestin 1L 18.3 WT-ΔCB 
Auxilin 1  5.1  WT 
GST- clathrin TD 60.0 WT 
His6 –epsin 1 3.3  WT 
His6 –epsin 1 2.7 257 
His6 –epsin 1 2.2 480 
His6 –epsin 1 3.0 DKO 
His6 –Epsin 1 14.2 ½ DPW 
His6 –Epsin 1 7.7 ¼ DPW 
His6 –Epsin 1 0.8 ΔDPW 
His6 -Hip1CC 0.7 WT 
His6 -Hip1RCC 2.8  WT 
β2 adaptin (β2 HA) 34 WT 
Table 1.6.0: All the purified WT and Mutant adaptor proteins used in 
this thesis along with their approximate concentrations (mg/ml) of the 
purified proteins.  
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!Chapter 4: Optimisation of 
binding interactions between 
clathrin and adaptors  
4.0.0 Overview 
The aim of this chapter was to investigate the interaction between whole 
clathrin cages and clathrin N-terminal domain (TD) with the two adaptor 
proteins epsin 1 and β-arrestin 1L. In this chapter, I discuss experiments 
comparing different buffer compositions for optimal binding between β-
arrestin 1 WT/mutants and whole clathrin cages using ultracentrifugation 
assays, and clathrin TD using GST- pulldown binding assays. I also explore 
the buffer/pH conditions for clathrin cages assembled with epsin 1 and β-
arrestin 1L individually and in combination using binding assays and negative 
stain electron microscopy (EM). 
 
4.1.0 Investigating clathrin cages: β-arrestin 1 interaction 
4.1.1 Optimisation of clathrin cages: active β-arrestin 
1L complex  
The active form of β-arrestin 1L was used, as this mutant is hypothesized to 
bind strongly to clathrin due to its two accessible clathrin box motifs (Kang et 
al., 2009). This mutant was used to investigate different buffer compositions 
and buffer pH for ideal β-arrestin 1L-clathrin cage complex formation using 
ultracentrifugation binding assays. It is important to note that, in previous 
work in this thesis, the purified active form of β-arrestin 1L demonstrated 
aggregation in solution and during overnight dialysis (data not shown) in 
different buffers other than its purification buffer.  
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A constant concentration of clathrin cages (2.5 μM) was incubated with a 
varying concentration of β-arrestin 1L from 10-40 μM, in HKM buffer (25 mM 
Hepes, 125 mM Potassium acetate, 5 mM Magnesium acetate, pH 7.2). The 
samples were incubated for 1 hour and centrifuged. The pellets, including the 
bound β-arrestin 1L:clathrin complex, were re-suspended in the HKM buffer 
and SDS-PAGE was used to analyse the bound and unbound samples. From 
the results in Figure 4.1.1 (A) and (B), we can observe that β-arrestin 1L is 
unstable at lower pH since lowering the pH (7.2) from its purification buffer 
pH (8.0) causes aggregation, causing the protein to pellet even when 
incubated alone. At pH 8.0 as clathrin is equally present in the pellet (Figure 
4.1.1 (B), lanes 1) and in the supernatant (Figure 4.1.1 (B), lanes 2), 
compared to the equivalent lanes in Figure 4.1.1 (A). This is because at high 
pH the cages disassemble to clathrin triskelia (clathrin cage assembly at pH 
6.4). Additionally, the active β-arrestin 1L appears to bind more favourably to 
the cages, possibly holding them together and hence we do not observe any 
clathrin in the supernatant (S) fractions in Figure 4.1.1 (A). 
 
Overall, it was a challenging task to find the ideal conditions where both 
clathrin and β-arrestin 1L are stable due to contrasting favourable buffer and 
pH conditions. However, HKM buffer at pH 7.2 was the most appropriate 
buffer for both proteins. Lastly, these SDS-PAGE results revealed that the 
approximate saturation molar ratio between β-arrestin 1L and cages was 
1:12, as observed in the Figure 4.1.1 (A) and (B), lanes 11 and 12), which 
formed the basis for the microscopy and SPR experiments carried out in this 
thesis. 
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4.2.0 Mutagenesis studies of β-arrestin 1L  
The optimal buffer conditions for β-arrestin 1L:clathrin cages complex 
formation was HKM buffer, pH 7.2, as observed in the previous section. 
Using ultracentrifugation binding assays, I investigated interactions between 
β-arrestin 1L WT/mutants with clathrin cages (described in Chapter 2), using 
the optimized conditions in the previous section. 
Figure 4.1.1: Ultracentrifugation binding assays were carried out showing 
saturation between β-arrestin 1L and clathrin cages in two different buffers. 
Increasing concentration of β-arrestin 1L (10-40 μM) with constant clathrin cage 
concentration of 2.5 μM. (A) Binding assays were carried out in HKM buffer, pH 7.2. 
Clathrin cages have been shown to be more stable in this buffer due to its equal 
presence in supernatant (S) and pellet (P) fraction when alone. The optimal 
saturation between β-arrestin 1L and cages was 1:12 ratio. (B) Binding assays were 
carried out in β-arrestin 1L purification buffer, pH 8.0, which revealed the instability of 
cages due to its presence in pellet (P) fraction. The optimal saturation between β-
arrestin 1L and cages was 1:12 ratio. 
 
(A) 
(B) 
β-arrestin 1L  
Active  
Clathrin Cages  
β-arrestin 1L  
Active  
Clathrin Cages  
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4.2.1 Investigating clathrin cages: β-arrestin 1L 
interaction 
Ultracentrifugation assays were carried out between purified WT/mutants β-
arrestin 1L proteins and clathrin cages in HKM buffer, pH 7.2. For each 
protein variant used, a constant concentration of clathrin cages (2.5 μM) was 
incubated with a constant concentration of β-arrestin 1L (30 μM) for a molar 
ratio of 1:12, which was the minimum concentration possible to reach binding 
saturation between the two proteins, as observed in the results from the 
previous section. 
 
The results of such experiments demonstrated that the active form of β-
arrestin 1L was shown to bind to clathrin completely as shown in lane 3 of 
Figure 4.2.1 (A), and the WT β-arrestin 1L binds with proportionally half as 
much, as seen in Figure 4.2.1 (B), lane 5. These results confirm the 
observations of Kang et al., 2009, that the active β-arrestin 1L binds the 
strongest due to its two accessible clathrin box motifs on the opposite side in 
β-arrestin 1L structure, whereas the WT β-arrestin 1L binds less due to 
having only one accessible clathrin box motif.  
 
The WT-ΔLIELD mutant showed a certain level of binding with clathrin 
cages, compared to the rest of the mutants, which showed no obvious 
binding to clathrin cages when compared with their control experiments in 
the absence of clathrin cages. The IVF-AAEA mutant was excluded from 
these experiments due degradation of the protein and which gave 
inconsistent results. It is important to note that all of the control experiments 
reveal β-arrestin 1L pelleting even in the HKM buffer, pH 7.2 (Figure 4.3.1 
(A) and (B)). Interestingly, the presence of clathrin cages in the pellet in the 
presence of β-arrestin 1L WT or mutants compared to the control where no 
β-arrestin 1L is present (lane 1 and 2), could suggest that either β-arrestin 1L 
is causing clathrin to aggregate or it is holding clathrin cages together. These 
experiments were carried multiple times, but due to the consistent pelleting of 
β-arrestin 1L in the absence of clathrin, it was not possible to judge whether 
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arrestin was binding to clathrin or pelleting due to aggregation. Since the 
SDS-PAGE analysis has a limited dynamic range and gives largely 
qualitative results, a more quantitative technique, surface plasmon 
resonance (SPR) was later used to explore these interactions.  
 
 
  
Figure 4.2.1: SDS-PAGE analysis from ultracentrifugation binding assays 
investigating β-arrestin 1L WT and mutants interaction with clathrin cages in 
HKM buffer, pH 7.2. β-arrestin 1L is at 30 μM concentration and clathrin cages 2.5 
μM concentration at a 1:12 molar ratio. (A) The active form of β-arrestin 1L was 
shown to bind to clathrin completely as shown in lane 3. There is no obvious 
binding between IVF-ΔLIELD mutant and clathrin cages except in the case of WT-
ΔLIELD mutant, which a slight binding is observed. (B) WT β-arrestin 1L binds less 
to clathrin cages as seen in lane 5, compared to the active β-arrestin 1L in (A). 
Due to aggregation and pelleting of the β-arrestin 1L alone, such SDS-PAGE 
analysis revealed limited conclusive results. The IVF-AAEA mutant was excluded 
from these experiments. 
 
(A) 
(B) 
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4.2.2 Visualization of clathrin cages: active β-arrestin 1L 
complex 
Ultracentrifugation assays were carried out with clathrin cages (3 μM) bound 
to active β-arrestin 1L (30 μM) in polymerisation (POL) buffer pH 6.4 or HKM 
buffer pH 7.2. The results demonstrate active β-arrestin 1L present in the 
pellet with clathrin cages in both buffer conditions. However, active β-arrestin 
1L aggregates and pellets when incubated in POL 6.4 buffer compared to 
HKM 7.2, as expected (Figure 4.2.2 (A)). Therefore, cages bound to active β-
arrestin 1L complex in HKM pH 7.2 was considered the most appropriate 
sample to visualize the complex using microscopy. 
 
Imaging was used to visualize the clathrin cages: active β-arrestin 1L 
complex. Negative stain transmission electron microscopy (TEM) microscope 
was used with 2% uranyl acetate as the negative stain and JEOL 2011 TEM. 
The samples were diluted in HKM buffer at pH 7.2, to a final concentration of 
0.5 μM clathrin cages. The heterogeneous nature of clathrin cage structures 
was observed in Figure 4.2.2 (B) (black circles), with smaller cage (e.g. mini 
coat) and larger structures (e.g. barrel), which were also observed Figure 
4.2.2 (C) as well after the addition of active β-arrestin 1L to the clathrin 
cages. The cage distribution is not altered by active β-arrestin 1L.  
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Figure 4.2.2: Analysis of clathrin cages: active β-arrestin 1L complex by 
SDS-PAGE from ultracentrifugation binding assays and negative stain 
electron microscopy. SDS-PAGE analysis of ultracentrifugation binding assays 
of clathrin cages bound to active β-arrestin 1L in two different buffers (POL 6.4 
and HKM 7.2) The ideal buffer for the cages: active β-arrestin 1L complex is the 
HKM 7.2 as demonstrated in the pellet (P) fraction (black square). (B) 2 % uranyl 
acetate was used as negative stain to visualise clathrin cages alone (B) and 
cages: active β-arrestin 1L complex (C) at a final concentration of 0.5 μM using 
HKM pH 7.2. The images are at 12000X magnification. 
(A) 
(B) (C) 
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4.3.0 Investigating β-arrestin 1L and clathrin TD 
interaction 
Because of the uncertain results in the previous section for binding between 
purified WT and the five mutant β-arrestin 1L proteins and clathrin cages; an 
alternative approach to monitor binding was used. In this approach, binding 
to only the clathrin N-terminal domain (TD) was monitored using GST-
pulldown binding assays between purified WT and mutant β-arrestin 1L 
proteins and GST-clathrin TD in HKM buffer, pH 7.2. These experiments 
were also used as the basis for the future SPR experiments in Chapter 6. A 
constant concentration of clathrin TD (2 μM) was incubated with beads prior 
the addition of a constant concentration of β-arrestin 1L (30 μM) WT and 
mutants at a molar ratio of 1:15, which was hypothesised to guarantee 
saturation between the two proteins, as the clathrin TD are significantly 
smaller particles with fewer binding sites than clathrin cages. 
 
The results of these experiments demonstrated that the active form of β-
arrestin 1L binds more strongly to clathrin TD as shown in lane 5 of Figure 
4.3.0 (A), compared to the WT β-arrestin 1L in Figure 4.3.0 (B), lane 11. 
These confirm the above results with clathrin cages (section 4.2.1) with 
active β-arrestin 1L binding more strongly to clathrin, whereas the WT β-
arrestin 1L binds significantly more weakly. The rest of the β-arrestin 1L 
mutants showed no specific binding to clathrin TD, as no β-arrestin 1L was 
observed in the pellet/bound samples on the SDS-PAGE (Figure 4.3.0(A) 
and (B)), compared to the β-arrestin 1L control experiments in absence of 
clathrin TD. The IVF-AAEA mutant has previously been shown to be prone to 
degradation, therefore the results in Figure 4.3.0 (B), lanes 1-4 could not be 
conclusive. 
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 4.4.0 Epsin 1 WT binding to clathrin TD 
Epsin 1 WT adaptor protein is one of the key adaptor proteins in this thesis, 
therefore I confirmed its interactions with clathrin TD, which was used in 
ultracentrifugation binding assays, imaging and SPR experiments. The 
results demonstrate an increase in epsin 1 WT binding to clathrin TD with 
(A) 
(B) 
Figure 4.3.0: SDS-PAGE analysis from GST-pulldown binding assays 
investigating β-arrestin 1L WT and mutants interaction with clathrin TD in 
HKM buffer, pH 7.2. β-arrestin 1L is at 30 μM concentration and clathrin cages 2 
μM concentration at a 1:15 molar ratio. (A) The active form of β-arrestin 1L was 
shown to bind to clathrin TD completely as shown in lane 5. There is no obvious 
binding between IVF-ΔLIELD and WT-ΔLIELD mutants and clathrin TD is 
observed. (B) WT β-arrestin 1L binds less to clathrin TD as seen in lane 11, 
compared to the active β-arrestin 1L in (A). The IVF-AAEA and WT-AAEA mutants 
do not demonstrate any obvious binding with clathrin TD, as they are not present in 
the pellet fraction. The protein amount loaded on the gels was equal to 1 μg/ml for 
comparable reasons between all samples. 
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increasing TD concentration, from 2 μM to 3 μM and a constant epsin 1 WT 
concentration of 10 μM (Figure 4.4.0, lanes 7 and 9).  
4.5.0 Clathrin cage: epsin 1 and β-arrestin 1L (C:E:β) 
complex formation 
4.5.1 Optimization for C:E:β complex formation 
Epsin 1, is an important clathrin assembly adaptor protein which has two 
clathrin box motifs (Drake et al., 2000; Kalthoff et al., 2002), like β-arrestin 
1L. Prior to using SPR to investigate the binding interaction of clathrin with 
these two adaptor proteins in combination, I aimed to explore this interaction 
using whole clathrin cages assembled with epsin 1 and β-arrestin 1L.  
 
GST-pulldown assays described in Chapter 2, were carried out to investigate 
whether epsin 1 WT and GST-active β-arrestin 1L interact with each other in 
the presence of GST beads. SDS-PAGE gels from such experiments 
illustrate no obvious interaction between these two proteins (Figure 4.5.1 
(A)), at a 1:1 and 1:3 molar ratio. However, we cannot rule out the possibility 
Figure 4.4.0: SDS-PAGE analysis from GST-pulldown binding assays 
investigating epsin 1 WT interaction with clathrin TD in HKM buffer, pH 7.2. A 
constant concentration of epsin 1 WT is at 10 μM was incubated with increasing 
concentration of clathrin TD of 2 μM to 3 μM concentration. The successful binding 
of epsin 1 with increasing concentration of clathrin TD was demonstrated in lane 7 
and lane 9, where the presence of epsin in lane 9 with 3 μM clathrin TD was 
stronger than in lane 7 with 2 μM clathrin TD. increasing concentration of clathrin 
TD. 
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of transient interactions or interactions that may only occur in the presence of 
clathrin. Ultracentrifugation binding assays were then carried out, where 
clathrin cages were dialysed overnight with WT epsin 1 at 1:10 molar ratio of 
clathrin cages: epsin 1, in different buffer compositions and pHs. Active β-
arrestin 1L was then added to the cages:epsin1 complex, at a concentration 
of 30 μM. The cages:epsin1:β-arrestin 1L complex was incubated for 1 hour 
prior centrifugation to separate bound and unbound (excess adaptors) in the 
samples. SDS-PAGE analysis was used to demonstrate the content of bound 
and unbound samples. Taking into account the challenging buffer 
composition and pH conditions between clathrin cages and β-arrestin 1L; the 
buffers used in the experiments were the polymerisation buffer (POL) at pH 
6.4 (POL6.4) (ideal for clathrin cage formation) and HKM buffer at pH 6.4 
(HKM6.4) and 7.2 (HKM7.2). HKM7.2 is a neutral buffer, which should 
provide optimum conditions for both clathrin cages and β-arrestin 1L.  
 
Initially, control experiments were carried out in order to confirm the 
appropriate buffer for all three proteins separately. The results revealed that 
clathrin cages were most stable in their polymerisation buffer at pH 6.4 (POL 
6.4) (Figure 4.5.1 (B), lane 1-2), and were less stable in POL 7.2 and HKM 
7.2 (Figure 4.5.1 (B), lane 3-4 and 5-6). β-arrestin 1L is most stable in 
HKM7.2 (Figure 4.5.1 (B), lane 9-10), where an equal amount of β-arrestin 
1L is observed both in the pellet and supernatant in the absence of clathrin. 
Finally, epsin 1 WT was most stable in POL6.4 and HKM7.2, but not in 
HKM6.4 (Figure 4.5.1 (C)). Overall, as seen in Figure 4.5.1 (C), lane 9, buffer 
HKM7.2 provided the best buffer for clathrin cages: epsin 1WT: active β-
arrestin 1L complex formation at a 1:10:10 molar ratio. 
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4.5.2 Imaging of C:E:β complex in different buffer 
conditions 
The C:E:β complex formation was successfully repeated and revealed 
complete binding of epsin 1 WT and active β-arrestin 1L in the presence of 
clathrin cages in HKM 7.2 buffer (Figure 4.5.2 (A), lane 5). This sample was 
further analysed using negative stain transmission electron microscopy (EM). 
The images obtained were compared with images obtained for cages with  
epsin 1WT and active β-arrestin 1L (C:E:β) formed in the other buffer 
conditions (POL 6.4 and HKM 6.4). It is important to note that epsin 1 has 
been suggested to form uniform cage size distribution in vitro (Kalthoff et al., 
2002). The EM images obtained in this investigation showed the presence of 
numerous uniform sized clathrin cages in all POL6.4, C:E:β and HKM7.2, 
(C) 
Figure 4.5.1: Analysis of binding interaction between epsin 1 WT and active β-
arrestin 1L and between clathrin cages (3 μM), epsin 1 WT (30 μM) and active 
β-arrestin 1L (30 μM) interaction. (A) The GST -pulldown binding assays revealed 
no obvious interaction between epsin 1 and GST- active β-arrestin 1L in the 1:1 and 
1:3 ratios of epsin1: β-arrestin 1L. Ultracentrifugation binding assays were carried 
out to determine the ideal buffer and pH conditions. The buffers used were POL 6.4, 
HKM 6.4, HKM 7.2. The most stable clathrin cages were observed in POL 6.4 buffer 
as observed in lane 1-2 (B) and active β-arrestin 1L was mostly stable in HKM 7.2 
as observed in lane 9-10 (B). The ideal buffer condition for the clathrin cages: epsin 
1: active β-arrestin 1L complex formation was in buffer HKM, 7.2 which 
demonstrates the complete binding of active β-arrestin 1L and most of the epsin 1 
in the pellet (P) fraction in lane 9 (C) (black square). 
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C:E:β buffer conditions (Figure 4.5.2 (E) and (G)) with the exception of 
HKM6.4, C:E:β in Figure 4.5.2 (F) which does not show uniformity in the 
cage sizes. This confirms the action of epsin 1 as an adaptor protein that 
promotes uniform sized clathrin cages assembly, especially in POL6.4 as 
observed in Figure 4.5.2 (C), compared to clathrin cages in the absence of 
epsin 1 (Figure 4.5.2 (B)). However, active β-arrestin 1L has been 
demonstrated in previous sections using SDS-PAGE analysis, not to be 
stable in POL6.4; but only in HKM7.2 (Figure 4.5.2 (D)). Overall, the most 
homogeneous cage structures of the cages: epsin1: active β-arrestin 1L 
complex were in HKM7.2 buffer (Figure 4.5.2 (G)). Adaptor proteins are 
smaller than clathrin cages and any visible electron density at the edges of 
clathrin cages in the EM images could not be interpreted as being adaptor 
proteins without refinement of the images and further cryogenic investigation. 
Hence, the only confirmation of adaptor presence is via the SDS-PAGE gel 
analysis. Nevertheless, the result of this section provides a novel foundation 
for future cryogenic EM imaging of clathrin cage bound to two adaptor protein 
combinations, which has not been investigated before.  
 
  (A) 
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4.6.0 Discussion 
Overall, clathrin cages are mostly stable in their polymerisation buffer 
(POL6.4), whereas active β-arrestin 1L is mostly stable in its purification 
buffer (CB1 buffer pH 8.0). However, the results above demonstrate that 
HKM buffer, pH 7.2 could be used for the formation of stable clathrin cages: 
β-arrestin 1L complexes. The ultracentrifugation/SDS-PAGE binding assays 
reveal a strong interaction of active β-arrestin 1L to clathrin cages or clathrin 
TD compared to WT β-arrestin 1L. These confirm the results from Kang et 
HKM 7.2, C:E:β HKM 6.4, C:E:β 
100$nm 
(F) (G) 
Figure 4.5.2: Analysis of the interaction between clathrin cages assembled 
with epsin 1 WT and the addition of the active β-arrestin 1L to the cage:epsin 
1 complex. (A) SDS-PAGE analysis from ultracentrifugation assays of the 
complete binding of epsin 1 WT and active β-arrestin 1L in the presence of clathrin 
cages in HKM 7.2 buffer was observed in the black square on the gel image. 
Negative stain transmission electron microscopy (EM) was used to obtain images of 
cages: epsin 1: active β-arrestin 1L (C:E:β) complex formed in different buffers. The 
complex formed in buffer POL6.4 (E) and HKM 7.2 (G) contain numerous uniform 
sized clathrin cages with the exception of HKM6.4 (F). These are compared to 
control samples imaged containing clathrin only in POL 6.4 (A), cages:epsin 1 in 
POL 6.4 (B) and cages:active β-arrestin 1L in HKM 7.2 (C). Images were obtained 
at 30000x magnification, with the exception of Figure (D), which was obtained at a 
12000x magnification. 
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al., 2009 which demonstrated a ~ 2-fold difference in binding affinity between 
active and WT β-arrestin 1L using SPR and clathrin TD.  
 
The SDS-PAGE analysis in the previous section, reveals no obvious 
interaction of clathrin with the rest of the β-arrestin 1L mutants (IVF-AAEA, 
WT-AAEA, IVF-ΔLIELD or WT-ΔLIELD). This demonstrates that the 
conserved clathrin box is the major box for clathrin TD interaction and that 
the second clathrin box has a low binding affinity to clathrin. However, it is 
possible that these two clathrin box motifs may work synergistically, because 
when the conserved box (LIELD) is either deleted or mutated in WT or active 
β-arrestin 1L, there is no interaction with clathrin in the results above. 
Although, this could be an in vitro only phenomenon because in vivo, Kang et 
al., 2009 stated that the second clathrin box ([LI][LI]GXL) is actually a low 
affinity site for clathrin but could effectively localize receptors to CCPs in vivo 
even in the absence of the conserved clathrin box motifs (Kang et al., 2009). 
 
Lastly, I demonstrate that buffer HKM at pH 7.2 was the most appropriate 
buffer and pH for clathrin cages: epsin 1: active β-arrestin 1L complex 
formation. As epsin 1 has been suggested to form uniform cage size 
distribution in vitro like AP180 (Kalthoff et al., 2002), I showed that epsin 1 is 
able to form uniform size cage distribution in POL 6.4 but also in the HKM 
7.2 buffer. 
 
4.7.0 Future work 
Due to the competition between epsin 1 and active β-arrestin 1L observed in 
later stage in this PhD project, further optimisation of the binding assays of 
cages: epsin1: active β-arrestin 1L, should be considered in the future. It 
would be interesting to identify the location of certain adaptor proteins in a 
clathrin cage, but as adaptor proteins are small in size (range from ~ 30kDa 
to 100 kDa molecular weight), they would not be visible under normal EM 
conditions. Single particle cryo-EM approach could be investigated to obtain 
high resolution 3D model of a complex of clathrin cages with two adaptor 
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proteins as carried out previously by Young et al., 2013 (Young et al. 2013) 
with auxilin and Hsc70. Such a technique is considered challenging and 
would require a great amount of optimisation. Another approach to detect 
adaptor protein location could be to use the method of “metalo-tagging” or 
nanogold-labelling (Ni-NTA Nanogold) (Dubendorff et al., 2010; Morphew et 
al., 2015; Clarke and Royle, 2017). 
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Chapter 5:  
Investigating clathrin N-terminal 
domain-adaptor protein 
interactions using surface 
plasmon resonance 
 
5.0.0 Overview  
This chapter documents the main principles and procedures of the surface 
plasmon resonance/antibody indirect method (SPR/IAC). The initial aim was 
to optimise this system before investigating clathrin:adaptor interactions, 
between β-arrestin 1L and epsin 1 with clathrin N-terminal domain (TD). The 
rationale behind this chapter was to gain further insight in how how the β-
arrestin 1L two clathrin box motifs promote clathrin TD interaction. The 
biggest aim was to gain quantitative insight into how epsin 1, one of the main 
clathrin assembly proteins, interacts with clathrin N-terminal domain (TD) 
(residues 1-363) via multiple clathrin-binding sites. Obtaining quantitative 
insight into these different clathrin binding sites on epsin 1 could reveal 
different binding affinities, which inform our understanding of how, when, and 
where epsin 1 is incorporated into the assembling lattice.  
 
5.1.0 Principles of the surface plasmon resonance (SPR)  
Surface plasmon resonance enables real time binding detection and 
quantification of interactions in microfluidic environments between 
macromolecules and small molecules without the need for labels.  
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SPR phenomenon occurs when polarized (incident) light hits a metal thin film 
(e.g. gold) under total internal conditions that has a boundary with different 
reflection index. This occurs at specific angle of incidence (larger than the 
critical angle), which causes total internal reflection. Under total internal 
reflection, an evanescent light is produced when the photons resonate with 
the free oscillating electrons (plasmons) in the gold layer on the surface. 
Changes to the surface from an increased mass of molecules attached or 
bound to the surface would result to be absorbed and detected by the 
machine. This detection would result in a dip in the intensity at a certain SPR 
angle (Figure 5.1.0). Any SPR angle change is proportional to the 
concentration of the molecules on the surface. This shift is detected on a 
sensorgram and measured in response units (RU) (Biacore – Sensor Surface 
Handbook – BR-1005-71 AB (GE Healthcare)).  
 
The sensorgram plot shows the response units (RU) on the y-axis with time 
in seconds on the x-axis. From the plots we extract information on the rate of 
association and dissociation, which could result in kinetic rate constants. 
Additionally, it provides binding affinity constants for quantitative applications 
(Guiducci, 2011). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.0: Schematic of how SPR works. SPR principles involve plasmons 
being excited on the gold-layered sensor chip from shining if the incident light under 
total reflection conditions. The reflected light causes a drop in the SPR angle, which 
shifts when the mass on the surface of the chip changes as ligand-analyte interact.  
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5.2.0 SPR detects binding interactions  
In general, one molecule (ligand) is immobilized on the surface of a gold-
layered sensor chip (e.g. CM-series) and another molecule (analyte) in 
solution is injected in a continuous manner over the surface with the 
immobilized ligand. If there is an interaction between the ligand and the 
analyte; an increase in the mass on the SPR interface is detected through a 
shift in the SPR angle due to the resulting change in refractive index. This 
response is observed via the sensorgram plot (Figure 5.2.0) (Biacore – 
Sensor Surface Handbook – BR-1005-71 AB (GE Healthcare)).  
 
The increase in the response units on the sensorgram can be fitted to allow 
the association rate constant (kass/kon) of the complex formed when the 
analyte binds to the ligand to be determined. The ligand-analyte complex is 
separated once buffer is injected over the flow cell, this decreases the mass 
on the surface and alters the SPR angle. This allows the dissociation rate 
constant (kdiss/koff) to be determined in a similar manner. Once the binding 
kinetics of the ligand-analyte complex have been determined from both the 
kon and koff rate constants, which give the equilibrium dissociation constant 
(KD) can be calculated using the equation below for the situation A + B = 
(equilibrium equals sign) AB (Biacore – Sensor Surface Handbook – BR-
1005-71 AB (GE Healthcare)):  K! = !!!""!!" = ! ! . [!][!"]  
 
The flow cells are then regenerated with harsh conditions such as low pH, 
which will break the binding interactions of the ligand-analyte, but will not 
interfere with the immobilized ligand on the chip. Hence, the sensor chip can 
be used for the next analyte injection (Biacore – Sensor Surface Handbook – 
BR-1005-71 AB (GE Healthcare)). 
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5.3.0 Ligand immobilization  
There are a variety of methods to bind the ligand to the dextran matrix, such 
as direct coupling, high affinity tag capture and hydrophobic absorption 
method (Lang et al., 2005). The most common method is the direct coupling 
via thiol-disulphide exchange, aldehyde groups and free amino group, via 
amine coupling, thiol coupling and aldehyde chemistry method (Lang et al., 
2005). The direct coupling method does not guarantee its orientation in a 
uniform manner thus rendering some of the ligand binding sites inaccessible 
due to the chemical conjugation (Lang et al., 2005). However, the indirect 
coupling method require affinity tagged-proteins to be used, which is thought 
to guarantee a better orientation of the ligand due to the position of the tag at 
the end of the protein sequence (Biacore – Sensor Surface Handbook – BR-
1005-71 AB (GE Healthcare; Lang et al., 2005).  
 
In this thesis, CM-series sensor chips were used. More specifically, CM5 
chips were used as they have a standard dextran surface.  The ligand is 
immobilized on the experimental flow cell (per sensor chip), which are 
covered with 150 nm inert, thin and uniform layer of gold, which has covalent 
Figure 5.2.0: SPR sensorgram with identified various components of a typical 
experiment progression. (A) Initially at the baseline (number 1) a flat line with 
zero response is observed, once the ligand and analyte interact the response 
increases (curve) at number 2 step. (B) Same components and numberings 
demonstrate the SPR angle shift due to the ligand-analyte interaction. Imaged 
adapted from the Sensor Surface Handbook- BR-1005-71 AB (GE Healthcare). 
 
(A) (B) 
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attachment of carboxymethylated (CM) dextran matrix layer of the chip. A 
reference (blank) flow cell with no ligand immobilization is used to detect any 
analyte non-specific binding to the matrix itself and subtract from the 
experimental flow cell. 
 
Also a high affinity tag capturing method was used, called indirect capturing 
method (IAC) (Figure 5.3.0). In this method, for example a GST- tagged 
protein e.g. GST-clathrin N-terminal domain (GST- clathrin TD) was used; 
therefore, a monoclonal anti-GST antibody was immobilized first on the chip 
dextran matrix surface, which would capture the GST- clathrin TD once 
passed over the chip. Additionally, a series of experiments were performed 
for comparison where the GST- clathrin TD was directly immobilized on the 
chip surface.  
 
 
 
 
 
5.3.1 Ligand coupling (scouting) conditions 
The dextran matrix is negatively charged above the pH 3.5 and would attract 
positively charged ligands via electrostatic forces. Hence, the buffer pH of 
the ligand needs to be between 3.5 and the isoelectric point (pI) for efficient 
ligand immobilization (Figure 5.3.1). In order to determine the appropriate 
conditions, pH scouting method is typically performed before immobilization. 
A range of buffer conditions above 3.5 and below the pI of the ligand need to 
be scouted. Hence, a 10mM sodium acetate as the buffer with a range of 
pHs of 3.5, 4.0, 4.5, 5.0 and 5.5 was used (Guiducci, 2011). 
Figure 5.3.0: A schematic of the ‘high affinity tag capturing’ method. The 
affinity tagged- ligand (GST-clathrin TD) of interest is indirectly coupled to the SPR 
chip surface via a secondary molecule such as an antibody.  
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5.3.2 Ligand immobilization via amine coupling method 
After determining the best pH for ligand immobilization, the ligand needs to 
be captured on the dextran surface using chemical immobilization 
reagents/kit. Figure 5.3.2 gives a simple illustration of the amine coupling 
immobilization method that was the only capturing method used in this thesis 
During the experiment itself, 0.4M EDC (1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide) is mixed with 0.1M NHS (N-hydroxysuccinimide) in a 1:1 ratio. 
The purpose is to activate the OH moieties of the carboxylic acid groups into 
a better leaving group by the conversion into a reactive succinimide ester. 
EDC and the NHS would stabilize the ester groups. Then the monoclonal 
anti- GST antibody in 10mM sodium acetate pH 5.5 will be conjugated on 
those ester groups and couple on the surface. Ethanolamine-HCL will then 
deactivate any remaining activated ester groups (Biacore – Sensor Surface 
Handbook – BR-1005-71 AB (GE Healthcare)); Fischer, 2010; Guiducci, 
2011). 
 
 
 
 
Figure 5.3.1: Electrostatic attraction between the ligand (antibody) on the chip 
and carboxymethylated (CM) dextran surface is necessary for efficient 
coupling. If the buffer pH is lower than 3.5 or when the buffer pH is larger than the 
pI of the protein, the ligand immobilization fails. Image adapted from Sensor 
Surface Handbook- BR-1005-71 AB (GE Healthcare). 
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5.6.0 Optimisation of the SPR/IAC method 
5.4.1 pH scouting for ligand immobilization 
Initially, a Biacore pH scouting routine program was performed to determine 
the optimal pH for the coupling of the ligand onto the SPR chip dextran, as 
described section 5.3.0. In this thesis, the monoclonal anti-GST antibody was 
used to couple on the SPR chip and the GST-tagged ligand e.g. GST-clathrin 
TD to bound on the antibody, and GST-clathrin TD was also immobilized on 
the SPR chip directly. A range of pHs were used (3.5-5.5) in 10 mM sodium 
acetate. For GST-clathrin TD as seen by the Figure 5.4.1 (B), the only pH 
where any attraction to the surface was measured was 5.5, while of the anti-
GST antibody attraction was measured both at 5.5 and 5.0 Figure 5.4.1. (A), 
but as customary in those cases we select the highest pH, which provides 
sufficient response units.   
Figure 5.3.2: An overview of the amine coupling method to immobilize the 
ligand on an activated chip surface. The diagram illustrates the EDC/NHS 
chemistry for activating the dextran surface. The ligand is then flown over the chip 
to couple to the surface on a primary amine groups. Image was taken from the 
Sensor Surface Handbook- BR-1005-71 AB (GE Healthcare). 
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File: GST-TD-WT-scouting-FC1-Chip8-270317.blr Date: 27-Mar-17
Page: 1
Immobilization pH Scouting Results
Cycle Fc Buffer pH Ligand RelResp
[RU]
1 1 10 mM Acetate 5.5 TD 32862.3
1 1 10 mM Acetate 5.0 TD 0.0
1 1 10 mM Acetate 4.5 TD 0.0
1 1 10 mM Acetate 4.0 TD 0.0
1 1 10 mM Acetate 3.5 TD 0.0
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File: scouting-300117.blr Date: 30-Jan-17
Page: 1
Immobilization pH Scouting Results
Cycle Fc Buffer pH Ligand RelResp
[RU]
1 1 10 mM Acetate 5.5 monoclonal Ab 9721.1
1 1 10 mM Acetate 5.0 monoclonal Ab 17132.5
1 1 10 mM Acetate 4.5 monoclonal Ab 1509.4
1 1 10 mM Acetate 4.0 monoclonal Ab -890.7
1 1 10 mM Acetate 3.5 monoclonal Ab -11232.1
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Figure 5.4.1: pH scouting for the immobilization of anti-GST antibody (A) or 
GST clathrin-TD (B). (A) pH 3.5 (pink curve), 4.0 (black curve) resulted in a 
negative relative response units and pH 4.5 (green curve) resulted in zero 
relative response units and were not used in the ligand immobilisation 
procedure. The best pH was 5.5 (red curve) and 5.0 (blue curve) for anti-GST-
antibody wirh relative response of ~ 20,000 RU and ~ 15,000 RU respectively (B) 
The only pH for GST-clathrin TD was 5.5 (red curve) with the highest relative 
response of ~ 35,000.RU. The remaining buffers with lower pH did not give any 
response. 
(A) 
(B) 
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  5.4.2 Regeneration scouting 
Another procedure which required optimization was the regeneration, which 
takes place after the ligand and analyte complex interact and need to be 
removed before the next interaction could be carried out on the same flow 
cell. Multiple regeneration tests were carried out part of the initial optimization 
stages, with regeneration solutions such as 3M MgCl2, 50mM NaOH and 10 
mM Glycine HCl pH 2.0-3.0 (data not shown). It is important to note that the 
regeneration reagent do not interfere with the anti-GST antibody coupled on 
the chip or the ligand that has been covalently attached on the chip. The best 
regeneration condition used for all the SPR experiments in this thesis was 10 
mM glycine, pH 2.2 with two injections of 30 seconds each, which was also 
recommended by the GST capturing kit -Instructions 22-0522-19 AG (GE 
Healthcare), and which was adequate to bring the response units 
approximately back to baseline (Figure 5.4.2). 
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Figure 5.4.2: Two injections of 30 seconds each of 10 mM glycine-HCl pH 
2.0-2.2 was used. The regeneration stages are shown in the blue box and 
demonstrate how the response returns to baseline after the regeneration 
conditions, ready for the next experiments. 
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  5.4.3 Immobilization of anti-GST antibody and GST-
clathrin TD 
After determining the optimal pH for ligand immobilization, the ligand was 
covalently immobilized on the chip surface via the free amine groups formed 
from the amine coupling method detailed in section 5.3.2. The sensorgram 
plot of the immobilized anti-GST antibody is shown in Figure 5.4.3 (A) and 
GST-clathrin TD is shown in Figure 5.4.3 (B). The anti-GST antibody was 
immobilized between ~ 10,000-15,000 RU on the experimental flow cell 
experiment with a final concentration of 0.5 μM of anti-GST antibody in 
10mM sodium acetate at pH 5.5. The GST-clathrin immobilization was 
achieved at ~ 35,000 RU, with 10 μM concentration of GST-clathrin TD in 
10mM sodium acetate at pH 5.5. 
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Figure 5.4.3: Sensorgrams demonstrating successful ligand immobilisation. 
Activation of the dextran matrix is carried out by EDC/NHS to form free amine 
groups. Immobilization of the anti-GST antibody (A) and GST-clathrin TD (B) was 
then determined at ~ 10,000-15,000 RU for the anti-GST (A) and ~ 32,000 RU for 
the GST-clathrin TD (B). Ethanolamine was then used to deactivate and cap the 
remainder of unbound free amine groups and cap the flow cell. 
(B) 
(A) 
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5.4.4 Direct capturing method results 
The GST-clathrin TD was successfully immobilized on the chip with ~ 35,000 
RU using the amine coupling method, as stated above. In order to determine 
whether the direct capturing method of the GST-clathrin TD was suitable to 
use for the SPR experiments; active β-arrestin 1L (analyte) was injected onto 
a flow-cell with immobilised GST- clathrin TD. The SDS-PAGE results from 
Chapter 4 and previous SPR experiments from Kang et al., 2009 have 
previously demonstrated that active β-arrestin 1L binds strongly to the GST- 
clathrin TD via tis two clathrin box motifs on C- and N- terminal domains 
exhibiting a high response (Kang et al., 2009). Hence, it was the most ideal 
adaptor protein to test the functionality of the direct capturing method. The 
results in Figure 5.4.4 showed no increase in response units (RU=0, t=100) 
when active β-arrestin 1L was flowed over the SPR chip bound directly to 
GST-clathrin TD. In the direct ligand coupling method proteins are randomly 
orientated and coupled on the chip (Lang et al., 2005), therefore we can 
hypothesize that this could be the case with the GST-clathrin TD. Thus, there 
is a possibly that this method is hindering certain TD binding sites (especially 
blade 1 and 2 and 4 and 5 where active β-arrestin 1L binds). This is most 
likely to prevent the active β-arrestin 1L from binding to the TD, resulting in 
lack of increase in response, as seen in Figure 5.4.4. 
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Figure 5.4.4: Sensorgram demonstrating unsuccessful analyte (adaptor 
protein) binding to ligand (GST-TD) under the direct capturing method. Once 
the GST-TD was successfully bound to the SPR chip via the amine coupling 
method, the active β-arrestin 1L (analyte) was flown over the flow cell for 200 
seconds to allow interaction between ligand and analyte. The results revealed no 
increase in the response units (R=0, t=0), which led to the hypothesis that the GST-
TD is orientated randomly in the direct capturing method, potentially obscuring its 
adaptor protein binding sites and thus preventing active β-arrestin 1L from binding. 
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5.4.5 Indirect Antibody Capture (IAC) method  
Due to the unsuccessful binding results of the GST-clathrin TD and active β-
arrestin 1L via the direct capturing method; the indirect antibody capturing 
(IAC) method was the next option, which to explore. 
 
To test this method the anti-GST antibody was coupled to the dextran matrix 
surface of the SPR chip, following optimization as stated in sections 5.4.3, 
previously in this chapter. Secondly, the ligand, in this case 1 μM GST-
clathrin TD was injected over the anti-GST antibody for 100 seconds. 
Successful binding of the GST-clathrin TD was indicated by the increase in 
response units (~ 1000 RU) detected (Figure 5.4.5 (A)(i)). A test analyte, 
purified GST, which is expected to bind, was injected over the cell for 200 
seconds, and an increase in the response units detected is shown in Figure 
5.4.5 A)(ii). BSA was used as a non-binding control analyte, which should not 
interact with the anti-GST antibody. No binding was observed when the BSA 
was injected onto the SPR chip (RU=0) Figure 5.4.5 (A)(iii), as expected. 
After the injection of the analyte SPR buffer 1 was injected for ~ 500 seconds 
to allow the dissociation of the complex before regeneration (Figure 5.4.5 
(A)(iv)).  
 
The advantage of using an antibody-capture method of an affinity-tagged 
protein is that it is more likely to orientate the protein (ligand) in a certain 
favored direction to expose its analyte binding sites (Lang et al., 2005). For 
the system tested this would mean a more appropriate orientation of the 
GST- clathrin TD (ligand) with the GST affinity tag being on N-terminal 
domain attached on chip allowing the ligand to be free in solution at a 
specific orientation. This would most likely expose its four adaptor binding 
sites to the adaptor proteins (analyte). A fresh ligand is captured in every 
new experiment, which is an advantage of the IAC method over the direct 
capturing method (Lang et al., 2005). A third advantage of the IAC method is 
that it does not require covalent modifications or interactions of the actual 
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ligand, in this case GST-clathrin TD, and thus it will not affect the ligand’s 
activity (Lang et al., 2005).  
 
The major disadvantage of the IAC method via antibody capturing, is that the 
antibody binding capacity decreases after each run and this is detected by a 
systematic decrease in the clathrin TD binding in majority of the SPR 
experiments of this thesis. Therefore, each flow cell was only used for up to 
6-7 experiments, which significantly increases the cost of this method. This 
could be because of the harsh regeneration conditions (10 mM glycine-HCl 
pH 2.0-2.2) applied at the end of each experiment, which removes the 
ligand-analyte complex, but does not detach the anti-GST antibody bound 
onto the chip. This decrease was also observed by Snopok et al., 2006 
(Snopok et al., 2006), therefore it was considered a systematic issue of this 
method, which was taken into consideration in the experiments.   
 
The main stages of the IAC method for the clathrin:adaptor system are 
illustrated in a diagram Figure 5.4.5 (B); based on Karlsson et al., 1994, as 
the active β-arrestin 1L did not bind to the directly coupled GST-clathrin TD, 
as described in section 5.4.4, in previous section of this chapter. For the 
subsequent SPR/IAC clathrin TD:adaptor experiments, GST- clathrin TD at 1 
μM concentration in SPR buffer 1 is defined as the ligand and the relevant 
adaptor protein used at 10 μM total concentration (ratio 1:10) in SPR Buffer 1 
is defined as the analyte. This ratio was also used in the GST-pulldown 
binding assays as well. 
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Figure 5.4.5: Control experiments run for the IAC method and illustrating the 
stages of the method for clathrin:adaptor interactions. (A) A sensorgram with 
results at each stage of sample injection (ligand first and analyte second) The GST-
TD is bound with an increase in response units detected on the sensorgram (i), the 
GST (positive control analyte) binds with an increase in response units (ii). The BSA 
(negative control analyte) does not bind to GST-TD or antibody hence there is no 
increase in response units over time (seconds) (iii). After a period of buffer being 
injected over the flow cell to allow dissociation of the complex of the ligand-analyte, 
the flow-cell is regenerated (iv) with glycine pH 2.2 in order to be re-used for the next 
experiment. (B) A simple illustration of the indirect antibody capturing method. The 
GST-TD (ligand) is bound on the immobilised anti-GST antibody on the selected flow 
cell. The analyte (adaptor proteins, GST tag or BSA) are then injected over the flow-
cell and bind to the GST-TD or antibody. Regeneration of the flow cell with 10 mM 
Glycine pH 2.2 is carried out. CM5 sensor chip image taken from Biacore Sensor 
Surface Handbook- BR-1005-71 AB (GE Healthcare). 
(B) 
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5.7.0 Optimisation for Binding Kinetics  
  5.5.1 Decreasing non-specific binding of epsin 1 
Following establishment of the binding method, the next step was to optimize 
the detection of adaptor protein binding. In the case of epsin 1 we 
encountered issues with non-specific binding, which was continuously 
detected as an increase in response on the reference/blank control flow cell 
trace on the sensorgram. The non-specific binding could be because of the 
overall negative charge of the surface and the attraction to the dextran matrix 
or could be due to the complex nature of the epsin 1 structure (long 
unstructured flexible region). This is a major disadvantage for kinetic runs 
and therefore needed to be addressed. 
 
Two potential approaches to disrupt the charge interactions between epsin 1 
and the dextran-carboxyl surface of the chip were employed and the results 
are detailed below: 
 
(a) covering the dextran surface of the reference flow cell with a non-
interacting protein such as BSA or a different antibody that does not 
have affinity to epsin 1,  e.g. β2-microglobulin Ab-1 (Mouse mAb). The 
β2-microglobulin Ab-1 antibody immobilization was utilized as the 
method of choice with same ratio as the anti-GST antibody 
immobilization. This forms an inert protein layer on the reference flow 
cell. This method successfully decreased the non-specific binding of 
epsin 1 (257 mutant) on the reference flow cell (Figure 5.5.1 (A)), but 
did not eliminate it completely. 
 
(b) SPR running buffer was used with increased NaCl concentrations 
from 150 mM to 500 mM, as high ionic strength disrupts non-specific 
binding. Figure 5.5.1 (B) shows the decrease in the non-specific 
binding of epsin 1 using the higher salt concentration in the running 
SPR buffer. 
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As a result of these investigations, it was decided that for any future epsin 1 
SPR experiments, a combination of a 500mM NaCl SPR buffer and antibody 
β2-microglobulin Ab-1 immobilised on the reference flow cell should be, 
which successfully decreases non-specific binding (Figure 5.5.1 (C)). It was 
noted that there would be a certain degree of non-specific binding for all 
proteins in general. For other adaptor protein SPR experiments the standard 
SPR buffer (150 mM NaCl) was used. 
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  5.5.2 Lowering the ligand (clathrin TD) and analyte 
(adaptor protein) density  
To obtain reliable kinetic binding constants for protein-protein interactions, 
the response for ligand-analyte complex formation needs to be in the range 
of 100-300 response units (Van Der Merwe, 2001). In the IAC method, the 
response obtained upon binding of GST-clathrin TD (ligand) at a final 
concentration of 1 μM to the SPR chip was ~ 1000 RU, which already 
exceeds the limit for determining kinetic constants, even without adding the 
adaptor protein analyte. This was because of the strong binding between the 
anti-GST antibody of the chip and the GST-affinity tag on the TD at that 
concentration. Therefore, a great amount of optimization was carried out to 
decrease the concentration of GST-clathrin TD and the adaptor proteins. 
Figure 5.5.1: Disrupting the charge interactions between epsin 1 and 
dextran- carboxyl surface of the chip on the reference flow cell. These 
response units are detected on the reference flow cell covered with 0.1 μM GST-
TD and 2.5 μM epsin 1. (A) A decrease in the non-specific binding of epsin 1 was 
determined from 2,500RU to 200 RU, when the reference flow cell was 
immobilized with a β2-microglobulin antibody (B) A decrease in the non-specific 
binding of epsin 1 was determined from 1,500RU to 500 RU, when a high salt 
(NaCl) concentration of 500 mM was used in the SPR buffer. Decreasing the salt 
(NaCl) concentration had no difference than the normal 150 mM salt SPR buffer, 
in the non-specific binding level of epsin 1. (C) The non –specific binding is 
decreased massively (<100 RU) when the flow cell is immobilized with the β2 
myoglobin in combination with using 500 mM NaCl in SPR buffer. 
0 100 200 300 400 500
0
100
200
300
400
500
Time (s)
R
es
po
ns
e 
D
iff
.
B2 Ab and 500 mM NaCl
(C) 
 108 
Decreasing the response units of the adaptor proteins, especially for epsin 1 
was the most challenging due to its complex interactions between 
epsin1:clathrin TD. The best result obtained was with the ligand immobilized 
at 100-200 RU of GST-clathrin TD at 0.1 μM concentration, and 500-600 RU 
of the adaptor protein (e.g. 257 epsin) at 1.25 μM concentration. This was 
achieved by decreasing the anti-GST antibody and the β2 myoglobin 
concentration by half. Overall, 1:10-1:12.5 molar ratios of clathrin:adaptor 
were kept even when lowering the ligand and analyte concentrations, which 
was the approximate saturation ratio between clathrin and epsin 1 and β-
arrestin 1L, which was previously determined in Chapter 4.  
 
5.6.0 Mass Transport Limitation 
  5.6.1 Overview of mass transport limitations 
In a SPR instrument, the analyte is delivered onto the dextran matrix surface 
of the SPR chip, by the process of bulk flow and diffusion, prior coming in 
contact with the ligand. However, mass transport could occur when the 
binding rate of the analyte to the ligand exceeds the rate at which the analyte 
is injected to the chip surface (Van Der Merwe, 2001; Lang et al., 2005). 
Mass transport limitation is detected on a sensorgram as changes in the 
binding curve shape with different flow rates (μl/min) (Van Der Merwe, 2001).   
  5.6.2 Decreasing mass transport issues 
It is important to consider whether there were any mass transport issues for 
the epsin 1 WT and mutants, which were key in most SPR/kinetic 
experiments. Figure 5.6.2 (A) shows how changing the flow rate of the 
experiments causes the epsin to interact with clathrin TD differently, which 
has been confirmed by observing the difference in the response curves 
obtained using different flow rates  (10, 20, 30 μl/min). The experiments were 
run with a longer injection time of 5 minutes (300 seconds) for fitting 
purposes. These results reveal possible mass transport issues in 
clathrin:epsin interactions even at 150 RUs. This mass transport observed 
could be due to: (a) the structure of epsin 1 with the unstructured region 
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between the two clathrin box motifs, which could promote flexiblility in its 
binding. (b) the hypothesized multiple interaction of epsin 1 with clathrin TD 
(c) high ligand density which could increase mass transport issues. 
 
To try to address with mass transport limitation, the following approaches 
can be used as suggested by Van Der Merwe, 2001: (a) lower the ligand 
density because high ligand densities on the chip surface would not allow 
accurate kinetic analysis because of mass transport issues caused (b) 
increase the flow rate until high enough to compensate for the mass 
transport limitation and no change is observed of the response curves (> 30 
μl/min), as suggested by Lang et al., 2005. (c) mass transport correction is 
included in certain kinetic fitting models.  
 
The ligand density was optimized in the previous section 5.5.2. Hence, a 
range of higher flow rates were investigated (40 and 60 μl/min), and a longer 
injection time of 5 minutes (300 seconds) to allow the epsin to reach 
saturation levels. Figure 5.6.2 (B) shows no significant difference in the 
shape in their response curves and response units of epsin 1 binding to the 
TD, at flow rate 40 μl/min (orange curve) and 60 μl/min (black curve). 
Overall, taking into account all of the above, the kinetic runs were performed 
with the lowest 40 μl/min flow rate which would require less protein 
concentrations. The flow rate of 40 μl/min reduced but did not completely 
eliminate mass transport issues, which proved challenging to overcome 
completely. Thus an approach utilizing appropriate kinetic experiments, 
which take into account the mass transport, was implemented. 
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Figure 5.6.2: SPR response curves demonstrating mass transport issues of 
epsin 1 once injected on an SPR chip with immobilised GST-clathrin-TD. (A) 
Epsin 1 -257 mutant (0.625 μM) was used in SPR/IAC experiments which yielded a 
response of a maximum of ~ 150 RU with a longer injection time of 300 seconds at 
different flow rates  (10, 20, 30 μl/min). These results illustrate the mass transport 
limitations. (B) Using a higher concentration of epsin 1 – 257 mutant (1.25 μM) and 
higher flow rates of 20,40,60 μl/min, resulted in eliminating mass transport at higher 
flow rates of 40 μl/min (orange curve) and 60 μl/min (black curve). 
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5.7.0 Quantitative measurements  
  5.7.1 Kinetics 
In order to obtain more quantitative results from the SPR/IAC data, I used the 
following kinetic models to fit certain SPR experimental data obtained in this 
project. The fitting software (BIAevaluation version 4.1) is based on the 
minimization of the least squares, built on the Levenberg-Marquardt 
algorithm used in minimizing the sum of the squared residuals (S) between 
the experimental data and the fitted model, as shown below (Biacore –
BIAevaluation software Handbook- BR-1002-29 (GE Healthcare)) 
 
! = ! !! − !!!!
!
 
! = !"#!!"!!ℎ!!!"#$%&'!!"#$%&'(#,! !! = !"##$%!!"#$%!!"!!"#$%!!"#$%,! !! = !"#!$%&!'()*!!"#$%!!"!!ℎ!!!"#$!!"#$% 
 
The basic principles to obtain binding rate constants and dissociation 
constants are based on an analyte being injected over a ligand coupled to a 
chip surface. The ligand-analyte complex formation and separation is 
recorded on a sensorgram as the ‘association phase’ (kon /kass) and the 
‘dissociation phase’ (koff/kdiss) respectively. During the ‘association phase’, A 
(ligand) + B (analyte) interact to form AB (ligand-analyte) complex, as shown 
in Eq. [1]. In the ‘dissociation phase’, the AB complex dissociate back to A + 
B, as seen in the Eq. [2]. Eq. [3.1] Equilibrium is reached when the rate of 
formation of product is equal to its rate of dissociation and as a result the 
concentration of the reactants in the system remains constant. The 
equilibrium dissociation constant is termed KD (Eq. [4]) and is derived from 
rearranging the Eq. [3.2] (equations adapted and modified from Biacore -
BIAevaluation software Handbook- BR-1002-29 (GE Healthcare)). The 
equations below demonstrate how the KD is obtained: 
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  5.7.2 Introduction: kinetic models of protein binding 
Here, the parameters of each kinetic model chosen are briefly explained and 
the rationale for deeming that they were appropriate for the clathrin:adaptor 
system. The data fitting with this models were carried out using the 
BIAevaluation version 4.1 program (Biacore) which was implemented in the 
SPR system, and supplementary information from BIAevaluation software 
Handbook BR-1002-29 (GE Healthcare) was used for guidance to 
understand the background of each model, as briefly explained below: 
I. 1:1 Langmuir, this is considered the simplest model, where one 
analyte molecule interacts with one ligand molecule at a 1:1 
interaction, as seen in the equation below: 
 ! + !!⇔ !", ! !"!#$%& ,! !"#$%& ,!"(!"#$%&') 
II. 1:1 binding with mass transport, which is an identical model of the 
above but takes into account the analyte mass transport issues 
observed in the experimental data even when the ligand density is low 
M/S  = M-1s-1      M   M          s-1      M 
[1] 
[2] 
[3.1] 
[4] 
[3.2] 
Reaction is at equilibrium when the concentrations do not change: 
Equilibrium is reached when: 
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and the flow rate is increased, which was the situation with the 
experiments in this thesis for clathrin:adaptor. 
III. Heterogeneous ligand/parallel reactions, which is used when one 
analyte e.g. adaptor protein, binds to two independent ligands e.g. two 
different clathrin TD molecules. 
IV. Bivalent analyte, which was the most appropriate model for the 
clathrin:adaptor system. It describes a situation where one analyte 
e.g. adaptor protein, can bind to one or two sites on the same ligand 
e.g. TD sites (multivalent binding). This model takes cooperative 
binding effect into account, but does not show any response of the 
second site interaction on the sensorgram, because the overall mass 
on the surface does not change. Thus, this model will provide a single 
set of rate constants for the first analyte-ligand site interaction and a 
second set of rate constants for the second analyte-ligand site 
interaction. The equations which form the basis of this model are 
presented below adapted from Biacore -BIAevaluation software 
Handbook- BR-1002-29 (GE Healthcare)).  
 !"#$%&'#()"!1:!! + !!⇔ !"; !!!!"#$!!"#$%&#%$: !!!!!"! 
 !"#$%&'#()"!2:!!" + !!⇔ !"2; !!!"#$!!"#$%&#%$:! !"2!"2!! 
 
!! < 10,!""#$%&&!!"!!"#![!! = ! !! − !!!! !! − ! ] ! = !"#$%&!!"!!"#$%& ! = !"#$%&!!"!!"##$%!!"#"$%&#' 
 
 
A (analyte); B (ligand); AB (analyte-ligand complex) 
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5.8.0 Investigating the binding interactions of adaptor 
proteins with clathrin TD using SPR 
5.8.1 Investigating β-arrestin 1L and clathrin TD interactions 
5.8.2 Introduction of β-arrestin 1 
β-arrestin 1 is a multifunctional protein involved in the “turning-off” 
(desensitization) and uncoupling of GPCRs from G-proteins causing loss of 
responsiveness of the receptor to ongoing stimulus. Its main role in CME is 
to recruit clathrin and other vital adaptors, such as β2-adaptin (AP2), via its 
conformational change to become an active (longer isoform (L)), and release 
its C-terminal domain flexible loop, to the plasma membrane to facilitate 
receptor internalization (Lefkowitz et al. 2006; Kang et al., 2009; Gurevich, 
2014; Lemmon and Traub, 2012). β-arrestin 1L/arrestin 2L (longer isoform) 
contains a LIELD (LØXØ[DE] single letter amino acid code where Ø 
represents a hydrophobic residue) clathrin box motif (357-383 amino acids), 
which is a conserved clathrin binding motif found in many adaptor proteins. 
An eight-amino acid β -arrestin 1L splice loop with a clathrin box motif 
([LI][LI]GXL) that has also been proposed to bind to clathrin TD at blades 4 
and 5 (Laporte et al., 2000; Lefkowitz et al., 2006; Burtey et al., 2007; Kang 
et al. 2009; Gurevich, 2014; Lemmon and Traub, 2012). Moreover, it has 
been confirmed that β-arrestin 1L with the LIELD clathrin box motif deleted 
still binds to clathrin TD upon agonist treatment (Laporte et al., 2000; Kang et 
al., 2009; Gurevich, 2014). 
 
 5.8.3 Aims and objectives  
 
The well-studied β-arrestin 1L was the first adaptor protein to be investigated 
for clathrin:adaptor interactions using the optimized SPR/IAC method. 
Experiments were conducted with the following aims in mind:  
1. To investigate further, and confirm the suggested functionality of the 
structure of β-arrestin 1L and whether the second ([LI][LI]GXL) clathrin 
box motifs acts antagonistically or synergistically with the conserved 
clathrin box motif (LIELD).  
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2. To decide if β-arrestin 1L is suitable to be used for adaptor 
competition experiments, detailed in Chapter 6. The active form of β-
arrestin 1L has two clathrin box motif in the opposite direction to its 
structure and has been hypothesized to have a linking effect with 
multiple TDs, which is similar to other adaptor protein’s functionality 
e.g. epsin 1. Hence, I aimed to investigate how the action of the 
second clathrin box motif, which has been shown to bind to the 
ArrestinBox site on the TD, would interact with clathrin TD in the 
presence of other adaptor proteins. 
3. To confirm that the optimised SPR/IAC method functioned with GST-
clathrin TD (ligand) and adaptor proteins (analyte) system before 
using it for future investigations in clathrin:adaptor competition studies. 
 
5.8.4 Mutagenesis studies of β-arrestin 1L  
Mutagenesis is carried out on the conserved clathrin box motif (LIELD), as 
described in the Table 1.7.0 below. The conserved clathrin box is located on 
the C-terminal domain flexible loop as illustrated in Chapter 1, section 1.8.1. 
The mutant abbreviations used in this thesis are as follows: active (IVF), IVF-
AAEA, WT-AAEA, IVF-ΔLIELD and WT-ΔLIELD), which were designed in 
line with Keyel et al., 2008. Each SPR experiment was performed in triplicate 
and the order of analyte injection was randomised. This was conducted to 
minimize any systematic error caused by the decreased binding capacity of 
anti-GST antibody after each regeneration, which was discussed previously. 
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5.8.5 The LIELD clathrin box motifs the major box  
The highest response obtained from the SPR results was determined by the 
active form of β-arrestin 1L mutant, as shown in the blue curve in Figure 
5.8.5 (A), with the WT response greatly reduced (red curve) (Figure 5.8.5 
(A)). The rest of the β-arrestin 1L mutants show a complete loss of response 
when the conserved clathrin box motif is deleted (ΔLIELD). However, in the 
case of the active mutant with an alanine substitution in the conserved box 
(IVF-AAEA), a slight increase in response is observed compared to the 
active mutant response is observed (Figure 5.8.5 (A)). These results 
represent three independent repeats where the mean of these repeats are 
plotted on a bar chart for each WT and mutant. This plot demonstrates that 
the active form has the highest binding response units of 1351 ± 198.6 RU 
with the WT next with 179 ± 19.96 RU, which is below the half. The rest of 
the mutants do not show any binding at all except the IVF-AAEA, which 
resulted in a 29.54 ± 14.81 RU binding only. 
 
These results are similar to the results by Kang et al., 2009 and the overall 
conclusion suggested that the conserved clathrin box (LΦXΦ[DE]), is the 
major binding site on the β-arrestin 1 for TD, as the IVF- ΔLIELD and WT- 
ΔLIELD failed to bind. The WT β-arrestin 1 is assumed to have a more 
Number 
Mutant Name  
(abbreviation) 
Original motif -> alanine substitution 
and/or deletions 
1 Active  386IVF->AAF 
2 IVF-AAEA 386IVF + 
376
clathrin box (LIELD->AAEA)   
3 WT-AAEA WT + 376clathrin box (LIELD ->AAEA)   
4 IVF-ΔLIELD 386IVF + 
376
clathrin box (LIELD) deleted 
5 WT-ΔLIELD WT + 376clathrin box (LIELD) deleted 
Table 1.7.0: Details of the β-arrestin 1L mutants. The main mutations are 
activation and release of the conserved clathrin box (LIELD) by mutation the IVF 
motif to AAF at the beginning of the unstructured loop containing the clathrin box or 
deleting this clathrin box. Mutations were not performed on the second clathrin box 
(LIEFD ([LI][LI]GXL)) on the N-terminal domain. 
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flexible and mobile unstructured loop where the conserved clathrin box is 
located, and hence this could suggest the binding of the WT observed in 
SPR results of this section. However, based on the above results, I appears 
that the two clathrin box motif act cooperatively, as the highest binding was 
detected with the active form of β-arrestin 1L with the two boxes open and 
accessible. Once, the conserved clathrin box motif is deleted, this causes a 
massive decrease in the binding of clathrin TD. Thus, these results suggest 
that the second clathrin box motifs is not as efficient for clathrin TD binding 
independently as the conserved clathrin box motif. 
 
The shape of the curve is indicative of the nature of the interaction The 
shape of the active β-arrestin 1L response curve could indicate a two binding 
phases of β-arrestin 1L to clathrin TD, therefore a more complex binding 
interaction, which has been suggested by Kang et al., 2009 as well as a 2:1 
β-arrestin 1L to clathrin (Kang et al., 2009). However, the WT (red curve) 
could be fitted as a single exponential function due to the smooth curvature 
of the curve. Additionally, both WT and active forms resulted in a very low 
dissociation rate form the GST- clathrin TD, as seen on the sensorgram 
(Figure 5.8.5 (A)). This could suggest strong binding between the β-arrestin 
1L and the GST-clathrin TD, as well as the presence of multiple interactions, 
which could be the cause of this observed stronger interactions due to the 
cooperative mechanism of the two clathrin box motifs. 
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Figure 5.8.5: Binding of β-arrestin 1L WT (10 μM) and mutants to GST-TD (1-
363) (1 μM). (A) Binding of purified β-arrestin 1L WT and 5 mutants to GST-TD. 
The Active beta-arrestin 1L binds the strongest, whereas the WT shows reduced 
binding. The IVF-AAEA mutant ha binding higher than all the rest of the mutants 
(WT-AAEA, IVF- ΔLIELD and WT- ΔLIELD), but shows significantly lower binding 
than Active or WT. These results are taken from 3 consecutive repeats on 
monoclonal anti-GST immobilised CM5 chips. (B) The results from (A) are plotted 
on a bar chart representing the mean from the highest response value of three 
independent repeats (n=3) and the standard deviation. The Active form has the 
highest binding response of 1351.0 RU with the WT next with 179.0 RU. The rest 
of the mutants do not show any binding at all except the IVF-AAEA, which 
resulted in a 29.54 RU binding only. 
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5.8.6 Discussion 
The SPR/IAC data obtained for the WT and mutant β-arrestin 1L were similar 
to the results of Kang et al., 2009. Overall, the second clathrin box 
([LI][LI]GXL) on the β-arrestin 1L is open and accessible for binding to the 
clathrin TD. A cooperative effect could be hypothesized between the two 
clathrin box motifs from this data, which contradicts the fact that CCPs in vivo 
can localize even in the absence of the conserved clathrin box motifs (Kang 
et al., 2009). However, SPR results from Kang et al., 2009 revealed a ~2-fold 
difference in binding affinity between active and WT β-arrestin 1L. The 
strongest binding was between the clathrin TD and active β-arrestin 1L with 
a KD of 0.98 ± 0.01 μM, whereas the KD of the WT β-arrestin 1L bound to 
clathrin TD was 2.1 ± 0.4 μM (Kang et al., 2009). These binding affinities 
confirm the SPR results in this section, stating how the active β-arrestin 1 
has the strongest binding capacity to clathrin compared to the WT (inactive 
β-arrestin 1 form). Further discussion is detailed in Chapter 7. 
 
5.8.7 Conclusion 
In conclusion, I confirmed that the optimized SPR/IAC method works 
successfully for investigating the binding of the GST-clathrin TD and β-
arrestin 1L as adaptor protein, and could later be used to determine binding 
of other adaptor proteins to the clathrin TD. β-arrestin 1L has two clathrin box 
motifs accessible, which interact strongly with clathrin TD resulting to the 
highest response and binding affinity (KD). I confirmed that the active β-
arrestin 1L is an ideal adaptor protein to use in the adaptor competition 
studies described in Chapter 7, as it has two clathrin box motifs and has 
been hypothesized to have a ‘linking effect’ of multiple TDs similar to other 
adaptor proteins such as epsin 1. 
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5.9.0 Investigating epsin 1 and clathrin TD interactions   
  5.9.1 Introduction to epsin 1 
Epsin 1 is an endocytic adaptor protein, which has been shown to have a 
fundamental role in clathrin assembly during clathrin- mediated endocytosis 
(CME), by membrane remodelling to facilitate lattice curvature but also by 
promoting clathrin assembly influencing the size of clathrin-coated pits and 
vesicle formation (Drake et al., 2000; Kalthoff et al., 2002; Ford et al., 2002; 
Holkar et al. 2015). However, the exact mechanism by which epsin 1 
interacts and facilitates efficient clathrin assembly is still unclear. 
 
The epsin 1 structure consists of two clathrin box motifs (LMDLA (starting 
residue 257) and LVDLD (starting residue 480)) at the central region, which 
have been shown to bind to clathrin TD of the clathrin heavy chain (CHC) 
(Drake et al. 2000). The unstructured region is in between the two clathrin 
box motifs and consists of eight DPW repeated motifs along the long flexible 
region, which have also been shown to bind to clathrin independently (Drake 
et al., 2000; Kalthoff et al., 2002; Brett et al., 2002). These DPW motifs also 
bind to the α-ear and β2 –ear subunit of AP2, which could promote a 
cooperative effect between epsin 1 and AP2 in clathrin assembly (Drake et 
al. 2002; Brett et al., 2002; Dafforn and Smith, 2004; Edeling et al., 2006a). 
Interestingly, epsin 1 is hypothesized to bind to three clathrin TD sites via its 
two clathrin box motifs and the DPW motifs in the unstructured region. The 
hypothesized TD sites are: 1(CBM), 2 (W box) and 3 (Arrestin box) (Drake et 
al. 2000; Kalthoff et al., 2002). The yeast homolog of epsin (Ent2) has been 
shown to bind to the CBox (site 1) and W-box (site 2) of the TD sites (Collette 
et al., 2009). However, it is still yet to be confirmed whether epsin 1 binds to 
the RoyleBox (site 4), which has been recently characterized (Muenzner et 
al., 2017). 
 
Epsin has been hypothesised to promote smaller uniform cage structures in 
vitro (Kalthoff et al., 2002). This has been previously seen with another 
adaptor called AP180, which has a similar unstructured flexible structure with 
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DLL motif that interact with clathrin (Ahle and Ungewickell, 1986; Greene et 
al. 2000; Morgan et al., 1999; Engvist-Goldstein et al., 2001;Kalthoff et al., 
2002). Negative stain electron microscopy was used to demonstrate the 
uniform sized cage distribution that epsin 1 promotes (Figure 5.9.1). Despite 
our existing knowledge of epsin 1 structure and functionality, questions 
remain to be answered as to how this unique and complex structure of epsin 
1, with its multiple ‘clathrin binding’ components, interacts with clathrin TDs 
and promotes efficient clathrin assembly and the alteration in size cage 
distribution.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 nm 
Figure 5.9.1: Images by negative stain EM demonstrating the uniform cage 
size distribution formed from epsin WT and clathrin cages in vitro. Clathrin 
cages were assembled (3 μM) alone (A) and with the presence of epsin 1 WT (30 
μM) and imaged using negative stain (2% uranyl acetate) EM at a final 
concentration of 1uM from the assembled clathrin. Images (A) demonstrate the 
heterogeneity of clathrin cages structures as seen inside the black box. However, in 
the presence of epsin 1 WT, uniform sized clathrin cages are observed in image (B) 
compared to (A). Figure (A) is at 25000X magnification and Figure (B) is at 30000X 
magnification using a JEOL 2011 microscope with Gatan Ultrascan 4000 CCD. 
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5.9.2 Mutagenesis studies of epsin 1 clathrin box motifs 
To investigate this we used mutagenesis studies, where we used full length 
WT epsin 1 (residues 1-575) and three epsin 1 mutants (257, 480 and DKO) 
proteins produced from the original WT construct. The mutants were 
designed in line with Drake et al., 2000 and Holkar et al., 2015. These 
mutants have alanine substitution at the clathrin binding motifs at the starting 
residue 257 or 480 or both (DKO), are described in Figure 5.9.2.  
Dr. Michael Baker from the Smith group at the University of Warwick first 
investigated these mutants using ultracentrifugation binding assays/SDS-
PAGE analysis and demonstrated that all three mutants of epsin (257, 480 
and DKO) still bind to clathrin cages, even when the clathrin box motifs were 
mutated. He concluded that in all three mutants there was a reduction in 
clathrin binding of the epsin mutants compared to with WT epsin, with the 
DKO mutant showing the greatest reduction. He also confirmed the loss of 
epsin 1 binding to clathrin by carrying out GST-pulldown binding assays of 
GST-clathrin TD with WT and DKO epsin 1 only. Therefore, he concluded 
that the deletion of the two clathrin box motifs significantly affects its ability to 
bind to clathrin TD (Baker, 2016). 
As SDS-PAGE analysis is a qualitative technique with a limited dynamic 
range, I aimed to extend these studies using a quantitative technique, such 
as the optimized SPR/IAC method, to investigate the binding difference 
between the WT and the three epsin 1 clathrin box motif mutants for clathrin 
TD binding. 
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5.9.3 Epsin 1 clathrin box motifs have an equivalent 
clathrin TD binding capacity as its unstructured/DPW region 
The SPR/IAC result obtained demonstrated a substantial reduction in binding 
– half the response of the WT epsin 1 (highest binding response) from the 
epsin clathrin box mutants. This reduction was equal in all the three mutants 
(257, 480 and DKO) (Figure 5.9.3 (A)), with no significant difference between 
them in their ability to bind clathrin TD. These results are representative of 
three independent repeats (n=3) for each WT and mutant with the mean of 
WT 
257 
480 
Figure 5.9.2: Diagram illustrating the ‘clathrin binding box’ motif mutants 
(257, 480 and DKO) on a linear representation of the epsin 1 structure. The 
mutants were designed in line with Drake et al., 2000 and Holkar et al., 2015. The 
WT form of the epsin 1 structure is represented at the top of the diagram. The 257 
mutant has one of the ‘clathrin binding boxes’ starting at residue 257 mutated to 
alanines (LMDLA-> AAAAA). The 480 mutant has one of the ‘clathrin binding boxes’ 
starting at residue 480 mutated to alanines (LVDLD-> AAAAA). The DKO mutant 
has both ‘clathrin binding boxes’ mutated to alanines (LMDLA->AAAAA and 
LVDLD-> AAAAA).  
 
Mutant Names Mutations 
257 LMDLA -> AAAAA  
 
257 LMDLA -> AAAAA  
480 LVDLD -> AAAAA  
 
- 
480 LVDLD -> AAAAA  
 
DKO 
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the highest response unit of each sample and standard deviation plotted. 
The WT epsin 1 has the highest response units of 1171 ± 287.5 RU and the 
257, 480 and DKO having significantly lower responses of 586.7 ± 147.2 RU, 
578.10 ± 94.43 RU and 550 ± 69.37 RU respectively (Figure 5.9.3 (B)). 
Overall, these results are consistent with the hypothesis of Drake et al. 2000, 
where reduction of clathrin binding was observed when one clathrin box 
motif- 257 is deleted and that the unstructured region/DPW between the two 
clathrin box motifs was suggested to bind to clathrin non-
specifically/independently (Drake et al., 2000). 
 
On the other hand, these results are partially consistent with 
ultracentrifugation assays conducted by Dr. Michael Baker with clathrin 
cages as described above, with the exception that the SPR data with clathrin 
TD indicates an equivalent reduction in binding between all three mutants, 
whereas a greater reduction for the DKO mutant for clathrin TD binding was 
observed from GST- pulldown assays, as conducted by Dr. Michael Baker 
(Baker, 2016). It is important to note that pulldown assays were carried out 
with whole clathrin cages, whereas SPR experiments were carried out using 
clathrin TD (residue 1-363). An overall reduction in binding is observed 
between the WT and the three epsin 1 mutants both in cases when clathrin 
cages (binding pulldown assays) or clathrin TD (SPR data) used. 
The two epsin clathrin box motifs function were hypothesized to function 
cooperatively (Drake et al., 2000; Drake and Traub, 2001), and promote 
clathrin assembly, a result which was confirmed with evidence from Holkar et 
al. 2015 (Holkar et al., 2015). However, the SPR data in this section indicate 
a similar binding affinity of the clathrin TD for each of the two clathrin box 
motifs and the unstructured region/DPW motifs suggesting that they bind in a 
cooperative manner to clathrin. This was shown from the SPR data, which 
revealed no significant difference in response between the three mutants 
(257, 480, DKO). This has not been previously suggested or observed and 
therefore adds an important insight into how the epsin 1 structure effects the 
interaction with clathrin. 
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Preliminary investigations from Dr. Michael Baker confirmed that mutating 
the epsin 1 clathrin box motifs (257 and 480 mutants) still had a subtle effect 
on altering the cage size distribution from an average radius of ~ 45 nm to ~ 
35 nm, in a manner similar to WT epsin as determined by DLS and EM 
(Baker, 2016). Even though there are different biodynamic interactions 
between clathrin cages and clathrin TD, the DLS/EM results could relate to 
the clathrin-TD SPR data obtained in this section, suggesting that even when 
the reduction in clathrin TD binding between the epsin 1 clathrin box mutants 
is equal there is more complex behavior of epsin 1:clathrin interaction is 
likely much more complex. 
A strong epsin-clathrin interaction is suggested due to the slow dissociation 
of the complex observed in WT and three epsin 1 mutants, with the response 
curve not reaching the baseline. This could possibility demonstrate the 
strong and cooperative behavior characteristic of multiple site interaction of 
epsin 1’s two clathrin box motifs and the unstructured/DPW motif region 
binding to clathrin TD- a much longer dissociation time will be required to 
disrupt many existing interactions.  
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(A) 
(B) 
Figure 5.9.3: Binding of epsin 1 full-length (residues 1-575) WT and ‘clathrin 
binding box’ mutants (10 μM) to GST-TD (1-363) (1 μM), to investigate 
epsin:clathrin interactions. (A) Binding of purified epsin 1 of WT and 3 mutants 
(257, 480 and DKO) to GST-TD. WT binds the strongest, with an unusual binding 
curve, which is hypothesized not to be a 1:1 stoichiometric binding with TD. Whereas 
all the 3 mutants have a very similar binding capacity to the GST-TD with a 
hypothesised 1:1 stoichiometric ratio, due to the shape of the binding curve. Each 
experiment was carried out in a series of three repeats in randomised order. Overall, 
no saturation was observed in the SPR experiments, even in 1:10 molar ratio of 
clathrin to epsin 1, which was the recommended ratio with excess epsin 1 
concentration (B) The results from (A) are plotted on a bar chart representing the 
mean from the highest response value of three independent repeats (n=3) and the 
standard deviation. The WT epsin 1 has the highest response of 1171.0 and the 257, 
480 and DKO having significantly equal lower responses of 586.7, 578.10 and 
550.00 respectively. 
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5.9.4 Mutagenesis studies of epsin 1 unstructured/DPW 
region 
Using the SPR/IAC technique, the observation that mutating single clathrin 
box motifs or both in epsin 1 resulted in a substantial reduction in its ability to 
bind to clathrin TD was confirmed. In addition, I demonstrated how the 
clathrin box motifs and the unstructured/DPW region could possibly have an 
equal contribution to epsin 1 binding to clathrin TD. Thus, both epsin 1 
structure components could be equivalently strong in their affinity to bind 
clathrin TD. A number of interesting questions arose from the above initial 
observations as to how the two clathrin box motifs and the unstructured/DPW 
motif function could promote clathrin assembly. Hence, after investigating the 
two clathrin box motifs; epsin’s unstructured/DPW motif region via 
mutagenesis studies and SPR/IAC technique was aimed to be investigated. 
 
In order to investigate this unstructured/DPW region of epsin 1, we designed 
and obtained mutants in which the unstructured/DPW region was deleted or 
shortened, hence reducing the distance between the two ‘clathrin box motifs. 
The mutants are illustrated in Figure 5.9.4 and are abbreviated as follows: ½ 
DPW, ¼ DPW and ΔDPW. Briefly, in the ½ DPW, 93 amino acids were cut 
(approx. half of the region) from the original 216 amino acid sequence of the 
unstructured region. No DPW motifs of the region were deleted in this 
mutant. In the ¼ DPW mutant, 153 amino acids were deleted (approx. 
quarter of the region), with four DPW motifs deleted. In the ΔDPW, 209 
amino acids were deleted together with all eight DPW motifs in this region. 
Thus the whole unstructured/DPW region has been completely deleted in this 
mutant. 
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5.9.5 Shortening the unstructured/DPW region 
massively reduces its binding for clathrin TD 
The primary observation of the SPR data demonstrated that the ½ DPW 
mutant and the ¼ DPW mutant cause a substantial reduction in clathrin TD 
binding, compared to the WT epsin binding response, as seen in Figure 
5.9.5. This reduction in response was approximately equivalent to the 
reduction in response of the clathrin box motifs (257, 480 and DKO) epsin 1 
mutants (Figure 5.9.3). The fact that the decreased response is very similar 
Mutant Names 
½ DPW 
¼  DPW 
ΔDPW 
Figure 5.9.4: Diagram illustrating the unstructured/DPW region mutants (½ 
DPW, ¼ DPW, ΔDPW). The ½ DPW mutant has a shorter unstructured/DPW 
region by half (93 amino acids shorter) retaining all eight DPW motifs. The ¼ DPW 
mutant has shortened by a quarter (60 amino acids shorter, deleting four of the 
eight DPW motifs. The ΔDPW mutant has deleted the entire unstructured/DPW 
region and all the eight DPW motifs.  
Mutations 
Shorten unstructured/DPW 
region (no DPW motifs 
deleted) by half. 
Shorten unstructured/DPW 
region (4 DPW motifs 
deleted) by a quarter 
Delete unstructured/DPW 
region (all 8 DPW motifs 
deleted) entirely 
- WT 
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between the two types of epsin mutants could add further insight to the 
hypothesis that the unstructured/DPW region has an equivalent importance 
and equal binding capacity as the two clathrin box motifs. A major 
observation from the SPR data is how the distance of the unstructured/DPW 
motif and the DPW motifs separately contribute equally to epsin 1 binding to 
the clathrin TD. This was demonstrated when the binding response of the ¼ 
DPW mutant was slightly less (~ 200 response units) than ½ DPW mutant 
(Figure 5.9.5 (B)), demonstrating that when the distance is shortened further 
and when four DPW motifs have been deleted, this further decreases the 
ability of the epsin 1 to bind to clathrin TD. Based on these results, I propose 
that both the distance and the presence of DPW motifs in that 
unstructured/DPW region are equally important for the manner in which the 
epsin 1 binds to clathrin TD, until otherwise proven. 
 
It is important to note that the overall maximum response unit of ½ DPW is 
766.7 ± 244.9 RU which is the highest in all the epsin 1 mutants used with ¼ 
DPW at 550.0 ± 233.3 RU which is similar to the response units of 257, 480 
and DKO epsin mutants as shown in Figure 5.9.5 (B). This supports the idea 
that the presence of the two clathrin box motifs, as in the case of ½ DPW, 
provides a strong binding interaction with clathrin TD, however shortening 
the unstructured/DPW region has clearly played a major role in reducing 
epsin’s ability to link multiple clathrin TDs. Shortening the unstructured/DPW 
region distance even further (¼ DPW mutant) demonstrates how this mutant 
has equal response units with mutating the clathrin box motifs individually 
(257 and 480) or both together (DKO).  
 
The lowest response (174.7 ± 44.47 RU) observed in these SPR results, was 
the ΔDPW epsin mutant (Figure 5.9.5) where the complete 
unstructured/DPW region and the eight DPW motifs have been deleted. 
There are several possible explanations for this observation. An initial 
observation could be that in the ΔDPW epsin mutant the two clathrin box 
motifs are in a very close proximity lacking the flexibility offered from the 
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unstructured/DPW region. This could affect the way the two clathrin box 
motifs bind to clathrin TD. If these two clathrin box motifs bind to different 
clathrin TD sites on multiple TDs from the cooperative behaviour with the 
unstructured/DPW region (Morgan et al., 1999; Greene et al., 2000; Drake et 
al., 2000; Drake and Traub, 2001; Kalthoff et al., 2002; Dafforn and Smith, 
2004), shortening the distance between the two clathrin boxes, could prevent 
epsin 1’s multiple TD linking interaction effect. This effect would result in a 
large reduction in the affinity of epsin 1 binding to clathrin TD, compared to 
the other mutants, as seen in the SPR data for ΔDPW mutant (Figure 5.9.5 
(B)). Alternatively, if epsin 1 normally binds to multiple TD sites (CBox, 
ArrestinBox and W-box) on a single clathrin TD; this would not be possible 
with a ΔDPW epsin 1 mutant, as the shortening of the unstructured/DPW 
motif region would not allow long-distance interactions and the two clathrin 
box motifs could bind on multiple TD sites on a single ~ 5 nm sized TD. 
Nevertheless, taking into account the above results, I conclude by proposing 
that both the distance of the unstructured region, and the DPW motifs of the 
region are equally important for efficient interaction of epsin 1 to clathrin TD. 
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Figure 5.9.5: Binding of epsin 1 full-length (residues 1-575) WT and 
‘unstructured/DPW’ mutants (10 μM) to GST-TD (1-363) (1 μM), to investigate 
epsin:clathrin interactions. (A) Binding of purified epsin 1 of WT and three 
mutants (½ DPW, ¼ DPW and ΔDPW) to GST- clathrin TD immobilized on the SPR 
chip via IAC method. WT binds the strongest, with an unusual binding curve, which 
is hypothesized not to be a 1:1 stoichiometric binding with TD. Whereas all the 
three mutants have a very similar binding capacity to the GST- clathrin TD with a 
hypothesised 1:1 stoichiometric ratio, due to the shape of the binding curve. Each 
experiment was carried out in a series of three repeats in randomised order. 
Overall, no saturation was observed in the SPR experiments, even in 1:10 molar 
ratio of clathrin to epsin 1, which was the recommended ratio with excess epsin 1 
concentration (B) The results from (A) are plotted on a bar chart representing the 
mean from the highest response value of three independent repeats (n=3) and the 
standard deviation. The WT has the highest response units followed by the ½ DPW 
which has a response unit of 766.7 and the ¼ DPW has a response unit of 550.0 
RU. The ΔDPW has the lowest response units of 174.7 RU. 
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5.9.6 Differences in TD binding modes between epsin 1 
mutants  
Epsin’s structure displays a level of complexity, which is hypothesized to be 
due to multiple factors as found in the published literature and the results in 
this chapter. The SPR response curves obtained have different shapes 
between the WT epsin 1 and the six epsin 1 mutants. Interestingly, the 
clathrin box motif mutants have a significant difference in the SPR response 
curves compared to the shortened/deleted unstructured/DPW region mutant 
SPR response curves. 
Initially, the shape of the WT epsin 1 curve in Figure 5.9.6 (blue curve) was 
observed to contain a change in the slope of the curve, which could suggest 
a two-phase binding interaction that would not be a 1:1 stoichiometry. This is 
consistent with the fact that there are two components in the epsin 1 
structure (WT form) that bind to clathrin TD, which are the two clathrin box 
motifs and the unstructured/DPW motif region. Thus, a ‘two level’ interaction 
could explain such a change in the slope of the curve. 
However, based on the observed SPR response curves, not all the epsin 1 
mutants demonstrate the two-phase binding as WT epsin 1. The clathrin box 
mutants (257, 480, DKO) and ‘unstructured/DPW motif mutants (½ DPW, ¼ 
DPW and ΔDPW), were observed to have similar curve shapes between 
each set of mutants, which could suggest a 1:1 stoichiometry of clathrin TD 
to epsin (Figure 5.9.6). Although, if we compare the curve shape of all the 
clathrin binding box mutants (257, 480 and DKO) with those of the 
unstructured/DPW motif region (½ DPW, ¼ DPW and ΔDPW) mutants; we 
can observe a subtle difference. A sharp increase in response at the start of 
the curve of the clathrin box mutants is observed, which is not seen in the 
unstructured/DPW region mutants (Figure 5.9.6). This could be because the 
clathrin box mutants could be associating with clathrin TD quicker and with a 
stronger interaction mode than the unstructured/DPW motif mutants. These 
differences in curve shape could give further insight into the different manner 
in which epsin 1 binds to the clathrin TD and the hierarchy in the binding of 
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the different clathrin binding components of epsin 1, and aid into future 
questions as to how the ‘multiple TD linking’ behaviour of epsin 1 changes 
depending on the mutating/deleting of different components of its structure.  
These observations are semi-quantitative, they could not be conclusive as 
further quantitative analysis is required which would result in obtaining 
binding and dissociation rate constants for the WT and all epsin 1 mutants, in 
order to verify such hypothesis. 
 
 
 
 
 
 
 
5.9.7 Interpreting complex interactions of 
disordered proteins using SPR kinetic analysis 
A binding affinity of ~ 156 μM ± 6.00 has been determined previously in the 
Smith’s group between 257 epsin 1 clathrin box peptide and clathrin TD 
using fluorescence anisotropy (Sarah Batson, unpublished data). This is 
considered a very weak binding, which could be due to the use of peptides. 
In this thesis, full-length epsin 1 WT and mutants (257, 480, DKO) were used 
for kinetic analysis. The outcome of binding rate and dissociation rate 
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Figure 5.9.6: A SPR sensorgram plot illustrating the difference in response 
curve results between epsin 1 ‘clathrin binding box’ mutants and 
‘unstructured /DPW region’ mutants. SPR/IAC experiments were carried out for 
WT and mutant epsin 1 for clathrin TD. We can clearly observe difference between 
the 257,480, DKO mutants compared to the ½, ¼, ΔDPW mutants. This could 
demonstrate the difference in the mode of interaction when different components of 
epsin 1 structure have been mutated or deleted. The WT epsin 1 response curve 
demonstrates how epsin could bind to clathrin TD in a multivalent manner linking 
different multiple TD together.  
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constants will be based on the data collected from SPR/IAC experiments. 
Careful optimization was carried out as discussed earlier in this chapter for 
epsin 1 WT and mutants, prior any kinetic experiments and analysis. The 
final parameters for the kinetic experimental runs for epsin 1 include six 
analyte concentrations ranging from 5 μM to 0.3125 μM, which would result 
to lower response units, ideal for kinetic model fitting analysis.  
Problems with the SPR instrument failure due to age of the instrument 
resulted into spikes in unfortunate positions in the resulting experimental 
data of the WT and mutant epsin 1, and time did not permit additional 
experiments. The only experimental data set with no anomalies/spikes was 
for the 480 epsin 1 mutant data, which was the only one fitted. The kinetic 
models fitted were 1:1 Langmuir, 1:1 binding with mass transport, 
heterogeneous ligand/ parallel reaction, bivalent analyte, which were 
discussed earlier as well. No binding rate and dissociation constants have 
yet been determined for the 480 epsin 1 mutant, binding to clathrin TD, thus 
this preliminary new data shown below and kinetic fits/rate constants provide 
a basic initial insight into the role of 480 epsin clathrin box. 
The kinetic analysis of the 480 epsin 1 mutant, illustrated the complexity of 
the epsin’s structure and the complex epsin:clathrin interactions. Initially, the 
simplest model, the 1:1 Langmuir model was fitted. The results demonstrated 
a χ2 of 71 (best χ2 <10) and a KD of 3.4 μM (Figure 5.9.7i (A), Table 1.8.0). 
Additionally, due to the mass transport limitation detailed previously in this 
chapter, the 1:1 binding with the mass transport model was the next to be 
explored. Even though the results revealed a better χ2 of 58.9 than the 1:1 
Langmuir χ2, the KD (3.1 μM) was not significantly better (Figure 5.9.7i (B), 
Table 1.8.0).  
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(A)  
(B)  
Figure 5.9.7i: Fitting of the experimental data of 480 epsin 1 mutant 1:1 simple 
kinetic models at a concentration range of 5 μM to 0.3125 μM (A) the initial model 
was the 1:1 Langmuir model, which is considered the simplest model (B) The same 
1:1 Langmuir model was fitted which took account the mass transport issue, which 
remained not an ideal model for the experimental data. These models are found in 
the BIAevaluation program version 4.1 of BIAcore system of the SPR instrument 
(Biacore 2000), and all the data fitting and rate constants obtained was carried in the 
BIAevaluation program implemented in the SPR system. 
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These results indicate that 480epsin:clathrin is not a 1:1 stoichiometry 
interaction. The heterogeneous ligand/parallel reaction model used resulted 
to a χ2 of 51.2, which is better than any of the 1:1 models above; and a KD of 
0.009623 μM (Figure 5.9.7ii (A), Table 1.8.0), which is not considered a 
better KD value. The best-suited model was the bivalent analyte model where 
we observed the lowest χ2 of 48.9 and KD of 21.4 μM (Figure 5.9.7ii (B), 
Table 1.8.0). However, the improvement of the χ2 value from a 1:1 to two-
step model analysis, the χ2 values are very high hence the fitting of the 
experimental data with the model is very poor. Assuming that mass transport 
is not a limiting factor here, we could hypothesize that the heterogeneous 
curve shape of the experimental data could result from an inherent property 
of 480epsin:clathrin. The challenge in fitting the experimental data has 
suggested that the 480epsin:clathrin interaction could be a multivalent 
interaction and not a 1:1 stoichiometric complex. This could add further 
information to the previous hypothesis in this thesis that such an epsin 1 
mutant could have a multivalent interaction with multiple clathrin TDs. This 
could be due to the interaction of the 257 clathrin box motif and the 
unstructured/DPW motif with the clathrin TD. This supports the proposed 
hypothesis that clathrin box motifs and the unstructured/DPW motif region 
are more likely to have a cooperative effect in binding to the clathrin TD. 
However, further optimization is required in analysis of these results, but due 
to the complexity and time constraints, this was not possible. The 
experiment-to-model fits were not a perfectly convincing fits thus a more 
complicated fitting model, which takes into account the ‘multiple site linking’ 
behavior of epsin 1 needs to be fitted to this experimental data. The 
development of a new kinetic model is a complex task, which is currently 
continuing in collaboration with Dr. Veselina Uzunova. 
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(B)  
Figure 5.9.7ii: Fitting of the experimental data of 480 epsin 1 mutant two-step  
kinetic models at a concentration range of 5 μM to 0.3125 μM (A) The 
heterogenous ligand/parallel reaction model was used where it involved the analyte 
interacting with two ligands at the same time (A). The bivalent analyte model was also 
used which involved the analyte interacting with two sites on the same ligand (B). The 
fitting of the experimental data (coloured curved) and the model (black curves) 
releaved very high χ2 values. However, the fits were better than in the 1:1 models 
and therefore epsin could be suggested to have a multivalent binding interaction 
manner with clathrin TD. This demonstrates the complexity of epsin structure as a 
whole constructs were used to carry out these kinetic analysis. These models are 
found in the BIAevaluation program version 4.1 of BIAcore system of the SPR 
instrument (Biacore 2000), and all the data fitting and rate constants obtained was 
carried in the BIAevaluation program implemented in the SPR system. 
(A)  
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5.9.8 Further optimization for kinetic analysis 
The majority of the preliminary work to optimize the SPR/IAC method for 
kinetic analysis for the clathrin-adaptor system has been already carried out 
in this thesis. The preliminary kinetic analysis provided essential information 
which confirms that epsin:clathrin complex is not a 1:1 binding interaction. 
Further kinetic optimisations were suggested by Prof. Richard Napier 
(University of Warwick) and Dr. Petr Kuzmic (BioKit Ltd., USA) through 
personal communication. These are listed below and could be addressed in 
the future: 
I. attach His6 -epsin 1 on the chip (sensor NTA chip), as the bigger 
protein of 78 kDa, and flow over the GST-TD (66 kDa) and compare 
Protein 
(Epsin) 
Model type ka 
(1/Ms) 
kd (1/s) kD = ( kd/ ka) 
(M) 
kD  
(μM) 
χ2 
480  1:1 Langmuir  308 
 
1.05x 10-3 
 
3.41x10-6 
 
3.4 71  
 
480 1:1 binding with 
mass transport 
318  
 
9.97x 10-4 
 
3.14x10-6 
 
3.1 58.2  
 
480 Heterogenous 
ligand/parallel 
reactions 
214 2.06x10-6 9.63x10-9 0.009
623 
51.2 
480 Bivalent analyte  107 2.3x10-3 
 
2.14x10-5 21.4 48.9 
Table: 1.8.0: Illustrating the results from kinetic analysis of the 480 epsin 
1 mutant data fitted in four different models The binding rate constants (ka), 
the dissociation rate constants (kd), the equilibrium constant  (KD) and the χ2 of each 
model-experimental fitting of the 480 epsin 1 mutant data using a concetrstion 
series of 5 μM – 0.3125 μM. The models are found in the BIAevaluation program of 
BIAcore system of the SPR instrument, and all the data fitting and rate constants 
obtained was carried in the BIAevaluation program. 
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these findings to the ones already obtained with GST- clathrin TD 
bound on the CM5 sensor chip via anti-GST antibody capturing. This 
will eliminate the use of an antibody capturing which is an additional 
complicating factor for the analysis and mass transport. 
II. Lower the response units obtained from the ligand-analyte interaction 
to ~ 100-200 RU. This is ideal as mass transport could still be 
observed in response units of even 500-600 RU (Lang et al., 2005). 
However, keeping low RU in all experiments has previously been 
challenging in this thesis due to the complex epsin 1 structure and its 
complications with non-specific binding and mass transport.  
III. Vary the concentration range and ratios of clathrin:epsin in order to 
reach an appropriate saturation level and targeted low response units.  
IV. A more complicated model needs to be derived which takes into 
consideration the ‘linking behavior’ of epsin for multiple clathrin TD(s) 
binding. 
V. Future kinetic experimental runs could be carried out using a more 
sensitive and advanced SPR instrument e.g. Biacore T200. The 
sensitivity of such an instrument could ideally minimize the mass 
transport issues and provide more accuracy in the data obtained. 
Hence, result to more accurate binding affinities obtained from kinetic 
analysis. 
 
5.10.0 Biological application of epsin’s structure in CME: 
how the epsin 1 structure facilitates clathrin TD binding 
for efficient clathrin assembly 
5.10.1 Scenarios based on epsin clathrin box mutants 
Taking into account the above SPR data of WT epsin1 and mutants (257, 
480, DKO), I propose the below three possible scenarios on how epsin 1 
could be interacting with clathrin TD to facilitate an efficient clathrin assembly 
and promote uniform smaller sized cage distribution. These scenarios are 
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based on the results obtained in this thesis as well as previous published 
information. 
(1) The two clathrin box motifs have been proposed to work cooperatively to 
assemble clathrin (Drake et al., 2000; Drake and Traub, 2001; Holkar et al., 
2015). However, based on the results in this Chapter, I propose that the 
unstructured/DPW motif region of epsin 1 could equally have a cooperative 
effect with the two clathrin box motifs, as well as the two clathrin box motifs 
between them, to promote efficient clathrin assembly. This scenario could be 
very plausible, as the unstructured/DPW motif region has been observed to 
have equivalent binding capacity as the two clathrin box motifs. This 
hypothesis is based on the SPR data in this chapter, where the highest 
response in the SPR data was observed from the WT epsin 1, whereas by 
mutating the two clathrin box motifs respectively (257 and 480) or together 
(DKO), the binding response was greatly reduced in all three mutants. 
Interestingly, the reduction was equivalent in all three mutants, even when 
both clathrin box motifs have been mutated (DKO). 
 
(2) Epsin 1 has previously been hypothesized to have a linking effect 
between multiple clathrin TDs (Morgan et al., 1999; Greene et al., 2000), 
Drake et al., 2000; Drake and Traub, 2001; Kalthoff et al., 2002; Dafforn and 
Smith, 2004; Holkar et al., 2015), but was yet to be proven. Quantitative data 
from SPR/IAC method, suggested that epsin 1 could be interacting with 
multiple adjacent clathrin TD. This could be due to the flexibility of the 
unstructured/DPW region (Dafforn and Smith, 2004), where the two clathrin 
box motifs are hypothesized to be separated by a distance shorter than 155 
nm (Kalthoff et al., 2002). Therefore, it has been hypothesized that a single 
epsin 1 molecule could simultaneously engage with two different sites on two 
different clathrin TD, which are in close proximity, instead of only a single TD. 
This states that epsin 1 could be promoting linking of multiple clathrin TD. 
This effect could potentially stabilize clathrin cages via the extra interactions 
between linked triskelia and offer a more compact cage structure. Hence, 
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facilitating uniform and smaller cage distribution, as suggested by Kalthoff et 
al., 2002 (Kalthoff et al., 2002). 
 
(3) the two clathrin box motifs on a single epsin 1 molecule could be binding 
and interacting with two different sites (TD has four distinct sites) on a single 
TD or on multiple TDs. More interestingly, one of the clathrin box motif in 
epsin 1 at residue 257 (LMDLA) has been proposed to be similar to the W-
box motif of amphiphysin (WLDWP) and hence may interact with the clathrin 
TD at the same site e.g. site 2, W-box site (Drake and Traub, 2001; Miele et 
al., 2004). The yeast homolog of epsin (Ent2) has been shown to bind to 
CBox and the W-box of the TD sites (Collette et al., 2009). Thus, I propose 
that epsin 1 might be interacting with sites 1 (C-box site), site 2 (W-box) and 
site 3 (Arrestin site) on the clathrin TD. In order for epsin 1 to perform such 
an interaction, the long and flexible unstructured/DPW motif region would be 
promoting the flexibility of the two clathrin box motifs to interact on the same 
clathrin TD. This permits the unstructured/DPW motif region to contact with 
the same TD or interacting with other adaptor proteins e.g. AP2 promoting 
efficient clathrin assembly (Drake et al., 2002; Brett et al., 2002; Dafforn and 
Smith, 2004; Edeling et al., 2006a).  
 
5.10.2 Scenarios based on unstructured/DPW region 
mutants 
According to Drake et al., 2000, the region between the two clathrin box 
motifs in the epsin 1 structure binds to clathrin independently, which I 
hypothesize has an equally strong contribution to epsin 1 binding to clathrin, 
similar to the two clathrin box motifs (Drake et al., 2000). Investigating this 
unstructured region further resulted in very interesting outcomes on how 
epsin 1 interacts with clathrin TD. Considering those outcomes, I propose 
below three possible scenarios to how epsin 1 interacts with clathrin TD: 
 
(1) I demonstrated using SPR/IAC method, that disrupting this region either 
by shortening this region by half (~ 78 nm) or by quarter (~ 38 nm) causes a 
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massive reduction to epsin 1’s ability to bind to clathrin TD. This reduction is 
equivalent to that of the clathrin box mutants (257, 480, DKO). Hence, I 
suggest that the unstructured/DPW motif region binds to clathrin with equal 
binding capacity as the two clathrin box motifs. This could validate the 
observation proposed in scenario (1), section 5.10.1.  
 
(2) the distance and the DPW motifs in the unstructured/DPW region are 
equally important in affecting how epsin 1 binds to the clathrin TD via long-
distance interactions. This was confirmed with the SPR data that revealed 
the response of the ½ DPW mutant and ¼ DPW mutant to bind to clathrin TD 
decreased compared to the WT epsin 1. The ~ 200 RU difference observed 
between the ½ DPW mutant and ¼ DPW mutant, with the ¼ DPW mutant 
being lower, could suggest that both the distance and DPW motifs are 
important without clearly prioritizing one over the other. Additionally, the 
unstructured/DPW region is hypothesized to be long enough and even if it 
has been shortened by half or by quarter, it most likely still promote long-
distance interactions between multiple clathrin TDs but in a lesser extend. 
Replacing the unstructured/DPW region with a fake linker sequence that 
does not bind to epsin 1 could clarify further as to whether distance of the 
DPW motifs is the most important component in this region for epsin 
1:clathrin interaction. However, additional motifs could be present in the 
unstructured/DPW region, which could aid to this long-distance interaction 
effect of epsin 1. However, this might not be the case in vivo, and thus 
shortening (half or quarter) the distance of the region could prevent epsin 1 
multiple TDs linking effect. Another option could be that the ½ DPW and ¼ 
DPW mutants could be binding to the same clathrin TD but on a different 
site, or one clathrin box motif would bind to single clathrin TD and the other 
clathrin box motif would be free in solution. 
 
(3) I propose that deleting the unstructured/DPW motif region (ΔDPW epsin 1 
mutant) and bring the two clathrin box motifs in very close proximity, would 
prevent the flexibility of epsin’s structure preventing the linking multiple TDs 
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effect. This should result in a massive reduction in the affinity of epsin 1 
binding to clathrin TD, which was observed in the SPR results. I suggest that 
the ΔDPW epsin 1 mutant would only bind to single TD, with the interaction 
of one of the clathrin box motifs, and the second clathrin box motif would be 
left free in solution. This is because the two clathrin box motifs would be in 
too close proximity with each other, which would prevent interaction of the 
clathrin box motifs with different TDs, but only with another site on the same 
TD, if possible. This also confirms the hypothesis that epsin 1 links multiple 
clathrin TDs. 
 
5.11.0 Future work 
Epsin 1 is considered one of the main clathrin assembly adaptor proteins, as 
it is highly expressed in the brain and has been implicated in synaptic 
development and plasticity (Vanlandingham et al., 2013). Therefore, 
understanding the mode in which it interacts with clathrin is crucial due to its 
role in the CME. In light with the above findings, a variety of scenarios have 
been proposed as to which components of epsin 1 structure interacts with 
clathrin and which parts of these components are important and could be 
hypothesized to promote a more efficient clathrin assembly. Certain results in 
this chapter open up questions for future avenues to verify certain 
conclusion.  
 
5.11.1 Exploring further the ‘unstructured/DPW’ region 
The experiments carried out using SRP/IAC method with clathrin box 
mutants and the unstructured/DPW motif region mutants have yielded 
interesting observations. I proposed that the unstructured/DPW motif region 
has equivalent strong binding capacity to clathrin TD as the two clathrin 
boxes promoting a linking effect with multiple TDs, and the distance and the 
DPW motifs of this region are essential clathrin binding components. More 
interestingly, I propose that the distance of this unstructured/DPW motif 
region could be considered the major factor for this hypothesized linking 
effect of epsin. In order to confirm this hypothesis, I suggest to obtain an 
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epsin 1 mutant where the unstructured/DPW region has been replaced with a 
fake linker sequence that does not bind to clathrin, therefore keeping the 
distance between the two clathrin box motifs in epsin’s structure. This will 
allow us to determine whether the distance between this two clathrin box 
motifs is the main factor for the TD bridging effect or whether DPW motifs, or 
any other motifs in that region do actually play a major role as well. Although, 
if this linking effect is a mechanical effect of epsin 1 linking multiple clathrin 
together in a cage; atomic-force microscopy (AFM) could be carried out to 
determine the force required for epsin’s mechanical effect, as previously 
used by Sousa et al., 2016 (Sousa et al, 2016).  
 
Through private communication with Stephen Royle, University of Warwick 
and with some of his group members; I obtained further information about 
epsin-clathrin interactions in vivo. They suggest that the distance between 
the two clathrin box motifs appears to be vital for artificial initiation of 
endocytosis in cells either. Their artificial constructs containing three epsin 
clathrin box motifs in close proximity did not efficiently promote endocytosis 
(private communication). More interestingly, one of their artificial constructs 
with the unstructured/DPW region of epsin 1 replaced with a different linker 
sequence which would not bind to clathrin, allowing the distance between the 
two clathrin box motifs to remain unchanged. This construct showed no 
endocytosis in cells, as well (private communication). These findings add 
further support to the hypothesis that both the DPW motifs of this 
unstructured/DPW region are a vital component for the linking effect of epsin 
1, but also that both the two clathrin box motifs and the distance between 
them (the unstructured/DPW region) are required for effective binding and 
functionality of epsin 1 via long-distance interactions.  
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5.11.2 Using clathrin TD mutants to investigate 
epsin:clathrin interactions 
Additionally, we hypothesize that epsin 1 binds to three different sites on the 
TD, like AP180 (Zhuo et al., 2015). In order to investigate and confirm this 
hypothesis, SPR/IAC method could be used with a series of TD mutants in 
which the four binding sites on TD have been selectively impaired. This 
would allow us to determine whether epsin clathrin box motifs and the 
unstructured/DPW region are preferentially favoured to bind to one TD over 
another, or whether they could bind to multiple different clathrin TD sites at 
the same time. This would provide a substantial new insight into the 
hypothesised scenarios in section 5.10.1.  
 
The clathrin TD mutants were designed in line with Muenzner et al., 2017 
(Muezner et al., 2017). These mutants were then tested for expression and 
purification conditions. Smaller scale expression confirmed the successful 
expression of the constructs, detailed in Chapter 10, but when scaling up the 
expression the proteins became unstable and were prone to degradation. 
Unfortunately, due to time constraints, the expression issues could not be 
further addressed and these mutants were not used in this thesis.  
 
5.11.3 Using epsin 1 peptides of clathrin box motifs 
with SPR/IAC method for understanding further epsin-
clathrin interaction 
Full-length epsin protein (residues 1-575) have been used in the SPR/IAC 
experiments which allow analyzing the protein as a whole, which has allowed 
to investigate all its clathrin components together. However, due to the 
complex nature of epsin structure as observed by the kinetic analysis in this 
chapter, and the mass transport limitations observed when using a full length 
protein construct; peptides could be a good replacement, as we can isolate 
the different clathrin components of epsin 1 and investigate them individually. 
Therefore, individual epsin clathrin box motif peptides and peptides produced 
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from sections of the unstructured/DPW region could be analyzed using the 
SPR/IAC method to determine binding and dissociation rate constants for 
clathrin TD binding. Such an investigation could result in discovering other 
motifs in the unstructured region, which have not been proven to interact with 
clathrin. Certain peptides are already available for use, designed and 
synthesised by Alta Bioscience, UK with the clathrin box residues are in bold:  
(1) peptide 1: 257 clathrin box motif: ESSLMDLADVF  (2) peptide 2: 480 
clathrin box motif: NAALVDLDSLV. Such experimental information could 
validate greatly certain hypothesis regarding the cooperative manner of 
these two clathrin box motifs and obtain appropriate binding affinity 
constants. 
 
5.11.4 Investigation of other adaptor proteins with 
similar structure to epsin 1  
Other long unstructured adaptor proteins such as AP180 could act in a 
similar manner to epsin 1, by linking multiple TDs together and allow 
effective clathrin assembly and promoting small uniform cage distribution 
(Kalthoff et al., 2002). In this thesis, AP180 construct was used, which lacks 
the ANTH domain and consists only with the unstructured D[IL][LF] motifs 
has been shown by circular dichroism to be fully unstructured. Thus, it may 
promote non-specific binding in a similar manner to epsin 1. It is important to 
state that preliminary optimization has been carried out in this thesis for 
AP180 binding with the SPR/IAC method (data not shown). The SPR/IAC 
method showed massive non-specific binding in the reference flow cell as 
expected. This was minimised to a certain extent by the use of β2-myoglobin 
antibody coupled on the reference flow cell and using SPR buffer 2 (500 mM 
NaCl), making it feasible to investigate AP180 with the SPR/IAC method. The 
goal of such investigations is to obtain further information as to whether or 
not other adaptor proteins share similar clathrin TD binding properties to 
epsin 1. Additionally, such adaptor proteins as AP180 could be used in 
adaptor competition studies (SPR/IAC (2-injection) method) described in 
Chapter 6. 
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5.12.0 Conclusion  
In conclusion, the results presented in this chapter confirm that disrupting 
one or both epsin 1 clathrin box motifs had a detrimental effect on binding to 
clathrin TD. However, binding persisted even when both clathrin box motifs 
were removed, suggesting a more complex mode of interaction, involving the 
unstructured/DPW region in between these two clathrin box motifs. After 
investigating this unstructured/DPW region, I hypothesize that the most 
effective binding of epsin 1 to clathrin is when the two clathrin box motifs and 
the unstructured/DPW motif region act synergistically to promote effective 
clathrin interactions via long-distance linking effect between multiple TDs or 
via multiple TD site interaction on a single TD. Deleting the 
unstructured/DPW region causes massive reduction in clathrin TD binding, 
hence the DPW motifs and the distance between the two clathrin box motifs, 
have been shown from the data above to play a critical role in the 
epsin:clathrin interactions. Additional future experiments using epsin 
peptides and TD mutants could further confirm the suggested mechanism 
and the exact TD site binding of epsin 1. We obtain additional understanding 
on how epsin 1 interacts with clathrin TD in the presence of other endocytic 
adaptor proteins in the adaptor competition studies described in Chapter 6. 
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Chapter 6: 
Clathrin-adaptor competition 
studies using surface plasmon 
resonance 
6.0.0 Overview   
The aim of this chapter was to investigate adaptor competition between 
certain combinations of adaptors present in different stages of CME. This 
would provide a vital insight into how adaptor proteins co-exist and act during 
the different stages of endocytosis. Here, I describe the newly established 
technique called SPR/IAC (2 –injection), which is a modification of the 
SPR/IAC method used in Chapter 5. The SPR/IAC (2-injection) method 
developed in this thesis is novel for investigating competition for clathrin N-
terminal (TD) domain binding between structurally and functionally diverse 
endocytic adaptor proteins, which has not been used before.  
 
In addition to β-arrestin 1L, epsin, which were studied in Chapter 6, the 
following adaptor proteins (β2-adaptin (part of the AP2 complex), auxilin 1, 
Hip1CC and Hip1RCC) were selected for this study. Initially, the interaction 
of the individual proteins with clathrin N-terminal domain (TD) was 
investigated using the SPR/IAC method before using them in the competition 
studies. Adaptor protein combinations for the competition studies were 
chosen according to their biological role in the CME. The SPR results from 
this chapter provide further insights into: 
I. the behaviour of different endocytic adaptor proteins in the presence 
of other endocytic adaptor proteins and clathrin TD. 
II. the mode of interaction between epsin 1 and clathrin TD. 
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6.1.0 The 2-injection SPR method  
  6.1.1 Introduction and description  
Initially, the SPR/IAC method was successfully optimized and used in 
Chapter 5, to investigate clathrin:adaptor interactions using one-step 
detection. This involves clathrin TD being attached on the chip via the IAC 
method and one adaptor protein injected over that flow cell to form a complex 
with the immobilized clathrin TD. In this chapter, I used the SPR/IAC method 
using a two-step detection process, where one adaptor protein is injected to 
form a complex with clathrin TD immobilized on the chip, prior to the injection 
of the second adaptor protein onto that complex. This technique is called 
SPR/IAC (2-injection). This method was developed in order to investigate 
clathrin adaptor protein competition for clathrin TD binding between 
combinations of adaptor proteins. 
 
An example sensogram of the outcome when the method is applied is shown 
on Figure 6.1.1 First, once the GST- clathrin TD is bound to the chip surface 
via the IAC method as explained in Chapter 5; following that, (i) one adaptor 
protein is injected over that flow cell to form a complex with clathrin TD (first 
purple curve) (ii) a small volume of buffer is injected to wash the flow cell and 
eliminate any excess adaptor protein not bound, but not to cause significant 
dissociation, (iii) a second injection of a different adaptor protein is then 
performed which is allowed to interact with the complex (second purple 
curve). This second interaction step is followed by a longer buffer injection 
time before regeneration of the flow cell.  
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6.1.2 Development of the ‘two step’ SPR technique 
The SPR/IAC (2-injection) method has not been utilized previously for 
studying protein-protein interactions. The rational behind the development of 
this technique was to investigate competition between different adaptor 
proteins for clathrin binding that could normally co-exist in vivo situation. 
Published knowledge on the principles of antibody analysis and competition 
detection using SPR described below: 
Epitope mapping analysis, where an antigen is coupled on the chip and a 
variety of antibodies are sequentially injected over the antigen to determine 
more efficient antibody binding. In 2014, Goh et al., used SPR to investigate 
relative binding of two compounds to a relative antibody in a similar mode to 
the SPR/IAC (2-injection) system introduced in this chapter. However, their 
system was based on antibody very well defined binding sites (Goh et al., 
2014). This SPR competition assays provided an initial basis for designing 
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Figure 6.1.1: Illustrating the stages of SPR/IAC (2-injection) method. (i) the first 
adaptor protein is injected over the flow cell, (ii) first injection is followed by a small 
buffer injection period to eliminate any of the excess unbound protein (iii) the 
same/different adaptor proteins are injected onto the flow cell (iv) a longer washing 
time is carried out before the normal regeneration step (10 mM Glycine pH 2.0). 
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the SPR/IAC (2-injection) experiments to investigate competition between 
two adaptor proteins for clathrin binding when injected one after the other. 
Such a method is considered novel for clathrin:adaptor interactions. Based 
on the successful competition assays published previously, SPR could be 
used to attempt to address such questions. 
‘Competitive BIAcore reactions’ reported by Karlsson, 1994 (Karlsson, 1994). 
Interestingly, the following year Karlsson et al., 1995 demonstrated how high 
molecular weight and a low molecular weight analytes injected at the same 
time over the chip surface coupled with a ligand, could demonstrate 
competition between these analytes for the binding sites on the immobilized 
ligand (Karlsson et al., 1995). This is analogous to radiolabelled and non-
radiolabelled ligand competing for the same binding site on a specific 
receptor (Karlsson et al., 1995; Morelock et al., 1995); Karlsson, 2004). In 
relation to endocytic adaptor proteins (analyte) in CME have different 
molecular weight depending on their structure, and such assays would not 
limit the ability to obtain competition between them due to variations in their 
molecular mass. However, optimisation needs to be carried out for such a 
system for each adaptor protein. 
6.1.3 Advantages of SPR/IAC (2-injection) method 
a) All experiments/controls could be carried out on the same flow cell for 
efficient comparison. However, this depends mainly on the 
performance of the chip and the antibody’s binding capacity following 
(harsh) regeneration. For this SPR/IAC system, a full set of 6-7 
experiments can be carried out on a single flow cell. Any further 
experiments result in a decrease in binding, which is noticed with a 
lower clathrin TD binding to the anti-GST antibody immobilized on the 
flow cell. 
b) Detect accurate competitive binding between purified proteins, instead 
of peptides, using a small sample size with low protein concentrations, 
compared to other techniques e.g. Isothermal Titration Calorimetry. 
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c) Label-free real-time straightforward method without the need of 
fluorescent tags, radiolabelled tags and isotope tag labeling. 
6.2.0 Investigating the molecular binding interactions of 
other adaptor proteins (β2-adaptin, Hip1CC/ Hip1RCC 
and auxilin 1) for clathrin TD 
 6.2.1 Overview 
Other endocytic adaptor proteins were used with the optimized SPR/IAC 
method in order to confirm their binding activity with clathrin TD. These 
adaptor proteins will be key in the adaptor competition experiments. These 
adaptor proteins are not full-length and the specific residues of the construct 
are detailed in the section below. 
 
6.2.2 SPR/IAC analysis: β2-adaptin-clathrin, auxilin 1-
clathrin and Hip1RCC-clathrin 
AP2 was of interest to investigate in our competition experiments due to its 
pivotal role in endocytosis and its ability to stimulate clathrin coat assembly. 
The AP2 clathrin box motif (LLNLD) is located on the long flexible 
unstructured linker of the large β2-subunit, which is hidden in the core of the 
AP2 structure when in its closed conformation (Collins et al., 2002). AP2 
interacts with the clathrin N-terminal domain TD (Shih et al., 1995; Clairmont 
et al., 1997; Owen et al., 2000) and with a stoichiometry of 3:1 AP2:clathrin 
according to peptide assays (Zhuo et al., 2015), which is contrary to the most 
recent data which suggest a 2:1 stoichiometry of AP2:clathrin (Muenzner et 
al., 2017). The SPR results confirm the strong binding of the β2-adaptin616-951 
construct (β2HA- longer hinge region making it more stable) to the clathrin 
TD (Figure 6.2.2, yellow curve), which is used in the adaptor competition 
studies. 
 
The Hip1/Hip1R endocytic adaptor protein on the other hand, has been found 
to preferentially bind to clathrin light chains (CLC) (Chen and Brodsky, 2005). 
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The coiled-coil (CC) domain of both proteins promotes dimerization of the 
protein and interaction with clathrin light chain (CLC), which in turn aids the 
formation of clathrin cages in vitro (Ybe et al., 2007; Niu and Ybe, 2007; Ybe 
et al., 2009). This allows the recruitment of Hip1/Hip1R to the membrane 
where it binds releasing the interactions with the CLC and allows it to interact 
with actin and promoting assembly (Hyun et al., 2004; Ybe et al., 2009; 
Gottfried et al., 2010). Hip1 consists of a clathrin box motif (LMDMD), which 
binds to clathrin N-terminal domain, and FXDXF and DPF motifs (X denotes 
any amino acid) bind to the AP2 complex (α-adaptin) (Mishra et al., 2001; 
Legendre-Guillemin et al., 2002; Chen and Brodsky, 2005; Hyun et al., 2004; 
Ybe et al., 2009). More interestingly, Hip1CC was demonstrated to interact 
with CHC via a proposed motif of VDLE, which has suggested by Waelter et 
al., 2001 (Waelter et al., 2001), in contrast to Hip1RCC (Chen and Brodsky, 
2005), which is included in the construct used for the SPR/IAC experiments. 
The SPR data (Figure 6.2.2) demonstrate that the Hip1RCC does not bind to 
the clathrin TD, which was observed via the zero response units on the 
sensorgram. However, with Hip1CC361-637 construct we observe an increase 
of ~ 200 RU, which demonstrates a weak interaction with clathrin TD. The 
reason for this increase in response could be due the interaction of Hip1 CC 
with clathrin TD via the proposed motif of VDLE, which has suggested by 
Waelter et al., 2001 that binds to clathrin heavy chain. The Hip1 CC was 
preferentially used in the competition assays, due to its binding capacity for 
clathrin TD. 
 
One of the major clathrin disassembly adaptor proteins is auxilin 1. Auxilin 1 
contains a clathrin box ‘LLGLE’ motif (residues 496-500), which interacts in 
peptide form with the clathrin TD (Smith et al., 2004). More specifically, DPF 
motifs bind to both the CHC and the ear domain of α-adaptin in AP2 and DLL 
motifs bind to clathrin (Scheele et al., 2001; Fotin et al., 2004). The SPR data 
revealed strong binding between the auxilin401-910 construct and the clathrin 
TD, as seen in Figure 6.2.2. 
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Overall, the β2-adaptin shows the highest response units of 840.30 ± 136.8 
RUs, followed by auxilin 1 with 589.8 ± 55.64 and Hip1CC with 168.0 ± 29.46 
RUs. Hip1RCC does not bind to clathrin and thus the response units are zero 
(RU=0).  
 
 
 
6.2.3 Conclusion 
This section confirms the binding capacity of the β2-adaptin, auxilin 1, 
Hip1CC and Hip1RCC to the clathrin TD. Using the SPR results above, I 
demonstrated that the β2-adaptin is the adaptor protein that shows the 
strongest response in the SPR/IAC experiments, as expected. The second in 
turn is the auxilin 1 with Hip1CC following next with a lower binding response 
and concluding that the Hip1RCC does not bind to clathrin TD, as expected. 
This confirms that the SPR/IAC can discriminate between non-specific and 
functional binding. These adaptor proteins are key for the competition studies 
detailed later in this chapter. 
 
Figure 6.2.2: Binding of β2-adaptin, Hip1R/Hp1 CC and auxilin 1 to GST- 
clathrin TD (1 μM). (A) The strongest binding to clathrin TD is by of β2-adaptin ~ 
1000 RU, with the auxilin 1 following at ~ 700 RU. The Hip1RCC does not bind to 
TD due to the zero RUs and Hip1CC binds with ~ 200 RU to clathrin TD. (B) The 
mean highest response units from three independent experiments (n=3) is plotted 
on a bar chart illustrating the difference in binding between the three adaptor 
proteins, which have different binding capacity. The β2-adaptin shows the highest 
response units of 840.30 RUs, followed by auxilin 1 with 589.8 and Hip1CC with 
168.0 RUs. Hip1RCC does not bind to clathrin and thus the response units are zero 
(RU=0).  
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6.3.0 Adaptor competition for clathrin TD binding 
  6.3.1 Introduction 
Approximately 25 different adaptor proteins are recruited in an ordered 
sequence to the plasma membrane during CME, requiring numerous 
potential clathrin-adaptor interactions (Merrrifield and Kaksonen, 2014; Traub 
2011). This raises the question of whether certain adaptor proteins compete 
for binding to clathrin or whether some adaptor proteins can bind to clathrin 
simultaneously, during the different stages of the CME. It has been 
hypothesized that certain adaptor proteins with high binding affinity for 
clathrin could possibly prevent low binding affinity adaptor proteins from 
interacting with clathrin, through competition for the same site (Lindner and 
Ungewickell, 1992).  More specifically, the majority of adaptor proteins bind 
to clathrin TD via their single or multiple clathrin box motifs. The TD has four 
distinct adaptor protein binding sites (CBox, ArrestinBox, W-Box, RoyleBox). 
Different adaptor protein peptide ligands have been shown to bind to one or 
more of these sites simultaneously (Muenzner et al., 2017). In theory, the 
affinity and number of clathrin binding sites could allow one adaptor protein 
to displace another from the clathrin TD sites, influencing the progress of 
CCV formation (Zhuo et al., 2015). It is critical to understand this mechanism 
of engagement, which will aid in the understanding of how CME is 
successfully regulated in vivo. Thus, our hypothesis is that the engagement 
of certain adaptor proteins with clathrin TD sites is managed through 
competition and simultaneous binding. In order to address this hypothesis in 
this chapter, I aimed to investigate combinations of the five adaptor proteins 
(Figure 6.3.1) choosen in my project based on the: 
I. Roles in endocytosis (e.g. assembly, disassembly etc.)  
II. Structural diversity  
III. Analogous ‘clathrin binding motifs’  
IV. Equivalent number of clathrin box motifs or components in the 
structure   
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These adaptor combinations were investigated for their binding to clathrin TD 
using GST pull-down binding assays and SDS-PAGE analysis with either 
cages or clathrin TD as an initial observation for obvious competition. Certain 
GST-pulldown binding assays were repeated in this thesis and demonstrated 
a reproducible competition or no competition pattern between different 
adaptor protein combinations in the presence of clathrin. However, the 
repeats did not result in consistent band intensities. The limited dynamic 
range of SDS-PAGE analysis led us to the use of a more quantitative 
method, such as the SPR/IAC (2-injection) method, detailed in the previous 
section. The concentration ratio used for all the SPR/IAC (2-injection) 
experiments was 1:10 molar ratio of 1 μM of GST-clathrin TD to 10 μM of 
each adaptor protein, which was used for most SDS-PAGE pulldown binding 
assays as the saturation level of adaptor to clathrin. 
 
6.4.0 β2-adaptin and β-arrestin 1 
  6.4.1 Introduction: structural and functional differences  
AP2 is considered the major clathrin assembly initiation adaptor protein, 
which interacts with the clathrin N-terminal domain TD via its clathrin box 
Figure 6.3.1: A diagram illustrating five different adaptor proteins (AP2, Hip1, 
Auxilin 1, β-arrestin 1L Epsin 1) with diverse structure and function in 
relation to their structure importance in binding to clathrin and other 
adapotors, such as AP2. Motifs are listed in the on the right along with their 
binding location on AP2 or clathrin. The other domains detailed in the figure are as 
follows: THATCH, talin-HIP1/ R/Sla2p actin-tethering C-terminal homologyANTH, 
AP180 N-Terminal Homology Domain, Arr, Arrestin Domain; EH, Epsin Hand; 
ENTH, Epsin N-Terminal Homology Domain; J, J-domain; UIM, Ubiquitin 
Interacting Motif. Image adapted from Smith et al., 2017. 
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motif (LLNLD) located in the long flexible unstructured β2 hinge (Shih et al., 
1995; Clairmont et al., 1997; Owen et al., 2000), which is hidden in the core 
of the AP2 structure when in its closed conformation (Collins et al. 2002). On 
the other hand, the β-arrestin 1L (longer isoform) structure consists of two 
independent clathrin box motifs (LIELD and LIEFD) on C- and N- terminal 
domains, which recruit clathrin to the plasma surface (Kang et al. 2009). It is 
important to note that these two adaptor proteins interact with each other via 
the IVF motif on the C-terminal domain of β-arrestin 1L and the β2-adaptin 
subunit of AP2 (Ferguson, 2001; Burtey et al., 2007). Both β2-adaptin and β-
arrestin 1L bind to two TD sites (CBox and ArrestinBox) in blades 1 and 2 
and blades 4 and 5 in the TD. β2-adaptin (part of AP2 complex) and the 
active form of β-arrestin 1L were used in the SDS-PAGE binding assays and 
SPR/IAC (2-injection) experiments, where the IVF motifs on β-arrestin 1L 
(which interacts with β2-adaptin) had been mutated to AAF motif in order to 
release the loop exposing the conserved clathrin box. β2-adaptin interacts 
with this β-arrestin 1L form (active) via the F-residue, as shown in ITC results 
from Burtey et al., 2007 (Burtney et al., 2007). 
6.4.2 Investigating binding between β2-adaptin and  
β-arrestin 1L to clathrin TD 
  6.4.3 GST-pulldown (SDS-PAGE) binding assays of β2-
adaptin and β-arrestin 1L for clathrin TD 
Initially, β2-adaptin and the active form of the β-arrestin 1L were investigated 
with GST-pulldown binding assays and analysed by SDS-PAGE. The 
pulldown assays revealed preferential binding of β2-adaptin to clathrin TD 
when in the presence of an increased concentration of active β-arrestin 1L 
(Figure 6.4.3 (B), lane 17) compared to WT β-arrestin 1L (Figure 6.4.3 (C), 
lane 17), and no obvious competition between the two adaptor proteins. This 
is revealed when the band intensity of the two adaptors in the pellet fraction 
is higher in the presence of clathrin TD, compared to the control experiments 
with the adaptors without the presence of clathrin TD. It is important to note 
that in previous studies, it has been demonstrated how active β-arrestin 1L 
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and β2-adaptin interact with each other (Burtey et al., 2007), which was not 
demonstrated in these pulldown results (Figure 6.4.3 (C), lanes 9 and 10). 
This could be because the mutation of I and V residues to alanine residues in 
the IVF motif on the active β-arrestin 1L, could have reduced the binding 
interaction between these adaptors. Nevertheless, I used the SPR/IAC (2-
injection) method to investigate the interaction between β2-adaptin and 
active form of β-arrestin 1L in the presence of to the clathrin TD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
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  6.4.4 SPR/IAC (2-injection) method of β2-adaptin and β-
arrestin 1L for clathrin TD 
A massive increase in response units (~ 1500 RU) was observed once the 
β2-adaptin (β2HA) was injected over the β-arrestin 1L (ActArr)-clathrin TD 
complex (Figure 6.4.4 (A), second blue curve). It is possible that a certain 
proportion of the response seen could be of β2-adaptin binding to clathrin TD 
and some of the response could relate to β2-adaptin binding to the ActArr, 
which has already been bound to the clathrin TD. Interestingly, this pattern 
was not observed when the order of adaptor protein injected was switched 
around (brown curve in Figure 6.4.4 (A)). A possible explanation could be 
that β2-adaptin has bound to both of the two TD sites (CBM and 
ArrestinBox), which can also bind β-arrestin 1L, thereby, blocking those 
sites.  Alternatively, β2-adaptin could be changing its conformation when 
bound to the clathrin TD and as a result causing sites for β-arrestin 1L 
(C) 
Figure 6.4.3: GST- SDS-PAGE pulldown assays between β2-adaptin (β2) and 
β-arrestin 1L(β) in the presence of clathrin TD. Clathrin TD is at a constant 
concentration of 3μM. (A) Controls are carried out with clathrin TD only and β2-
adaptin only as well as active and WT β-arrestin 1L at a 1:3 to 1:10 molar ratio. (B) 
Control and experimental analysis of WT β-arrestin 1L with an without the clathrin 
TD, which reveals no obvious competition between the two adaptor proteins (C) 
Control and experimental analysis of active β-arrestin 1L demonstrating no obvious 
competition the two adaptor proteins, but increasing the concentrations of active β-
arrestin promotes the binding of β2-adaptin to clathrin TD at 1:10:10 molar ratio. 
These experiments and SDS-PAGE analysis are representative of multiple 
experiments. 
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interaction to be hidden (Figure 6.4.4 (A)). These experiments were run in 
duplicates or triplicates and the difference between the maximum point of 
curve one (peak 1) and curve two (peak 2) (Δpeak2-peak1) is plotted from 
each repeats in Figure 6.4.4 (B)).  
 
 
 
  6.4.5 Discussion: β2-adaptin and β-arrestin 1L 
In this section, I have investigated possible competition between β2-adaptin 
and active β-arrestin 1L using two methods. The pulldowns reveal a 
cooperative interaction effect between the two adaptor proteins for binding to 
clathrin TD. The SPR results could suggest simultaneous binding of the two 
adaptor proteins onto clathrin TD. Although, due to the result where β-
arrestin 1L does not bind to the β2-adaptin:clathrin TD complex, we could 
suggest that no other TD sites are free and available for β-arrestin 1L to bind 
and that it is most likely unable to compete off the β2-adaptin bound to the 
clathrin TD due to β2-adaptin having a stronger binding affinity for those TD 
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Figure 6.4.4: SPR sensorgrams showing the binding between β2-adaptinHA 
(26kDa) (10 μM) and active β-arrestin 1L (48kDa) (10 μM) for GST-clathrin TD 
(1 μM) using SPR/IAC (2-injection) method. The plot clearly suggests competition 
between β2-adaptinHA and active beta-arrestin 1L as per the orange coloured 
curve, when β-arrestin 1L is flowed over the chip first. This was confirmed with a 
reduced binding of the β-arrestin 1L when injected second over the chip (black 
curve). These plots are repeats of two or three series of trials averaged together. 
The ActArr-ActArr demonstrates a low response than expected even when 
repeated; this could be due to the deterioration of the chip. 
(A) (B) 
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sites than the active β-arrestin 1L. Overall, I partially confirm existing results 
that state that AP2 (β2-adaptin subunit) and β-arrestin 1L work cooperatively 
in binding to clathrin TD (Burtey et al., 2007). In an in vivo scenario, 
cooperative binding will allow β-arrestin 1L to bind and recruit AP2 and 
clathrin to the surface allowing the AP2 complex to bind to clathrin TD at the 
same time and initiate clathrin assembly. Further discussions of these 
findings are described in Chapter 7. In conclusion, this initial analysis 
confirmed that the newly developed SPR/IAC (2-injection) method works for 
the clathrin:adaptor system to obtain reliable results. 
 
6.5.0 Epsin 1 and β-arrestin 1L 
  6.5.1 Introduction: structural and functional differences  
Epsin 1 is recruited at the clathrin assembly initiation stage of CME as a key 
clathrin assembly protein, whereas β-arrestin 1 is also recruited during the 
CME initiation stage but is not involved in the clathrin assembly process. 
Structurally, epsin 1 contains two clathrin box motifs (LMDLA and LVDLD), 
which interact with clathrin, and eight DPW motifs located between the two 
clathrin box motifs which have been suggested that bind to clathrin non-
specifically (Drake et al., 2000), which have a role in the clathrin assembly 
and are hypothesized to link multiple clathrin triskelia (bridging effect) during 
assembly, thus forming uniform cage sizes (Drake et al., 2000; Kalthoff et al., 
2002). Interestingly, β-arrestin 1L’s structure consists of two independent 
clathrin box motifs (LIELD and LEFD) on opposite sites (each C- and N- 
domains), just like epsin 1 (Kang et al., 2009). The LIELD motif has been 
found in other adaptor proteins such as AP2, AP180, amphiphysin, and epsin 
(Owen et al., 2004), therefore β-arrestin 1L could promote competition with 
other adaptor proteins for clathrin TD.  These two independent clathrin box 
motifs have been hypothesized to bridge between two clathrin molecules in a 
lattice (Kang et al., 2009), but not yet proven. This linking effect has been 
hypothesized because the two clathrin box motifs are ~ 68 Å apart, and the 
clathrin triskelion within the lattice has a distance of ~ 64 Å between adjacent 
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clathrin terminal domains, as suggested by Kang et al., 2009 (Kang et al., 
2009). This multiple clathrin linking manner has been hypothesized for epsin 
1 as well, but not yet proven. These two adaptor proteins have structural 
similarities regarding their clathrin components, however, the difference in 
their role in CME and binding manner could suggest competition for clathrin 
binding between them. 
6.5.2 Competition between epsin 1 and β-arrestin 1 
  6.5.3 Preliminary SDS-PAGE binding assay data reveal 
competition between epsin 1 and β-arrestin 1L for clathrin 
TD  
Epsin 1 and β-arrestin 1L were ideal candidates for studying adaptor 
competition studies due to their different roles in CME and their structural 
and functional diversity. Importantly, epsin 1 and active β-arrestin 1L do not 
have a common site for interaction with each other. This was confirmed by 
GST-pulldown SDS-PAGE binding assays using GST- β-arrestin 1L active 
form with epsin 1 WT without the presence of clathrin TD. The results 
illustrated in Figure 6.5.3 (A), lanes 1,3,5,7 show that epsin 1 does not pellet 
even in increasing active or WT/active β-arrestin 1L concentration, at molar 
ratio of 1:1 or 1:3 of epsin1: β-arrestin 1L. 
Interestingly, the SDS-PAGE analysis of the GST-pulldown binding assays 
reveal reduction in band intensity of epsin in the pellet (Figure 6.5.3 (C), 
lanes 3 and 5) in the presence of constant concentration of β-arrestin 1L at 
10 μM. The band intensity is compared with pellets from the control 
experiments of epsin with clathrin TD alone (Figure 6.5.3 (B), lanes 1 and 3) 
at the same 1:3 and 1:10 molar ratios. Interestingly, increasing the 
concentration of β-arrestin 1L approximately 3 folds, the epsin band in the 
pellet remains reduced as observed in Figure 6.5.3 (C), lanes 7 and 9), 
compared to the control experiments Figure 6.5.3 (B), lanes 1 and 3). 
Overall, these results revealed competition between epsin 1 and β-arrestin 
1L for clathrin TD. These primary observations were the basis of further 
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investigation between these two adaptor proteins using the SPR/IAC (2-
injection) method in order to confirm this competition in a more quantitative 
way. 
 
 
 
 
 
(A) 
(B) 
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  6.5.4 Competition between epsin 1 (WT and mutants) 
and β-arrestin 1L for clathrin TD binding confirmed by SPR 
The SPR/IAC (2-injection) results revealed a high response of ~ 1000 RU 
(blue first curve, Figure 6.5.4 (A) when active β-arrestin 1L (ActArr) was 
injected first on the flow cell, forming a complex with the clathrin TD coupled 
on the chip. Once epsin 1 WT was injected over the ActArr-clathrin TD 
complex, a large increase in response of ~1000 RU was observed (second 
blue curve, Figure 6.5.4 (A)). Interestingly, by switching the order of the 
injection of adaptor proteins, with epsin 1 WT injected first (forming epsin 1-
clathrin TD complex) and ActArr injected second on the clathrin:epsin 1 
Figure 6.5.3: GST- SDS-PAGE pulldown assays which reveal competition 
between β-arrestin 1L (β) and epsin 1 WT (E) for clathrin TD. Clathrin TD is at a 
constant concentration of 3μM. (A) Controls are carried out with clathrin TD only 
and epsin 1 WT only as well as active GST- β-arrestin 1L with different epsin 1 WT 
concentrations without the presence of clathrin TD. The results revealed no 
interaction between epsin and GST- β-arrestin 1L. (B) Representing control 
experiments of epsin with clathrin TD at 1:1 and 1:3 molar ration and β-arrestin 1L 
control experiments without the presence of clathrin TD (lanes 9-14). (C) and (D) 
SDS PAGE gels demonstrating competition between epsin 1 and active β-arrestin 
1L for clathrin TD, at 1:10:3 TD:E:β molar ratio ratio (lanes 7 and 8) and even at 
high concentrations of β-arrestin at 1:10:10 TD:E:β molar ratio (lanes 9 and 10) 
using active β-arrestin 1L. These experiments and SDS-PAGE analysis are 
representative of multiple experiments. 
 
(C) 
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complex, we observed no increase in response  (second brown curve, Figure 
6.5.4 (A)). These experiments were run in duplicates and triplicates and the 
difference between the maximum point of curve 1 (peak 1) and curve two 
(peak 2) (Δpeak2-peak1) is plotted from each repeats in Figure 6.5.4 (E), 
column 1-2). A concentration titration for both adaptor proteins was not 
conducted due to time constraints. 
 
A number of questions arose after these initial observations with wild type 
(WT) epsin 1. Would mutations in the epsin 1 structure cause resistance to 
the competition observed between epsin 1 and β-arrestin 1L? To address 
this question, I aimed to investigate whether this competition pattern was 
also observed with epsin 1 clathrin box motif mutants (used in chapter 5) and 
the ActArr. These mutants were 257 (mutating clathrin box 1), 480 (mutating 
clathrin box 2) and the DKO (mutation of both clathrin box motifs). This study 
would provide more insight into whether the synergistic action of both epsin 
clathrin box motifs is required in order to promote competition with another 
endocytic adaptor protein for clathrin TD binding, and whether epsin’s 
unstructured/DPW region would still be sufficient to promote this competition. 
These experiments were run in duplicates or triplicates and the difference 
between the maximum point of curve 1 (peak 1) and curve two (peak 2) 
(Δpeak2-peak1) is plotted from each repeats in Figure 6.5.4 (E), column 1-
2).  
 
The results from SPR/IAC (2-injection) experiment are in Figure 6.5.4 (B), 
(C),(D) where the colour scheme and injection order is as described above. 
To our surprise, the SPR results revealed the same competition pattern as 
observed with the wild type (WT) form of epsin 1, with the difference of lower 
response units, which are expected for these epsin mutants. As observed in 
previous SPR/IAC results in Chapter 6; the responses of the 257, 480, DKO 
mutants are half of that of the epsin 1 WT, thus the mutant response units 
ranged between 400-600 RUs. The slight difference in response units 
between control runs (orange and black curves) and experimental runs (blue 
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and brown curves) is considered due to the deterioration of the SPR chip and 
the antibody binding capacity, as explained in previous chapters.  
 
The 480 mutant showed half the response units  (~ 400 RU) (Figure 6.5.4 
(C)) than the 257 mutants (~ 800 RU) (Figure 6.5.4 (B)). This difference 
could suggest that one clathrin box motif has an increased ability to compete 
off ActArr from its already occupied sites on TD, or it has a greater capacity 
to bind to other sites on the TD, however this cannot be conclusive. On the 
other hand, the DKO mutant which is expected to have a lower response 
than either of the other mutants, as both clathrin box motifs have been 
mutated, resulted to an increase of ~1300 RUs when injected on the ActArr-
clathrin TD complex (Figure 6.5.4 (D)). As this was of surprise to us, we are 
unsure as to why we observe such a higher response for the DKO mutant. 
Based on previous data in this thesis (Chapter 5), the unstructured/DPW 
region has equal binding capacity to TD compared to the two clathrin box 
motifs on epsin. We could therefore expect the response units to be 
somehow similar to those observed by the 257 and 480 epsin mutants, of 
around 400-800 RUs. However, the DKO/ActArr experiments were run once, 
so additional repeats are required before we can be certain of these results. 
Overall, I demonstrate that cooperative effect between the two clathrin box 
motif on β-arrestin 1L are not strong enough to outcompete the strong 
interaction epsin 1 makes with clathrin TD, due to the ‘three clathrin 
component’ structure of epsin 1. This could also confirm that the second 
clathrin box of β-arrestin 1L has a weak affinity for clathrin, which was 
suggested by Kang et al., 2009 (Kang et al., 2009). 
 
The shape of the curves for epsin 1 and the three epsin mutants was 
observed to differ since there was a clear change in the slope of the epsin 
mutant curves in comparison to the smooth curvature observed in the epsin 
WT curves. This could be due to issues with the BIAcore 2000 SPR 
instrument during data collection, as this was observed in other experiments 
as well. However, if this is not due to instrumental failure, it could be a result 
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of the inherent structure of epsin 1, where mutating important clathrin binding 
components in epsin 1 structure could affect the manner in which it binds to 
clathrin TD. In order to confirm this hypothesis, these experiments should be 
repeated on a more sensitive SPR instrument e.g. Biacore T200. 
 
 
 
(D) 
ActArr(10 µM) - EpsinWT(10 µM)
EpsinWT (10 µM) - ActArr (10 µM)
EpsinWT (10 µM) - EpsinWT (10 µM)
ActArr-ActArr (10 µM)
0 500 1000
0
500
1000
1500
2000
2500
Time (s)
R
es
po
ns
e 
D
iff
0 500 1000
0
200
400
600
800
1000
Time (s)
R
e
s
p
o
n
s
e
 D
if
f 257 (10 µM) - ActArr (10 µM)
ActArr (10 µM) - 257 (10 µM)
257 (10 µM) - 257 (10 µM)
ActArr (10 µM) - ActArr (10 µM)
0 500 1000
0
200
400
600
800
1000
Time (s)
R
es
po
ns
e 
D
iff
ActArr (10 µM) - 480 (10 µM)
480 (10 µM) - ActArr (10 µM)
480 (10 µM) - 480 (10 µM)
ActArr (10 µM) - ActArr (10 µM)
0 500 1000
0
500
1000
1500
Time (s)
R
es
po
ns
e 
D
iff DKO  (10 µM) - ActArr (10 µM)
ActArr (10 µM) - DKO (10 µM)
ActArr (10 µM) - ActArr (10 µM)
DKO (10 µM) - DKO (10 µM)
Ep
sin
WT
 (1
0µ
M)
 - A
ctA
rr 
(10
 µM
)
Ac
tA
rr 
(10
µM
) - 
Ep
sin
WT
(10
 µM
)
25
7 (
10
µM
) - 
Ac
tA
rr 
(10
 µM
)
Ac
tA
rr(
10
µM
) - 
25
7 (
10
 µM
)
48
0 (
10
µM
) - 
Ac
tA
rr 
(10
 µM
)
Ac
tA
rr 
(10
µM
) - 
48
0 (
10
 µM
)
DK
O 
(10
 µM
) - 
Ac
tA
rr 
(10
 µM
)
Ac
tA
rr 
(10
 µM
) - 
DK
O 
(10
 µM
)
-500
0
500
1000
1500
Δ
pe
ak
2-
pe
ak
1
(C) 
(B) 
(A) 
(E) 
Figure 6.5.4: Competitive binding between epsin 1 WT and clathrin box 
mutants (10 μM) and active β-arrestin 1L (10 μM) for GST-clathrin TD (1 μM) 
using SPR/IAC (2-injection) method. The overall pattern is similar between the 
WT epsin 1 (A) and the mutants (B), (C), (D). When the epsin 1 WT or mutant is 
injected on the clathrin:ActArr complex, the epsin binds to the complex as shown by 
the increase in the second blue curve in (B),(C),(D). However, when switching the 
order around, the ActArr does not bind on the clathrin:epsin 1 complex as seen in 
the second brown curve of (B), (C), (D). The active β-arrestin 1L control (black) 
curve has lower response units than the experimental (blue) curve. This might be 
due to the deteriorating performance of the SPR chip. ActArr; active β-arrestin 1L. 
Control and experiments are run on the same flow cell, but due to the deterioration 
of the SPR chip after 6 experiments, the each epsin mutant experiment was run on 
a different flow cell in a randomised order to prevent any significant systematic error 
in the binding responses. (E) The Δpeak2-peak1 of triplicate runs of 2-injection 
experiments plotted for all the epsin 1 WT and mutant combinations with the ActArr. 
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6.5.5 SDS-PAGE binding assay data revealed 
competition between WT β-arrestin 1 and epsin 1 WT and 
mutants  
As we were unclear whether these two clathrin box motifs could be working 
antagonistically, I also carried out identical GST-pulldown assays and 
SPR/IAC (2-injection) experiments with the WT (inactive) form of β-arrestin 
1L. The WT form has only the second clathrin box on the N-terminal end 
available for binding to clathrin, whereas the conserved clathrin box in the 
unstructured loop is hidden.  
 
Interestingly, the SDS-PAGE analysis of the GST-pulldown binding assays 
reveal reduction in band intensity of epsin in the pellet (Figure 6.5.5 (B), 
lanes 13 and 15) in the presence of constant concentration of β-arrestin 1L 
at 10 μM. The band intensity is compared with pellets from the control 
experiments of epsin with clathrin TD alone (Figure 6.5.5 (A), lanes 1 and 3) 
at the same 1:3 and 1:10 molar ratios. Interestingly, increasing the 
concentration of β-arrestin 1L approximately 3 folds, the epsin band in the 
pellet remains reduced as observed in Figure 6.5.5 (B), lanes 17 and 19), 
compared to the control experiments Figure 6.5.5 (A), lanes 1 and 3). 
Overall, these results revealed competition between epsin 1 and β-arrestin 
1L for clathrin TD. These primary observations were the basis of further 
investigation between these two adaptor proteins using the SPR/IAC (2-
injection) method in order to confirm this competition in a more quantitative 
way. Overall, there was no significant difference between the band intensity 
of epsin in the pellet in the presence of either WT β-arrestin 1 (Figure 6.5.5 
(B), lanes 19 and 20) and active β-arrestin 1L (Figure 6.5.3 (B), lanes 9 and 
10 in previous section) with clathrin TD, as observed in the GST-pulldown 
assays. Thus, in both cases we observe equal competition between β-
arrestin 1 active and WT form and epsin 1 for clathrin TD. However, due to 
the SDS-PAGE assay’s limited accuracy, this competition was investigated 
with the SPR/IAC (2-injection) technique as well. 
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Figure 6.5.5: SDS-PAGE analysis of GST- pulldown assays demonstrate 
competition between WT β-arrestin 1L (β) and epsin 1 WT (E) for clathrin TD. 
GST- clathrin TD (3 μM) was incubated with GST-affinity beads in the presence of 
WT β-arrestin 1L and epsin 1 WT in increasing molar ratios. The pellet (P) and 
supernatant (S) fractions were analysed by SDS-PAGE. (A) epsin WT binds to 
clathrin TD in both 1:5 or 1:15 molar ratio.  (B) SDS PAGE gels demonstrating 
competition between epsin 1 and WT β-arrestin 1L for clathrin TD, even at high 
concentrations of WT β-arrestin at 1:10:10 C:E:β molar ratio. These experiments 
and SDS-PAGE analysis are representative of multiple experiments.  
 
(A) 
(B) 
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  6.5.6 Competition between WT β-arrestin 1 and 
epsin 1 WT and mutants confirmed by SPR 
The SPR/IAC (2- injection) results are shown in Figure 6.5.6 (A) and (B) 
demonstrate how the competition pattern observed between epsin 1 WT and 
active β-arrestin 1L, was also observed with WT β-arrestin form. No increase 
in response from the WT β-arrestin was observed when epsin 1 WT was 
injected first and formed a complex with clathrin TD. This is also observed in 
Figure 6.5.6 (C) where no significant difference is observed between the 
pairs of WT or active form of β-arrestin for the difference between the 
maximum point of curve 1 (peak 1) and curve two (peak 2) (Δpeak2-peak1) 
plotted for each repeated experiment. 
 
One interpretation of these results could be that the second clathrin box of β-
arrestin 1 does not have a sufficiently strong binding affinity to displace epsin 
1 in the epsin:clathrin complex, hence no increase in the response units (RU) 
was observed in the SPR results below. Another interpretation could be due 
to epsin 1’s length (long unstructured region) and binding manner (occupy 
larger space on TD); once epsin 1 is bound to clathrin TD, it may block some 
of the available sites that β-arrestin could occupy, and β-arrestin 1L is not 
able to displace epsin 1 from its occupied TD site since neither the WT nor 
the active β-arrestin can interact with clathrin TD in the presence of epsin 1.  
 
All in all, as adaptor proteins have weak electrostatic interactions with fast on 
and off rate, it is important to note that epsin 1 due to its strong binding 
affinity and complex binding manner to clathrin, it would occupy majority of 
the clathrin TD sites and leave rarely unoccupied for β-arrestin 1L to bind, 
and would not allow β-arrestin 1L to outcompete for epsin 1’s occupied TD 
sites, due to its possible weaker affinity and binding manner to clathrin TD. 
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  6.5.7 Epsin mutants (257,480, DKO) and WT β-arrestin 
1L 
WT β-arrestin 1L (WTArr) binding was also investigated in the presence of 
the clathrin box motif epsin mutants, in order to confirm whether the 
competition pattern observed with the WT epsin 1 is not altered due to the 
mutations of important components in epsin 1’s structure. To address this 
question, SPR/IAC (2-injection) experiments were carried out, where the 
colour scheme and injection order is as described above. An overall 
competition between the epsin mutants (257,480, DKO) and WT β-arrestin 
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Figure 6.5.6: Competitive binding between epsin 1 WT (10 μM) and WT β-
arrestin 1L (48kDa) (10 μM) for GST-clathrin TD (1 μM) using SPR/IAC (2-
injection) method. The overall pattern is similar with the Figure 6.5.4 and 6.5.5. 
When the epsin 1 WT is injected on the clathrin:WTArr complex, the epsin 1 binds to 
the complex as shown by the increase in the second blue curve in (A) and (B). 
However, when switching the order around, the WTArr does not bind on the 
clathrin:epsin 1 complex as seen in the second brown curve of (A) and (B). The 
active β-arrestin 1L control (black) curve has lower response units than the 
experimental (blue) curve. This might be due to the deteriorating performance of the 
SPR chip. WTArr; active β-arrestin 1L. Control and experiments are run on the same 
flow cell, but due to the deterioration of the SPR chip after 6 experiments, the each 
epsin mutant experiment was run on a different flow cell in a randomised order to 
prevent any significant systematic error in the binding responses. (E) The Δpeak2-
peak1 of single or dublicate runs of 2-injection experiments plotted for all the epsin 1 
WT combinations with the WTArr and ActArr (taken from Figure 6.5.4 for comparison 
reasons). 
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1L was observed (Figure 6.5.7 (A),(B),(C)). There is a strong interaction of 
the epsin mutants 257 and 480 epsin with clathrin TD even when injected 
over a β-arrestin 1L:clathrin TD complex, which resulted in an increased 
difference (Δpeak2-peak1) of ~ 900 RU for 257 and 480, and ~ 800 RU for 
DKO as seen in the single point plots in Figure 6.5.7 (D). This confirms that 
epsin 1’s structure remains complex even when mutating important clathrin 
binding component of its structure and despite these mutations it still seems 
to be able to occupy or occlude clathrin TD sites, and prevent WT β-arrestin 
1L binding.  
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Figure 6.5.7: Competitive binding between epsin 1 clathrin box mutatns (10 
μM) and WT β-arrestin 1L (10 μM) for GST-clathrin TD (1 μM) using SPR/IAC 
(2-injection) method. The overall pattern is similar with the Figure 7.5.4. When the 
epsin 1 mutant is injected on the clathrin:WTArr complex, the epsin 1 binds to the 
complex as shown by the increase in the second blue curve in (B),(C),(D). 
However, when switching the order around, the WTArr does not bind on the 
clathrin:epsin 1 complex as seen in the second brown curve of (B), (C), (D). The 
active β-arrestin 1L control (black) curve has lower response units than the 
experimental (blue) curve. This might be due to the deteriorating performance of the 
SPR chip. WTArr; active β-arrestin 1L. Control and experiments are run on the 
same flow cell, but due to the deterioration of the SPR chip after 6 experiments, the 
each epsin mutant experiment was run on a different flow cell in a randomised order 
to prevent any significant systematic error in the binding responses. (E) The 
Δpeak2-peak1 of dublicate or triplicate runs of 2-injection experiments plotted for all 
the epsin 1 mutant combination with the WTArr. 
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  6.5.8 Discussion: epsin 1 and β -arrestin 1L 
From the SDS-PAGE binding assay analysis I have shown how epsin and β-
arrestin 1L do not interact, however we are uncertain whether there is an 
interaction between these two adaptors in the present of clathrin. In this 
section, I demonstrate competition between epsin 1 WT and active form of β-
arrestin 1L (ActArr). This is based on the SPR data observations that ActArr 
does not bind to the clathrinTD:epsin1 complex, whilst epsin 1 can bind to 
the clathrin TD:ActArr complex. This competition pattern was observed with 
the WT β-arrestin form and the epsin clathrin box motif mutants as well. This 
could be a result of: (a) once epsin 1 binds to clathrin TD at certain single or 
multiple TD sites, ActArr might not have sufficient binding affinity to displace 
epsin 1 from its originally bound site on TD (b) epsin 1 length (long 
unstructured region) and binding manner (occupy larger space on TD) is 
different from β-arrestin 1L, such that when epsin 1 forms a complex with the 
clathrin TD it could be blocking other available TD sites that β-arrestin could 
bind to. Therefore, considering the results above, we could hypothesize that 
in either of these scenarios, epsin 1’s structure could be blocking the binding 
of other endocytic adaptor proteins during clathrin assembly initiation such as 
β-arrestin 1L.  
 
On the other hand, β-arrestin 1L would only be recruited when a GPCR is 
required desensitization and recycling (Gurevich, 2014), thus β-arrestin 1L is 
not an adaptor protein that would be continually present at the surface, but is 
only likely to be recruited “on demand”. Thus, in a situation where β-arrestin 
is required, a ‘burst’ of high concentration would be accumulating at the 
surface. This could possibly promote binding to the unoccupied TD sites. In 
addition it could be that β-arrestin 1 is only required for initial clathrin 
recruitment and that epsin 1 displaces it during the growth of the vesicle. 
Therefore, if by increasing the β-arrestin 1 active or WT form concentration 
(doubling the concentration), would we see the same competition pattern? 
This suggests future investigation of a concentration titration of both epsin 1 
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WT and mutants and β-arrestin with the SPR/IAC (2-injection) method, which 
was not possible to be carried out for this thesis due to time restraints.  
 
All in all, I demonstrate how using this novel SPR/IAC (2- injection) technique 
I was able to obtain interesting in vitro insights into how two adaptor proteins 
behave when mixed simultaneously, in the presence of clathrin TD. 
Additionally, I further demonstrate insights into the binding of epsin 1 and 
how it could interfere with the functionality of other adaptor proteins during 
the initial clathrin assembly stages of CME. However, such results need to 
be confirmed with in vivo experiments for more conclusive outcome. Further 
discussion and future work is described in Chapter 7. 
 
6.6.0 Epsin 1 and auxilin 1 
  6.6.1 Introduction: structural and functional differences 
between epsin 1 and auxilin 1 for clathrin binding 
Epsin 1 and auxilin 1 have ‘opposing’ roles in CME. Epsin 1 is involved in 
clathrin assembly in the initiation stage and auxilin 1 is involved in clathrin 
disassembly. Structurally, epsin 1 structure consists of two clathrin box 
motifs on each C- and N- domains (LMDLA and LVDLD), and the 
unstructured/DPW region which is hypothesized to interact with clathrin 
independently and aid in clathrin assembly into a uniform cage size 
distribution (Drake et al., 2000; Kalthoff et al., 2002). On the other hand, 
auxilin 1 has several DLL and DPF motifs in its structure, which have been 
suggested to bind to clathrin (Scheele et al., 2001; Fotin et al., 2004), but 
more specifically, auxilin contains a clathrin box motif ‘LLGLE’, which binds 
to the clathrin TD (Smith et al., 2004). Auxilin 1 promotes interaction of 
Hsc70 with assembled clathrin after the CCV has been formed.  
 
These adaptor proteins are an ideal combination to investigate competition 
for clathrin TD due to their different roles in CME. They have been 
hypothesized to bind to three similar TD sites (CBox site 1, W-box site 2 and 
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Arrestin Box site 3), although this has yet to be confirmed (Scheele et al., 
2001; Drake et al., 2000; Kalthoff et al., 2002). However, the epsin yeast 
homolog (Ent2) has been shown to bind to the CBox as well as W-box on the 
TD sites (Collette et al., 2009), and DLL motifs are hypothesized to bind to 
the CBox and ArrestinBox, due to their similarity to these sites. Additionally, 
the F residue of the DPF motifs of auxiln 1 is hypothesized to bind to the W-
box of the clathrin TD, as it is a largely hydrophobic. The adaptor proteins 
used for the GST-pulldowns and SPR/IAC (2-injection) competition studies 
were the epsin 1 WT form and the auxilin 1 WT form of the clathrin box motif. 
The concentration ratio used was 1 in 10 molar ratio with 1 μM of GST 
clathrin TD to 10 μM of each adaptor protein.  
 
  6.6.2 Preliminary SDS-PAGE binding assay data reveal 
competition between epsin 1 and auxilin 1 
Ultracentrifugation binding assays were carried out initially by Dr. Michael 
Baker to demonstrate whether there was any obvious competition between 
these two adaptor proteins for clathrin binding. The binding assay results 
show no strong interaction between these two adaptor proteins when mixed 
together (Figure 6.6.2 (B)). Although, we cannot rule out the possibility of 
transient interactions or interactions that may only occur in the presence of 
clathrin. Interestingly, no obvious competition was observed at a 1:1 ratio of 
the two adaptor (epsin1:auxilin1) in the gels, but by increasing the auxilin 1 
concentration 5 folds (1:5), we observed a decrease in bound epsin 1 (Figure 
6.6.2 (A), lane 12). This demonstrated competition between the two adaptor 
proteins with increased auxilin 1 concentration in the presence of clathrin 
cages. As SDS-PAGE analysis has a limited dynamic range, I aimed to use a 
more quantitative technique to investigate this competition using clathrin TD. 
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Figure 6.6.2: Ultracentrifugation and GST- SDS-PAGE pulldown assays were 
carried out showing competition between auxilin 1 and epsin 1 WT for clathrin 
TD. Clathrin cages  (3 uM) were incubated with increasing molar ratios of auxilin 
(Aux) with or without the presence of epsin (E). The pellet (P) and supernatant (S) 
fractions were analysed by SDS-PAGE. (A) Both auxilin (C:Aux 1:1 and 1:5) and 
epsin (CE) bind to clathrin. When increasing the concentration of auxilin in the 
presence of epsin we can see a decrease in the epsin band present in the pellet 
fraction in the 1:1:1 C:E:Aux ratio and the complete shift of epsin to the supernatant 
at the high concentration of auxilin (CE:Aux 1:1:15). (B) GST-pulldown assays were 
used to analyse GST-auxilin in the presence or absence of epsin and supernatant 
and pellet fractions were analysed by SDS-PAGE. GST-auxilin is pulled down in the 
presence of beads where as epsin is not. When epsin and auxilin are mixed epsin 
remains in the supernatant and GST-auxilin is present both in the supernatant and 
pellet. These experiments and SDS-PAGE were conducted by Dr. Michael Baker 
(Baker Michael, 2016). 
 
 
(A) 
(B) 
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6.6.3 Competition between epsin 1 WT and auxilin 1  
  6.6.4 A 1:1 ratio of epsin 1WT:auxlin 1  
SPR/IAC (2-injection) was used to confirm such competition using the same 
colour scheme and injection order are as described in the above sections. 
Interestingly, the SPR results show competition between epsin 1 and auxilin 
1 for clathrin TD binding at a 1:1 molar ratio of epsin:auxilin. This was 
demonstrated in the SPR results when an increase in response of ~ 700RU 
was detected in the SPR sensorgram when auxilin 1 was injected first (first 
blue curve) (Figure 6.6.4). This corresponds to the clathrinTD:auxilin1 
complex formation. When the epsin 1 is injected onto the clathrinTD:auxilin1 
complex  as a second adaptor injection, we observe an equivalent increase 
of response (second blue curve) of ~ 1000 RU, which could suggest that all 
epsin was able to bind to the TD sites (Figure 6.6.4). 
 
From this strong response of epsin 1 WT, we could hypothesize that epsin 1 
WT could be binding to available TD sites, which are un-occupied from 
auxilin 1. However, this does not rule out the possibility that epsin 1 WT 
could be displacing and competing for the same TD sites that auxilin 1 was 
already bound when injected first. This is because epsin 1 has been shown 
to have greater binding capacity for clathrin TD in Chapter 6 due to its 
complex structure.  On the other hand, by switching the order of the adaptor 
protein injection, with epsin 1 WT injected first and auxilin 1 injected second; 
we do not see the same pattern. We observe that auxilin 1 does not bind to 
the epsin 1:clathrin TD complex (second brown curve), as there is no 
significant increase in response on the sensorgram (Figure 6.6.4). This could 
be a result caused by the inability of auxilin 1 to displace epsin 1 from the 
occupied TD sites due to the possibility of low binding affinity to those sites, 
which are common with epsin 1. Due to SPR instrumental failure, these 
experiments were carried out as single runs and repetitions are necessary in 
order to validate these observations. 
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  6.6.5 A 1:2 ratio of epsin 1 WT:auxilin 1 
The initial competition observed posed multiple questions as to how certain 
endocytic adaptor proteins perform assembly and disassembly efficiently in 
vivo. Therefore, I aimed to investigate this further by doubling the 
concentration of each adaptor protein sequentially. This phenomenon would 
mirror in vivo situation where each specific adaptor protein would have a 
‘burst’ of high concentration to initiate its role in the different stages of CME. 
 
Thus, the concentration of auxilin 1 was doubled to 20 μM and the epsin 1 
WT concentration was kept constant at 10 μM as in the previous 
experiments, resulting to a 1:2 molar ratio of epsin1:auxilin1. The SPR/IAC 
(2-injection) experiments were run as detailed above and the results are 
demonstrated in Figure 6.6.5 as dotted response curved following the 
previous colour scheme, and the straight lined response curves are from 
previous section 6.6.4 at a 1:1 molar ratio of epsin 1: auxilin 1. These results 
are merged together for comparison reasons between 1:1 and 1:2 epsin 
1:auxilin 1 molar ratios.  When injecting auxilin 1 (20 μM) first (first dotted 
blue curve) to form the auxilin:clathrin TD complex and then injecting the 
epsin 1 WT (10 μM) (second dotted blue curve) a binding of epsin 1 WT to 
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Figure 6.6.4: Competition between epsin 1 WT and auxilin 1WT using SPR/IAC 
(2-injection) method. When the epsin 1 mutant is injected on the clathrin:auxilin1 
complex, the epsin 1 binds to the complex as shown by the increase in the second 
blue curve However, when switching the order around, the auxilin 1 does not bind 
on the clathrin:epsin 1 complex as seen in the second brown curve. Due to SPR 
instrumental failure, these experiments were carried out as single runs and 
repetitions are necessary in order to validate these observations. 
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the complex at a response of ~ 1000 RU is observed (Figure 6.6.5). This 
binding of epsin 1 WT suggest two scenarios:  (a) epsin 1 WT is able to bind 
to other clathrin TD sites even in the presence of higher auxilin 1 
concentration, (b) epsin 1 WT could completely displace auxilin 1 from its 
occupied clathrin TD binding site(s). More interestingly, we observed that the 
competition between epsin 1 and auxilin 1 is altered when the concentration 
of auxilin 1 is doubled. This is confirmed when epsin 1 WT (10 μM) was 
injected first in our experiment (first dotted brown curve) to form the epsin 
1:clathrin TD complex, and then auxilin 1 (20 μM) was injected over the 
complex. Auxilin 1 bound to the complex with an increase response of ~1300 
RU (brown dotted line), which was not observed when the auxilin 1 
concentration was at 10 μM (brown smooth line). However, the ~ 1300 RU 
increase observed which is not equal to the ~2300 RU observed when auxilin 
1 is bound alone to clathrin-TD. This could be because of epsin 1 blocking 
some of the clathrin TD sites where auxilin 1 binds, due to its larger length 
(large unstructured region) and binding manner (occupy larger space on TD). 
Also epsin 1’s affinity to clathrin TD might be stronger for certain clathrin TD 
sites than auxilin 1’s. Though, by increasing the concentration of the auxilin 
1, the number of auxilin 1 molecules injected onto the immobilized clathrin 
TD surface increases compared to the injected epsin 1 samples. This could 
provide more possibility for auxilin 1 to enter un-occupied TD sites or 
outcompete epsin 1 for its occupied TD sites, which are common between 
the two adaptor proteins (CBox, W-box, ArrestinBox TD sites). However, we 
are uncertain whether this concentration of auxilin 1 is actually saturating all 
TD binding sites on the chips surface. The Δpeak2-peak1 of the runs of 2-
injection experiments plotted for all the epsin 1 and auxilin 1 for the 1:1 molar 
ratio and the 1:2 molar ratio (Figure 6.6.5 (B)).  
 
Overall, there could still be competition between epsin 1 WT and auxlin 1 
even at higher auxilin 1 concentrations, as epsin 1 WT could be initially 
bound to different TD site(s) which are common with auxilin 1, but due to 
auxilin 1’s hypothesized lower binding affinity for some of those common TD 
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site, it could be hypothesized that auxilin 1 would not be able to compete and 
displace all of the epsin 1 form those TD sites. Due to SPR instrument 
deterioration I was not able to carry out the experiments where epsin 1 
concentration is increased (double) and auxilin 1 concentration is kept 
constant. I hypothesize that the results from these experiments would not 
alter the competitive effect observed between epsin 1 and auxilin 1. 
 
  
  6.6.6 Discussion: epsin 1 and auxilin 1 
Competition between epsin 1 WT and auxilin 1 WT was investigated based 
on previous results from pulldown/SDS-PAGE assays that have revealed 
competition between these two adaptor proteins for clathrin TD. In order to 
address these results further with a more quantitative technique, the newly 
developed SPR/IAC (2-injection) technique was employed. 
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Figure 6.6.5: The competitive binding between epsin 1 and auxilin 1 for GST-
clathrin TD at 1:1 molar ratio and 2:1 molar ratio. (A) The sensorgram plot from 
the SPR/IAC (2-injection) method demonstrated that when the epsin 1 mutant is 
injected on the clathrin:auxiln 1 complex, the epsin 1 binds to the complex as shown 
by the increase in the second blue curve. However, when switching the order 
around, the auxilin 1 does not bind on the clathrin:epsin 1 complex as seen in the 
second brown curve. Increasing the auxilin 1 concentration to 20 μM and keeping 
epsin 1 concentration constant still promotes competition and an increase in 
response is observed when auxilin 1 was bound on the clathrin:epsin 1 complex. 
However, this competition is caused by auxilin either binding to unoccupied TD or 
outcompeting epsin 1 from its already bound TD sites. Due to SPR instrumental 
failure, these experiments were carried out as single runs and repetitions are 
necessary in order to validate these observations. (E) The Δpeak2-peak1 of the 
runs of 2-injection experiments plotted for all the epsin 1 and auxilin 1 for the 1:1 
molar ratio and the 1:2 molar ratio.  
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The initial SPR results obtained in this section demonstrate clear competition 
between epsin 1 and auxilin 1 at a 1:1 molar ratio of epsin1:auxilin1. 
Increasing the concentration of auxilin, we noticed that competition was 
altered with auxilin 1 being able to bind on the epsin1:clathrinTD complex. In 
addition, other binding motifs such as the DLL and DPF/W motifs are shared 
between auxilin 1 and adaptors such as epsin 1 (Drake et al., 2000; Scheele 
et al, 2001; Kalthoff et al., 2002), which could contribute to the competition 
observed. It has been hypothesised that auxilin 1 may actively compete with 
adaptor binding to clathrin to displace adaptors from binding to clathrin 
(Scheele et al., 2001; Smith et al., 2004). Taking into consideration these 
observations, along with the structural nature of epsin 1 (two clathrin box 
motifs and unstructured/DPW region), and auxilin 1, the following 
interpretations of these results is proposed: 
(a) based on the previous hypothesis in this thesis on how epsin interacts 
with clathrin, I suggest that epsin 1 WT once injected first onto the SPR chip 
surface could possibly bind to one or multiple hypothesized TD sites on a 
single TD e.g. CBox, ArrestinBox and W-box, which are suggested to be 
common to auxilin 1 as well (Drake et al., 2000; Scheele et al., 2001; Collette 
et al., 2009), with a stronger binding affinity than auxilin 1 and occupying a 
larger space on the TD. Thus, if epsin 1 WT occupies majority of the TD sites 
on a single TD, this would limit the chance for auxilin 1 to bind when injected 
on the clathrinTD:epsin1 complex. Auxilin 1 might not be able to compete off 
the epsin 1 from its occupied TD sites. However, in the case where auxilin 1 
is injected first and forms the clathrinTD:auxilin1 complex, epsin 1 once 
injected could either outcompeting the site(s) where auxlin 1 was bound to 
TD or bind to other multiple available TD sites which have not be bound to 
auxilin 1. Interestingly, pulldown assays from Scheele et al., 2001 show that 
AP180, a similar assembly protein as epsin 1, is blocked from interacting 
with TD when auxilin is added in excess, even at lower concentration 
(Scheele et al., 2001). 
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(b) epsin 1’s length and binding manner and the large unstructured structure 
of epsin 1, could occupy a larger space on the TD,  potentially hindering 
other available clathrin TD sites that auxilin 1 could potentially bind. 
Therefore, auxilin 1 would not be able to bind to clathrin TD, once injected in 
the epsin1:clathrin TD complex. However, in a situation where the auxilin 1 
concentration is increased, it either to interacts with other available TD sites 
or outcompete epsin 1 for these binding sites. This causes an alteration in 
the competition intitially observed between these two adaptors and it is still 
detected as an increase in band intensity or response units in pulldowns and 
SPR results. 
These in vitro observations and hypotheses provide more insight into how 
assembly adaptor proteins act in the presence of other disassembly 
endocytic adaptor proteins. Most interestingly, once again we can elucidate 
that epsin 1’s complex structure prevents other endocytic adaptor binding to 
clathrin. However, these observations are in vitro, and could be the basis for 
in vivo future work to confirm such interactions. 
6.7.0 Biological relevance of the competition between 
epsin 1 and auxilin 1 
Epsin 1 is a vital clathrin assembly protein for initiation of CME, whereas 
auxilin 1 is a clathrin disassembly protein, which is used at the conclusion of 
clathrin-mediated endocytosis. However, as epsin 1 is one of the first adaptor 
proteins to arrive at the site of initiation, compared to auxilin 1, and interact 
with clathrin TD before auxilin 1 in an in vivo situation. The precise location of 
epsin 1 during cage disassembly is still not known (Chen et al., 1998; 
Rappoport et al., 2006; Edeling et al., 2006a; Hawryluk et al., 2006; Henne et 
al., 2010). However, it has been suggested that at least some epsin 1 is 
present in CCP at the point of clathrin disassembly (Rapport et al., 2006; 
Hawryluk et al., 2006; Edeling et al., 2006a). Although, epsin 1 is suggested 
to be present in 90% of endocytic events in various cell lines (Taylor et al., 
2011), this could vary within cell lines, especially at a mature CCV where 
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epsin 1’s concentration could be low and could make way for other adaptor 
proteins e.g. auxilin 1 to bind to clathrin. Epsin 1 has a concentration 
dependent inhibitory effect on clathrin cage disassembly of CCVs (Baker, 
2016) and thus would play a role in making clathrin cages more resistant to 
disassembly in vivo. In vivo auxilin 1 and Hsc70 play a role in remodelling the 
clathrin lattice (Popova and Petrenko, 2013) and the presence of epsin 1 
could therefore play a role in stabilising structures due to its ‘linking effect’ of 
clathrin. Thus, this could play a role in forming lattices and in driving a CCP 
towards maturation. 
Additionally, Massol et al., 2006 states that small and variable amounts of 
auxilin are recruited transiently with a ‘burst’ of higher concentration seen 
after the dynamin recruitment peak and interaction with lipid head groups. 
Thus, the timing of auxilin 1 recruitment determines the onset of uncoating 
(Massol et al., 2006). Based on this knowledge, I suggest that the 
competition between epsin 1 and auxilin 1 for clathrin TD observed in the 
SPR results above is expected and hence comparable to the epsin inhibitory 
effect observed with the clathrin cages. Thus, I hypothesize that the 
concentration of auxilin 1 in the presence of epsin 1 affects the extent of 
disassembly in vivo. We clearly also observe this in the SPR results in this 
chapter where, at a higher concentration of auxilin 1, competition is still 
observed where auxilin 1 is able to bind to the epsin:clathrin TD complex 
either in the unoccupied TD sites or outcompeting epsin 1 in its already 
bound TD sites. It would be interesting to use mutants with impaired TD sites 
in order to attempt to obtain confirmation as to whether epsin 1 and auxlin 1 
have common TD sites as hypothesised. Nevertheless, from this 
investigation we obtained novel information on the mechanism of epsin 
1:clathrin TD interactions as well as how this could affect the way other 
adaptor proteins bind to clathrin TD e.g. auxilin 1.   
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6.8.0 Competition between β2-adaptin and auxilin 1 
  6.8.1 Introduction: structural and functional differences 
between β2-adaptin and auxilin 1 
AP2 and auxilin 1 are considered an ideal combination to investigate 
competition for clathrin TD as they have very ‘opposing’ roles in the CME. An 
AP2 peptide has been shown to bind to the CBox site 1, W-box site 2 and 
Arrestin Box site 3 on the TD (Zhuo et al., 2015), which are hypothesized to 
be common sites for auxilin 1 with clathrin TD (Drake et al., 2000; Scheele et 
al., 2001; Kalthoff et al., 2002). 
 
  6.8.2 SDS-PAGE binding assay data reveal no 
competition between β2-adaptin and auxilin 1 
Ultracentrifugation SDS-PAGE assays were previously conducted by Dr. 
Michael Baker with these two structurally diverse adaptor proteins to 
determine competition for clathrin TD binding (Baker, 2016). Based on 
previous literature, there is no specific interaction between these two adaptor 
proteins in vitro and that β2-adaptin and auxilin 1 has previously been shown 
to bind to clathrin at the same time (Boecking et al., 2011). No obvious 
competition was observed between these two adaptors for clathrin TD 
(Figure 6.8.2) at a 1:1 molar ratio of β2-adaptin:auxilin1 and a 1:5 of clathrin 
cages:adaptor. In the contrast, Smith et al., 2004 demonstrate a level of 
competition for clathrin TD binding between β2-adaptin and auxilin with 
clathrin box peptides of both adaptor proteins in peptide competition assays. 
To address this opposing results, the SPR/IAC (2-injection) technique was 
used to investigate whether there is competition between β2-adaptin and 
auxilin 1 at a 1:1 and 2:1 molar ratio β2-adaptin:auxilin1 in the presence of 
clathrin TD.  
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  6.8.3 SPR data reveal no significant competition 
between β2-adaptin and auxilin 1  
To add further insight into the opposing views regarding β2-adaptin and 
auxilin 1 competition for clathrin TD, the newly established SPR/IAC (2-
injection) method was used, where the colour scheme and injection order as 
well as the clathrin TD: adaptor (1:10) ratio are as described above. In Figure 
6.8.3 (A) of the SPR results, we observe that when the β2-adaptin was 
injected (second blue curve) after formation of auxilin1:clathrin complex (first 
blue curve), we observe an increase in response to ~ 380 RU. When the 
adaptor protein order was switched around, with auxilin 1 injected (second 
brown curve) on β2-adaptin:clathrin complex (first brown curve), we observe 
an increase in response of ~ 750 RU. The Δpeak2-peak1 of the runs of 2-
injection experiments plotted (Figure 6.8.3 (C)). This is a relatively small 
Figure 6.8.2: Ultracentrifugation analysis was conducted for β2HA and GST-
auxilin 1 binding to clathrin cages. Both β2HA and GST-auxilin 1 bind to clathrin 
cages (3 μM), as 1:5 molar ratio of clathrin cages:β2 show β2 present in the pellet 
(P) suggesting binding. Similarly, the GST-auxilin 1 pellets with clathrin cages at a 
1:5 molar ratio. Both GST-aux and β2 HA can bind to clathrin cages when mixed 
together (C: β2:Aux) as both bands can be seen in the pellet(P) with clathrin. These 
experiments and SDS-PAGE analysis was conducted by Dr. Michael Baker (Baker 
Michael, 2016).  
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difference, suggesting that these two adaptor proteins could favorably bind to 
clathrin TD simultaneously but with slight difference in their binding affinity. 
Based on these in vitro results, I suggest that β2-adaptin and auxilin 1 could 
bind to clathrin TD at the same time, and disassembly would not be inhibited 
at such ratios of adaptor proteins in vivo. This might be due to similar binding 
capacity of this two adaptor proteins to clathrin TD as seen in section 6.2.2.  
 
When the β2-adaptin concentration was doubled it caused a complete 
inhibition of the auxilin 1 to the binding to clathrin TD. This is seen in the SPR 
data in Figure 6.8.3 (B), where injecting auxilin 1 (second brown dotted 
curve) on the β2-adaptin-clathrin complex (first brown dotted curve), no 
increase in response is observed. However, the sharp decrease during the 
buffer wash, after the first injection in the brown dotted curve, is considered 
unusual and possibly to the instrument failure. Thus, repetition is required to 
confirm the observed results. SPR experiments were run once with higher 
auxilin concentration keeping the β2-adaptin concentration the same. 
However, due to SPR instrument failure, the results were not presented, and 
all the experiments in Figure 6.8.3 were run only once. 
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  6.8.4 Discussion: β2-adaptin and auxilin 1 
In this section, I demonstrate how β2-adaptin and auxilin 1 would not 
compete for clathrin TD binding at a 1:1 molar ratio of adaptor proteins. 
However, competition is more obvious when increasing the concentration of 
one of the adaptor proteins as seen in the SPR data above. For example, 
doubling the concentration of β2-adaptin (β2HA) inhibited the binding of the 
Figure 6.8.3: The competitive binding between β2-adaptin and auxilin 1 for 
GST-clathrin TD at 1:1 molar ratio, which is more obvious when the β2-
adaptin concentration is increased. (A) The sensorgram plot from the SPR/IAC 
(2-injection) method demonstrated that when β2-adaptin is added to the 
clathrin:auxilin1 complex, the β2-adaptin binds to the complex as shown by the 
increase in the second blue curve with ~ 380 RU difference between peak 1 and 
peak 2. When switching the order around, the auxilin 1 binds on the clathrin:β2-
adaptin complex as seen in the second brown curve, but with ~ 750 RU difference 
between peak 1 and peak 2. (B) Increasing the β2-adaptin concentration to 20 μM 
and keeping auxilin 1 concentration constant enhances this competition as no 
increase in response curve was observed when auxilin 1 was injected on the 
clathrin: β2-adaptin complex (brown dotted line). Due to SPR instrumental failure, 
these experiments were carried out as single runs and repetitions are necessary in 
order to validate these observations. (C) The Δpeak2-peak1 of the runs of 2-
injection experiments plotted for all the epsin 1 and auxilin 1 for the 1:1 molar ratio 
and the 1:2 molar ratio.  
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auxilin 1 to the clathrin: β2HA complex, and more specifically to clathrin TD. 
This causes displacement of certain adaptor proteins with others for certain 
TD sites. For example, β2-adaptin has been suggested to bind to three of TD 
binding sites (Cbox, ArrestinBox and W-box), as AP2 clathrin box motif 
peptide has demonstrate that has a 3:1 stoichiometric binding ratio of AP2 to 
clathrin TD with a low affinity (Zhuo et al., 2015). Auxilin 1 has also been 
hypothesized to bind to the same three TD sites, CBox, ArrestinBox and W-
box (Scheele et al., 2001). Thus, in an in vivo situation we can hypothesize 
that during the ‘burst’ of β2-adaptin concentration at clathrin assembly 
initiation stage, β2-adaptin could bind to majority of the TD sites available 
with possibly a stronger binding affinity than auxilin 1. Thus, due to this 
hierarchy auxilin 1 could not displace β2-adaptin and inhibit the assembly 
process.  
Focusing on the clathrin disassembly process, Massol et al., 2006 state that 
small and variable amounts of auxilin are recruited transiently but that a 
much larger burst of association occurs after the peak of dynamin signal at 
scission (Massol et al., 2006; Taylor et al., 2011) and interaction with lipid 
head groups. Thus, the timing of auxilin 1 recruitment determines the onset 
of uncoating (Marssol et al., 2006). It is interesting to note that the 
clathrin:AP2 ratio changes during flat-to-curved transition of the clathrin 
lattice in vivo, with a clathrin content of ~ 70%, which indicates completion of 
coat assembly (Bucher  et al., 2017). Thus the concentration of AP2 varies at 
various stage of CCV assembly. Therefore, during the disassembly stage in 
vivo, AP2 could be in low concentrations and thus the auxilin 1 ‘burst’ in 
concentration could initiate the disassembly process without any competition 
for clathrin binding between the two adaptor proteins. Future experiments 
should be performed where the concentration of auxilin 1 is doubled whilst 
the concentration of β2HA is kept constant, in order to observe whether this 
competition can be eliminated in the presence of higher auxilin 1 
concentration, as in a disassembly environment. 
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In the 1:1 adaptor molar ratio in the SPR results, we observed that in both 
situations where auxilin 1 was injected second or when β2-adaptin was 
injected second, we still observed a significant binding of the second adaptor 
to clathrin TD. Therefore, according to the SPR results I suggest that neither 
assembly nor disassembly processes would be completely terminated in an 
in vivo environment at 1:1 molar ratio. This could be because a redundant 
auxilin 1 binding site on the clathrin TD would ensure that auxilin 1 binds 
even in the presence of potentially competing proteins (Scheele et al., 2001). 
However, it is still not certain that other factors, such as the binding of other 
adaptor proteins to a clathrin:β2-adaptin:auxilin 1 complex could be altering 
auxilin binding due to their highly dynamic interaction which is caused from 
hierarchical and sequential interaction with clathrin TD. 
In 2004, Smith et al., demonstrate a level of competition for clathrin TD 
binding between β2-adaptin and auxilin using peptide competition assays 
with clathrin box peptides of both adaptor proteins. Smith et al., used a 
peptide, which give a weak binding interaction for clathrin TD to be 
determined (Smith et al., 2004). In the SPR/IAC experiments, protein 
constructs have been used so we see how these binding sites operate in 
their original context within the protein. Our observations suggest that the 
protein binds with stronger affinity to terminal domain than an isolated 
peptide ligand. Therefore, the competitive effect between these two adaptors 
for clathrin TD binding observed in the results from Smith et al., 2004 oppose 
the results from SPR/IAC (2-injection) method and pulldown/SDS-PAGE 
assays, which reveal no obvious competition between the two adaptors for 
clathrin TD. However, increasing the ratio of adaptor proteins could result 
into a more visible competitive effect. In addition, Dr. Michael Baker has 
demonstrated no significant inhibitory effect on clathrin cage disassembly 
from the addition of β2-adaptin (in excess) at 1:1 and 1:5 molar ratio of 
clathrin to β2-adaptin (Baker, 2016). It is important to note that auxilin 1 is 
able to interact with other clathrin heavy chain regions (Fotin et al., 2004) 
where β2-adaptin cannot and so we do not see inhibition of disassembly, nor 
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obvious competition in cage pull down assays.  
6.9.0 No competition between Hip1 CC and β-arrestin 1L 
  7.9.1 Introduction: structural and functional differences 
between Hip1 CC and β-arrestin 1L 
β-arrestin 1L structure consists of two independent clathrin box motifs 
(LIELD and LEFD) on opposite sites (each C- and N- domains), which could 
bridge two clathrin molecules in a lattice (Kang et al., 2009). The role of β-
arrestin 1L is to bind and recruit clathrin to the plasma surface, for clathrin 
assembly. Hip 1/Hip1R endocytic adaptor protein on the other hand, has 
been stated to preferentially bind to CLC (Chen and Brodsky, 2005). The 
coiled-coil (CC) domain of both proteins promotes dimerization of the protein 
and interaction with clathrin light chain (CLC), which promotes the formation 
of clathrin cages in vitro (Ybe et al., 2007; Niu and Ybe, 2007), (Ybe et al., 
2009). This allows the recruitment of Hip1/Hip1R to the membrane and 
release of the interactions with the CLC (Hyun et al., 2004; Ybe et al., 2009; 
Gottfried et al., 2010). More specifically, Hip1 has a potential clathrin box 
motif (VDLE), which is hypothesized to bind to CHC (Waelter et al. 2001). 
Thus, SDS-PAGE pulldowns and the SPR/IAC (2-injection) method were 
carried out to demonstrate whether there is competition between two adaptor 
proteins (the active form of beta-arrestin 1L and Hip1 coil-coil domain), which 
are required at different stages of the CME, and functionally different 
  6.9.2 SDS-PAGE binding assay data revealed no 
competition between Hip1CC and β-arrestin 1L 
Initial investigation of competition of these two structurally diverse adaptor 
proteins, was carried out using GST- pulldown binding assays, which 
revealed no obvious competition between these two adaptors for clathrin TD 
with increasing concentration of either adaptor. More specifically, at a 1:1 
molar ratio of β-arrestin 1L:Hip1CC, both adaptor proteins bind to clathrin TD 
(Figure 6.9.2 (B), lane 7 and 9; Figure 6.9.2 (D) lanes 1 and 3) compared to 
the control experiments with the adaptors alone, without the presence of 
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clathrin TD (Figure 6.9.2 (A) lanes 3-6, 11-14), with Hip1CC slightly pelleting 
on its own. At 1:3 molar ratios of β-arrestin 1L:Hip1CC (Figure 7.9.2 (B), lane 
11 and 13; Figure 6.9.2 (D) lanes 5 and 7), the same results are observed, 
with the slight difference Figure 6.9.2 (D), lane 5, where the Hip1CC in the 
pellet has a less intense band then expected. However, this could be an 
anomaly in the results. Overall, Hip1 CC and active or WT β-arrestin 1L 
could bind to clathrin and co-exist. Additionally, we can confirm from the 
results that there is no specific interaction between these two adaptor 
proteins in vitro. 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
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Figure 6.9.2: SDS-PAGE analysis of GST-pulldown assays demonstrating no 
obvious competition between β-arrestin 1L (β) and Hip 1 (H) for clathrin TD (C). 
At 1:1 or 1:3 of Hip1:β-arrestin 1L. GST-clathrin TD (3 μM) was incubated with 
GST-affinity beads in the presence of active and/or WT β-arrestin 1L in increasing 
concentrations with His-Hip 1 at 1:1 and 1:3 molar ratios. The pellet (P) and 
supernatant (S) fractions were analysed by SDS-PAGE. (A) and (C) Controls are 
carried out with clathrin TD only (lanes 1 and 2) and His-Hip1 only (lanes 3-6) as well 
as GST- β-arrestin 1L (lanes 11-14), but also Hip1 in combination with clathrin TD at 
1:3 and 1:10 ratio (lanes 7-10). (B) These two adaptor proteins have been shown 
that they do interact with each other (lane1-2). (B) and (D) No obvious significant 
competition between Hip 1 and active or WT β-arrestin 1L for clathrin TD, even at 
high concentrations of WT β-arrestin at 1:10:10 C:E:β molar ratio (lanes 13-14). 
However, due to the pelleting of Hip1 on its own, this competition is not conclusive. 
These experiments and SDS-PAGE analysis are representative of multiple 
experiments.  
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  6.9.3 Hip1 CC and β-arrestin 1L could be competing for 
clathrin TD binding as revealed from SPR data 
In order to confirm the absence of any competition between these two 
adaptor proteins for clathrin TD binding, we carried out experiments using the 
newly developed SPR/IAC (2-injection) method using Hip1CC WT and active 
β-arrestin 1 (ActArr). The SPR results in Figure 6.9.3 revealed interesting 
observations where Hip1CC binding was negligible once injected on the 
ActArr-clathrin TD complex (Figure 6.9.3, second blue curve). But ActArr was 
able to bind to Hip1-clathrin TD complex (Figure 6.9.3, second brown curve). 
However, we have to note that the binding capacity of ActArr to clathrin TD 
alone is massively lower in these experiments, which could be the result of 
chip malfunction; these experiments need to be repeated to confirm such 
observations. 
 
 
 
 
 
 
 
   
 
 
 
Figure 6.9.3: SPR sensorgram plot demonstrating the binding between Hip1 
CC (10 μM) and active β-arrestin 1L (10 μM) to GST- clathrin TD (1 μM). Once 
the Hip1CC is injected onto the immobilised clathrin TD, the response units are very 
low (~ 50 RU), and the ActArr injected second was able to bind even with low 
reponse units. The response units of the ActArr:clathrin TD are very low (first blue 
curve) compared to previous experiments in this Chapter, hence the low response 
units observed when bound to clathrin:Hip1 complex is expected. These results 
could be due to the deterioration of the SPR chip and would require repetition to 
confirm the results. Due to SPR instrument failure these were not repeated. 
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  6.9.4 Discussion: Hip1 and β-arrestin 1L 
The observed SPR results between Hip1 CC and active β-arrestin 1L based 
on the SPR results could not be conclusive due to reasons stated in section 
7.9.3. Based on previous knowledge, these adaptor proteins are functionally 
diverse. More importantly, the Hip1 is hypothesized to be mainly located on 
the outside of the clathrin cage rather than on the inner layer (Wilbur et al. 
2008), due to its role in actin recruitment and organisation. Hip1 CC 
demonstrated a weak interaction with clathrin TD, which could be via the 
proposed motif of VDLE, suggested by Waelter et al., 2001. Compared to β-
arrestin 1L, which most likely localizes on the inside of the clathrin cage 
(Gurevich V.V., 2014). β-arrestin 1L’s main interaction with clathrin is via the 
TD, whereas for Hip 1 this interaction is primarily via CLC but with TD as well 
via weak interactions  (Waelter et al. 2001; Kang et al. 2009; Gurevich, 
2014). However, the mechanism to disrupt an interaction between Hip1 and 
clathrin is not yet known.  
 
6.10.0 Conclusion  
In conclusion, the newly established SPR/IAC (2-injection) technique was 
used to investigate competition between structurally and functionally diverse 
endocytic adaptor proteins (epsin 1, auxilin 1, β-arrestin 1, β2-adaptin, Hip1 
CC) for clathrin TD. The results from such investigation provided a vital 
insight into how certain adaptor proteins co-exist and could bind to clathrin 
TD together, such as auxilin 1 and β2-adaptin (AP2), however it is yet 
unclear whether a certain level of competition could inhibit assembly or 
disassembly processes. Additionally, epsin 1’s structure and complex binding 
behaviour to clathrin, seems to relate to the competition observed between 
various adaptor proteins, such as β-arrestin 1L and auxilin 1. Overall, varying 
concentrations of the adaptor proteins as well as obtaining binding rate 
constants from SPR/IAC (2-injection) method would provide us with a greater 
understanding on the binding interactions with clathrin between different 
proteins in the presence of others. More detailed discussion and further work 
are to be found in Chapters 7. 
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Chapter 7: Final Discussion 
7.0.0 Overview 
Although our understanding has grown on the roles of adaptors at different 
stages of the CME, due to their complex structure, we currently have limited 
knowledge of their binding interactions with the clathrin TD. In this thesis, I 
aimed to address the manner in which β-arrestin 1L and epsin 1 bind to 
clathrin TD using mutagenesis studies, SDS-PAGE binding assays and 
SPR/IAC method.  
Initially, I focused on whether the two clathrin box motifs on β-arrestin 1L 
structure, act antagonistically or synergistically. The action of the second 
clathrin box ([LI][LI]GXL)) and its potential to link multiple clathrin TDs could 
alter the interaction of other adaptor proteins which bind to clathrin TD, at the 
same time. This could also be the case for epsin 1 which also has two 
clathrin box motifs and an unstructured/DPW region structure, which were 
investigated in this thesis that could work cooperatively to link TDs and 
promote efficient clathrin assembly. This complex mode of binding by epsin 1 
could interfere with the action of other adaptor proteins for clathrin TD.  
I developed the SPR/IAC (2-injection) method in this thesis, in order to 
explore and gain further insight into whether certain adaptor proteins, which 
are structurally and functionally diverse, would compete for binding to clathrin 
TD or whether they would co-exist and bind simultaneously. This method 
was used along with mutagenesis studies and SDS-PAGE binding assays. In 
this chapter I discuss the implications of these interesting results based on 
the aims as per Chapter 1, section 1.11.0, and how this information relates to 
the situation in vivo. This chapter includes potential avenues for future work 
that could be explored based on the current results as well as further 
optimization of the SPR/IAC (2-injection) technique for clathrin:adaptor 
investigations. 
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7.1.0 SPR/IAC (2-injection) method: a tool used for 
investigating competition between adaptor proteins for 
clathrin TD binding  
A ‘two step’ method was developed where an adaptor protein would bind to 
clathrin TD forming a complex (as in SPR/IAC), prior to the addition of 
another adaptor protein to the complex, in order to determine their binding 
interaction. The results obtained from this technique have yielded information 
regarding how certain adaptor proteins act in the presence of others for 
clathrin TD binding. These results open up additional questions, which can 
be addressed in future assays, described in section 7.6.0. Currently, this 
method is at the early stages of development and it is considered a semi-
quantitative method, which we aim to progress to a fully quantitative analysis 
method for clathrin:adaptor interactions with certain future optimization steps. 
This progression will make it possible to obtain direct comparisons of binding 
affinity constants at a ‘two-step’ binding level between two adaptor proteins 
bound to clathrin TD at the same time (3 protein interactions). This type of 
assessment would be novel for the field of clathrin:adaptor, indicating any 
competition between adaptor proteins for clathrin in a quantitative way. 
7.2.0 The conserved LIELD clathrin box motif in β-
arrestin 1L is the major box for clathrin interaction 
The SPR/IAC data obtained in this thesis for the purified WT and mutant β-
arrestin 1L were mostly comparable to the results of Kang et al., 2009. 
Overall, the second clathrin box ([LI][LI]GXL) on the β-arrestin 1L is 
accessible for binding to the clathrin TD, and therefore the active form of β-
arrestin 1L with both clathrin box motifs accessible, demonstrated the 
strongest binding to clathrin TD in the SPR results of this thesis. The WT β-
arrestin 1 which has the conserved clathrin box hidden, presents 
approximately half the binding response to the TD, which suggests that the 
conserved LIELD clathrin box motif is the major box for clathrin interaction. 
This is supported by the evidence from by Kang et al. 2009, that there is a ~ 
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2-fold difference in binding affinity between active and WT β-arrestin 1L 
(Kang et al., 2009). The strongest binding was between the clathrin TD and 
active β-arrestin 1L with a KD of 0.98 ± 0.01 μM, whereas the KD of the WT 
β-arrestin 1L bound to clathrin TD was 2.1 ± 0.4 μM (Kang et al. 2009). 
Evidence from this thesis shows that mutating or deleting the conserved 
LIELD clathrin box motif acts negatively on how β-arrestin 1L interacts with 
clathrin TD causing a large decrease in the SPR response. This adds further 
support to the idea that the conserved clathrin box is the major clathrin 
interacting box, and that the second clathrin box ([LI][LI]GXL) cannot act as 
efficiently in isolation. However, we would still be uncertain whether these 
two clathrin box motifs act synergistically to link multiple clathrin TD, as 
suggested by Kang et al., 2009, as we have not investigated mutants of the 
second clathrin box motif. However, evidence from Kang et al., 2009 utilising 
TIRF microscopy for GPCR trafficking in HEK293 cells shows that β-arrestin 
1L still interacts with clathrin and promotes effective localization of β2AR to 
CCPs even in the absence of the conserved LIELD clathrin box motif (Kang 
et al., 2009). It is still unclear whether they bind to the same TD but a 
different sites (CBox- site 1 or ArrestinBox-site 3), and/or via multiple TD 
interactions. Hence, in future, the use of clathrin TD mutants with impaired 
sites could provide substantial information on the suggested linking TD effect 
of β-arrestin 1L.   
 
As the second clathrin box is suggested to have a low affinity for clathrin and 
does not function in isolation (Kang et al., 2009), it could be that these 
clathrin box motifs act cooperatively. Such a cooperative effect is supported 
by that fact that the two independent clathrin box motifs are ~ 68 Å apart and 
could be bridging multiple adjacent clathrin molecules in a lattice which are ~ 
64 Å in distance (Kang et al., 2009). This ‘linking effect’ for multiple adjacent 
TDs has been hypothesized for other adaptor proteins such as epsin 1 (more 
details in Chapter 6). The conserved clathrin box motif (LIELD) has been 
found in other adaptor proteins such as AP2, AP180, amphysisin and epsin 
1, and the second clathrin box motif of β-arrestin 1L has also been found in 
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other endocytic adaptor proteins, and binds to the ArrestinBox TD site (Kang 
et al., 2009; Lemmon and Traub, 2012), suggesting that β-arrestin 1L has 
the potential to compete for binding with other adaptor proteins. 
 
7.3.0 The complex interaction of epsin 1 and clathrin TD 
The clathrin adaptor epsin 1 is crucial for CME but the mechanism by which 
it interacts with clathrin and regulates clathrin assembly remains unclear. It 
has been hypothesized that epsin’s mode of interaction with clathrin is not 
simple and is most likely to consist of multiple components of its structure. 
Mutating any of those components massively decreases epsin’s binding to 
clathrin TD.  
The two clathrin box motifs of epsin 1, which interact with clathrin via specific 
motifs, have been proposed to work cooperatively to assemble clathrin 
(Drake et al., 2000; Drake and Traub, 2001; Holkar et al., 2015), and 
mutation of either of these motifs inhibits clathrin assembly on liposomes in 
vivo (Holkar et al., 2015). However, using the epsin clathrin box mutagenesis 
and SPR results in this thesis, I propose that the unstructured/DPW region, 
which has been suggested to bind to clathrin non-specifically (Drake et al., 
2000), has an equal binding capacity for clathrin TD as the two clathrin box 
motifs. This effect provides an interesting discussion point as to whether the 
two clathrin box motifs have a cooperative effect between them, as well as 
with the unstructured/DPW region in binding to clathrin. Would this 
hypothesized cooperative effect promote efficient clathrin assembly in vivo?  
Further investigations using epsin 1 unstructured/DPW region mutants 
confirmed the value of this region and the DPW motifs in the 
unstructured/DPW region, in the manner in which epsin 1 interacts with 
clathrin TD. The two clathrin box motifs are separated by 233 amino acids of 
a distance shorter than 155 nm (Kalthoff et al., 2002; Dafforn and Smith, 
2004).  Shortening (by half or quarter) this distance significantly decreased 
the binding capacity of epsin to bind to clathrin TD. This decrease is 
approximately equal with the decrease observed with the clathrin box epsin 
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mutants (257,480 and DKO). Thus, shortening the distance by half (~ 50 nm) 
or by quarter (~ 78 nm) decreases greatly the extent of the long-distance 
interactions between epsin 1 and clathrin. Based on previous structural 
studies on clathrin cages, the approximate distance between CBox site 1 
clathrin TD site is approximately ~ 5-10 nm depending on the cage size 
formation (Kirchhausen,  2000), (Fotin et al., 2004). Hence, shortening or 
deleting this distance, would prevent the stretching of the epsin molecule to 
link multiple clathrin TD together. This information also confirms the 
proposed scenario where the two clathrin box motifs and the 
unstructured/DPW region have a cooperative effect in binding to clathrin. 
More interestingly, deleting the whole unstructured/DPW region resulted in 
an even lower binding capacity for clathrin TD, confirming once again the 
importance of the distance and DPW motifs, in the unstructured/DPW region. 
Alternatively, two different sites on a single TD could be occupied with a 
single epsin 1 (Morgan et al., 1999; Greene et al., 2000; Drake et al., 2000; 
Drake and Traub, 2001; Kalthoff et al., 2002; Dafforn and Smith, 2004; 
Holkar et al., 2015). Epsin 1 has been suggested to interact with three TD 
sites e.g. site 1 (CBox), site 2 (W-box) and site 3 (ArrestinBox) as the first 
clathrin box of epsin 1 (LMDLA) has been proposed to be similar to the W-
box motif of amphiphysin (WLDWP) which binds to W-box TD site (Drake 
and Traub, 2011; Scheele et al., 2001; Miele et al., 2004), and the epsin 
yeast homolog (Ent2) has been shown to bind to CBox and the W-box of the 
TD sites  (Collette et al., 2009). Therefore, the cooperative effect of the two 
clathrin box motifs and long and flexible unstructured/DPW region could very 
well promote epsin 1’s linking effect on multiple adjacent clathrin TDs or the 
interaction with multiple sites on the same TD by stretching of this region, 
which could be prevented once this region is shortened or deleted. 
Additionally, such a flexible region could reduce mobility of the clathrin TD by 
wrapping around the TD and stabilizing the conformation, thereby forming a 
compact environment which permits cooperative assembly with other binding 
partners, such as AP2 (Drake et al. 2002; Brett et al. 2002; Dafforn and 
Smith, 2004; Edeling et al., 2006a).This is consistent with the hypothesis that 
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clathrin assembly in vivo requires the action of both epsin clathrin box motifs, 
but also facilitating membrane curvature by generating steric hindrance 
especially via this unstructured/DPW region (Busch et al., 2015). This could 
be key for determining the hierarchy of molecular interactions in CME 
budding in vivo (Holkar et al., 2015). Overall, these results have opened 
certain future avenues, which are described in Chapter 6, section 6.7.0. 
 
Epsin 1 has been shown to have an inhibitory effect on clathrin cage 
disassembly through competition with auxilin 1, where epsin 1 could 
effectively block the preferred binding sites of auxilin 1 at low concentrations 
(Baker, 2016). This effect could be explained by epsin’s complex binding 
manner which could block other available TD sites or cause competition for 
the same occupied TD sites between other endocytic adaptor proteins from 
different CME stages, at the same time. This is further explored in the 
following section.  
 
7.4.0 Adaptor competition studies 
 7.4.1 Overview 
The timeframe of complete CCP formation and clathrin uncoating is ~ 90 
seconds (Loerke et al., 2009), with a combination of at least 25 different 
adaptor proteins recruited to the plasma membrane during CME in an 
ordered sequence and timing, orchestrating clathrin polymerization and 
disassembly (Traub, 2011; Taylor et al., 2011; Merrrifield and Kaksonen, 
2014). This makes CME a complex mechanism to understand. Adaptors 
could undergo rapid cycles of binding and dissociation from clathrin via weak 
molecular binding interactions (~ 1 second) causing sequences with weaker 
clathrin binding affinity to be displaced by others (Shih et al., 1995; Traub, 
2011; Zhuo et al., 2015; Muenzner et al., 2017). It has been stated that a 
single clathrin TD could bind to three peptides, thereby enabling variety of 
different adaptor proteins to simultaneously interact with single or multiple 
sites on clathrin TD, (Willox and Royle, 2012; Zhuo et al., 2015; Muenzner et 
al., 2017). A great deal of knowledge already exists on the individual role and 
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functionality of adaptor proteins in CME. However, it is still unclear whether 
certain adaptor proteins, which are structurally and functionally diverse, 
cooperate or compete for clathrin TD binding, at the different stages of CME. 
Such information could support certain hypothesis on how adaptor proteins 
promote successful clathrin coat assembly and disassembly during CME in 
vivo. 
  7.4.2 Adaptor competition for clathrin TD 
At the early stages of CME, AP2 (β2-adaptin subunit) and activated β-
arrestin 1L have been demonstrated to work cooperatively in binding to 
clathrin TD due to their different roles. β-arrestin 1L only recruits clathrin to 
the plasma surface whilst AP2 initiates clathrin assembly (Owen and Evans, 
1998; terHaar et al., 2000; Collins et al., 2002; Burtey et al., 2007). A AP2/ β-
arrestin 1L/clathrin interaction targets GPCRs for internalization via efficient 
localization in CCPs (Laporte et al., 2000; Tian et al., 2014). The SPR results 
in this thesis, demonstrate that β2-adaptin binds to clathrinTD:β-arrestin 1L 
complex, but β-arrestin 1L does not bind to the clathrinTD:β2-adaptin 
complex. One explanation could be that β2-adaptin obscures β-arrestin 1L 
interacting sites because of the way it is bound to the clathrin TD on the SPR 
chip. In an in vivo situation, this could suggest that β2-adaptin can stop β-
arrestin 1L or the GPCR/ β-arrestin 1L complex from entering into the CCPs.  
 
An alternative model suggested by Laporte et al., 2000 was that AP2 would 
be recruited once β-arrestin 1L binds to the phosphorylated GPCR (Laporte 
et al., 2000; Kim and Benovic, 2002; Tian et al., 2014). Hence, the β2-
adaptin (AP2) would bind to β-arrestin 1L and be recruited to the surface and 
cooperatively bind with clathrin TD in a sequential manner, as previously 
stated (Kim and Benovic, 2002; Tian et al., 2014). Such cooperative manner 
could be suggested from SPR/IAC (2-injection) results where β2-adaptin 
binds to the clathrin:β-arrestin 1L complex. 
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Another important adaptor protein, epsin 1, has been previously suggested 
to promote uniform sized clathrin cages due to its interaction with multiple 
neighbouring triskelia (Drake et al., 2000; Drake and Traub, 2011; Kalthoff et 
al., 2002). The observation that epsin 1 and β-arrestin 1L compete at a 1:1 
molar ratio in the same manner as epsin 1 and auxilin 1, could further 
confirm the complex epsin 1 interaction with clathrin via long-distance 
multiple TD linking interactions through the hypothesized three TD sites 
(CBox, ArrestinBox and W-box). This is due to the cooperative behavior of its 
two clathrin box motifs and its long unstructured region, as mutating any of 
the epsin 1 clathrin box motifs still promotes competition between epsin 1 
and WT or active form of β-arrestin 1L. This suggests that epsin 1 most likely 
occupies more TD sites than any other adaptor proteins studied in this 
thesis, potentially blocking a greater extent of TD sites and space, which 
could have been occupied with a different adaptor protein such as β-arrestin 
1L or auxilin 1. Additionally, clathrin:epsin 1 interactions could be strong 
enough to prevent β-arrestin 1L or auxilin 1 to outcompete for its occupied 
TD sites, due to its presence in 90% of most cell lines in the initiation stage 
(Taylor et al., 2011) but most importantly due to its multiple clathrin binding 
components which are in line with the SPR results in Chapter 5.  
 
Considering GPCR internalization via CME, β-arrestin 1L would only be 
recruited when a GPCR is targeted for internalization via a desensitization 
and recycling pathway (Gurevich, 2014). β-arrestin 1L is an activator of cell 
signaling and modulator of endocytic trafficking, hence it is considered to 
have multiple functions. Therefore, its role in CME is not considered broad, 
unlike an adaptor protein such as epsin 1. This makes β-arrestin 1L an 
adaptor protein “on demand”, where it is not continually required and present 
at the plasma membrane (Gurevich, 2014). In a situation where β-arrestin 1L 
is required in vivo, a ‘burst’ of high concentration would accumulate at the 
plasma membrane during the initiation process of CME. This could possibly 
promote binding to the unoccupied TD sites, aiding in the initial clathrin 
recruitment to the surface and interaction with AP2. Epsin 1 could then 
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displace it immediately after the clathrin assembly initiation process begins. 
In addition, it could be that β-arrestin 1L is only helpful in initial clathrin 
recruitment after its activation by a phosphorylated GPCR, so that epsin 1 
displaces it during the growth of the clathrin coated vesicle (CCV). It has 
been suggested that β-arrestin 1L is present during CCV formation but 
dissociates before the CCV is pinched off (Koppen and Jakobs, 2004). Such 
competition suggests that the second clathrin box on β-arrestin 1L would not 
be sufficient on its own or in combination with the conserved clathrin box on 
β-arrestin 1L, to outcompete the epsin 1 from its already occupied TD sites. 
Overall, this could suggest the importance of the hierarchy of the adaptor 
proteins during CME. 
 
During clathrin disassembly at the later stages of CME, the precise location 
and fate of epsin 1 is unknown (Chen et al., 1998; Rappoport et al., 2006; 
Edeling et al., 2006a; Hawryluk et al., 2006; Saffarian et al., 2009; Henne et 
al., 2010) and debatable whether epsin would most likely be present in CCPs 
at the point of clathrin disassembly, after completion of its clathrin assembly 
initiation role. While epsin 1 is suggested to be present in 90% of endocytic 
events in various cell lines (Taylor et al., 2011), this could vary within cell 
lines, especially at a mature CCV where epsin’s concentration could be low 
and would allow other adaptor proteins e.g. auxilin 1 to outcompete epsin 1 
for clathrin binding. Interestingly, epsin 1 has been suggested to have a 
concentration dependent inhibitory effect on clathrin cage disassembly in 
vitro though competition with auxilin 1 (Baker, 2016). If this was the case in 
vivo as well, it would play a role in making clathrin cages more resistant to 
clathrin disassembly. This information could elucidate the competition 
observed between epsin 1 and auxilin 1 at a 1:1 molar ratio in the SPR 
experiments in Chapter 6. In vivo, a ‘burst’ of auxilin 1 recruitment at the 
plasma membrane determines the onset of clathrin uncoating (Massol et al., 
2006; Taylor et al., 2011). Thus, increasing the concentration of auxilin 1 in 
the SPR experiments (1:2 molar ration of epsin1:auxilin1), the competition for 
clathrin binding between the adaptors was altered, as auxilin 1 was able to 
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bind to either unoccupied TD sites or compete off epsin 1 from its already 
bound TD sites. The exact TD sites that epsin 1 and auxilin 1 bind are still 
unclear, but it is hypothesised that they share the same clathrin TD site 
interactions as well as DLL and DPF/W motifs (Drake et al., 2000; Scheele et 
al., 2001; Kalthoff et al., 2002). Consequently, if the TD competition between 
these two adaptors is the case in vivo as well, the concentration of auxilin 1 
in the presence of epsin 1 is the key factor in the extent of cage disassembly. 
On the other hand, it is important to consider however that auxilin 1 interacts 
with the CHC leg domains as well in order to perform its dissasmbly role 
(Edeling et al., 2006), thus auxilin 1 rearrangement would be different in the 
different classes of cages eg. hexagonal, pentagonal etc. In this case 
competition between epsin 1 and auxilin 1 for the TD would not affect auxilin 
1 binding to the leg and disassembly could still proceed.  
 
AP2 has been suggested to be present during the clathrin uncoating process 
(Mettlen et al., 2009; Saffarian et al., 2009; Taylor et al., 2011), which could 
promote competition between the adaptors for clathrin TD binding and affect 
the onset of the disassembly process. Smith et al., 2004 demonstrated a 
level of competition for clathrin TD binding between β2-adaptin and auxilin 1 
clathrin box peptides using competition assays in vitro. However, based on 
the SDS-PAGE binding assays and preliminary SPR results in Chapter 6, it is 
debatable as to whether β2-adaptin and auxilin 1 do actually compete with 
each other for clathrin TD binding. At a 1:1 molar ratio of β2-adaptin:auxilin 
1, a certain level of competition is observed in the SPR/IAC (2-injection) 
results, which is not as obvious or significant as other adaptor competition 
profiles such as epsin 1 and β-arrestin 1L. Thus, I suggest that overall β2-
adaptin and auxilin 1 would preferentially bind to different TD sites and in an 
in vivo situation neither assembly nor disassembly processes would be 
completely terminated, as assembled clathrin can be disassembled even 
when auxilin does not bind to the clathrin TD directly (Ungewickell et al., 
1995), as auxilin 1 binds to multiple sites on the clathrin leg (Edeling et al., 
2006b; Young et al., 2013). 
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More obvious competition was observed when increasing the concentration 
of the β2-adaptin in the preliminary SPR experiment (these results are 
preliminary and the reasons behind it are stated in Chapter 6). This could be 
addressed with the recent evidence from Bucher et al., 2017, where the 
AP2/clathrin ratio changes in a flat-to-curved transition of the clathrin lattice 
in vivo. This transition occurs when the content of clathrin is around 70% 
indicating the completion of the coat assembly (Bucher et al., 2017). 
Therefore, β2-adaptin, more specifically AP2, would be present during 
uncoating but perhaps at a low concentration and thereby a ‘burst’ of high 
concentration of auxilin 1 (Massol et al., 2006; Taylor et al., 2011) could be 
enough to outcompete any TD sites occupied by β2-adaptin. Similarly, auxilin 
1 could bind to TD sites, which are not occupied by β2-adaptin. This could be 
a plausible scenario as β2-adaptin has been suggested to bind to three of 
TD binding sites (Cbox, ArrestinBox and W-box), where AP2 clathrin box 
motif peptide has demonstrate a 3:1 stoichiometric binding ratio of AP2 to 
clathrin TD but with a low affinity (Zhuo et al., 2015). Auxilin 1 has also been 
hypothesised to bind to the same three TD sites, CBox, ArrestinBox and W-
box (Scheele et al., 2001). Overall, to confirm such hypothesis, SPR 
experiments with auxilin 1 increased concentration to be carried out in the 
future as well as clathrin TD mutants, which have impaired each TD site 
separately in order to confirm the favored TD site interaction of auxilin 1. 
Further evidence demonstrating how these two adaptors can bind to clathrin 
at the same time was shown when no significant inhibitory effect on clathrin 
cage disassembly was observed from the addition of β2-adaptin (in excess) 
(Baker, 2016). β2-adaptin did not inhibit the normal cage disassembly and 
the action of auxilin 1 as the initiator of the disassembly process. Auxilin 1 is 
able to interact with other clathrin heavy chain regions (Fotin et al., 2004) 
where β2-adaptin cannot and so we do not see inhibition of disassembly, nor 
obvious competition in clathrin cage (Baker, 2016).  
 
Lastly, the SDS-PAGE binding assays and SPR results observed between 
Hip1CC and β-arrestin 1L suggest no obvious or significant competition 
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between these two adaptors for clathrin TD. This is confirmed with our 
current knowledge of their location in the clathrin cage and primary clathrin 
binding interaction, which is discussed in section 6.9.0. However, SPR 
experiments require repetition due to the low response units observed due to 
potential SPR chip deterioration. 
 
In vivo, the AP2/clathrin ratio changes at the end of the initiation stage in 
CME (flat to curved transition) (Bucher et al., 2017), therefore, a ‘burst’ of 
higher concentration of specific adaptor protein according to their primary 
role in CME, could outcompete other adaptor proteins for clathrin binding 
which are already occupied on TD. And even though Willox and Royle, 2012, 
has suggested that a single clathrin binding box motif is sufficient to promote 
endocytosis in vivo; such competition patterns demonstrate the importance 
of such adaptor proteins binding to multiple specific sites on the TD (Willox 
and Royle, 2012). Although, it is of course possible that multiple interactions 
are required for the stabilisation of clathrin:adaptor interactions as shown by 
Zhuo et al., 2015, where most adaptor proteins cooperatively interact with 
clathrin in vivo to allow dynamic reorganization of clathrin during its assembly 
and disassembly. The major test is to transfer the mutagenesis and 
competition between adaptor proteins investigation to an in vivo system, 
which would clarify whether these competitions exist and are important for 
the CME. Nevertheless, the SPR competition results from this thesis have 
expanded certain novel aspects of the mechanism and behavior of certain 
adaptor proteins in the presence of others for clathrin TD binding.  
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7.5.0 Clathrin cages assembled with epsin 1 and β-
arrestin 1L 
Optimisation of different buffer conditions has shown that cages containing 
epsin 1 and active β-arrestin 1L are most stable in HKM pH 7.2 have more 
uniform cage structures. In future, the location of adaptor proteins in clathrin 
cages could be identified through a cryo EM model of such a complex. This 
was further described in Chapter 4. Investigations for epsin 1, active β-
arrestin 1L and cages were performed before the development of the adaptor 
competition studies and SPR/IAC (2-injection) technique (more details in 
Chapter 6), which reveal competition between epsin 1 and active β-arrestin 
1L for clathrin TD binding at 1:1 molar ratio.  However, it is important to note 
that this competition may not exist in the presence of whole clathrin cages as 
saturation of all binding sites could not be full field.  
 
7.6.0 Future work: optimization of SPR/IAC (2-
injection) method  
In order to progress the SPR/IAC (2-injection) method to a fully quantitative 
technique and obtain appropriate binding rate constants (KD) for a ‘two level’ 
interaction, further optimization stages are required which have been 
suggested through personal communication with Prof. Richard Napier and 
Prof Petr Kuzmic. Lowering the response units of a protein-protein interaction 
to 100-300 RU, was the initial suggestion, which will help eliminate mass 
transport issues and allow more accurate data for kinetic analysis to be 
obtained. Due to the complex structural behavior of epsin 1, a range of 
concentrations is necessary in order to obtain the appropriate ratio for 
lowering the RUs. However, in this thesis I have tested lowering the 
response to 100-300 RU of epsin-clathrin interactions with little success. This 
is hypothesized to be due to the complex epsin 1 structure and its 
complications on non-specific binding and mass transport.  
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A more sensitive SPR instrument needs to be used, e.g. Biacore T200, to 
carry out all the adaptor competition experiments. However, a T200 
instrument could also offer ‘single cycle kinetic’ (SCK) method for SPR 
assays to be carried out for adaptor competition. SCK was introduced from 
Karlsson and co-workers in 2006, which offers automatic kinetic titration 
series experimental runs without surface regeneration required between 
each injection (Karlsson et al., 2006; Palau and Primo, 2013) However, initial 
optimization would be required to test if this method is appropriate for the 
complex clathrin:adaptor system. The advantages of this method are: (a) 
lower the antibody deterioration issue, improving the systematic error 
observed in the SPR/IAC method (b) less time consuming due to automated 
set up to run experiments compared to the manual operation used in 
SPR/IAC (2-injection) method in this thesis. (c) direct quantitative comparison 
between binding affinities of adaptor protein combinations on the same flow 
cell, and carrying out a series of concentration ranges and fit an appropriate 
kinetic model to experimental data, in order to obtain binding constants (KD). 
Overall, the results obtained from the SCK method could be comparable to 
the results obtained from (manual set up) of SPR/IAC (2-injection) method 
used in this thesis. 
 
7.7.0 Future work: Adaptor protein competition for 
clathrin binding  
  7.7.1 Different adaptor protein combinations 
Another avenue of exploration would be to investigate different adaptor 
protein combinations for competition assays. AP180 does not have a specific 
clathrin box motifs that bind to clathrin TD, but it consists of eight repeated 
D[IL][LF] motifs throughout its unstructured region that primarily binds to 
clathrin TD non-specifically with a strong affinity (Drake et al. 2000; Kalthoff 
et al., 2002; Zhuo et al., 2015). Additionally, four sequence repeats of 
D[IL][LF] motifs have also been found in auxilin 1 (Scheele et al., 2001). 
AP180 has been shown to compete with auxilin 1 for the same site on the α-
 209 
ear domain of the AP2 complex (Scheele et al., 2001). Furthermore, Zhuo et 
al., 2015 has demonstrated that AP2 and AP180 peptides can 
simultaneously bind to three TD sites (CBM, W-box and ArrestinBox) (Zhuo 
et al., 2015). It would be interesting to test whether AP180 has an inhibitory 
effect on disassembly similar to that of epsin 1. Taking all this into 
consideration, AP180 could be a possible new adaptor protein to investigate 
with SPR/IAC (2-injection) method in combination with β-arrestin 1L, epsin 1 
and β2-adaptin.   
7.7.2 Clathrin TD mutants 
The results presented in Chapter 6, have opened a number of avenues of 
enquiry on the exact TD site interaction of adaptor proteins in the presence of 
others, especially with the complex adaptor protein epsin 1. Interestingly, 
both epsin 1 and auxilin 1 have been hypothesized to have common multiple 
binding sites on the TD, which are site 1 (CBox), site 2 (W-box) and site 3 
(ArrestinBox), these are yet to be confirmed. Thus, it would be interesting to 
use clathrin TD (residues 1-363) mutants with the four TD sites impaired 
separately and SPR/IAC method in order to add further support on the 
preferred TD sites of epsin 1 and auxilin 1. The newly established SPR/IAC 
(2- injection) method could then be used, with the analogous adaptor protein 
combinations to observe the competition patterns in the presence of 
immobilized clathrin TD mutants on the SPR chip.  
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Chapter 8: Appendix 
8.0.0 Overview 
The results presented in Chapter 6 and 7, have opened a number of 
avenues of enquiry on the exact TD site interaction of epsin 1 and auxilin 1. 
They have been hypothesized to have common multiple binding interactions 
with the TD, via the site 1 (CBox), site 2 (W-box) and site 3 (ArrestinBox). 
However, these TD site interactions have not yet been confirmed. By using 
clathrin TD (residues 1-363) mutants with the four TD sites mutated 
separately and binding interactions tested using the SPR/IAC method, we 
could add further support on the preferred TD sites of the epsin 1 based on 
its complex multiple clathrin binding components and auxilin 1.  
 
8.1.0 Mutagenesis of clathrin TD mutants 
The TD mutants in pGEX (4T-2) plasmid were designed in line with 
Muenzner et al., 2017 and detailed in the Table 1.10.0, with mutations at the 
four TD motifs alone or in combination. Three mutants ((CBox/ArrB), 
ArrestinBox and Full del) were tested for expression and purification 
conditions, in this thesis. 
 
Number 
Mutant Name  
(abbreviation) 
Details of mutation 
1 CBox and ArrestinBox 
(CBox/ArrB)  
T87A, Q89A and Q192Y 
2 ArrestinBox Q192Y 
3 W-box Q152L, I154Q 
4 Royle box F9W 
5 CBox, ArrestinBox, W-
box, Royle box (Full del) 
F9W, T87A, Q89A, Q152L, I154Q, Q192Y 
Table 1.9.0: Details of the clathrin TD mutants and the details on the exact 
sites being impaired. 
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8.2.0 Small-scale protein expression of clathrin TD 
mutants 
8.3.0 Increasing IPTG concentration 
The three GST-tagged TD mutants ((CBox/ArrB), ArrestinBox and Full del) 
were initially expressed in a small scale of 20 ml total volume using different 
conditions, such as increasing final concentrations of IPTG or decreasing the 
temperature during expression. Initially, the mutants were expressed in 
varying IPTG concentrations (0.1 mM, 0.2 mM, 0.5 mM and 1 mM) with 
either a longer incubation time (20 hours) or shorter incubation time (16 
hours) post-induction at the same temperature of 22oC at 180 rpm. Soluble 
and insoluble fractions were taken prior to induction, at 2 hours post 
induction, 4 hours post-induction and after overnight harvesting of the 
cultures. These fractions were analysed by western blot using anti-GST 
antibody (data not shown) and showed an equally weak expression yield 
between all the mutants at the appropriate molecular weight, compared to 
the well-expressed WT GST-clathrin TD. Largely intense bands at lower 
molecular weight range (~ 26 kDa) were present which is likely to be the 
GST-tag, which demonstrates possible degradation of proteins in all the TD 
mutants. There was no obvious difference in expression between the 
different IPTG concentrations or between the 2 hour, 4 hour or harvested 
cells post-induction. 
 
8.4.0 Decreasing the temperature 
The following modification to increase the expression yield was to lower the 
temperature of the expression to provide enough time for stable expression. 
The temperatures used were 18 oC and 16 oC, in combination with two 
different IPTG final concentrations (0.2 mM and 1 mM), 0.2 % glucose (to 
potentially reduce leaky expression) added to the cultures and incubated for 
20 hours post-induction. The harvested fractions were analysed by western 
blot and the results of ArrestinBox TD mutant are shown in Figure 8.4.0. The 
results were almost identical as with the previous section, with a weak 
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expression yielded of the mutants and no obvious difference in band intensity 
between the two temperatures. The intense lower band (e.g. GST-tag) was 
present in these expression trials as well, suggesting the degradation and 
unstable behaviour of all the TD mutants. There was no obvious difference of 
expression between the two different IPTG concentrations or between the 2 
hour, 4 hour or harvested cells post-induction. These mutants were 
characterised using circular dichroism by Muenzner et al., 2017, and the 
most stable mutants were used for this thesis. However, the difference 
between Muezner’s constructs was the presence of a NEMO tag, whereas 
our constructs were designed with a GST-tag due to the SPR/IAC method. 
NEMO tags could have provided more stability to these mutants. 
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(B) 
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(C) 
(D) 
Figure 8.4.0 Western blot analysis of the soluble (S) and insoluble (P) sample 
from harvested pellets from small-scale expression of ArrestinBox clathrin TD 
mutant. GST- clathrin TD WT is expressed in 0.2 mM and 1mM IPTG at 18 oC (A) 
and 16 oC (C), and the harvested samples (soluble and insoluble) fractions 
demonstrate a good yield of the expressed protein at 66 kDa at 2 hours, 4 hours 
and after overnight harvest. These act as control experiments. The ArrestinBox TD 
mutant expressed in 0.2 mM and 1mM IPTG at 18 oC (B) and 16 oC (C) at 2 hours, 4 
hours and overnight harvested cells. The results demonstrate weak expression of 
the TD mutant at 66 kDa and there is no difference in the expression yielded at the 
different IPTG concentrations or the two different temperatures. There is an intense 
band at around 26 kDa, which is suggested to be the GST-tag. This illustrates the 
unstable behaviour and degradation of the ArrestinBox TD mutant. 
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8.5.0 Protein purification of clathrin N-terminal domain 
(TD) mutants 
Despite the results from small-scale expression, I attempted to express the 
TD mutants in a large scale (4.8 liters) using final concentration of 1 mM 
IPTG, 0.2 % glucose at 16 oC for 18-20 hours incubation, 180 rpm. The 
harvested pellet from this expression was purified as per the WT GST 
clathrin TD construct, as described in Chapter 2. The affinity chromatography 
trace is not shown here but the SDS-PAGE analysis of the fractions eluted 
from the purification of the Full del TD mutant, are shown in Figure 8.5.0. 
However, purifications have been carried out using large scale expressed 
pellets from ArrestinBox TD mutant and well as CBox/ArrB TD mutant, which 
resulted in similar results as the Full del mutant once analysed by SDS-
PAGE. 
 
The concentrated sample in Figure 8.5.0, which should include the purified 
mutant, is not considered pure due to the presence of other unknown 
proteins (intense bands). A smearing effect is visible in the concentrated 
sample, which suggests degradation of the protein. A size exclusion 
chromatography step could have been used in the purification. In addition, 
mass spectrometry could have been used to determine the nature of those 
unknown bands. However, most importantly, further optimization is required 
to establish appropriate expression and purification conditions for these TD 
mutants, which was not explored in this thesis due to time restraints.  
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High salt wash Flow Through Elution 
 
Figure 8.5.0 SDS-PAGE analysis of the fractions eluted at each stage of GST-
affinity chromatography to confirm the purity of the Full del clathrin TD 
mutant. The harvested expressed pellet from large scale (4.8 litres) by 
centrifugation and re-suspended in CB1 buffer before loaded on the GST-affinity 
column. The flow-through of the sample is shown in lanes 1-6 and the elution from 
a high salt wash (500mM NaCl) (lanes 7-10) does not elute the protein. The TD 
mutant elutes after the addition of GSH+CB1 Buffer (lanes 11-12) and 
concentrated down to ~ 1 ml. The concentrated fraction in lane 13, which 
demonstrate that the sample is not as pure as needed and the smearing effect 
observed could suggest degradation of the protein. 
Lanes 
 217 
Chapter 9: References 
 
 
AHLE, S. & UNGEWICKELL, E. 1990. Auxilin, a newly identified clathrin- 
associated protein in coated vesicles from bovine brain. Journal of 
Cell Biology, 111, 19-29. 
ANDERSON, D., HARRIS, R., POLAYES, D., CICCARONE, V., DONAHUE, 
R., GERARD, G. & JESSEE, J. 1996. Rapid Generation of 
Recombinant Baculoviruses and Expression of Foreign Genes Using 
the Bac-To-Bac® Baculovirus Expression System. 17, 53-58. 
AVINOAM, O., SCHORB, M., BEESE, C. J., BRIGGS, J. A. G. & 
KAKSONEN, M. 2015. Endocytic sites mature by continuous bending 
and remodeling of the clathrin coat. Science, 348, 1369-1372. 
BAKER, M. 2016. The Assembly and Disassembly of Clathrin Cages. Doctor 
of Philosophy, University of Warwick. 
BARAK, L. S., OAKLEY, R. H., LAPORTE, S. A. & CARON, M. G. 2001. 
Constitutive arrestin-mediated desensitization of a human vasopressin 
receptor mutant associated with nephrogenic diabetes insipidus. Proc 
Natl Acad Sci U S A, 98, 93-8. 
BEAUTRAIT, A., PARADIS, J. S., ZIMMERMAN, B., GIUBILARO, J., 
NIKOLAJEV, L., ARMANDO, S., KOBAYASHI, H., YAMANI, L., 
NAMKUNG, Y., HEYDENREICH, F. M., KHOURY, E., AUDET, M., 
ROUX, P. P., VEPRINTSEV, D. B., LAPORTE, S. A. & BOUVIER, M. 
2017. A new inhibitor of the beta-arrestin/AP2 endocytic complex 
reveals interplay between GPCR internalization and signalling. Nat 
Commun, 8, 15054. 
BIRNBAUMER, M. 2000. Vasopressin receptors. Trends Endocrinol Metab., 
11, 406-410. 
BOCKING, T., AGUET, F., RAPOPORT, I., BANZHAF, M., YU, A., ZEEH, J. 
C. & KIRCHHAUSEN, T. 2014. Key interactions for clathrin coat 
stability. Structure, 22, 819-29. 
 218 
BOECKING, T., AGUET, F., HARRISON, S. C. & KIRCHHAUSEN, T. 2011. 
Single-molecule analysis of a molecular disassemblase reveals the 
mechanism of Hsc70-driven clathrin uncoating. Nature Structural & 
Molecular Biology, 18, 295-301. 
BOETTNER, D. R., FRIESEN, H., ANDREWS, B. & LEMMON, S. K. 2011. 
Clathrin light chain directs endocytosis by influencing the binding of 
the yeast Hip1R homologue, Sla2, to F-actin. . Molecular Biology of 
the Cell, 22, 3699- 3714. 
BRADY, R. J., DAMER, C. K., HEUSER, J. E. & O'HALLORAN, T. J. 2010. 
Regulation of Hip1r by epsin controls the temporal and spatial 
coupling of actin filaments to clathrin-coated pits. J Cell Sci, 123, 
3652-61. 
BRETT, T. J., LEGENDRE-GUILLEMIN, V., MCPHERSON, P. S. & 
FREMONT, D. H. 2006. Structural definition of the F-actin-binding 
THATCH domain from HIP1R. Nature Structural & Molecular Biology, 
13, 121-130. 
BRETT, T. J., TRAUB, L. M. & FREMONT, D. H. 2002. Accessory protein 
recruitment motifs in clathrin-mediated endocytosis. Structure, 10, 
797-809. 
BRODSKY, F. M. 2012. Diversity of clathrin function: new tricks for an old 
protein. Annu Rev Cell Dev Biol, 28, 309-36. 
BRODSKY, F. M., HILL, B. L., ACTON, S. L., NATHKE, I., WONG, D. H., 
PONNAMBALAM, S. & PARHAM, P. 1991. Clathrin light-chains - 
arrays of protein motifs that regulate coated-vesicle dynamics. Trends 
in Biochemical Sciences, 16, 208-213. 
BUCHER, D., FREY, F., SOCHACKI, K. A., KUMMER, S., BERGEEST, J. 
P., GODINEZ, W. J., KRÄUSSLICH, H. G., ROHR, K., W.TARASKA, J., 
SCHWARZ, U. S. & BOULANT, S. 2017. Flat-to-curved transition 
during clathrin-mediated endocytosis correlates with a change in 
clathrin-adaptor ratio and is regulated by membrane tension. bioRxiv. 
BURTEY, A., SCHMID, E. M., FORD, M. G., RAPPOPORT, J. Z., SCOTT, 
M. G., MARULLO, S., SIMON, S. M., MCMAHON, H. T. & 
 219 
BENMERAH, A. 2007. The conserved isoleucine-valine-phenylalanine 
motif couples activation state and endocytic functions of beta-
arrestins. Traffic, 8, 914-31. 
BUSCH, D. J., HOUSER, J. R., HAYDEN, C. C., SHERMAN, M. B., LAFER, 
E. M. & STACHOWIAK, J. C. 2015. Intrinsically disordered proteins 
drive membrane curvature. Nat Commun, 6, 7875. 
BUSS, F., LUZIO, J. P. & KENDRICK-JONES, J. 2001. Myosin VI, a new 
force in clathrin mediated endocytosis. FEBS Lett, 508, 295-9. 
CAHILL, T. J., 3RD, THOMSEN, A. R., TARRASCH, J. T., PLOUFFE, B., 
NGUYEN, A. H., YANG, F., HUANG, L. Y., KAHSAI, A. W., BASSONI, 
D. L., GAVINO, B. J., LAMERDIN, J. E., TRIEST, S., SHUKLA, A. K., 
BERGER, B., LITTLE, J. T., ANTAR, A., BLANC, A., QU, C. X., 
CHEN, X., KAWAKAMI, K., INOUE, A., AOKI, J., STEYAERT, J., 
SUN, J. P., BOUVIER, M., SKINIOTIS, G. & LEFKOWITZ, R. J. 2017. 
Distinct conformations of GPCR-beta-arrestin complexes mediate 
desensitization, signaling, and endocytosis. Proc Natl Acad Sci U S A, 
114, 2562-2567. 
CHANDRASEKAR, I., GOECKELER, Z. M., TURNEY, S. G., WANG, P., 
WYSOLMERSKI, R. B., ADELSTEIN, R. S. & BRIDGMAN, P. C. 
2014. Nonmuscle myosin II is a critical regulator of clathrin-mediated 
endocytosis. Traffic, 15, 418-32. 
CHEN, C. Y. & BRODSKY, F. M. 2005. Huntingtin-interacting protein 1 
(Hip1) and Hip1-related protein (Hip1R) bind the conserved sequence 
of clathrin light chains and thereby influence clathrin assembly in vitro 
and actin distribution in vivo. J Biol Chem, 280, 6109-17. 
CHEN, C. Y., REESE, M. L., HWANG, P. K., OTA, N., AGARD, D. & 
BRODSKY, F. M. 2002. Clathrin light and heavy chain interface: 
alpha-helix binding superhelix loops via critical tryptophans. Embo 
Journal, 21, 6072-6082. 
CHEN, H., FRE, S., SLEPNEV, V. I., CAPUA, M. R., TAKEI, K., BUTLER, M. 
H., DI FIORE, P. P. & DE CAMILLI, P. 1998. Epsin is an EH-domain-
 220 
binding protein implicated in clathrin-mediated endocytosis. Nature, 
394, 793-797. 
CLAIRMONT, K. B., BOLL, W., ERICSSON, M. & KIRCHHAUSEN, T. 1997. 
A role for the hinge/ear domain of the beta chains in the incorporation 
of AP complexes into clathrin-coated pits and coated vesicles. Cellular 
and Molecular Life Sciences, 53, 611-619. 
CLARKE, N. I. & ROYLE, S. J. 2017. FerriTag: A Genetically-Encoded 
Inducible Tag for Correlative Light-Electron Microscopy. bioRxiv. 
COCUCCI, E., AGUET, F., BOULANT, S. & KIRCHHAUSEN, T. 2012. The 
first five seconds in the life of a clathrin-coated pit. Cell, 150, 495-507. 
COLLETTE, J. R., CHI, R. J., BOETTNER, D. R., FERNANDEZ-GOLBANO, 
I. M., PLEMEL, R., MERZ, A. J., GELI, M. I., TRAUB, L. M. & 
LEMMON, S. K. 2009. Clathrin Functions in the Absence of the 
Terminal Domain Binding Site for Adaptor-associated Clathrin-Box 
Molecular Biology of the Cell, 20, 3401–3413. 
COLLINS, B. M., MCCOY, A. J., KENT, H. M., EVANS, P. R. & OWEN, D. J. 
2002. Molecular architecture and functional model of the endocytic 
AP2 complex. Cell, 209, 523-535. 
COOKE, R. M., BROWN, A. J., MARSHALL, F. H. & MASON, J. S. 2015. 
Structures of G protein-coupled receptors reveal new opportunities for 
drug discovery. Drug Discov Today, 20, 1355-64. 
CORDELLA, N., LAMPO, T. J., MELOSH, N. & SPAKOWITZ, A. J. 2015. 
Membrane indentation triggers clathrin lattice reorganization and 
fluidization. Soft Matter, 11, 439-48. 
DAFFORN, T. R. & SMITH, C. J. 2004. Natively unfolded domains in 
endocytosis: hooks, lines and linkers. EMBO Rep, 5, 1046-52. 
DANNHAUSER , P. N., PLATEN, M., BOENING, H., UNGEWICKELL, H., 
SCHAAP, I. A. T. & UNGEWICKELL, E. J. 2015. Effect of Clathrin 
Light Chains on the Stiffness of Clathrin Lattices and Membrane 
Budding. Traffic 16, 519-533. 
 221 
DANNHAUSER, P. N. & UNGEWICKELL, E. J. 2012. Reconstitution of 
clathrin-coated bud and vesicle formation with minimal components. 
Nat Cell Biol, 14, 634-9. 
DE LUCA-FLAHERTY, C., MCKAY, D. B., PARHAM, P. & HILL, B. L. 1990. 
Uncoating protein (hsc70) binds a conformationally labile domain of 
clathrin light chain lca to stimulate atp hydrolysis. Cell, 62, 875-887. 
DELL'ANGELICA, E. C., KLUMPERMAN, J., STOORVOGEL, W. & 
BONIFACINO, J. S. 1998. Association of the AP-3 Adaptor Complex 
with Clathrin. Science, 280, 431-434. 
DELOM, F. & FESSART, D. 2011. Role of Phosphorylation in the Control of 
Clathrin-Mediated Internalization of GPCR. Int J Cell Biol, 2011, 
246954. 
DOHERTY, G. J. & MCMAHON, H. T. 2009. Mechanisms of Endocytosis. 
Annual Review of Biochemistry, 78, 857-902. 
DONG, Y. Z., WU, H., RAHMAN, H. N. A., LIU, Y. J., PASULA, S., 
TESSNEER, K. L., CAI, X. F., LIU, X. L., CHANG, B. J., MCMANUS, 
J., HAHN, S., DONG, J. L., BROPHY, M. L., YU, L. L., SONG, K., 
SILASI-MANSAT, R., SAUNDERS, D., NJOKU, C., SONG, H., 
MEHTA-D'SOUZA, P., TOWNER, R., LUPU, F., MCEVER, R. P., XIA, 
L. J., BOERBOOM, D., SRINIVASAN, R. S. & CHEN, H. 2015. Motif 
mimetic of epsin perturbs tumor growth and metastasis. Journal of 
Clinical Investigation, 125, 4349-4364. 
DORR, J. M., SCHEIDELAAR, S., KOORENGEVEL, M. C., DOMINGUEZ, J. 
J., SCHAFER, M., VAN WALREE, C. A. & KILLIAN, J. A. 2016. The 
styrene-maleic acid copolymer: a versatile tool in membrane research. 
Eur Biophys J, 45, 3-21. 
DRAKE, M. T., DOWNS, M. A. & TRAUB, L. M. 2000. Epsin binds to clathrin 
by associating directly with the clathrin-terminal domain - Evidence for 
cooperative binding through two discrete sites. Journal of Biological 
Chemistry, 275, 6479-6489. 
 222 
DRAKE, M. T. & TRAUB, L. M. 2001. Interaction of two structurally distinct 
sequence types with the clathrin terminal domain beta-propeller. J Biol 
Chem, 276, 28700-9. 
DRUGMAND, J., SCHNEIDER, Y. & AGATHOS, S. 2012. Insect cells as 
factories for biomanufacturing. . Biotechnology Advances, 30, 1140-
1157. 
DUBENDORFF, J. W., LYMAR, E., FURUYA, F. R. & HAINFELD, J. F. 2010. 
Gold Labeling of Protein Fusion Tags for EM. Microsc. Microanal, 16. 
EDELING, M. A., MISHRA, S. K., KEYEL, P. A., STEINHAUSER, A. L., 
COLLINS, B. M., ROTH, R., HEUSER, J. E., OWEN, D. J. & TRAUB, 
L. M. 2006a. Molecular switches involving the AP-2 beta2 appendage 
regulate endocytic cargo selection and clathrin coat assembly. Dev 
Cell, 10, 329-42. 
EDELING, M. A., SMITH, C. & OWEN, D. N. R. 2006b. Life of a clathrin coat: 
insights from clathrin and AP structures. Molecular Cell Biology, 7, 32-
44. 
ENGQVIST-GOLDSTEIN, A. E., WARREN, R. A., KESSELS, M. M., KEEN, 
J. H., HEUSER, J. & DRUBIN, D. G. 2001. The actin-binding protein 
Hip1R associates with clathrin during early stages of endocytosis and 
promotes clathrin assembly in vitro. J Cell Biol, 154, 1209-23. 
ERDELYI, L. S., MANN, W. A., MORRIS-ROSENDAHL, D. J., GROSS, U., 
NAGEL, M., VARNAI, P., BALLA, A. & HUNYADY, L. 2015. Mutation 
in the V2 vasopressin receptor gene, AVPR2, causes nephrogenic 
syndrome of inappropriate diuresis. Kidney Int, 88, 1070-8. 
FERGUSON, F. 2001. Evolving concepts in G protein-coupled receptor 
endocytosis: the role in receptor desensitization and signaling. . 
Pharmacol Rev., 53, 1-24. 
FERREIRA, F., FOLEY, M., COOKE, A., CUNNINGHAM, M., SMITH, G., 
WOOLLEY, R., HENDERSON, G., KELLY, E., MUNDELL, S. & 
SMYTHE, E. 2012. Endocytosis of G protein-coupled receptors is 
regulated by clathrin light chain phosphorylation. Curr Biol, 22, 1361-
70. 
 223 
FISCHER, M. J. 2010. Amine coupling through EDC/NHS: a practical 
approach. Methods Mol Biol, 627, 55-73. 
FORD, M. G. J., MILLS, I. G., PETER, B. J., VALLIS, Y., PRAEFCKE, G. J. 
K., EVANS, P. R. & MCMAHON, H. T. 2002. Curvature of clathrin-
coated pits driven by epsin. Nature, 419, 361-366  
FORD, M. G. J., PEARSE, B. M. F., HIGGINS, M. K., VALLIS, Y., OWEN, D. 
J., GIBSON, A., HOPKINS, C. R., EVANS, P. R. & MCMAHON, H. T. 
2001. Simultaneous binding of PtdIns(4,5)P-2 and clathrin by AP180 
in the nucleation of clathrin lattices on membranes. Science, 291, 
1051-1055. 
FORTIAN, A., DIONNE, L. K., HONG, S. H., KIM, W., GYGI, S. P., 
WATKINS, S. C. & SORKIN, A. 2015. Endocytosis of Ubiquitylation-
Deficient EGFR Mutants via Clathrin-Coated Pits is Mediated by 
Ubiquitylation. Traffic, 16, 1137-1154. 
FOTIN, A., CHENG, Y., SLIZ, P., GRIGORIEFF, N., HARRISON, S. C., 
KIRCHHAUSEN, T. & WALZ, T. 2004. Molecular model for a complete 
clathrin lattice from electron cryomicroscopy. Nature, 432, 573-9. 
FUJIMOTO, L. M., ROTH, R., HEUSER, J. E. & SCHMID, S. L. 2000. Actin 
assembly plays a variable, but not obligatory role in receptor-mediated 
endocytosis in mammalian cells. Traffic, 1, 161-171. 
FUTATSUMORI-SUGAI, M. & TSUMOTO, K. 2010. Signal peptide design for 
improving recombinant protein secretion in the baculovirus expression 
vector system. Biochem Biophys Res Commun, 391, 931-5. 
GHOSH, E., KUMARI, P., JAIMAN, D. & SHUKLA, A. K. 2015. 
Methodological advances: the unsung heroes of the GPCR structural 
revolution. Nat Rev Mol Cell Biol, 16, 69-81. 
GIRARD, M., ALLAIRE, P. D., MCPHERSON, P. S. & BLONDEAU, F. 2005. 
Non-stoichiometric relationship between clathrin heavy and light 
chains revealed by quantitative comparative proteomics of clathrin-
coated vesicles from brain and liver. Mol Cell Proteomics, 4, 1145-54. 
 224 
GODLEE, C. & KAKSONEN, M. 2013. From uncertain beginnings: Initiation 
mechanisms of clathrin-mediated endocytosis. The Journal of Cell 
Biology, 203, 717-725. 
GOH, A. X., BERTIN-MAGHIT, S., PING YEO, S., HO, A. W., DERKS, H., 
MORTELLARO, A. & WANG, C. I. 2014. A novel human anti-
interleukin-1beta neutralizing monoclonal antibody showing in vivo 
efficacy. MAbs, 6, 765-73. 
GOLDSTEIN, J. L., BROWN, M. S., ANDERSON, R. G. W., RUSSELL, D. W. 
& SCHNEIDER, W. J. 1985. Receptor-mediated endocytosis - 
concepts emerging from the ldl receptor system. Annual Review of 
Cell Biology, 1, 1-39. 
GOODMAN, O., KRUPNICK, J., GUREVICH, V., BENOVIC, J. & KEEN, J. 
1997. Arrestin/Clathrin Interaction. Journal of Biological Chemistry, 
272, 15017-15022. 
GOTTFRIED, I., EHRLICH, M. & ASHERY, U. 2010. The Sla2p/HIP1/HIP1R 
family: similar structure, similar function in endocytosis? Biochem Soc 
Trans, 38, 187-91. 
GREENER, B., LIU, S. H., WILDE, A. & BRODSKY, F. M. 2000. Complete 
reconstitution of clathrin basket formation with recombinant protein 
fragments: Adaptor control of clathrin self-assembly. Traffic, 1, 69-75. 
GUIDUCCI, C. 2011. Surface Plasmon Resonance Based Systems [Online]. 
Available: 
http://lben.epfl.ch/files/content/sites/lben/files/users/179705/Surface 
Plasmon Resonance Handout.pdf  
GUREVICH, V. 2014. Arrestins - Pharmacology and therapeutic potential, 
USA, Springer. 
HALEBIAN, M., MORRIS, K. & SMITH, C. 2017. Structure and Assembly of 
Clathrin Cages. In: HARRIS, R. & WRIGHT, J. (eds.) Subcellular 
Biochemistry. Switzerland: Springer. 
HAMDAN, F. F., ROCHDI, M. D., BRETON, B., FESSART, D., MICHAUD, D. 
E., CHAREST, P. G., LAPORTE, S. A. & BOUVIER, M. 2007. 
Unraveling G protein-coupled receptor endocytosis pathways using 
 225 
real-time monitoring of agonist-promoted interaction between beta-
arrestins and AP-2. J Biol Chem, 282, 29089-100. 
HAN, M., GUREVICH, V., VISHNIVETSKIY, S., SIGLER, P. & SCHUBERT, 
C. 2001. Crystal Structure of β-Arrestin at 1.9 Å: Possible Mechanism 
of Receptor Binding and Membrane Translocation. . Structure, 9, 869-
880. 
HANNAN, L., NEWMYER, S. & SL, S. 1998. ATP- and cytosol-dependent 
release of adaptor proteins from clathrin-coated vesicles: a dual role 
for hsc70. . Mol Biol Cell 1998, 9, 2217-2229. 
HAWRYLUK, M. J., KEYEL, P. A., MISHRA, S. K., WATKINS, S. C., 
HEUSER, J. E. & TRAUB, L. M. 2006. Epsin 1 is a polyubiquitin-
selective clathrin-associated sorting protein. Traffic, 7, 262-81. 
HENNE, W. M., BOUCROT, E., MEINECKE, M., EVERGREN, E., VALLIS, 
Y., MITTAL, R. & MCMAHON, H. T. 2010. FCHo Proteins Are 
Nucleators of Clathrin-Mediated Endocytosis. Science, 328, 1281-
1284. 
HIRST, J., MILLER, S. E., TAYLOR, M. J., VON MOLLARD, G. F. & 
ROBINSON, M. S. 2004. EpsinR is an adaptor for the SNARE protein 
Vti1b. Molecular Biology of the Cell, 15, 5593-5602. 
HOLKAR, S. S., KAMERKAR, S. C. & PUCADYIL, T. J. 2015. Spatial Control 
of Epsin-induced Clathrin Assembly by Membrane Curvature. J Biol 
Chem, 290, 14267-76. 
HOLLOPETER, G., LANGE, J. J., ZHANG, Y., VU, T. N., GU, M. Y., AILION, 
M., LAMBIE, E. J., SLAUGHTER, B. D., UNRUH, J. R., FLORENS, L. 
& JORGENSEN, E. M. 2014. The Membrane-Associated Proteins 
FCHo and SGIP Are Allosteric Activators of the AP2 Clathrin Adaptor 
Complex. Elife, 3, 65. 
HOLSTEIN, S. E. H., UNGEWICKELL, H. & UNGEWICKELL, E. 1996. 
Mechanism of clathrin basket dissociation: Separate functions of 
protein domains of the DnaJ homologue auxilin. Journal of Cell 
Biology, 135, 925- 937. 
 226 
HOM, R. A., VORA, M., REGNER, M., SUBACH, O. M., CHO, W., 
VERKHUSHA, V. V., STAHELIN, R. V. & KUTATELADZE, T. G. 2007. 
pH-dependent binding of the Epsin ENTH domain and the AP180 
ANTH domain to PI(4,5)P2-containing bilayers. J Mol Biol, 373, 412-
23. 
HUANG, R., ZHU, G., JING ZHANG, YUXIONG LAI, YU XU, HE, J. & XIE, J. 
2017. Betanodavirus-like particles enter host cells via clathrin-
mediated endocytosis in a cholesterol-, pH- and cytoskeleton-
dependent manner. Veterinary Research, 48. 
HYUN, T. S., RAO, D. S., SAINT-DIC, D., MICHAEL, L. E., KUMAR, P. D., 
BRADLEY, S. V., MIZUKAMI, I. F., ORAVECZ-WILSON, K. I. & 
ROSS, T. S. 2004. HIP1 and HIP1r stabilize receptor tyrosine kinases 
and bind 3- phosphoinositides via epsin N-terminal homology 
domains. Journal of Biological Chemistry, 279, 14294-14306. 
JACKSON, L. P., KELLY, B. T., MCCOY, A. J., GAFFRY, T., JAMES, L. C., 
COLLINS, B. M., HOENING, S., EVANS, P. R. & OWEN, D. J. 2010. 
A Large-Scale Conformational Change Couples Membrane 
Recruitment to Cargo Binding in the AP2 Clathrin Adaptor Complex. 
Cell, 141, 1220-1229. 
JAKOBSSON, J., GAD, H., ANDERSSON, F., LOW, P., SHUPLIAKOV, O. & 
BRODIN, L. 2008. Role of epsin 1 in synaptic vesicle endocytosis. 
Proc Natl Acad Sci U S A, 105, 6445-50. 
JAMSHAD, M., CHARLTON, J., LIN, Y. P., ROUTLEDGE, S. J., BAWA, Z., 
KNOWLES, T. J., OVERDUIN, M., DEKKER, N., DAFFORN, T. R., 
BILL, R. M., POYNER, D. R. & WHEATLEY, M. 2015. G-protein 
coupled receptor solubilization and purification for biophysical analysis 
and functional studies, in the total absence of detergent. Biosci Rep, 
35. 
JAMSHAD, M., LIN, Y. P., KNOWLES, T. J., PARSLOW, R. A., HARRIS, C., 
WHEATLEY, M., POYNER, D. R., BILL, R. M., THOMAS, O. R., 
OVERDUIN, M. & DAFFORN, T. R. 2011. Surfactant-free purification 
 227 
of membrane proteins with intact native membrane environment. 
Biochem Soc Trans, 39, 813-8. 
KALTHOFF, C., ALVES, J., URBANKE, C., KNORR, R. & UNGEWICKELL, 
E. J. 2002. Unusual structural organization of the endocytic proteins 
AP180 and epsin 1. J Biol Chem, 277, 8209-16. 
KANG, D. S., KERN, R. C., PUTHENVEEDU, M. A., VON ZASTROW, M., 
WILLIAMS, J. C. & BENOVIC, J. L. 2009. Structure of an arrestin2-
clathrin complex reveals a novel clathrin binding domain that 
modulates receptor trafficking. J Biol Chem, 284, 29860-72. 
KANG, Y., ZHOU, X. E., GAO, X., HE, Y., LIU, W., ISHCHENKO, A., 
BARTY, A., WHITE, T. A., YEFANOV, O., HAN, G. W., XU, Q., DE 
WAAL, P. W., KE, J., TAN, M. H. E., ZHANG, C., MOELLER, A., 
WEST, G. M., PASCAL, B. D., VAN EPS, N., CARO, L. N., 
VISHNIVETSKIY, S. A., LEE, R. J., SUINO-POWELL, K. M., GU, X., 
PAL, K., MA, J., ZHI, X., BOUTET, S., WILLIAMS, G. J., 
MESSERSCHMIDT, M., GATI, C., ZATSEPIN, N. A., WANG, D., 
JAMES, D., BASU, S., ROY-CHOWDHURY, S., CONRAD, C. E., 
COE, J., LIU, H., LISOVA, S., KUPITZ, C., GROTJOHANN, I., 
FROMME, R., JIANG, Y., TAN, M., YANG, H., LI, J., WANG, M., 
ZHENG, Z., LI, D., HOWE, N., ZHAO, Y., STANDFUSS, J., 
DIEDERICHS, K., DONG, Y., POTTER, C. S., CARRAGHER, B., 
CAFFREY, M., JIANG, H., CHAPMAN, H. N., SPENCE, J. C. H., 
FROMME, P., WEIERSTALL, U., ERNST, O. P., KATRITCH, V., 
GUREVICH, V. V., GRIFFIN, P. R., HUBBELL, W. L., STEVENS, R. 
C., CHEREZOV, V., MELCHER, K. & XU, H. E. 2015. Crystal 
structure of rhodopsin bound to arrestin by femtosecond X-ray laser. 
Nature 523, 561-567. 
KARIYA, K., KOYAMA, S., NAKASHIMA, S., OSHIRO, T., MORINAKA, K. & 
KIKUCHI, A. 2000. Regulation of complex formation of 
POB1/epsin/adaptor protein complex 2 by mitotic phosphorylation. 
Journal of Biological Chemistry, 275, 18399-18406. 
 228 
KARLSSON, R. 1994. Real-Time Competitive Kinetic Analysis of Interactions 
between Low-Molecular-Weight-ligands in Solution and Surface-
Immobilized Receptors. Analytical Biochemistry, 221. 
KARLSSON, R. 2004. SPR for molecular interaction analysis: a review of 
emerging application areas. J Mol Recognit., 17, 151-61. 
KARLSSON, R., JENDEIERG, L., NILSSON, B., NILSSON, J. & NYGREN, 
P.-A. 1995. Direct and competitive kinetic analysis of the interaction 
between human IgGl and a one domain analogue of protein A. Journal 
of Immunological Methods 183, 43-49. 
KARLSSON, R., KATSAMBA, P. S., NORDIN, H., POL, E. & MYSZKA, D. G. 
2006. Analyzing a kinetic titration series using affinity biosensors. Anal 
Biochem, 349, 136-47. 
KARNIK, R., LUDLOW, M. J., ABUARAB, N., SMITH, A. J., HARDY, M. E. 
L., ELLIOTT, D. J. S. & SIVAPRASADARAO, A. 2013. Endocytosis of 
hERG Is Clathrin-Independent and Involves Arf6. PLoS ONE 8. 
KAVRAN, J. M. & LEAHY, D. J. 2014. Lysis of mammalian and Sf9 cells. 
Methods Enzymol, 536, 47-52. 
KELLY, B. T., GRAHAM, S. C., LISKA, N., DANNHAUSER, P. N., HONING, 
S., UNGEWICKELL, E. J. & OWEN, D. J. 2014. Clathrin adaptors. 
AP2 controls clathrin polymerization with a membrane-activated 
switch. Science, 345, 459-63. 
KELLY, B. T., MCCOY, A. J., SPAETE, K., MILLER, S. E., EVANS, P. R., 
HOENING, S. & OWEN, D. J. 2008. A structural explanation for the 
binding of endocytic dileucine motifs by the AP2 complex. Nature, 
456, 976-981. 
KEYEL, P., THIEMAN, J., ROTH, R., ERKAN, E., EVERETT, E., WATKINS, 
S., HEUSER, J. & TRAUB, L. 2008. The AP-2 adaptor beta2 
appendage scaffolds alternate cargo endocytosis. Molecular Biology 
of the Cell, 19, 5309–5326. 
KIM, Y. M. & BENOVIC, J. L. 2002. Differential roles of arrestin-2 interaction 
with clathrin and adaptor protein 2 in G protein-coupled receptor 
trafficking. J Biol Chem, 277, 30760-8. 
 229 
KIRCHHAUSEN, T., OWEN, D. & HARRISON, S. C. 2014. Molecular 
structure, function, and dynamics of clathrin-mediated membrane 
traffic. Cold Spring Harb Perspect Biol, 6, a016725. 
KNUEHL, C., CHEN, C. Y., MANALO, V., HWANG, P. K., OTA, N. & 
BRODSKY, F. M. 2006. Novel binding sites on clathrin and adaptors 
regulate distinct aspects of coat assembly. Traffic, 7, 1688-700. 
KOPPEN, C. J. V. & JAKOBS, K. H. 2004. Arrestin-Independent 
Internalization of G Protein-Coupled Receptors. Mol Pharmacol 66, 
365–367. 
KOVTUN, O., TILLU, V. A., ARIOTTI, N., PARTON, R. G. & COLLINS, B. M. 
2015. Cavin family proteins and the assembly of caveolae. J Cell Sci., 
7, 1269-78. 
KUMARI, P., SRIVASTAVA, A., BANERJEE, R., GHOSH, E., GUPTA, P., 
RANJAN, R., CHEN, X., GUPTA, B., GUPTA, C., JAIMAN, D. & 
SHUKLA, A. K. 2016. Functional competence of a partially engaged 
GPCR–β-arrestin complex. Nature Communications, 7, 13416. 
LADDS, G., GODDARD, A. & DAVEY, J. 2005. Functional analysis of 
heterologous GPCR signalling pathways in yeast. . Trends in 
biotechnology, 23, 367--373. 
LAI, C. L., JAO, C. C., LYMAN, E., GALLOP, J. L., PETER, B. J., 
MCMAHON, H. T., LANGEN, R. & VOTH, G. A. 2012. Membrane 
Binding and Self- Association of the Epsin N-Terminal Homology 
Domain. Journal of Molecular Biology, 423, 800-817. 
LANG, B. D., DELMAR, M. & COOMBS, W. 2005. Surface Plasmon 
Resonance as a Method to Study the Kinetics and Amplitude of 
Protein- Protein Binding. In: DHEIN, S., MOHR, F. W. & DELMAR, M. 
(eds.) Practical Methods in Cardiovascular Research. Berlin, 
Heidelberg: Springer Berlin Heidelberg. 
LAPORTE, S. A., MILLER, W. E., KIM, K. M. & CARON, M. G. 2002. beta-
Arrestin/AP-2 interaction in G protein-coupled receptor internalization: 
identification of a beta-arrestin binging site in beta 2-adaptin. J Biol 
Chem, 277, 9247-54. 
 230 
LAPORTE, S. A., OAKLEY, R. H., HOLT, J. A., BARAK, L. S. & CARON, M. 
G. 2000. The interaction of beta-arrestin with the AP-2 adaptor is 
required for the clustering of beta 2-adrenergic receptor into clathrin-
coated pits. J Biol Chem, 275, 23120-6. 
LE CLAINCHE, C., PAULY, B. S., ZHANG, C. X., ENGQVIST-GOLDSTEIN, 
A. E. Y., CUNNINGHAM, K. & DRUBIN, D. G. 2007. A Hip1R-cortactin 
complex negatively regulates actin assembly associated with 
endocytosis. Embo Journal, 26, 1199-1210. 
LEE, S. C., KNOWLES, T. J., POSTIS, V. L., JAMSHAD, M., PARSLOW, R. 
A., LIN, Y. P., GOLDMAN, A., SRIDHAR, P., OVERDUIN, M., 
MUENCH, S. P. & DAFFORN, T. R. 2016. A method for detergent-
free isolation of membrane proteins in their local lipid environment. 
Nat Protoc, 11, 1149-62. 
LEFKOWITZ, R., RAJAGOPAL, K. & WHALEN, E. 2006. New Roles for β-
Arrestins in Cell Signaling: Not Just for Seven-Transmembrane 
Receptors. Molecular Cell Biology, 24, 643-652. 
LEGENDRE-GUILLEMIN, V., METZLER, M., CHARBONNEAU, M., GAN, L., 
CHOPRA, V., PHILIE, J., HAYDEN, M. R. & MCPHERSON, P. S. 
2002. HIP1 and HIP12 display differential binding to F-actin, AP2, and 
clathrin. Identification of a novel interaction with clathrin light chain. J 
Biol Chem, 277, 19897-904. 
LEGENDRE-GUILLEMIN, V., WASIAK, S., HUSSAIN, N. K., ANGERS, A. & 
MCPHERSON, P. S. 2004. ENTH/ANTH proteins and clathrin-
mediated membrane budding. J Cell Sci, 117, 9-18. 
LEMMON, S. K. & TRAUB, L. M. 2012. Getting in touch with the clathrin 
terminal domain. Traffic, 13, 511-9. 
LINDNER, R. & UNGEWICKELL, E. 1992. Clathrin-associated proteins of 
bovine brain coated vesicles. An analysis of their number and 
assembly-promoting activity. J Biol Chem, 15, 16567-73. 
LIU, S., XIONG, X., ZHAO, X., YANG, X. & WANG, H. 2015. F-BAR family 
proteins, emerging regulators for cell membrane dynamic changes-
from structure to human diseases. J Hematol Oncol, 8, 47. 
 231 
LIU, S. H., WONG, M. L., CRAIK, C. S. & BRODSKY, F. M. 1995. Regulation 
of clathrin assembly and trimerization defined using recombinant 
triskelion hubs. Cell, 83, 257-267. 
LOERKE, D., METTLEN, M., YARAR, D., JAQAMAN, K., JAQAMAN, H., 
DANUSER, G. & SCHMID, S. L. 2009. Cargo and Dynamin Regulate 
Clathrin-Coated Pit Maturation. Plos Biology, 7, 628-639. 
MA, L., UMASANKAR, P. K., WROBEL, A. G., LYMAR, A., MCCOY, A. J., 
HOLKAR, S. S., JHA, A., PRADHAN-SUNDD, T., WATKINS, S. C., 
OWEN, D. J. & TRAUB, L. M. 2016. Transient Fcho1/2.Eps15/R.AP-2 
Nanoclusters Prime the AP-2 Clathrin Adaptor for Cargo Binding. 
Developmental Cell, 37, 428-443. 
MASSOL, R. H., BOLL, W., GRIFFIN, A. M. & KIRCHHAUSEN, T. 2006. A 
burst of auxilin recruitment determines the onset of clathrin-coated 
vesicle uncoating. Proc Natl Acad Sci U S A, 103, 10265-70. 
MASSOTTE, D. 2003. G protein-coupled receptor overexpression with the 
baculovirus–insect cell system: a tool for structural and functional 
studies. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1610, 
77-89. 
MATTHEYSES, A. L., ATKINSON, C. E. & SIMON, S. M. 2011. Imaging 
Single Endocytic Events Reveals Diversity in Clathrin, Dynamin and 
Vesicle Dynamics. Traffic, 12, 1394-1406. 
MAYOR, S., PARTON, R. G. & DONALDSON, J. G. 2014. Clathrin-
Independent Pathways of Endocytosis. Cold Spring Harbor 
Perspectives in Biology, 6. 
MCMAHON, H. T. & BOUCROT, E. 2011. Molecular mechanism and 
physiological functions of clathrin-mediated endocytosis. Nat Rev Mol 
Cell Biol, 12, 517-33. 
MELLMAN, I. & YOSEF, Y. 2013. Endocytosis and Cancer. Cold Spring 
Harb Perspect Biol  
MERRIFIELD, C. J. & KAKSONEN, M. 2014. Endocytic accessory factors 
and regulation of clathrin-mediated endocytosis. Cold Spring Harb 
Perspect Biol, 6, a016733. 
 232 
MESSA, M., FERNANDEZ-BUSNADIEGO, R., SUN, E. W., CHEN, H., 
CZAPLA, H., WRASMAN, K., WU, Y., KO, G., ROSS, T., 
WENDLAND, B. & DE CAMILLI, P. 2014. Epsin deficiency impairs 
endocytosis by stalling the actin-dependent invagination of endocytic 
clathrin-coated pits. Elife, 3, e03311. 
METTLEN, M., LOERKE, D., YARAR, D., DANUSER, G. & SCHMID, S. L. 
2010. Cargo- and adaptor-specific mechanisms regulate clathrin-
mediated endocytosis. J Cell Biol, 188, 919-33. 
METTLEN, M., STOEBER, M., LOERKE, D., ANTONESCU, C. N., 
DANUSER, G. & SCHMID, S. L. 2009. Endocytic Accessory Proteins 
Are Functionally Distinguished by Their Differential Effects on the 
Maturation of Clathrin- coated Pits. Molecular Biology of the Cell, 20, 
3251-3260. 
MIELE, A. E., WATSON, P. J., EVANS, P. R., TRAUB, L. M. & OWEN, D. J. 
2004. Two distinct interaction motifs in amphiphysin bind two 
independent sites on the clathrin terminal domain beta-propeller. Nat 
Struct Mol Biol, 11, 242-8. 
MILANO, S. K., PACE, H., KIM, Y., BRENNER, C. & BENOVIC, J. 2002. 
Scaffolding Functions of Arrestin-2 Revealed by Crystal Structure and 
Mutagenesis. Biochemistry, 41, 3321-3328  
MILIC, D. & VEPRINTSEV, D. B. 2015. Large-scale production and protein 
engineering of G protein-coupled receptors for structural studies. Front 
Pharmacol, 6, 66. 
MILLER, S. E., SAHLENDER, D. A., GRAHAM, S. C., HONING, S., 
ROBINSON, M. S., PEDEN, A. A. & OWEN, D. J. 2011. The 
molecular basis for the endocytosis of small R-SNAREs by the clathrin 
adaptor CALM. Cell, 147, 1118-31. 
MILOSEVIC, I., GIOVEDI, S., LOU, X. L., RAIMONDI, A., COLLESI, C., 
SHEN, H. Y., PARADISE, S., O'TOOLE, E., FERGUSON, S., 
CREMONA, O. & DE CAMILLI, P. 2011. Recruitment of Endophilin to 
Clathrin-Coated Pit Necks Is Required for Efficient Vesicle Uncoating 
after Fission. Neuron, 72, 587- 601. 
 233 
MISHRA, M., HUANG, J. & BALASUBRAMANIAN, M. K. 2014. The yeast 
actin cytoskeleton. FEMS Microbiol Rev, 38, 213-27. 
MISHRA, S. K., AGOSTINELLI, N. R., BRETT, T. J., MIZUKAMI, I., ROSS, 
T. S. & TRAUB, L. M. 2001. Clathrin- and AP-2-binding sites in HIP1 
uncover a general assembly role for endocytic accessory proteins. J 
Biol Chem, 276, 46230-6. 
MOLLAY, C., VILAS, U. & KREIL, G. 1982. Cleavage of honeybee 
prepromelittin by an endoprotease from rat liver microsomes: 
identification of intact signal peptide. Proc Natl Acad Sci U S A, 79, 
2260-2263. 
MORELOCK, M. M., INGRAHAM, R. H., BETAGERI, R. & JAKESS, S. 1995. 
Determination of Receptor-Ligand Kinetic and Equilibrium Binding 
Constants using Surface Plasmon Resonance: Application to the Zck 
SH2Domain and Phosphotyrosyl Peptides. J. Med. Chem. , 38, 1309-
1318. 
MORGAN, J. R., ZHAO, X., WOMACK, M., PRASAD, K., AUGUSTINE, G. J. 
& LAFER, E. M. 1999. A Role for the Clathrin Assembly Domain of 
AP180 in Synaptic Vesicle Endocytosis. Journal of Neuroscience 19, 
10201-10212. 
MORPHEW, M. K., O'TOOLE, E. T., PAGE, C. L., PAGRATIS, M., MEEHL, 
J., GIDDINGS, T., GARDNER, J. M., ACKERSON, C., JASPERSEN, 
S. L., WINEY, M., HOENGER, A. & MCINTOSH, J. R. 2015. 
Metallothionein as a clonable tag for protein localization by electron 
microscopy of cells. J Microsc, 260, 20-9. 
MUENZNER, J., TRAUB, L. M., KELLY, B. T. & GRAHAM, S. C. 2017. 
Cellular and viral peptides bind multiple sites on the N-terminal 
domain of clathrin. Traffic, 18, 44-57. 
NEUMANN, S. & SCHMID, S. L. 2013. Dual Role of BAR Domain-containing 
Proteins in Regulating Vesicle Release Catalyzed by the GTPase, 
Dynamin-2. Journal of Biological Chemistry, 288, 25119-25128. 
 234 
NIU, Q. & YBE, J. A. 2008. Crystal structure at 2.8 A of Huntingtin-interacting 
protein 1 (HIP1) coiled-coil domain reveals a charged surface suitable 
for HIP1 protein interactor (HIPPI). J Mol Biol, 375, 1197-205. 
NOBLES, K. N., GUAN, Z., XIAO, K., OAS, T. G. & LEFKOWITZ, R. J. 2007. 
The active conformation of beta-arrestin1: direct evidence for the 
phosphate sensor in the N-domain and conformational differences in 
the active states of beta-arrestins1 and -2. J Biol Chem, 282, 21370-
81. 
NUBER, S., ZABEL, U., LORENZ, K., NUBER, A., MILLIGAN, G., TOBIN, A. 
B., LOHSE, M. J. & HOFFMANN, C. 2016. beta-Arrestin biosensors 
reveal a rapid, receptor-dependent activation/deactivation cycle. 
Nature, 531, 661-4. 
OLUSANYA, O., ANDREWS, P. D., SWEDLOW, J. R. & SMYTHE, E. 2001. 
Phosphorylation of threonine 156 of the mu 2 subunit of the AP2 
complex is essential for endocytosis in vitro and in vivo. Current 
Biology, 11, 896-900. 
OWEN, D. J. & EVANS, P. R. 1998. A structural explanation for the 
recognition of tyrosine-based endocytotic signals. Science, 282, 1327-
1332. 
OWEN, D. J., VALLIS, Y., PEARSE, B. M. F., MCMAHON, H. T. & EVANS, 
P. R. 2000. The structure and function of the beta 2-adaptin 
appendage domain. The EMBO Journal, 19, 4216-4227. 
PACZKOWSKI, J. E., RICHARDSON, B. C. & FROMME, J. C. 2015. Cargo 
adaptors: structures illuminate mechanisms regulating vesicle 
biogenesis. Trends Cell Biol, 25, 408-16. 
PARTON, R. G. & DEL POZO, M. A. 2013. Caveolae as plasma membrane 
sensors, protectors and organizers. Nature Reviews Molecular Cell 
Biology, 14, 98-112. 
PEARSE, B. M. 1975. Coated vesicles from pig brain: purification and 
biochemical characterization. J Mol Biol, 97, 93-98. 
PETTERSEN, E. F., GODDARD, T., HUANG, C., COUCH, G., 
GREENBLATT, D., MENG, E. & FERRIN, T. 2004. CSF Chimera – a 
 235 
visualization system for exploratory research and analysis. U J 
Comput Chem, 25, 1605–1612. 
PICCO, A., KUKULSKI, W., MANENSCHIJN, H. E., SPECHT, T., BRIGGS, 
J. A. G. & KAKSONEN, M. 2017. The contributions of the actin 
machinery to endocytic membrane bending and vesicle formation. 
bioRxiv. 
PICHVAEE, B., COSTAGUTA, G., YEUNG BG, RYAZANTSEV S, 
GREENER T, GREENE L, EISENBERG E, MCCAFFERY JM & GS, 
P. 2000. A yeast DNA J protein required for clathrin-coated vesicle 
uncoating in vivo. Nat Cell Biol, 2, 958-963. 
PIZARRO-CERDA, I., J., , BONAZZI, M. & COSSART, P. 2010. Clathrin-
mediated endocytosis: What works for small, also works for big.32, 
496- 504. 
POPOVA, N.V., DEYER, I.E., PETRENKO, A.G. 2013. Clathrin-Mediated 
Endocytosis and Adaptor Proteins. ACTA NATURE, 5, 62-73 
POSTIS, V., RAWSON, S., MITCHELL, J. K., LEE, S. C., PARSLOW, R. A., 
DAFFORN, T. R., BALDWIN, S. A. & MUENCH, S. P. 2015. The use 
of SMALPs as a novel membrane protein scaffold for structure study 
by negative stain electron microscopy. Biochim Biophys Acta, 1848, 
496-501. 
PRAEFCKE, G. J. K., FORD, M. G. J., SCHMID, E. M., OLESEN, L. E., 
GALLOP, J. L., PEAK-CHEW, S. Y., VALLIS, Y., BABU, M. M., 
MILLS, I. G. & MCMAHON, H. T. 2004. Evolving nature of the AP2 
alpha-appendage hub during clathrin-coated vesicle endocytosis. The 
EMBO Journal, 23, 4371-4383. 
RAHMEH, R., DAMIAN, M., COTTET, M., ORCEL, H., MENDRE, C., 
DURROUX, T., SHARMA, K., DURAND, G., PUCCI, B., TRINQUET, 
E., ZWIER, J., DEUPI, X., BRON, P., BANÈRES , J., MOUILLAC, B. & 
GRANIER, S. 2012. Structural insights into biased G protein-coupled 
receptor signaling revealed by fluorescence spectroscopy. PNAS, 
109, 6733–6738. 
 236 
RANJAN, R., DWIVEDI, H., BAIDYA, M., KUMAR, M. & SHUKLA, A. K. 
2017. Novel Structural Insights into GPCR-beta-Arrestin Interaction 
and Signaling. Trends Cell Biol, 30087-9. 
RAPOPORT, I., BOLL, W., YU, A., BOCKING, T. & KIRCHHAUSEN, T. 
2008. A motif in the clathrin heavy chain required for the Hsc70/auxilin 
uncoating reaction. Molecular Biology of the Cell, 19, 405-413. 
RAPPOPORT, J. Z., KEMAL, S., BENMERAH, A. & SIMON, S. M. 2006. 
Dynamics of clathrin and adaptor proteins during endocytosis. Am J 
Physiol Cell Physiol, 291, 1072-81. 
REITER, E., AYOUB, M. A., PELLISSIER, L. P., LANDOMIEL, F., MUSNIER, 
A., TREFIER, A., GANDIA, J., DE PASCALI, F., TAHIR, S., YVINEC, 
R., BRUNEAU, G., POUPON, A. & CREPIEUX, P. 2017. beta-arrestin 
signalling and bias in hormone-responsive GPCRs. Mol Cell 
Endocrinol, 449, 28-41. 
REN, X. R., REITER, E., AHN, S., KIM, J., CHEN, W. & LEFKOWITZ, R. J. 
2005. Different G protein-coupled receptor kinases govern G protein 
and beta-arrestin-mediated signaling of V2 vasopressin receptor. Proc 
Natl Acad Sci U S A, 102, 1448-53. 
RICOTTA, D., CONNER, S. D., SCHMID, S. L., VON FIGURA, K. & 
HONING, S. 2002. Phosphorylation of the AP2 mu subunit by AAK1 
mediates high affinity binding to membrane protein sorting signals. 
Journal of Cell Biology, 156, 791-795. 
ROSENTHAL, J. A., CHEN, H., SLEPNEV, V. I., PELLEGRINI, L., SALCINI, 
A. E., DI FIORE, P. P. & DE CAMILLI, P. 1999. The epsins define a 
family of proteins that interact with components of the clathrin coat 
and contain a new protein module. Journal of Biological Chemistry, 
274, 33959-33965. 
ROTHNIE, A., CLARKE, A., KUZMIC, P., CAMERON, A. & SMITH, C. 2011. 
A sequential mechanism for clathrin cage disassembly by 70-kDa 
heat-shock cognate protein (Hsc70) and auxilin. Proceedings of the 
National Academy of Sciences, 108, 6927-6932. 
 237 
SAFFARIAN, S., COCUCCI, E. & KIRCHHAUSEN, T. 2009. Distinct 
dynamics of endocytic clathrin-coated pits and coated plaques. PLoS 
Biol, 7, e1000191. 
SCHEELE, U., ALVES, R., FRANK, R., DUWEL, M., KALTHOFF, C. & 
UNGEWICKELL, E. 2003. Molecular and functional characterization of 
clathrin- and AP-2-binding determinants within a disordered domain of 
auxilin. Journal of Biological Chemistry, 278, 25357-25368. 
SCHEELE, U., KALTHOFF, C. & UNGEWICKELL, E. 2001. Multiple 
interactions of auxilin 1 with clathrin and the AP-2 adaptor complex. J 
Biol Chem, 276, 36131-8. 
SCHEERER, P. & SOMMER, M. E. 2017. Structural mechanism of arrestin 
activation. Curr Opin Struct Biol, 45, 160-169. 
SCHMID, E. M., FORD, M. G., BURTEY, A., PRAEFCKE, G. J., PEAK-
CHEW, S. Y., MILLS, I. G., BENMERAH, A. & MCMAHON, H. T. 
2006. Role of the AP2 beta-appendage hub in recruiting partners for 
clathrin-coated vesicle assembly. PLoS Biol, 4, e262. 
SCOTTI, P. 1977. End-point dilution and plaque assay methods for titration 
of cricket paralysis virus in cultured Drosophila cells. J Gen Virol, 35, 
393-396. 
SHENOY, S. K. & LEFKOWITZ, R. J. 2011. beta-Arrestin-mediated receptor 
trafficking and signal transduction. Trends Pharmacol Sci, 32, 521-33. 
SHIH, W., GALLUSSER, A. & KIRCHHAUSEN, T. 1995. A clathrin-binding 
site in the hinge of the beta 2 chain of mammalian AP-2 complexes. 
Journal of Biological Chemistry, 270, 31083-31090. 
SHUKLA, A. K., MANGLIK, A., KRUSE, A. C., XIAO, K., REIS, R. I., TSENG, 
W. C., STAUS, D. P., HILGER, D., UYSAL, S., HUANG, L. Y., 
PADUCH, M., TRIPATHI-SHUKLA, P., KOIDE, A., KOIDE, S., WEIS, 
W. I., KOSSIAKOFF, A. A., KOBILKA, B. K. & LEFKOWITZ, R. J. 
2013. Structure of active beta-arrestin-1 bound to a G-protein-coupled 
receptor phosphopeptide. Nature, 497, 137-41. 
SHUKLA, A. K., WESTFIELD, G. H., XIAO, K., REIS, R. I., HUANG, L. Y., 
TRIPATHI-SHUKLA, P., QIAN, J., LI, S., BLANC, A., OLESKIE, A. N., 
 238 
DOSEY, A. M., SU, M., LIANG, C. R., GU, L. L., SHAN, J. M., CHEN, 
X., HANNA, R., CHOI, M., YAO, X. J., KLINK, B. U., KAHSAI, A. W., 
SIDHU, S. S., KOIDE, S., PENCZEK, P. A., KOSSIAKOFF, A. A., JR, 
V. L. W., KOBILKA, B. K., SKINIOTIS, G. & LEFKOWITZ, R. J. 2014. 
Visualization of arrestin recruitment by a G-protein-coupled receptor. 
Nature, 512, 218-222. 
SKRUZNY, M., DESFOSSES, A., PRINZ, S., DODONOVA, S. O., GIERAS, 
A., UETRECHT, C., JAKOBI, A. J., ABELLA, M., HAGEN, W. J., 
SCHULZ, J., MEIJERS, R., RYBIN, V., BRIGGS, J. A., SACHSE, C. & 
KAKSONEN, M. 2015. An organized co-assembly of clathrin adaptors 
is essential for endocytosis. Dev Cell, 33, 150-62. 
SMITH, C. J., DAFFORN, T. R., KENT, H., SIMS, C. A., KHUBCHANDANI-
ASWANI, K., ZHANG, L., SAIBIL, H. R. & PEARSE, B. M. F. 2004. 
Location of Auxilin Within a Clathrin Cage. Journal of Molecular 
Biology, 336, 461-471. 
SMITH, C. J., GRIGORIEFF, N. & PEARSE, B. M. F. 1998. Clathrin coats at 
21 angstrom resolution: a cellular assembly designed to recycle 
multiple membrane receptors. . Embo Journal, 17. 
SMITH, C. M. & CHIRCOP, M. 2012. Clathrin-Mediated Endocytic Proteins 
are Involved in Regulating Mitotic Progression and Completion. 
Traffic, 13, 1628- 1641. 
SMITH, J. S. & RAJAGOPAL, S. 2016. The beta-Arrestins: Multifunctional 
Regulators of G Protein-coupled Receptors. J Biol Chem, 291, 8969-
77. 
SMITH, S. M., BAKER, M., HALEBIAN, M. & SMITH, C. J. 2017. Weak 
Molecular Interactions Implicated in Clathrin-Mediated Endocytosis. 
In: WARWICK, U. O. (ed.). Frontiers: . 
SNOPOK, B., YURCHENKO, M., SZEKELY, L., KLEIN, G. & KASHUBA, E. 
2006. SPR-based immunocapture approach to creating an interfacial 
sensing architecture: mapping of the MRS18-2 binding site on 
retinoblastoma protein. Anal Bioanal Chem, 386, 2063–2073. 
 239 
SOUSA, R., LIAO, H. S., CUELLAR, J., JIN, S., VALPUESTA, J. M., JIN, A. 
J. & LAFER, E. M. 2016. Clathrin-coat disassembly illuminates the 
mechanisms of Hsp70 force generation. Nat Struct Mol Biol, 23, 821-
9. 
STEFAN, C. J., AUDHYA, A. & EMR, S. D. 2002. The yeast synaptojanin-like 
proteins control the cellular distribution of phosphatidylinositol (4,5)- 
bisphosphate. Molecular Biology of the Cell, 13, 542-557. 
STEFAN, C. J., PADILLA, S. M., AUDHYA, A. & EMR, S. D. 2005. The 
phosphoinositide phosphatase Sjl2 is recruited to cortical actin 
patches in the control of vesicle formation and fission during 
endocytosis. Molecular and Cellular Biology, 25, 2910-2923. 
SULEYMANOVA, N., CRUDDEN, C., SHIBANO, T., WORRALL, C., OPREA, 
I., TICA, A., CALIN, G. A., GIRNITA, A. & GIRNITA, L. 2017. 
Functional antagonism of beta-arrestin isoforms balance IGF-1R 
expression and signalling with distinct cancer-related biological 
outcomes. Oncogene, 1-11. 
TAYLOR, M. J., PERRAIS, D. & MERRIFIELD, C. J. 2011. A High Precision 
Survey of the Molecular Dynamics of Mammalian Clathrin-Mediated 
Endocytosis. Plos Biology, 9. 
TER HAAR, E., HARRISON, S. C. & KIRCHHAUSEN, T. 2000. Peptide-in-
groove interactions link target proteins to the β-propeller of clathrin. 
Proceedings of the National Academy of Sciences, 97, 1096-1100. 
TER HAAR, E., MUSACCHIO, A., HARRISON, S. C. & KIRCHHAUSEN, T. 
1998. Atomic structure of clathrin: A beta propeller terminal domain 
joins an alpha zigzag linker. Cell, 95, 563-573. 
TERRILLON, S., BARBERIS, C. & BOUVIER, M. 2004. Heterodimerization of 
V1a and V2 vasopressin receptors determines the interaction with 
beta-arrestin and their trafficking patterns. Proc Natl Acad Sci U S A, 
101, 1548-53. 
THOMSEN, A. R., PLOUFFE, B., CAHILL, T. J., 3RD, SHUKLA, A. K., 
TARRASCH, J. T., DOSEY, A. M., KAHSAI, A. W., STRACHAN, R. T., 
PANI, B., MAHONEY, J. P., HUANG, L., BRETON, B., 
 240 
HEYDENREICH, F. M., SUNAHARA, R. K., SKINIOTIS, G., 
BOUVIER, M. & LEFKOWITZ, R. J. 2016. GPCR-G Protein-beta-
Arrestin Super-Complex Mediates Sustained G Protein Signaling. Cell, 
166, 907-19. 
TIAN, X., KANG, D. S. & BENOVIC, J. L. 2014. beta-arrestins and G protein-
coupled receptor trafficking. Handb Exp Pharmacol, 219, 173-86. 
TRAUB, L. M. 2005. Common principles in clathrin-mediated sorting at the 
Golgi and the plasma membrane. Biochim Biophys Acta, 1744, 415-
37. 
TRAUB, L. M. 2009. Tickets to ride: selecting cargo for clathrin-regulated 
internalization. Nat Rev Mol Cell Biol, 10, 583-96. 
TRAUB, L. M. 2011. Regarding the amazing choreography of clathrin coats. 
PLoS Biol, 9, e1001037. 
TRAUB, L. M. & BONIFACINO, J. S. 2013. Cargo recognition in clathrin-
mediated endocytosis. Cold Spring Harb Perspect Biol, 5, a016790. 
UMEDA, A., MEYERHOLZ, A. & UNGEWICKELL, E. 2000. Identification of 
the universal cofactor (auxilin 2) in clathrin coat dissociation. 
European Journal of Cell Biology,, 79, 336-342. 
UNGEWICKELL, E. & BRANTON, D. 1981. Assembly units of clathrin coats. 
Nature, 289, 420-422. 
UNGEWICKELL, E., UNGEWICKELL, H., HOLSTEIN, S. E. H., LINDNER, 
R., PRASAD, K., BAROUCH, W., MARTIN, B., GREENE, L. E. & 
EISENBERG, E. 1995. Role of auxilin in uncoating clathrin-coated 
vesicles. Nature, 378, 632-635. 
UNGEWICKELL, E. J. & HINRICHSEN, L. 2007. Endocytosis: clathrin-
mediated membrane budding. Curr Opin Cell Biol. , 19, 417-25. 
VAN DER MERWE, P. A. 2001. Surface Plasmon Resonance. In: HARDING, 
E. E. & CHOWDHRY, B. Z. (eds.) Protein-Ligand Interaction: 
Hydrodynamics and Calorimetry. 
VANLANDINGHAM, P. A., FORE, T. R., CHASTAIN, L. R., ROYER, S. M., 
BAO, H., REIST, N. E. & ZHANG, B. 2013. Epsin 1 Promotes 
 241 
Synaptic Growth by Enhancing BMP Signal Levels in Motoneuron 
Nuclei. PLoS One, 8, e65997. 
VASSILOPOULOS, S., ESK, C., HOSHINO, S., FUNKE, B. H., CHEN, C. Y., 
PLOCIK, A. M., WRIGHT, W. E., KUCHERLAPATI, R. & BRODSKY, 
F. M. 2009. A Role for the CHC22 Clathrin Heavy-Chain Isoform in 
Human Glucose Metabolism. Science, 324, 1192-1196. 
VERSTREKEN, P., KOH, T. W., SCHULZE, K. L., ZHAI, R. G., HIESINGER, 
P. R., ZHOU, Y., MEHTA, S. Q., CAO, Y., ROOS, J. & BELLEN, H. J. 
2003. Synaptojanin is recruited by Endophilin to promote synaptic 
vesicle uncoating. Neuron, 40, 733-748. 
VIGERS, G. P. A., CROWTHER RA & PEARSE, B. M. F. 1986. Three-
dimensional structure of clathrin cages in ice. The EMBO Journal, 5, 
529–534. 
WAELTER, S., SCHERZINGER, E., HASENBANK, R., NORDHOFF, E., 
LURZ, R., GOEHLER, H., GAUSS, C., SA THASIV AM, K., BA TES, 
G. P., LEHRACH, H. & WANKER, E. E. 2001. The huntingtin 
interacting protein HIP1 is a clathrin and alpha-adaptin-binding protein 
involved in receptor- mediated endocytosis. Human Molecular 
Genetics, 10, 1807-1817. 
WHALEN, E. J., RAJAGOPAL, S. & LEFKOWITZ, R. J. 2011. Therapeutic 
potential of beta-arrestin- and G protein-biased agonists. Trends Mol 
Med, 17, 126-39. 
WHEATLEY, M., CHARLTON, J., JAMSHAD, M., ROUTLEDGE, S. J., 
BAILEY, S., LA-BORDE, P. J., AZAM, M. T., LOGAN, R. T., BILL, R. 
M., DAFFORN, T. R. & POYNER, D. R. 2016. GPCR-styrene maleic 
acid lipid particles (GPCR-SMALPs): their nature and potential. 
Biochem Soc Trans, 44, 619-23. 
WILBUR, J. D., CHEN, C. Y., MANALO, V., HWANG, P. K., FLETTERICK, 
R. J. & BRODSKY, F. M. 2008. Actin Binding by Hip1 (Huntingtin-
interacting Protein 1) and Hip1R (Hip1-related Protein) Is Regulated 
by Clathrin Light Chain. Journal of Biological Chemistry, 283, 32870-
32879. 
 242 
WILBUR, J. D., HWANG, P. K., YBE, J. A., LANE, M., SELLERS, B. D., 
JACOBSON, M. P., FLETTERICK, R. J. & BRODSKY, F. M. 2010. 
Conformation switching of clathrin light chain regulates clathrin lattice 
assembly. Dev Cell, 18, 841-8. 
WILLOX, A. K. & ROYLE, S. J. 2012. Functional analysis of interaction sites 
on the N-terminal domain of clathrin heavy chain. Traffic, 13, 70-81. 
WINKLER, F. & STANLEY, K. K. 1983. Clathrin heavy chain, light chain 
interactions. The EMBO Journal, 2, 1393–1400. 
WU, F. & YAO, P. J. 2009. Clathrin-mediated endocytosis and Alzheimer's 
disease: an update. Ageing Res Rev, 8, 147-9. 
XING, Y., BOCKING, T., WOLF, M., GRIGORIEFF, N., KIRCHHAUSEN, T. & 
HARRISON, S. C. 2010. Structure of clathrin coat with bound Hsc70 
and auxilin: mechanism of Hsc70-facilitated disassembly. EMBO J, 
29, 655-65. 
YANG, F., YU, X., LIU, C., QU, C. X., GONG, Z., LIU, H. D., LI, F. H., 
WANG, H. M., HE, D. F., YI, F., SONG, C., TIAN, C. L., XIAO, K. H., 
WANG, J. Y. & SUN, J. P. 2015. Phospho-selective mechanisms of 
arrestin conformations and functions revealed by unnatural amino acid 
incorporation and (19)F-NMR. Nat Commun, 6, 8202. 
YBE, J. A., BRODSKY, F. M., HOFMANN, K., LIN, K., LIU, S. H., CHEN, L., 
EARNEST, T. N., FLETTERICK, R. J. & HWANG, P. K. 1999. Clathrin 
self- assembly is mediated by a tandemly repeated superhelix. 
Nature, 399, 371- 375. 
YBE, J. A., CLEGG, M. E., ILLINGWORTH, M., GONZALEZ, C. & NIU, Q. 
2009. Two Distantly Spaced Basic Patches in the Flexible Domain of 
Huntingtin-Interacting Protein 1 (HIP1) Are Essential for the Binding of 
Clathrin Light Chain. Res Lett Biochem, 2009, 256124. 
YBE, J. A., GREENE, B., LIU, S. H., PLEY, U., PARHAM, P. & BRODSKY, 
F. M. 1998. Clathrin self-assembly is regulated by three light-chain 
residues controlling the formation of critical salt bridges. Embo 
Journal, 17, 1297- 1303. 
 243 
YBE, J. A., MISHRA, S., HELMS, S. & NIX, J. 2007. Crystal structure at 2.8 
A of the DLLRKN-containing coiled-coil domain of huntingtin-
interacting protein 1 (HIP1) reveals a surface suitable for clathrin light 
chain binding. J Mol Biol, 367, 8-15. 
YOUNG, A., STOILOVA-MCPHIE, S., ROTHNIE, A., VALLIS, Y., HARVEY-
SMITH, P., RANSON, N., KENT, H., BRODSKY, F. M., PEARSE, B. 
M., ROSEMAN, A. & SMITH, C. J. 2013. Hsc70-induced changes in 
clathrin-auxilin cage structure suggest a role for clathrin light chains in 
cage disassembly. Traffic, 14, 987-96. 
ZHANG, C. X., ENGQVIST-GOLDSTEIN, A. E., CARRENO, S., OWEN, D. 
J., SMYTHE, E. & DRUBIN, D. G. 2005. Multiple roles for cyclin G-
associated kinase in clathrin-mediated sorting events. Traffic, 6, 1103-
13. 
ZHUO, Y., CANO, K. E., WANG, L., ILANGOVAN, U., HINCK, A. P., 
SOUSA, R. & LAFER, E. M. 2015. Nuclear Magnetic Resonance 
Structural Mapping Reveals Promiscuous Interactions between 
Clathrin-Box Motif Sequences and the N-Terminal Domain of the 
Clathrin Heavy Chain. Biochemistry, 54, 2571-80. 
 
 
